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Abstract 
UNIVERSITY OF SOUTHAMPTON 
FACULTY OF MEDICINE, HEALTH AND LIFE SCIENCES 
INFECTION, INFLAMMATION AND IMMUNITY DIVISION 
Doctor of Philosophy 
MOLECULAR BASIS OF GENE-ENVIRONMENT INTERACTIONS IN THE 
PATHOGENESIS OF ASTHMA AND COPD 
by Matthew JJ Rose-Zerilli 
The origins of respiratory disease, such as asthma in childhood and COPD in later life are 
unclear.  Maternal  smoking  during  pregnancy  and  low  birth  weight i s  a s s o c i a t e d  w i t h  
increased risk of asthma, poor lung function in adults and COPD in old age. Exposure to 
oxidative stress and poor nutrition in utero is thought to cause damage to the lung and 
alter the normal course of lung development. 
  Glutathione  S-transferases  (GST)  are  potent  antioxidants.  In  this  work,  genetic 
polymorphisms  that  alter  GST  enzyme  activity  were  genotyped  in  a  family-based 
childhood asthma cohort (341 families, n = 1508) and analysed to investigate whether 
they alter the risk of developing asthma when individuals are exposed to environmental 
tobacco  smoke.  Real-time  PCR  based  copy  number  variation  methodology  was 
developed to genotype the common gene deletion polymorphism of GSTT1 and GSTM1 
genes, for other GST genes (GSTP1 and GSTO2) SNP haplotypes were constructed. A 
rare  GSTO2 h a p l o t y p e  w a s  n e g a t i v e l y  a s s o c i a t e d  w i t h  a s t h m a  s u s c e p t i b ility,  atopy 
severity, and FEV1 values. Asthmatic children with a GSTT1 gene deletion, or a common 
GSTP1 haplotype, developed more severe asthma compared to individuals with a GSTT1 
gene or non-carriers of the GSTP1 haplotype. Total IgE levels were increased in GSTT1*0 
individuals when exposed to tobacco smoke in early life, suggesting a gene-environment 
interaction.  GSTO2  may  be  a  shared  susceptibility  locus  for  asthma  in  childhood  and 
COPD in later life. 
  Animal models of maternal protein-restriction during pregnancy can induce hypertension, 
diabetes and endothelial dysfunction in offspring and in some of these models alterations 
to lung gene expression and lung architecture have been reported. This work established 
that a rat model of maternal dietary protein-restriction during pregnancy known to induce 
hypertension in the offspring, results in persistent alterations to the expression of genes in 
the lungs of adult offspring (120 days), including genes involved in glucocorticoid action 
(Hsd11b2),  growth  (Igf1 &  2  a n d  Pcdh1)  and  alveolar  development  (Tp53).  Lung 
microRNA  expression  profiles  were  also  altered  in  response  to  exposure  to  protein 
restriction in utero. These findings suggest a role for nutritional programming in respiratory 
disease  susceptibility  in  later  life  and  a  role  for  microRNAs  in  the  study  of  the 
developmental  origins  of  health  and  disease  in  general.  Further  work  will  include  the 
investigation of epigenetic mechanisms that control nutritional programming in lungs of 
animals exposed to protein-restriction in utero. 
  This work has demonstrated that GST polymorphism is a risk factor for childhood asthma 
and  certain  genotypes  can  offer  some  protection  against  the  development  of  severe 
asthma. T h e r e  w a s  l i t t l e  e v i d e n c e  t o  s u g g e s t  t h a t  G S T  p o l y m o r p h i s m  m o d u l a t e s  t h e  
effects of smoke exposure in early life.  In addition, we have demonstrated that maternal 
diets that are poor in nutrition could predispose her offspring to respiratory disease in later 
life  by  altering  the  course  of  normal  lung  development  in  early  life  or  response  to 
environmental stimuli in later life.   iii  
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EDTA   EthyleneDiamineTetraacetic 
Acid 
ETS  Environmental Tobacco 
Smoke 
FEV1  Forced Expiratory Volume in 1 
second 
GCS  Glutamylcysteine 
GLP  Good Laboratory Practice 
GM-CSF  Granulocyte Monocyte Colony 
Stimulating Factor 
GR  Glucocorticoid Receptor 
Abbreviation  Full name 
grm  gram 
GSH  Glutathione 
GSSG  Glutathione disulphide 
GST  Glutathione S-Transferase 
H2O2  Hydrogen Peroxide 
HDM  House dust Mite 
htSNP  Haplotype tagging  Single 
Nucleotide Polymorphism 
HWE  Hardy-Weinberg Equilibrium 
IgE  Immunoglobulin E 
IL-13  Interleukin-13 
IL-4  Interleukin-4 
IL-5  Interleukin-5 
IL-9  Interleukin-9 
IUGR  Intrauterine Growth 
Restriction 
LAR  Late phase Allergic Response 
LNA  Locked Nucleic Acids 
LPS  Lipopolysaccharide 
LTs  Leukotrienes 
Mb  Megabase (DNA) 
miRNA  microRNA 
ml  millilitre 
NAPDH  Nicotinamide Adenine 
Dinucleotide Phosphate 
NFKB  Nuclear Factor kappa B 
nM  Nano Molar 
NO  Nitric Oxide 
NOS  Reactive Nitrogen Species   xvi  
   
Abbreviation  Full name 
PEF  Peak Expiratory Flow 
PGs  Prostaglandins 
pM  Pico Molar 
PR  maternal Protein-Restriction 
qPCR  quantitative PCR or Real-
Time PCR 
RISC  RNA Induced Silencing 
Complex 
ROS  Reactive Oxygen Species 
RTLF  Respiratory Tract Lining Fluid 
RT-PCR  Reverse Transcription PCR 
RT-ve  Reverse Transcriptase 
Negative Control 
Abbreviation  Full name 
SNP  Single Nucleotide 
Polymorphism  
TGF!  Transforming Growth Factor 
beta 
TH1  T helper Cell Type 1 response 
TH2  T helper Cell Type 2 response 
Tm  Melting Temperature 
TNF  Tissue Necrosis Factor 
TNF"  Tissue Necrosis Factor alpha 
#M  Micro Molar 
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1  Chapter 1: Introduction 
1.1  Asthma 
1.1.1  Incidence  
The current estimate of asthma incidence worldwide by the World Health 
Organisation was 300 million in 2005 and is now the most common chronic 
disease in children.
1 In the UK there are 5.2 million asthmatics (1.1 million of which 
are children) and the healthcare burden of asthma is around £996 million in the 
UK, with a total economic cost of £2.3 billion per annum.(www.asthmauk.org.uk) It 
is important to remember that this disease can be a killer with just over 1,300 
deaths in the UK and 255,000 individuals dying in 2005 from fatal asthma 
exacerbations worldwide.
1 
1.1.2  Prevalence 
Worldwide prevalence of asthma symptoms (current wheeze) in 6-7 year old 
children was ~11% and ~13% in 13-14 year olds in 2006 (mean increase of 0.13%  
and 0.06% per year).
2, 3 The International Study of Asthma and Allergies in 
Children (ISAAC) determined that asthma prevalence had decreased slightly in 
English speaking countries and Western Europe (-0.51% and -0.09%; for 13-14 
and 6-7 year olds respectively) in the last 10 years, while asthma had increased in 
those countries where prevalence was previously low.
3 However, the percentage 
of children reported to have had asthma at some time in their lives increased by 
0.28% per year in the 13-14 year age group and by 0.18% per year in the 6-7 year 
age group.
3 The increases in asthma symptom prevalence in Africa, Latin America 
and parts of Asia indicate that the global burden of asthma is continuing to rise, 
but global prevalence differences are lessening.
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1.1.3  Clinical Symptoms 
Asthma is a chronic respiratory disease involving episodic narrowing of the 
airways by bronchoconstriction and inflammation. Acute asthma exacerbations 
(commonly known as ‘asthma attacks’) can be triggered by various aero-allergens 
(pollen, house dust mite, chemicals and animal allergens), respiratory virus 
infections, exercise, cold air, tobacco smoke and pollution (e.g. diesel exhaust 
particles). Asthma triggers vary person to person and can worsen the asthma 
symptoms of wheeze, shortness of breath, chest tightness and coughing without 
always causing an asthma attack. 
1.1.4  Diagnosis 
Asthma is simply defined as a reversible airways obstruction. The British Thorax 
Society (BTS) published updated asthma management guidelines in 2007, 
detailing asthma diagnosis by combining symptoms with a family history of asthma 
or atopy and several objective measurements of lung function (updated guidelines 
are available via www.brit-thoracic.org.uk; originally published in Thorax in 2003
4). 
As symptoms are shared with other respiratory disorders is it important for the 
diagnosing practitioner to have clear guidelines for diagnosis and be aware of the 
co-morbidity of the symptoms to avoid misdiagnosis. In the UK, practitioners 
examine adult patients for any signs of wheeze (diffuse, bilateral or expiratory), or 
tachypnea (rapid breathing) it is common for patients to present with no signs. 
Records of personal or family history of asthma or atopy (eczema, allergic rhinitis), 
adverse effects after aspirin/NSAID ingestion or use of !-blockers, recognised 
triggers, and pattern and severity of symptoms or exacerbations aid in diagnosis. 
They also perform at least one of the following objective spirometry measurements 
to measure airway function in order to confirm airway obstruction (see table 1.1). 
Table 1-1: Objective Measurements for Asthma Diagnosis 
Objective Measurements for Asthma Diagnosis 
>20% diurnal variation on $3 days in a week for two weeks on Peak Expiratory flow  (PEF) diary 
FEV1 $ 15% (and 200ml) increase after short acting !-agonists (eg salbutamol) 
FEV1 $ 15% (and 200ml) increase after trial of steroid tablets (prednisolone 30mg/day for two weeks) 
FEV1 $ 15% decrease after 6 minutes of exercise (running) 
Histamine or methacholine challenge in difficult cases   3  
   
If the diagnosis is unclear or in doubt the patient is referred to a specialist. In 
children the diagnosis of asthma can be more complicated, as it is not often 
possible to measure airway function, so the BTS provide alternative guidelines. 
These guidelines recommend identifying a key feature of asthma, monitor the 
child’s response to trials of asthma treatments and perform repeated assessment 
of the child to detect if management is ineffective.
4 
1.1.4.1  Lung function testing 
Pulmonary function tests objectively measure the ability of the respiratory system 
to perform gas exchange by assessing its ventilation, diffusion and mechanical 
properties. Spirometry and measurements of lung volumes determine the 
presence and severity of obstructive and restrictive pulmonary dysfunction. 
Asthma causes obstructive pulmonary dysfunction and sufferers generally have 
less than predicted airflow rates as shown in table 1.2. 
Table 1-2: Static and Dynamic Pulmonary Function Tests Used to Diagnose and Monitor 
Asthma 
 
Bronchial hyperresponsiveness and Percent Predicted Forced Expiratory Volume 
in first second (%FEV1 predicted) are two commonly used pulmonary function 
measurements used to monitor asthma severity and airways obstruction. 
Static Tests  Dynamic Tests 
Vital capacity (VC): 
Change in volume of gas in the lung from complete 
inspiration to complete expiration 
Forced Expiratory Volume in first second (FEV1): 
The volume of air expelled in the first second of a forced 
expiration starting from full inspiration. 
FEV1%: This is the FEV1 expressed as a percentage of the 
total volume (FEV1 Ratio or FEV1/VC% or FEV1/FVC%) 
Forced Vital Capacity (FVC): 
The maximum volume of air in litres that can be forcibly and 
rapidly exhaled following a maximum inspiration.  
FVC is the basic manoeuvre in spirometry tests 
Peak Expiratory Flow Rate (PEFR): 
The greatest flow that can be sustained for 10 milliseconds 
on forced expiration from full inflation, this is measured with 
a peak flow meter in Litres per minute. 
 
Forced Expiratory Flow Rate (FEFR 25%-75%):  
Average expiratory flow rate at the middle part of the FVC 
manoeuvre. Expressed in litres per second it gives an 
indication of the function of the lower airways and can act as 
an early warning sign of disease.   4  
   
1.1.4.1.1 Bronchial Hyperresponsiveness: Methacholine Challenge 
Bronchial Hyperresponsiveness (BHR) is a hallmark of asthma and is classed as 
‘specific’, when the airways narrow in response to allergen (e.g. cat dander) or 
‘non-specific’, when the airways narrow in response to agonists (e.g. ozone, 
histamine). Non-specific responsiveness can occur in both asthmatics and non-
asthmatics. In response to a challenge the smooth muscle around airways 
contract and narrow the airway, reducing lung function. A histamine or 
methacholine challenge is used as an objective measurement for diagnosis and in 
determining asthma severity. BHR can be induced by inhaling increasing 
concentrations (0.06 - 16 mg/ml) of nebulised methalcholine or histamine; the 
concentration required to induce a 20% reduction in FEV1 is termed as the 
‘Provocative Concentration’ or PC20 (mg/ml).  Asthmatic airways in general, require 
a smaller dose of stimulant to induce bronchoconstriction than normal airways (this 
is defined as airways sensitivity).   
The FEV1 values can be plotted against stimulant concentration and the reciprocal 
of the linear regression slope is used as measure of the individuals airway 
reactivity.  Thus, the slope will be in general steeper in asthmatics as the airways 
are more reactive (i.e. airway narrowing per unit of agonist is greater) and the 
maximum reduction in FEV1 will be larger than normal airways, this is referred to 
as ‘maximal response’. 
1.1.4.1.2 Percent Predicted FEV1  
FEV1 is the volume of air expelled in the first second of a forced expiration starting 
from full inspiration; this dynamic test of pulmonary function is the most widely 
used index of assessing airways obstruction. Percent predicted FEV1 is an 
individual’s baseline FEV1 expressed as a percentage of the predicted FEV1 value 
according to their height and age using this formula (see equation 1).  
Equation 1: Percent Predicted FEV1 Formula 
 
Predicted FEV1 values are determined from large population based 
epidemiological studies of lung function such as the standardised lung volume and 
forced ventilatory flow tables of the European Community for steel and coal 
(ESCS) workers.
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1.2  Pathogenesis of Asthma 
Asthma is an inflammatory disease of the airways characterised by airways hyper-
activity, chronic eosinophilic inflammation, mucus hyper-secretion and reversible 
bronchoconstriction (see figure 1.1).
6 Various cellular pathophysiological pathways 
are therefore involved in asthma, and sufferers can be categorised as atopic, non-
atopic or aspirin sensitive asthmatics. The majority of asthma (especially in 
childhood) is mediated by allergic inflammation.
7 Childhood asthma tends to have -
TH2 driven responses to allergens such as house dust mite and therefore has 
significant co-morbidity with atopic IgE mediated diseases like allergic rhinitis and 
eczema.
8 Adult onset asthma on the other hand tends to be more severe and is 
often not mediated by IgE (non-atopic).
9 Finally, some asthmatics are sensitive to 
aspirin (and other cyclooxygenase inhibitors) and  exhibit symptoms when 
exposed to these agents.
10 This form of asthma is also considered to be non-
atopic and sufferers can be desensitised to aspirin.
10 Therefore, not all asthmatics 
are atopic, non-atopic asthma is particularly prevalent in adult-onset asthma but is 
also found in children and may result from reactions to cold air, respiratory virus 
infection and environmental air pollution.
11  
 
Figure 1-1: Structural Changes in Asthmatic Airways 
Asthmatic airways are generally characterised by the influx of inflammatory cells, hypersecretion of 
mucus (yellow), thickening of the airway smooth muscle (purple) and collagen deposition (brown 
layer).   6  
   
1.2.1  Atopic Asthma 
Atopic Asthma is also referred to as extrinsic asthma; this type of asthma is 
triggered by identifiable external allergens. Patients with this form of asthma have 
IgE mediated allergic responses to common allergens. Atopic asthma is also 
known as early-onset asthma and is the type commonly seen in children. 
Numerous population based studies have shown that prevalence of atopy can 
range from 4 - 64% and asthma from 1 - 38%.
11 Therefore, atopy is not always 
associated with asthma, and not all asthmatics are atopic.  
1.2.2  Non-Atopic Asthma 
In non-atopic asthma (intrinsic asthma or late onset asthma) the agents or 
conditions responsible for attacks are generally unknown but can include pollution 
(diesel exhaust particulate matter and ozone), cold air and infection with virus. The 
sufferers tend to be adults that are not atopic. 
1.2.3  Categories of Asthma 
1.2.3.1  Seasonal Asthma 
Asthma may be exacerbated by seasonal increases in specific aeroallergens 
(pollens, e.g. birch pollen and ragweed) in certain sensitised individuals. Seasonal 
asthma is usually associated with allergic rhinitis and can occur intermittently with 
the patient being completely asymptomatic between seasons.  
1.2.3.2  Occupational Asthma 
Occupational asthma is asthma acquired in the workplace due to exposure to 
chemicals by inhalation. A wide range of chemicals are known to induce asthma, 
from chemicals such as isocyanates to animal and plant products. Occupational 
asthma can be misdiagnosed as chronic bronchitis or COPD; absence of asthma 
before employment and reduction in symptoms when absent from the workplace 
are key signs for diagnosis. 
1.2.3.3  Cough Variant Asthma 
This type of asthma is characterized by recurrent cough particularly at night. 
These patients seldom have wheezing episodes and consequently display normal  
signs under examination; administration of bronchodilators can be diagnostic.   7  
   
1.2.4  Allergic Inflammation  
The allergic cascade is crucial in the development of airway inflammation in 
allergic asthma.
7 Inhaled allergens that escape mucociliary clearance are taken up 
by antigen presenting cells (APCs) that are found throughout the respiratory tract 
(nasal mucosa to lung pleura). After migrating to the draining lymph nodes, the 
processed antigen is presented to allergen specific T and B cells. Activation of T 
helper (Th) cells by APCs leads to the production of cytokines (IL-4, IL-5, IL-9, IL-
13) that regulate the iso-type switching of B-cells to produce immunoglobulin E 
(IgE), mast cell development, mucus overproduction, airway hyperresponsiveness 
(IL-4, IL-13 & IL-9) and eosinophil accumulation (IL-5). Released IgE antibodies 
circulate in the blood before binding to the high affinity IgE receptor Fc%R1 on mast 
cells in tissue or on peripheral blood basophils. 
After re-exposure, the allergen cross-links to mast cell bound specific IgE 
(activating membrane and cytosolic pathways) triggering the release of preformed 
pro-inflammatory mediators such as, histamine, tryptase, chymase, and newly 
synthesised prostaglandins (PGs), leukotrienes (LTs), and cytokines are 
transcribed (TNF! & VEGF). The release of these mediators cause the early-
phase asthmatic reaction (EAR) which is characterised by mucus production, 
vascular leakage, constriction of airway smooth muscle (ASM) cells and enhanced 
airway hyperresponsiveness. The EAR is immediate, lasting up to one hour and is 
followed by the late-phase asthmatic reaction (LAR) between 4-6 hours later. 
Table 1.3 and 1.4 details the role of immune cells in asthma and key cytokine 
molecules that are essential for maintaining inflammation. 
The late phase asthmatic reaction consists of persistent and excessive 
inflammation driven by recruitment of inflammatory cells such as 
macrophages/monocytes and eosinophils, that in the long-term results in structural 
changes to the airways tissue. This is known as tissue remodelling and is 
discussed in detail in section 1.2.5.   8  
   
 
Table 1-3: Immune Cell Types Involved in Asthma.  
This table provides brief overview of the role of different immune cells involved in the disease. 
Lineage  Cell type  Role in inflammation  Role in asthma  
Lymphocytes  B cell   Matured in bone marrow. Synthesis and display of 
immunoglobulin (antibody) molecules that bind 
antigen. Clonal differentiation into specific plasma 
cells (effector cell) or memory cells. Interactions with 
T cells and macrophages by presenting processed 
antigen bound on Class II MHC molecules 
Induction of the asthmatic 
reaction  
  T cell  Matured in the thymus. Binds processed antigen 
though T-cell receptor. Recognises only antigen 
bound to MHC molecules on APC or virus infected 
cells, cancer cells or grafts.  
Induction of the asthmatic 
reaction, but important during 
all of the allergic response 
especially TH2 lymphocytes. 
       
Mononuclear  Dendritic cell  Express MHC class II on cell surface. Antigen 
presenting cell. Presents antigen to blood T 
lymphocytes. 
Involved in late phase 
asthmatic reaction 
  Monocyte  Circulates in the bloodstream then differentiates into 
tissue specific Macrophage cells 
See macrophage. 
  Macrophage  Phagocytic cell. Antimicrobial and cytoxic 
activity.Antigen processing and presentation (to TH 
cells). Secretion of cytokine factors. Promotes pro-
inflammatory response.  
Involved in late phase 
asthmatic reaction 
Airways remodelling 
       
Granulocytes  Basophils  Circulating non-phagocytic cells. Release of 
pharmacologically active substances such as 
histamine and MBP. 
Involved in early phase 
asthmatic reaction.  
  Eosinophil  Motile phagocytic cells.  
Cytotoxic defence against parasitic organisms. 
Secretes major basic protein (MBP) and Eosinophilic 
cationic protein. 
Involved in late phase 
asthmatic reaction.  
Airways inflammation and 
remodelling 
Shedding of respiratory 
epithelium 
eosinophilia in the surrounding 
lung tissue is a characteristic of 
severe asthma exacebations 
  Neutrophil  Accumulates at the site of infection. Phagocytic cell. 
Antimicrobial defence via production of ROS and 
RNS.  
Involved in late phase 
asthmatic reaction 
Neutrophilia a marker of severe 
asthma 
  Mast cells  Releases Histamine, prostaglandins and leukotrienes, 
TNF", VEGF and other active substances. Pro-
inflammatory. 
Involved in early phase 
asthmatic reaction  
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Table 1-4: Key Cytokine Signalling Molecules Involved in Asthma Pathogenesis.  
This table details only a few examples of the many cytokines involved in asthma.  
Type  Cytokine  Role in Inflammation  Effect in asthma 
Lymphokine  IL-4  T cell differentiation (TH2 cells & & TH1 
cells ') 
isotype switching of B cells  
cell adhesion  
eosinphil growth & 
Induces allergic airways inflammation 
associated with increased BHR 
  IL-5  eosinphil maturation 
apoptosis ' 
TH2 cells & 
Chemoattraction of  eosinophils 
increased BHR 
  IL-9  Mast cell protease expression 
Goblet cell hyperplasia 
increased mucus production 
  IL-13  similar to IL-4, except it does not drive 
TH2 differentiation 
activates eosinophils 
IgE  & 
Airway eosinophilia  
increased BHR 
Growth factor  TGF!  Cell proliferation, differentiation and 
angiogenesis 
Lung remodelling 
Pro-inflammatory  GM-CSF  Granulocyte macrophage colony 
stimulating factor 
Regulates growth of several airways 
cells, macrophages, eosinophils, T cells, 
fibroblasts, endothelial, smooth muscle 
and epithelial cells 
Chronic eosinophila  and airways 
remodelling 
  TNF"  Induced by IL-1, IL-13, GM-SCF, IFN( 
Pro-inflammatory 
Induction of ICAM1 
Up regulation of IL-1, 8 & MHC which 
attracts neutrophils 
Amplifies asthmatic inflammation and may 
initiate chronic inflammation  
Increased neutrophils in sputum 
 
Anti-inflammatory  IFN(  Produced by TH1 cells. 
Inhibits TH2 cells.  
Amplifies release of THF" from 
macrophages  
Promotes cell cytotoxic responses while 
Inhibiting allergic inflammation and IgE 
synthesis  
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1.2.5  Remodelling of Asthmatic Lung Tissue 
Research into the pathogenesis of asthma has mainly focused on the 
immunological component of disease; however histological examination of lung 
tissue from asthmatics reveals extensive tissue remodelling and this is now 
recognised as an important aspect of this condition. Changes in lung tissue involve 
a range of processes. Goblet cell hyperplasia and metaplasia; these cells are 
responsible for hypersecretion of mucus during exacerbation. Myofibroblast cells 
increase in number and thicken the reticular basement membrane by collagen 
deposition resulting in oedema, increased airways obstruction and is correlated 
with airway responsiveness.
12 Remodelling in the smooth muscle layer (smooth 
muscle cell hyperplasia) and proliferation of airway blood vessels and nerves 
results in increased hypersensitivity of the airways and airway narrowing.
13 
Long-standing inflammation is considered to cause remodelling. But signs of 
remodelling have been detected in tissue biopsies from children up to 4 years 
before the onset of asthma symptoms.
14 It has been suggested that rather than 
being a consequence of airway inflammation, airway remodelling may run in 
parallel or is required for the establishment of persistent inflammation.
15 
Tissue remodelling is required for the normal development of the human lung in 
early life and starts in utero.
16 In asthmatic lungs it appears that an aberrant 
epithelium repair response may lead to the reactivation of these developmental 
pathways. A number of studies have provided evidence for an abnormal response 
to inflammation by the structural cells of the airways in asthmatics. Epithelial cells 
from asthmatics are more susceptible to damage from oxidative stress
17 and 
environmental oxidative stress agents (diesel particulates) may trigger epithelial 
activation in response to injury.
18 Increased clusters of sloughed epithelial cells 
(creola bodies) are observed in the sputum, especially during exacerbations and 
BAL fluids of asthmatics contain more epithelial cells.
12 
Injury to the epithelium causes the release of fibrogenic growth factors, such as 
TGF-!, which promotes the proliferation of underlying fibroblasts and 
differentiation into myofibroblasts that secrete interstitial collagens and growth 
factors (Endothelin 1 and VEGF). These growth factors are mitogens for smooth 
muscle and endothelial cells.
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Signals from the repairing epithelium are amplified deep into the submucosa layer; 
this communication between the epithelium and mesenchymal cells has been 
termed the Epithelium-Mesenchymal Trophic Unit (EMTU) and is similar to the 
remodelling process in embryonic lung development.
16 It is thought that the EMTU 
remains active or is re-activated in asthma, driving the remodelling process of 
asthmatic airways (see figure 1.2).
20 
The lung remodelling model suggests that in certain people lung epithelial cells are 
more susceptible to injury from inhaled environmental exposures and/or have 
impaired repair mechanisms that induce airways inflammation and remodelling, 
leading to the development of asthma. 
 
Figure 1-2: Lung Remodelling in Asthmatic Airways  
Injury to the respiratory epithelium causes the release of fibrogenic growth factors (red arrow) and 
the signal is amplified into the deep submucosa, promoting proliferation of fibroblasts and 
differentiation into myofibroblasts (blue arrow). The myofibroblasts secret growth factors and 
collagen into the interstitial space (green arrow)   12  
   
1.3  Aetiology of Asthma 
The exact cause of asthma remains uncertain; several factors are known to 
influence the disease, genetic factors (e.g. family history of asthma and atopy), 
environmental factors (e.g. allergen exposure, viral infection, air pollution, 
occupational exposure) and life style choices (e.g. smoking and nutrition).  
Asthma is a complex disease formed from the interaction of multiple genetic and 
environmental factors; these interactions are still not fully understood even though 
in recent years there have been remarkable advances in understanding the 
disease pathogenesis and the availability of improved treatments. Genetic and 
environmental factors can also influence the severity of the disease and the 
patient’s response to medication. Certain factors only affect asthma when they 
form a gene-environment interaction, for example genetic factors may only have 
disease relevance in a particular environment. This makes elucidating the genetic 
component of asthma extremely challenging. Differences in asthma prevalence 
between populations provide evidence for certain environmental exposures 
(including life style choices) contributing to the development of this disease. 
Several theories have been proposed for the main environmental causes of 
asthma and are outlined below:  
1.3.1  Environment 
1.3.1.1  Hygiene Hypothesis: Role of Infection 
Early childhood exposures to infection inhibit the tendency to develop allergic 
disease. Westernised lifestyles are protective against early life infections common 
in the developing world, but increase the risk of developing allergic disease. 
Numerous exposures have been found to be protective against asthma and atopy, 
living on a farm,
21,22 drinking unpasteurised milk,
21 living with animals
23,24 and 
having several siblings.
23,25,26 Abundant microorganism exposure in childhood 
seems to provide protection by switching the child’s immunological memory to a 
TH1 phenotype so that TH2 cell responses do not dominate when exposed to 
allergens. The hygiene hypothesis cannot account for the 67-75% of adult 
asthmatics who are not atopic; therefore other causes of this disease must exist.
27   13  
   
1.3.1.2  Antibiotics 
Antibiotic use in early life has been associated with the development of asthma;
28-
31 although this is not conclusive as several studies have refuted those findings.
32-
35 A recent prospective study of Canadian children (n = 13,116) found a 1.86 fold 
increased risk of developing asthma by age seven, when using broad spectrum 
antibiotics (cephlasporin) to treat non-respiratory tract infections.
28 Treatment with 
antibiotics can be thought of as an extension of the hygiene hypothesis, where 
exposure to microbial endotoxin in early life can be protective against the 
development of allergy and asthma. The microflora hypothesis proposes that 
external microbial exposure is not as important as the presence of commensal 
microbial flora in the gastro-intestinal (GI) tract, for the maturation of the mucosal 
immune system during infancy.
36 Several epidemiological studies have linked 
variation in GI flora and probiotic administration with less allergy and asthma.
37-39 
Murine models of antibiotic administration reports altered flora, impaired barrier 
function, diminished TH1 responses and allergic disease.
40, 41 It is still not clear 
whether antibiotics are responsible for the development of asthma and allergy as it 
is difficult to control for differences in antibiotics, environmental exposures, and 
population variability. Reverse causality in any association with risk of disease is 
difficult to exclude.     
1.3.1.3  Vaccination 
Early life vaccination programmes in westernised countries has been suggested 
as a cause for the increased prevalence of allergic disease in these nations by 
limiting the induction of a TH1 immune response in infants by protecting against 
common childhood infections.
42  There is no recent evidence to support an 
increased risk of atopy or asthma from vaccination.
43, 44 In fact, a recent cross-
sectional study that found a positive association between pertussis infection and 
atopic disorders in pertussis vaccinated children could not conclude whether this 
was a causal association or resulted from reverse causality.
45 Moderate to severe 
asthmatic individuals are prone to exacerbations caused by respiratory tract 
infections and influenza vaccination is considered as a preventative measure; 
even though there is uncertainty to the level of protection it affords.
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There is inconclusive evidence to suggest there is an increased risk of allergy or 
asthma with early life vaccination. But from an evidenced based viewpoint there is 
also no evidence to suggest that vaccination has absolutely no effect on 
susceptibility to atopy or asthma and may even be protective against respiratory 
tract infection induced exacerbations in later life. 
1.3.1.4  Air Pollution  
Ozone and particulate matter (diesel exhaust) have been associated with 
increased asthma exacerbations with increased levels of both pollutants in Mexico 
City
47  and cities in the US.
48, 49 There is a close correlation between daily asthma 
symptom scores and exposure to ozone and particulates;
50 in addition exposure to 
diesel exhaust increases the airways response to allergens in experimental airway 
challenges.
51 In vitro studies have shown that small particulate matter ()10 #M in 
diameter; PM10) is responsible for the production and release of inflammatory 
cytokines by the respiratory tract epithelium as well as activating the NF*B 
transcription factor.
52-53 It is hypothesised that oxidative stress may be a 
component of the mechanism of this response because many of the absorbed 
materials on the particles surfaces are direct oxidants (metals & quinones) that 
indirectly produce reactive oxidant species.
52 
1.3.1.5  Environmental Tobacco Smoke 
Environmental Tobacco smoke exposure (ETS) has been found to increase both 
the prevalence and severity of asthma;
54 evidenced by the increased frequency of 
attack and resulting hospitalisations.
55,56 In utero smoke exposure (maternal 
smoking during pregnancy) is associated with wheezing and reduced lung function 
in children
57,58 and elevated levels of IgE in cord blood.
59 Passive smoking has 
been shown to induce oxidative damage in vivo
60 and markers of oxidative stress 
are elevated in children exposed to passive smoking.
61, 62 A small prospective 
asthma exacerbation study has found that levels of malondialdehyde (MDA) a 
biomarker for lipid peroxidation are elevated during asthma attacks and correlate 
with urinary cotinine levels.
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1.3.1.6  Maternal Paracetamol Intake 
Shaheen et al.
64 proposed that as paracetamol can cross the placenta and the 
foetus has the ability to metabolise paracetamol (acetaminophen), the production 
of the toxic paracetamol metabolite, N acetyl-p-benzoquinoneimine (NAPQI), could 
deplete foetal antioxidant glutathione molecules resulting in oxidative stress and 
as a consequence altered lung development and increased susceptibility to 
asthma.
64 Furthermore, NAPQI clearance by conjugation to glutathione may be 
reduced in late gestation because of a decline in expression of foetal Glutathione 
S-Transferases (GSTs) enzymes (Fryer
65 and Cossar
66 cited in Shaheen et al, 
2005
64). This could cause damage to the foetal airway epithelium and increase the 
vulnerability of the airways to more profound oxidant damage after birth.
64 High 
doses of paracetamol can deplete pulmonary glutathione and cause necrosis of 
bronchiolar epithelium in mice;
67, 68 it is not known in humans whether therapeutic 
doses have the same effect. Oxidative stress can promote TH2 responses in 
animals and these changes to immune cell differentiation could lead to increased 
production of IgE after birth.
64 Epidemiological studies have shown that 
paracetamol use in late pregnancy (20-32 weeks) is associated with an increased 
risk of early wheeze in the offspring; this exposure would account for 1% of the 
population prevalence of wheezing in early childhood.
69 At age 7, maternal intake 
of paracetamol in late pregnancy was positively associated with asthma, wheeze 
and IgE levels; the proportion of asthma attributable to paracetamol use in late 
pregnancy was 7% assuming a causal relationship.
64 Frequent use of paracetamol 
in adults may also contribute to asthma morbidity and rhinitis.
70 Subsequent 
epidemiological studies in several different countries also support an association 
with paracetamol intake by children and increased asthma risk.
71-75 
1.3.1.7  Oxidant/Antioxidant Balance 
Changes in the oxidant/antioxidant balance are evident during an asthma attack, 
as antioxidant levels (Glutathione peroxidise) measured in saliva and serum are 
lower compared to levels after recovery.
76, 77 Reactive oxygen species (superoxide 
anion generation by leukocytes, lipid peroxidation products, total nitrates and 
nitrites, total protein carbonyls, total protein sulfhydrils) levels in blood are elevated 
in asthmatics compared to non-asthmatics.
78    16  
   
Elevated exhaled NO levels and the presence of inflammatory biomarkers in 
Exhaled Breath Condensate (EBC) can be used to predict the presence, control 
and severity of asthma.
79  
Epidemiological studies of diets low in antioxidants (Selenium, Vitamin A, C & E) 
have reported an increased risk for asthma and allergy,
80, 81 asthma severity,
82 
deficits in lung function
83 and supplementation can reduce ozone mitigated lung 
function decline.
84  
A maternal diet deficient of vitamin D in combination with lack of exposure to 
sunlight has been postulated as the cause of the increase of asthma, allergies and 
other autoimmune diseases.
85 In recent years, changes in diet and lifestyle (time 
spent indoors) have ran in parallel with increased prevalence of TH2 diseases 
(asthma, allergic rhinitis, eczema and food allergy) and also TH1 type diseases in 
industrial countries at higher longitudes, that cannot be explained by the hygiene 
hypothesis alone.  Vitamin D is a micro-nutrient that is not normally sourced from 
the diet, but is synthesised via exposure to sunlight. Vitamin D insufficiency leads 
to dysfunctional T cell regulation by a lack of down regulation of TH1 and TH2 
inflammation;
85 and can potentially explain all of the epidemiological aspects of 
recent increase in allergic and autoimmune disease. 
Selenium supplementation of a small group of tourism workers exposed to ETS 
showed a reduction in lipid peroxidation and levels of antioxidant enzyme levels 
(GSH peroxidise) after 60 days of supplementation.
86 Subsequent randomised 
placebo-controlled trials of selenium and vitamin E have shown no benefit to 
supplementation in adult asthma.
87, 88 Most intervention studies have been 
performed on a small sample size and the benefit of supplementation is neither 
conclusive nor corroborated by placebo control trials performed to date. In 
consideration of the supporting evidence for oxidative stress in asthma, 
therapeutic intervention (dietary or pharmacological) with antioxidants is a rational 
cost effective approach to combat the deleterious effects of excessive reactive 
oxygen species in lung tissue but nevertheless it remains controversial.   17  
   
1.3.2  Genetics of Asthma 
1.3.2.1  Heritability 
It has been recognised that asthma results from both inherited (familial factors) 
and environmental exposures for over three hundred and fifty years (by Sennartus 
in 1650, cited in Wiener, 1936.
89 and Salter, 1868.
90, 91). The existence of a genetic 
component to asthma and BHR has been confirmed in a plethora of more recent 
twin and family studies with current estimates of asthma heritability ranging from 
50-90%.
92-95 The large range in asthma heritability estimates between studies are 
due to factors such as differences between the populations studies, age of onset 
of disease, the type of environment exposure and study design. In several twin 
studies, the consistent finding is that the non-shared environment between twin 
pairs is a more important risk factor than the shared environment and that the 
heritable asthma component may be higher in males (74%) than females (58%).
96, 
97 
1.3.2.2  Candidate Asthma Genes 
Candidate gene analysis has been extensively used in identifying the genetic 
contribution to asthma or atopy phenotypes. Association tests are used to 
determine the presence of a relationship between genetic variation in genes 
thought to be involved in disease pathogenesis and asthma phenotypes.  
It is possible to use categorical phenotypes in the study of asthma genetics, but 
because of the heterogeneity of the disease, interpretation of an association can 
be problematic. Therefore, quantitative intermediate phenotypes such as BHR and 
FEV1 are an attractive alternative as ‘affected’ individuals can be defined as those 
exceeding a certain threshold. The design of candidate gene studies will not be 
mentioned here as the concepts are discussed at length in section 1.6.2.2. 
An extensive review by Ober & Hoffjan in 2006 found over 500 papers on asthma 
or atopy that had identified over 100 genes with an association to one or more 
phenotypes.
98  In total, 54 genes were associated in two to five independent 
studies and a further 25 genes were replicated in six or more populations. The 
remaining studies have failed or are as yet to be replicated.    18  
   
Reassuringly, a number of positionally cloned asthma genes such as GPRA, 
PHF11, HLA-G, DPP10 and ADAM33 (see section 1.3.2.4) have shown 
subsequent association in candidate gene studies performed in different 
populations.
98  
It has been reported that in 2006-2007 alone an extra 53 candidate asthma genes 
have been discovered.
99 The acceleration in discovery of new asthma genes in 
recent years can be accredited to the development of high throughput genotyping 
and advances in technology have facilitated the first genome-wide association 
studies of asthma.
100 A review of the literature identifies a selection of elite 
candidate asthma genes that have consistently shown association with asthma 
phenotypes in numerous populations. Although, the exact type of association may 
not be replicated in every study because of differences in phenotype definitions, 
environmental exposures or ethnicity. Even so, it is clear that these genes play a 
major role in the genetic contribution to asthma pathogenesis. This elite group 
contains the genes for IL-4, IL-4RA, IL-13, ADRB2, TNF!, HLA-DRB1 & DQB1, 
FCER1B, CD14 and ADAM33.
98 Some of the elite genes will be examined in more 
detail in the next part of this section, along with a couple of more recently 
discovered candidate asthma genes. 
IL-4 and IL-13 were chosen as candidate genes because they are key effector TH2 
cytokine molecules (see table 1.4) expressed by T-cells and their genetic location 
on 5q31-33 (see section 1.3.2.4). Several polymorphisms in the promoter (-
1111C/T) and coding region (R130Q) of IL-13 are associated with asthma and/or 
atopy and related phenotypes.
101, 102 Resequencing of  the gene in different ethnic 
groups revealed that R130Q is the only non-synonymous substitution present in all 
populations
103 and that this variant may act synergistically with other functional 
variants in the IL-4 receptor gene (IL-4RA).
104-106 In functional assays, IL-13 130Q 
showed more activity than the wild type, therefore it has been concluded that this 
polymorphism can enhance the pathways of allergic inflammation.
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Polymorphism in CD14 has shown strong interactions and risk of atopy and 
asthma, with environmental exposures (House dust mite, farms, animals, ETS and 
LPS).
108-111 CD14 is part of a membrane bound pattern recognition receptor on 
macrophage cells that binds bacterial ligands and activates innate antimicrobial 
defences; early life infection is thought to be protective against the development of 
atopy and asthma (section 1.3.1.1). Polymorphism in this gene that alters 
expression or function of the protein could be expected to module responses to 
microbial exposure. Initial reports of association in asthma atopy were 
inconsistent,
112 indicating that the level of environmental exposure may alter the 
effect of CD14 polymorphism.
113 Further studies of the CD14 -159 C/T 
polymorphism provide evidence for an ‘endotoxin switch’ where there is a dose-
dependant response to endotoxin for each genotype.
114-116 
The recent groundbreaking discovery of the role of the Filaggrin gene in 
maintaining epithelial barrier function in atopic dermatitis
117 has highlighted that 
skin defence systems are important in allergic pathways. Two stop mutations 
(R501X & 2282 del4) that result in complete loss of peptide production were 
consistently associated with atopic dermatitis,
117 and with asthma and asthma 
severity, but only in the presence of atopic dermatitis.
118, 119 A defective epidermal 
barrier allows allergens easier entry through the skin to initiate local and systemic 
allergy and predisposes the individual to allergic disease.  
Findings to date confirm the efficacy of candidate gene association strategies for 
identifying common gene variation that can modulate either the risk of developing 
asthma and subsequent severity of disease; or identify gene-environmental 
interactions that alter with type, time, length and strength of exposure. Functional 
studies of the mechanism of genetic variation are essential to fully understand 
interactions in this disease. 
1.3.2.3  Problem of Non-replication of Candidate Gene Associations in Asthma 
As described earlier (section 1.3.2.2), hundreds of candidate gene association 
studies have been performed in asthma alone; with tens of thousands of studies 
performed in other diseases. A common problem in all genetic association studies 
and especially those in asthma is that of replicating an association. In the early 
years of genetic association studies many findings were hard to replicate because 
of poor study design (see section 1.4.2.2).    20  
   
It has become apparent with improvements in study design that the genetic nature 
of asthma is difficult to study as many components of the disease have shared 
genetic loci with atopy and other allergic diseases. Asthmatic individuals from 
different populations could have a shared genetic component but with different 
associations of the same genetic marker because this is dependant on differences 
in the type, time and level of environmental exposures that interact with asthma. 
Therefore, it is prudent for asthma researchers to qualify replication primarily as 
the repeated association of the same gene region with an asthma phenotype in 
different populations. Rather than discounting a new association that could 
potentially replicate a previous association just because the opposite allele is 
associated when compared to the first study. 
1.3.2.4  Positionally Cloned Asthma Genes 
Positional cloning uses genetic linkage in affected families to search for 
susceptibility loci in an hypothesis independent manner; through this technique 
regions of the genome can be identified which contain genes with previously 
unknown function in the pathogenesis of disease. The principles of positional 
cloning are described in detail in section 1.4.2.1.  
This technique has been highly successful in indentifying loci involved in single 
gene diseases (such as Huntingdon’s and Cystic Fibrosis) because of the strong 
genetic signal transmitted to the next generation of affected individuals. However, 
positional cloning does not have the same sensitivity in complex diseases as many 
genes of moderate effect are likely to be involved and their role can be modified by 
environmental exposures, as in the case of asthma. Nevertheless, several regions 
of the genome are repeatedly identified in different populations as having an 
important contribution to the development of asthma. For example, atopy, and by 
extension asthma, have been consistently showing linkage to Chromosome 5q33, 
this locus contains the inflammatory interleukin gene cluster (IL-4, IL-5, IL9, IL-13) 
and to Chromosome 6p21 which contains HLA, TNF" and LT" genes.  
Conversely, regions have been linked to atopy only, such as the STAT6 
transcription factor on Chromosome 12q13 with gene polymorphisms associated 
with increased IgE levels and eosinophil cell count. Therefore, this locus is likely to 
contribute to eosinophilia and changes in IgE levels seen in asthmatics rather than 
susceptibility.
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As atopy is a component of a majority of asthma it can be difficult to separate out 
the contribution to the linkage signal for the different phenotypes at shared genetic 
regions. There has been some success in identifying novel regions using 
intermediate asthma phenotypes such as bronchial hyperresponsiveness; where 
addition of BHR produces a stronger linkage signal than an asthma/atopy 
phenotype (i.e. asthma + IgE levels), as in the discovery of the ADAM33 BHR 
susceptibility gene.
121 In theory, positional cloning is less sensitive for complex 
diseases, but in practice several important discoveries have still been made that 
further the understanding of asthma and highlight novel biological mechanisms. 
Several novel asthma and BHR susceptibility genes such as ADAM33, DPP10, 
PHF11, HLA-G and IRAK-M
121-124 have been discovered to date and their 
probable functional roles are shown in table 1.5. It now remains for further 
candidate polymorphism, immunohistochemical and gene function analyses of 
these positional cloned asthma genes to elucidate the actual role they play in the 
susceptibility and subsequent progression of asthma    22      
Table 1-5: Table of Positionally Cloned Asthma Genes 
Gene 
Name 
(GeneID) 
Chr  Associated Phenotypes  Gene Product: possible functional role in asthma  Associated 
Variation 
Size of study  Population  Reference of Initial Study  Replication 
of association 
DPP10 
(57628)  2q14.1 
Asthma 
Atopy (SPT) 
Asthma severity 
 
Dipeptidyl peptidase:  
Potassium channel regulator with no detectable protease 
activity.Involved in Cytokine processing (especially in T-
cells) 
 
D2S308*3/*5 
Multiple SNPs 
Haplotypes 
244 families 
 
 
Australian 
UK 
German 
 
Allen et al
122  YES
122 
CYFIP2 
(26999)  5q33.3  Atopic Asthma 
Childhood Asthma 
 
Cytoplasmic fragile X mental retardation (FMRP) interaction 
protein 2: 
May be involved in differentiation of T-cells 
 
Multiple SNPs 
Haplotypes 
 
155 families 
 
Korean  Noguchi et al
125  NO 
HLA-G 
(3135)  6p21.3 
Asthma 
BHR 
Atopy 
Class I, Histo-compatibility antigen-G: 
Inhibits Th1-mediated inflammation and only the soluble 
form (HLA-G5) is expressed in asthmatic bronchial 
epithelial cells. 
D6S1281 
MOGc 
Multiple SNPs 
129 families 
 
Caucasian 
Hutterite 
Dutch 
 
Nicolae et al
124  YES
124 
GPRA 
(387129) 
7q14.3 
 
Asthma 
Total IgE 
BHR 
Specific IgE 
Childhood asthma 
 
G-Protein coupled receptor: 
Bronchial epithelial and smooth muscle surface receptor. 
May modulate asthma by increasing expression levels in 
tissues and potential inhibitory effect of GPRA-A on cell 
growth
126 
Haplotypes  86 families & 103 trios 
Finnish 
Canadian 
German 
Italian 
Chinese 
Laitinen et al
127  YES
127-131 
IRAK-M 
(11213)  12q14.3  Early onset persistent 
asthma 
 
Interleukin-1 receptor associated kinase 3: 
Negative regulator of TOLL-like receptor/IL-1R pathways. 
Master regulator of NF-Kappa! and inflammation. 
 
Haplotypes 
 
100 families 
 
Sardinian 
Italian  Balaci et al
123  YES
123 
PHF11 
(51131) 
13q14.3 
 
Total IgE 
Asthma 
Asthma severity 
 
 
Zinc Finger transcription factor: 
Possibly involved in Chromatin mediated transcription 
regulation. B-cell clonal expansion and regulation of 
immunoglobulin expression may operate through shared 
mechanisms at this locus. 
 
 
Multiple SNPs 
Haplotypes 
 
230 families 
Australian 
UK 
European 
 
Zhang et al
132  YES
132, 133 
ORMDL3 
(94103)  17q12-21.1  Child onset asthma 
ORM1 (Saccharomyces cerevisiae)-like 3: 
Third member of a novel class of genes of unknown 
function that encode transmembrane proteins anchored in 
the endoplasmic reticulum. Involved in protein folding. 
Multiple SNPs 
 
Increased gene 
expression in 
asthmatics 
Genome wide 
Association & 
combined gene 
expression 
994 cases 
1243 controls 
British 
German  Moffat et al
100  YES
100 
ADAM33 
(80332)  20p13  Asthma+BHR 
 
Metalloproteinase: 
Involved in Airway remodelling by fibroblasts and smooth 
muscle hyperactivity 
 
D20S482 
Multiple SNPs 
Haplotypes 
460 families  Caucasian 
(UK & US)  Van Eerdewegh et al
121  YES
134-141.   23  
   
1.4  Genetic Epidemiology 
1.4.1  Population Genetics 
Population genetics is the study of the genetic structure of populations and 
changes to the genetic composition of populations because of influence from 
natural selection, genetic drift, mutation, and gene migration. Population 
geneticists study the allele frequencies in a population by using mathematical 
models that can monitor any changes in genotype frequency of a population over 
time and question why this is occurring. This discipline linked the most important 
theories of evolution and genetics, Darwin’s theory of natural selection and 
Mendelian inheritance together. Natural selection provides a mechanism for 
evolution to occur, but did not explain how ‘fitness’ was inherited. Mendel’s theory 
of genetic inheritance provided the mechanism and the independent work of G.H. 
Hardy and W. Weinberg worked out the mathematical basis of population genetics 
in 1908.
142 Their formula predicts the expected genotype frequencies using allele 
frequencies in a diploid Mendelian population; this formula is known as Hardy-
Weinberg Equilibrium (HWE). 
1.4.1.1  Hardy-Weinberg Equilibrium  
Hardy and Weinberg showed that if the population size is very large and random 
mating takes place, allele frequencies (of a biallelic locus) will remain the same 
and the genotype frequencies will follow equation 2: 
Equation 2: Hardy-Weinberg Equilibrium Calculation 
HWE:      
Genotypes:    AA    Aa   aa   24  
   
If the expected genotype frequencies match the observed frequencies then that 
population is said to be in Hardy-Weinberg Equilibrium. Should the population 
genotypes deviate from HWE then some selective pressure has been applied to 
that population and the following assumptions do not hold: 
1.  Genotypes have equal fitness (no selection for a particular genotype) 
2.  No mutation (germline) and migration (loss of one allele from population) 
affecting allele frequencies in population 
3.  Males and Females have similar genotype frequencies  
4.  Random mating 
5.  Infinite population size 
In the laboratory, HWE calculations are routinely used to validate that genotyping 
techniques are not biasing genotype calls. A genotyping methodology that is 
inaccurate in assigning genotypes will increase or decrease the observed 
frequency of a particular genotype and the genotype frequencies will rapidly 
deviate from HWE. This basic quality control procedure is applied to each data set 
to ensure that a genetic association is not due to experimental error. 
1.4.1.2  Genetic Association 
Genetic association is the association of a particular genotype with a non-genetic 
trait (phenotype). A phenotype is an observable trait in an organism. Some 
phenotypes are purely genetic, while the majority are formed from interactions of 
the genotype with the environment. Phenotypic plasticity is the ability of an 
organism with a particular genotype to change its phenotype to adapt to an 
environmental change. This concept of genetic association and phenotypic 
plasticity is the fundamental principle for genetic studies into disease 
pathogenesis. Genetic polymorphisms are screened against disease phenotypes 
in an affected population. The association of certain genotypes with altered 
disease susceptibility, severity or the presence of disease modifying gene-
environment interactions, indentifies at risk individuals and can further 
understanding into the pathogenesis of that disease.   25  
   
1.4.1.3  Genetic Linkage 
Genetic Linkage occurs when genetic markers are inherited together on a region 
of a chromosome, linkage between markers can be severed by recombination at 
meiosis.  This term is also used to describe the linkage of a marker to an unknown 
disease contributing gene. Randomly spaced genetic markers are used to search 
for regions within or near to disease contributing genes in an affected family or 
population.  
1.4.1.4  Linkage Disequilibrium 
Linkage disequilibrium is the non-random association of adjacent polymorphisms 
on a single strand of DNA in a population; the allele of one polymorphism in an LD 
block can predict the allele of adjacent polymorphisms.
143 The size of the LD 
blocks depends on the recombination rate in that region and the number of 
generations since the first variant arose in an ancestral individual in that 
population. LD can be measured in a number of ways and common measures of 
LD used are D’ and r
2.
144 D’ is the deviation of observed haplotypes from the 
expected haplptypes, that has been normalised, by dividing it with the theoretical 
maximum for the observed allele frequencies.
143 r
2 is the squared correlation 
coefficient of linkage disquilibrium between pairs of loci.
145 
1.4.1.5  Haplotypes 
A haplotype is a set of closely linked genetic markers present on one chromosome 
which tend to be inherited together in a population. Haplotypes can be as few as 
two genetic markers in length and can extend for thousands of basepairs until a 
recombination event occurs between two loci and breaks the link; thereby forming 
a new haplotype block. Table 1.6 displays all possible haplotype combinations that 
could occur in a two marker haplotype. When an individual is heterozygous at two 
or more loci it is impossible to ‘phase’ the haplotype on each chromatid.   26  
   
Table 1-6: Two-SNP Haplotype Combinations
a.  
  AA  AT  TT 
GG  AG/AG  AG/TG  TG/TG 
GC  AG/AC  AG/TC or AC/TG  TG/TC 
CC  AC/AC  AC/TC  TC/TC 
aThere are nine possible haplotype combinations from two biallelic markers. When an individual is 
heterozygous for both markers it is impossible to phase the haplotypes (i.e. allele 1 could be AG or 
AC) with out sequencing the region on one chromatid 
 
There are several mathematical techniques that can predict haplotypes by using 
the frequencies of genotypes in the studied population. A widely used technique is 
the Expectation-Maximisation (EM) algorithm that predicts the most probable 
haplotypes for an individual based on the likelihood of that haplotype occurring in 
the population.
146 
The International HapMap project’s goal was to determine the common pattern of 
DNA sequence variation in the human genome in four different populations 
(Yoruba in Ibadan, Nigeria; Japanese in Tokyo, Japan; Han Chinese in Beijing, 
China and CEPH which  are Utah residents with ancestry from northern and 
western Europe).
147 Researchers can freely access this information and select a 
panel of SNPs that act as markers (Haplotype tagging or htSNPs) for all known 
genetic variation in a region of linkage disequilibrium and test for association with 
disease, as an allele in a haplotype can mark for the unknown disease-causing 
functional variant.
147 Selecting htSNPs for genetic association studies is a 
statistically more powerful technique than using single SNPs, as htSNPs provide 
information on the entire genetic region in that particular linkage disequilibrium 
block; thereby reducing the number of statistical comparisons required to test for 
association.
148   27  
   
1.4.2  Genetic Association Techniques 
1.4.2.1  Positional Cloning  
Positional cloning involves family based co-inheritance analysis of genetic markers 
spread evenly throughout a genetic region of interest. The region of interest can 
be genome–wide or a region of a single chromosome. At the whole genome-level, 
positional cloning is a hypothesis-independent approach; it has the potential to 
identify genes and biological pathways that were not previously implicated in the 
pathogenesis of the disease. Micro-satellite polymorphisms are the marker of 
choice for positional cloning because they are highly polymorphic in the general 
population. All members of the family group are genotyped and the increased 
transmission of a particular allele to disease affected individuals indicates genetic 
linkage with the unknown disease gene. Linkage is broken down by 
recombination, therefore in a family group the resulting linkage region can be 
relatively large (approximately 1Mb in length) as only one recombination event is 
likely to occur between generations over this distance.
149 
A region of the genome identified as being linked to a disease phenotype will 
contain several to hundreds of potential disease contributing genes. Traditionally, 
DNA sequencing of the linkage region in individuals will identify new 
polymorphisms or mutations that may be closer to the gene of interest. These can 
be used as further markers to narrow the linkage region in subsequent analyses.  
In the era of the Human Genome Project researchers do not have to sequence 
large regions of a chromosome to find extra markers as a simple database search 
will provide a summary of all known polymorphism previously identified in that 
region. The positional cloning technique as been successful in identifying high 
penetrance, high risk genes responsible for Mendelian inherited disorders, such as 
Huntingtons,
150 and cystic fibrosis.
151 This technique does not have the same 
statistical power to identify low penetrance, low-medium risk genes involved in 
complex diseases.
152, 153 Linkage analysis has less power than an equivalently 
sized case-control study as association is only tested in the probands. In complex 
diseases it is often difficult to define an appropriate disease phenotype.
154 There is 
variability in the severity of the disease in individuals and the age of disease onset 
may vary leading to individuals being inaccurately identified as unaffected at 
recruitment.    28  
   
Also, diagnosed individuals may have apparently identical symptoms but they 
result from different aetiologies involving various biological pathways. Researchers 
may also have difficulty in choosing the best population to study and studies may 
be confounded by population stratification.  
1.4.2.2  Candidate Gene Analysis 
This technique is a hypothesis dependant approach because rather than utilising a 
random selection of evenly spaced genetic markers, genes are chosen on the 
basis of a priori hypothesis about their role in a disease. The selection of a 
candidate gene is based on the involvement of the gene product in biological 
processes relevant to the disease in question. Evidence for candidate gene 
selection can be drawn from a broad range of areas, for example: involvement in 
other diseases with phenotypic overlap, biological function, differential expression, 
affected tissues, cell type(s) involved and findings from animal models. Candidate 
gene analysis has been extensively utilised in the study of complex diseases 
states. For example, more than 500 studies have now examined the association of 
genetic variants in over 200 genes with atopic and allergic diseases alone.
98, 155, 156 
Case-Control studies are commonly used in the candidate approach. They are 
essentially a population based sample of affected and unaffected individuals. Any 
significant differences in genotype frequency found between the two groups are 
potentially associated with the disease or susceptibility phenotype. Findings 
should be interpreted with caution as genetic variants showing association with a 
disease are not necessary causal because of the phenomenon of linkage 
disequilibrium (LD). Case-control association studies have greater statistical power 
to detect genes of small effect than linkage based approaches.
154 This is highly 
relevant as it is assumed that polymorphisms of milder functional effect in multiple 
genes in the general population play a role in susceptibility to complex genetic 
disorders. The candidate gene approach has been criticised for non-replication of 
findings which may be due to a number of factors including poor study design, 
population stratification and different LD patterns between individuals of different 
ethnicities. Unfortunately, the genetic association approach can also be limited by 
under-powered studies and loose phenotype definitions.
157 Therefore it is 
important that due consideration is given to all aspects of genetic epidemiological 
study design to ensure that relevant conclusions can be drawn.   29  
   
1.4.2.3  Combination Techniques 
A hybrid of the two approaches described above is the selection of candidate 
genes based on their function and on their position within a genetic region 
previously linked to the disease. A good example of the ‘positional candidate’ 
approach is the identification of the SOCS5 gene as a potential candidate gene 
responsible for linkage to BHR susceptibility on Chromosome 2p in 364 asthmatic 
families.
158 The region of linkage was 12.2Mb in size and contained approximately 
75 genes; rather than continue with comprehensive analysis of the region, SOCS5 
(suppressor of cytokine signalling 5; GeneID: 9655, MIM: 607094) was selected as 
an interesting candidate because SOCS proteins are implicated in the control of 
the balance of Th1 and Th2 cells
159 and SOCS5 is a specific inhibitor of IL-4 
signalling.
160 The confirmation of SOCS5 as an asthma susceptibility gene awaits 
further studies. 
While this linkage study design is sound and a reasonable candidate gene choice 
has been made to reduce the considerable workload required to narrow a large 
linkage region of DNA to a single gene to test for association with the disease. It 
clearly identifies the difficulties facing researchers in identifying the causal gene(s) 
under a peak of linkage. A disadvantage of this technique is that without further 
high-resolution association analysis to narrow the genetic region carrying the risk 
allele, researchers can only pursue potential candidate genes based on limited 
current knowledge rather than directly identifying the causal gene by hypothesis 
independent approaches. With the advent of the first whole genome association 
studies in asthma this combined approach may become less prevalent.
100  
Another combination approach is to select potential candidate genes on the basis 
of their differential expression in diseased tissue.
161-163 An example of this is the 
gene encoding tenascin-C (TNC), located in a region of the genome previously 
linked with asthma
164 and whose mRNA expression was found to be up-regulated 
in bronchial epithelial cells exposed to a TH2 cytokine environment.
165 A 
subsequent case-control study by Matsuda et al.
166 has shown association of TNC 
polymorphisms with asthma susceptibility. It will not be uncommon in the near 
future to combine whole genome expression micro-array and whole genome 
association data sets in order to elucidate the roles of specific polymorphisms on 
gene expression in complex disease states.
100, 167   30  
   
1.4.2.4  Whole Genome Association Studies 
The advances brought about by the Human Genome Project and the International 
HapMap Project
168 in cataloguing and mapping the extent of human genetic 
variation and the availability of new genotyping methodologies providing high 
throughput with low cost per genotype call, has given rise to the possibility of 
genome-wide association studies in complex genetic diseases. In these studies of 
cases and controls, array-based technology (over 1 million genetic markers in the 
latest chips) is used to genotype single nucleotide polymorphisms (SNPs) or copy 
number variations (CNV) across the genome. Recent results from large disease 
genetics consortia have provided exciting gene discovery results for genetic 
susceptibility to chronic diseases.  
For example, the Wellcome Trust Case Control Consortium (WTCC) studied 
~2,000 cases with 7 chronic diseases and a shared set of ~3,000 controls, and 
discovered genes associated with bipolar disorder, coronary artery disease, 
Crohn’s disease, rheumatoid arthritis, and type I and type II diabetes mellitus, with 
p values < 5 x 10
-7.
169  High density SNP arrays scale up genetic association 
studies to the whole genome level and combine the advantages of association 
studies (greater statistical power for a given number of subjects and easier cohort 
recruitment) with the hypothesis independent whole genome approach. The 
examples provided by the WTCC study together with recent publications for 
obesity,
170 diabetes,
171, 172 and breast cancer
173, 174 demonstrate that this approach 
can be applied successfully to the identification of complex disease genes. The 
first whole genome association study of asthma has already identified a novel 
gene of unknown function; several SNPs were found to regulate ORMDL3 
expression and contribute to the risk of childhood asthma.
100 
With the advent of genome on a chip technology, researchers can rapidly 
investigate family or case-control studies for up to millions of SNPs spread over 
the genome for any association. The high density arrays provide greater genome 
coverage ensuring that the maximum amount of linkage information can be 
retrieved and reduce the size of the critical linkage region for further analysis. By 
using cohorts with environmental exposure variables it may possible to define how 
genes interact with the environment to cause disease.   31  
   
1.5  Role of Glutathione S-Transferases in Protection Against 
Oxidative Stress 
Free radicals, reactive oxygen species (ROS) and reactive nitrogen species (NOS) 
are a by-product of normal metabolic pathways and are present in such 
abundance in the environment that they can cause damage to cellular molecules 
such as, lipid membranes, protein, amino acids and DNA.  Therefore, cells have 
evolved mechanisms to limit and repair damage caused to molecules. Glutathione 
molecules and the action of Glutathione S-Transferase enzymes are one 
mechanism that provides protection from oxidative stress. 
1.5.1  Role of Glutathione 
Glutathione (GSH) is an abundant low molecular weight thiol synthesised from the 
three amino acids: glutamate, cysteine and glycine in a two step process by !-
glutamylcysteine (GCS) and GSH synthetase. 85-90% of all GSH molcules are 
found in the cytosol with the remaining in organelles. GSH is a potent scavenger of 
free radicals (such as Superoxide anion O2
•), ROS and NOS. Scavenging of 
electrophilic compounds by GSH can occur directly or via an enzymatic reaction 
such as the reduction of H2O2 by glutathione peroxidase by oxidising GSH as seen 
in equation 3.   
Equation 3: Glutathione Redox Reactions.  
Reduction of hydrogen peroxide by glutathione peroxidase 
    H2O2 + 2GSH   ---> GSSG + 2H2O    (1) 
GSSH + NADPH + H
+  ---> 2GSH + NADP
+    (2) 
 
Presence of a cysteine amino acid allows for the GSH molecule to be readily 
oxidised by many electrophilic compounds into the pro-radical, GS
• which in turn 
binds to another GS
• forming Glutathione disulphide (GSSG). As cysteine is only 
found at low concentrations in intracellular pools it is considered to be the rate 
limiting amino acid for the synthesis of more GSH molecules a cell or tissue may 
require. It is known that increasing cysteine uptake or providing methionine 
supplementation (a precursor of cysteine) will increase GSH synthesis and reduce 
oxidative stress.    32  
   
GSH and GSSG molecules form a redox couple which allows for the homeostasis 
of GSH levels in cells. Normal (0.5-10 mmol/L) cellular levels of GSH can be 
maintained by reduction of the oxidised glutathione back to GSH by the NAPDH 
dependant glutathione reductase. 
If the normal ratio of [GSH]:[GSSH] (>10 under normal physiological conditions) 
cannot be maintained the demand for NADPH will increase and this will 
necessitate an increase in glucose metabolism via the pentose cycle. If NADPH 
cannot be replenished the scavenging rate of GSH will be less than the production 
of free radicals and oxidative damage will occur in those cells or tissues. The 
presence of GSH molecules at sufficient concentrations in the cytosol negatively 
regulates the production of more GSH by GCS. Shifting the GSH:GSSG redox 
couple to the oxidising state activates key signalling pathways (PK-B, NF-"B and 
MAPK) that reduces cell proliferation and increases cell apoptosis. Therefore 
oxidative stress plays a key role in the pathogenesis of many diseases such as 
cancer, inflammation, myocardial infarction and diabetes.    
1.5.2  Role of Glutathione S-Transferases 
Glutathione-S-transferases (GSTs) (EC 2.5.1.18) are phase II detoxification 
enzymes that are freely found in the cytosol and catalyse the conjugation of 
electrophilic compounds such as xenobiotics (activated by Phase I detoxification 
enzymes, such as Cytochrome P450) to Glutathione (GSH), UDP-glucuronic acid 
or glycine; producing stable more soluble compounds that can be excreted or 
compartmentalised by phase III enzymes.
175 The hydrophilic GSH molecule stops 
the conjugated hydrophobic compound from freely diffusing across plasma 
membranes and causing cell damage via lipid peroxidation; the GSH-conjugate 
has to be actively pumped out of the cell by a transmembrane ATPase such as the 
GS-X pump.
176  
GSTs catalyse the conjugation of glutathione to many substrates including free 
radicals, xenobiotics and physiological metabolites producing mercapturates 
(ultimately Mercapturic acid) that can be excreted from the cell and tissues (see 
equation 4 and figure 1.3). This mechanism produces a net loss of GSH as it is not 
recycled as in the NAPDH-dependent redox couple catalysed by GSH reductase.    33  
   
Equation 4:  Glutathione S-Transferases  
GSTs catalyse the conjugation of reduced glutathione to free radicals, xenobiotic and physiological 
metabolites. Utilising the thiol group from the GSH molecule GSTs produce a variety of thiolesters. 
GSTs perform the initial step in the synthesis mercapturic acid. Key: R = aliphatic, aromatic or 
heterocyclic group; X = sulphate, nitrile or halide group and HX = Halo acid. 
 
If a tissue is exposed to a high concentration or mixtures of xenobiotics or 
eletrophillic compounds, such as cigarette smoke, this can result in an imbalance 
in the [GSH]:[GSSG] ratio. The action of GST enzymes could place the cell in 
greater risk from oxidative stress by free radicals and other eletrophilic compounds 
if the GSH sink becomes depleted. GSH homeostasis plays an important role in 
the maintenance of the epithelial barrier forming the lung airspace (cited in 
Rahman & MacNee
177). Decreased levels of GSH in lung tissue have been shown 
to lead to the loss of this barrier and increased permeability into the surrounding 
tissue.
178  
GSTs have other functions besides GSH conjugation. The Alpha class GST 
molecules can isomerise steroids and provide direct protection against oxidative 
stress by its selenium-independent GSH peroxidase activity.
179 The Pi class 
molecules provide further defence by inhibiting Jun N-terminal Kinase, via its 
ligandin function and therefore prevent hydrogen peroxide induced cell death.
180  
GSTs 
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+ 
 
HX 
 
+ 
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All GSTs are able to non-catalytically bind a wide range of endogenous and 
exogenous ligands. The theta class GST have been shown to be distinct from the 
Alpha/Mu and Pi classes; they only have an overall 7% sequence identity and 
have a catalytically essential serine rather than a tyrosine in the N-terminus.
181 
The theta GST enzymes are catalytically more efficient than the other classes who 
appear to have evolved to remove electrophilic compounds by product retention 
over catalytic action.
182 
 
 
Figure 1-3: Glutathione Metabolism Downstream of Glutathione S-Transferases.  
The actions of GSTs can produce a net loss of glutathione as it is excreted from the cell as 
mercapturic acid 
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1.5.3  Genetics of GSTs 
1.5.3.1  Human GST Superfamily 
The Glutathione-S-Transferase (GST) gene family in humans is grouped into the 
‘canonical’ classes: Alpha, Mu, Pi, Sigma, Theta, Zeta and Omega based on the 
similarity of primary and tertiary protein structures, substrate/inhibitor specificity 
and immunological identity. The four most prevalent soluble dimeric cytosolic 
protein classes Alpha (GSA), Mu (GSTM) Pi (GSTP) and Theta (GSTT) have been 
widely studied. Kappa class GSTs are also found in humans and localised to 
mitochondria and peroxisomes;
183 but their physiological substrates are not 
known.  Forty percent amino-acid sequence similarity is required to become a 
member of a class of GST enzyme
184 and the Alpha, Mu and Pi protein structure 
alters at two sites. The sub unit interface is conserved within each class, this 
allows for the formation of heterodimers only within classes. The second difference 
is at the active site, Alpha and Mu enzymes have partially occluded sites 
compared to Pi
185 and the electrophile binding is always hydrophobic. These 
structural differences determine substrate specificity between the classes of GSTs. 
Theta GSTs on the other hand have the active site tyrosine replaced with a serine 
residue that can still activate the glutathione molecule. Theta GST enzymes have 
a higher Km value for glutathione than the other classes and act more like a 
catalyst than the other classes (Alpha, Mu, Pi) which lose catalytic efficiency but 
act as a sink for their own products.
186 
1.5.3.2  Expression of GST Enzymes 
GST enzymes are widely expressed in most human tissues. GSTP1 is highly 
expressed in the lung, placenta, brain and oesophagus.
187-189 In embryonic and 
early fetal tissues glutathione and GSTs are present in high amounts with the 
GSTP1 isoform the most predominantly expressed in all organs, with highest 
concentrations in the small intestine, kidney and lung.
188 GSTA is the predominant 
isoform of GST in liver and GSTM and GSTT are present in relatively low 
concentrations in numerous organs including the lung.
188, 190 
1.5.3.3  Polymorphism of GST Genes 
The human GST gene superfamily consists of 21 genes that are highly 
polymorphic; hundreds of polymorphic sites have been indentified in the genome,   36  
   
the majority of which are of unknown function.
191 The table below details common 
functional polymorphisms that alter enzyme activity for GSTM1, GSTO2, GSTP1 
and GSTT1 (see table 1.7). Also, there are numerous promoter polymorphisms 
that could affect the regulation of gene expression though altering transcription 
factor binding sites, enhancer and repressor sequence motifs. However, these 
polymorphisms have not been well characterised and the effect of each of these 
polymorphisms on gene function is not fully understood.
192, 193 
Common copy number variation (full gene deletions are present at ~50% for 
GSTM1 and ~20% for GSTT1 in Caucasian populations) have a dose effect on 
GSTM1 and GSTT1 protein levels, affecting that individual’s ability to efficiently 
detoxify compounds and provide protection from oxidative stress.
194, 195 
Table 1-7: Glutathione S-Transferase Gene Polymorphisms 
Gene (Gene ID)  Chromosome  Alleles 
Nucleotide  
Change 
Amino Acid  
Change 
Functional Consequence 
GSTM1 (2944)  1p13.3  M1*A 
M1*B 
M1*0 
M1*Ax2 
519G 
519C 
Gene Deletion 
Gene Duplication 
Lys173 
Asn173 
No protein 
Overexpression 
Reference
196 
No change
197 
No Activity
198 
Increased Activity
199 
GSTO2 
(119391)
  
10q25.1  O2*A
† 
O2*B
† 
O2*C
† 
1052A
 
1052G 
del at residue 155 
Asn142
 
Asp142 
loss of residue 155 
Reference
200 
No change
200 
loss of heat stability & 
increased activity.
200 
GSTP1 (2950)  11q13  P1*A 
P1*B 
P1*C 
P1*D 
313A,341C, 555C 
313G,341C, 555T 
313G,341T, 555T 
313A, 341T 
Ile105,Ala114,Ser185 
Val105,Ala114,Ser185 
Val105,Val114,Ser185 
Ile105,Val114 
 
Reference
201, 202 
Substrate dependant
201, 202 
Substrate dependant
201, 202 
No change
201, 202 
 
GSTT1 (2952)  22q11.23  T1*A 
T1*B 
T1*0 
310A 
310C 
Gene Deletion 
Thr104 
Pro104 
No Protein 
Reference
203 
Decreased Activity
203 
No Activity
203 
† These are provisional allele designations as GSTO2 has not been fully characterised.   37  
   
1.5.3.4  Glutathione S-Transferases and Disease 
Due to the pleiotropic nature of the GST gene family there have been many 
diseases with varying aetiologies associated with polymorphic variants in the 
canonical GST genes. Cancers of the head, neck, lung and bowel have been 
associated with GSTM1, GSTP1, and GSTT1 polymorphism.
191 GSTM1 deficiency 
may be a risk factor for cancer by providing increased sensitivity to particular 
chemical carcinogens.
204 Single or combined GST gene deletions increase 
susceptibility to lung cancer in smokers,
205 and in non-smokers exposed to 
household environmental tobacco smoke (ETS).
206  A recent meta-analysis of lung 
cancer  using data from 130 studies, involving a total of 23,452 lung cancer cases 
and 30,397 controls has shown a weak positive association (Relative Risk (RR) = 
1.18; 95% CI = 1.14-1.23) and (RR = 1.09; 95% CI = 1.02-1.16) with GSTT1 and 
GSTM1 null alleles.
207 
There is also an increased cardiovascular disease risk in smokers who a have 
GST deficiency.
208 GSTP1 polymorphism is a risk factor for increased 
susceptibility to Parkinson’s disease when exposed to pesticide or herbicides.
209 
The age of onset of type 1 diabetes is associated with the presence of a GSTM1 
gene, although the mechanism is not clear it could involve cellular GSH depletion 
or a decrease in inflammatory response.
209, 210 Polymorphism in GSTO2 have 
been associated with ovarian and gastric cancer and some studies have examined 
the age of onset of Parkinson’s disease.
211-214  
1.5.3.5  Glutathione S-Transferases and Drug Response 
GSTM1 and GSTT1 gene deletion polymorphisms have consequences for the 
detoxification of xenobiotics.
215 This impacts the efficacy of drug treatments in the 
general population and outlines the clinical relevance of a personalised medicine 
based approach in the post genome era, namely the introduction of 
phamacogenetics.
216 As an example, GST polymorphisms have been shown to be 
indicative of response to treatment and event-free survival in acute paediatric 
acute lymphoblastic leukaemia and in ovarian cancer.
217 It is thought that patients 
with GST gene deletions respond better because of their inability to metabolise 
and inactivate anti-cancer treatment.
218   38  
   
1.6  Developmental Origins of Health and Disease 
Epidemiological studies worldwide have established a link between low birth 
weight and increased risk from chronic diseases in adulthood.
219, 220 Low birth 
weight is not the cause, but rather it is a surrogate indicator for impaired growth 
during pregnancy.
221 The associations are not down to genetics alone, but rather 
the interaction between the early-life environment and genetic influences that 
predispose individuals to susceptibility to disease in adult life. These observations 
have lead to the proposal of several hypotheses: 
1.6.1  Thrifty Phenotype or Barker’s Fetal Origins of Disease 
Hypothesis 
This hypothesis proposes that in utero under-nourishment results in permanent 
detrimental changes in the foetus leading to the development of chronic disease in 
later life.
222 The Dutch hunger winter famine of 1944-45 provided the initial 
supporting evidence for this hypothesis in humans.
223-225 The enforced famine 
conditions in Nazi controlled Holland during World War II provided epidemiological 
evidence that under-nutrition in early pregnancy resulted in an increased incidence 
coronary heart disease, body mass index, and glucose intolerance in the offspring 
in later life. Famine exposure in early or mid-gestation was also associated with 
decreased adult lung function (FEV1, FVC, FEV1/FVC) and increased risk of 
COPD.
226 Subsequent studies have shown that peri-natal nutritional deficiencies 
predispose adult offspring to chronic diseases such as, metabolic syndrome, 
obesity, cardio-vascular disease (CVD), hypertension and type II 
diabetes.(reviewed in McMillen et al, 2005)
227  
1.6.2  Predictive Adaptive Response (PAR) Hypothesis 
This hypothesis was proposed in 2004
228 as an extension to the Thrifty phenotype, 
and theorises that the foetus makes adaptations based on the predicted postnatal 
environment. Prenatal nutrition is believed to be the primary predictor of the post-
natal environment available to the foetus.    39  
   
When the PAR is appropriate the offspring’s phenotype is normal, when there is a 
‘mis-match’ (either a high or low pre-natal nutritional environment) during critical 
developmental periods and the adult environment disease will develop in the 
offspring. The timings of these windows of developmental plasticity will vary 
between organs, so there is the potential for the plasticity phase to bridge across 
in to early post-natal development and environments. This hypothesis extends the 
Barker hypothesis
222 to include the effect of over-nutrition on subsequent 
susceptibility to adult disease.  
1.6.3  Nutritional Programming 
Nutritional programming in utero can affect the incidence and severity of disease 
in adults. The hypothesis states that:  
‘A relationship exists between the nutritional environment during critical windows 
of developmental plasticity and offspring disease in adult life’.   
This hypothesis is derived from the two prior hypotheses: 
•  Thrifty phenotype or Barker foetal origins of disease.
229 
•  Predicted Adaptive Response (PAR) hypothesis.
228  
This hypothesis seeks to establish the link between nutritional environment during 
critical windows of developmental plasticity and disease in the offspring in later life. 
Understanding nutritional programming during critical developmental periods will 
have enormous potential for improving the health of future generations. 
1.6.4  Developmental Plasticity 
The definition of developmental plasticity is the ability of a single genotype to 
produce more than one alternative form of structure, or behaviour in response to 
environmental conditions.
230 Programming mechanisms can act at several critical 
windows of developmental plasticity that occur in utero and post-natal life to adapt 
the offspring’s phenotype (see Table 1.8). The nature of the adaptation, is in part, 
dependant on the type of the environmental exposure.    40  
   
Adaptations made to the offspring’s phenotype during these windows of 
development may have a life long impact such as aiding survival to reproductive 
age at the expense of a healthy old age. The duration of the windows of 
developmental plasticity is time-limited, because when organogenesis is 
completed, plasticity is no longer possible.  
Table 1-8: Windows of Developmental Plasticity.  
Adapted from Mcmillen et al, 2005.
227 
Critical windows of developmental plasticity  Programming mechanisms 
Primordial germ cell 
 
Mature germ cell 
 
Ovulation 
 
Fertilisation: Zygote 
 
Blastocyst: Inner cell mass & Trophectoderm 
 
Differentiation 
 
Organogenesis 
 
Fetal growth &  
development of integrated system responses 
 
Postnatal growth 
 & development of integrated system responses 
 
Puberty 
 
Pregnancy 
 
 
 
 
 
 
Epigenetic regulation of gene expression 
 
 
 
Cell cycle regulation: proliferation & apoptosis 
 
 
 
Adaptive cardiovascular, metabolic, 
neuroendocrine responses: hormonal programming 
 
 
 
 
 
 
Placental development 
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1.6.5  Modelling the DOHAD Hypothesis 
All of the hypotheses in the developmental origins of adult disease concept have 
been established on the basis of the outcomes of epidemiological studies or in 
utero undernourishment in humans. In order to test these hypotheses 
experimentally and establish a greater understanding of the mechanisms involved 
it is necessary to use animal models of nutritional restriction. Numerous models 
have been developed in several species; all involve some form of change to the 
offspring’s nutritional intake during and/or after gestation.    
1.6.5.1  Animal Models 
An extensive review of the literature on the different animal models utilised in the 
study of the DoHaD hypothesis is beyond the scope of this introduction. 
Nevertheless, this section aims to provide an overview of the contribution of 
animal models in furthering the understanding the developmental origins of 
cardiovascular disease, hypertension, obesity and type 2 diabetes.   
1.6.5.1.1 Cardiovascular Disease and Hypertension 
One of the first models to show experimental evidence for the DoHaD hypothesis 
was a study using guinea pigs. In this model, one uterine horn was ligated in 
pregnancy to restrict fetal growth; resulting in severely restricted fetal growth and 
hypertension in the offspring.
231 Since then nearly all animal models (mainly rat 
and sheep) of intrauterine growth restriction have shown similar programming of 
hypertension.
232-234 Low protein diets have been extensively used in study of 
hypertension, these models do not seem to display an effect on cardiac function 
(i.e. cardiac hypertrophy), but do appear to affect endothelial-dependant 
vasodilation and kidney development (changes to nephron, glomeruli number & 
kidney/body weight ratios).
232, 235-237 It is thought that protein under-nutrition is not 
directly responsible for programming of cardiovascular function per se.
238 Rather, 
that the imbalance of amino acids and other nutrients in this diet is disrupting the 
correct pattern of DNA methylation, through increased homocyteinemia, during 
critical periods of organogenesis and vasculogenesis.
238 
Meanwhile, chronic hypoxia (10.5% O2) of pregnant animals can induce 
cardiomyocyte hyperplasia, hypertrophy and apoptosis in rat and sheep 
offspring.
239 Prenatal exposure to dexamethasone (synthetic glucocorticoid   42  
   
steroid) increases the cardiac output of sheep at 40 months; these animals also 
show ventricular hypertrophy, reduced cardiac reserve and increased collagen 
content in adult life.
240, 241 
1.6.5.1.2 Obesity 
Severely restricted maternal diets during pregnancy in animals have resulted in 
growth restriction at birth with later hyperphagia (increase in appetite and food 
consumption) that can be amplified by hypercaloric diets post weaning.
242 
Maternal under-nutrition has also been associated with decreased voluntary 
locomotor activity in offspring and changes to the programming of appetite and 
behaviour that could acerbate any effects of metabolic programming in later adult 
life.
243, 244  In rodents, if there is a reduction in litter size early in life, the remaining 
pups show an increased growth rate and remain over-weight.
245 Cross-fostering 
experiments have shown that ‘catch up’ pups (experienced maternal protein 
restriction and born small) gain weight more than the control pups; whereas 
normal birth weight animals grow slowly and show no additional weight gain on a 
highly palatable diet compared to control animals on a standard chow diet.
246 
Leptin is an adipose derived hormone that controls appetite and metabolism.
247 
Administration of leptin to pregnant rats late in gestation makes their male 
offspring less susceptible to high-fat diet induced weight gain and insulin 
resistance.
248 It is thought that increased maternal leptin programs the ability of the 
offspring to respond better to a high fat diet in the post-natal environment. This is 
an example of a predictive adaptive response (see section 1.6.2).
227 
1.6.5.1.3 Type 2 Diabetes 
Numerous animal models of intra-uterine growth restriction (IUGR) have been 
extensively used in the study of pancreatic development. These models have 
utilised uterine artery ligation, restricted maternal nutrition or a low protein diet.
249-
251 All of the different IUGR challenges have resulted in changes to foetal 
pancreatic development and interaction with the pattern of pancreatic development 
in post-natal life.(Reviewed in McMillen et al, 2005
227) The low protein model 
results in normal foetal glycemia, but diabetic phenotypes can be induced through 
a decrease in specific amino acids (taurine), impacting the proliferation/apoptosis 
of #-cells and insulin response.
252 Global energy reduction predominantly affects 
pancreatic cellular neogenesis.
249    43  
   
Overall, as reviewed in McMillen et al., 2005
227 IUGR results in a reduction of #-
cell mass and secretory capacity in the pancreas; decreased glucose uptake and 
increased gluconeogenesis in the liver. In skeletal muscle, IUGR has been found 
to increased lipid oxidation and decrease insulin sensitivity and in adipocytes, 
lipolysis in inhibited by insulin. These effects of IUGR result in decreased 
pancreatic functional capacity, glucose intolerance and insulin resistance. Thus, 
IUGR can program all of the hallmark pathways underlying type 2 diabetes.  
1.6.6  Mechanisms of Developmental Plasticity 
In order for the offspring to make a predictive adaptive response for the expected 
post-natal environment a dynamic mechanism must exist to ‘program’ the 
offspring’s phenotype during windows of plasticity in gestation. It is proposed that 
the offspring achieves this via epigenetic regulation of cellular processes. The next 
section discusses the mechanisms of epigenetic regulation in more detail. 
1.6.6.1  Epigenetic Regulation 
The word ‘Epigenetic’ literately means ‘on top of’ genetics (Greek ‘Epi’ prefix). So 
‘epigenetic regulation’ describes regulatory mechanisms that control the 
expression of genes without altering the DNA sequence. As a general rule, 
organisms (or cells) are exposed to environments that change all the time, in order 
to survive they must adapt to the changing environment. The common 
misconception (especially in the post genome era) is to think cells as fixed (in 
relation to gene expression) in their metabolism and cellular processes. However, 
every cell has to differentiate during embryogenesis, respond to injury and 
changes in the micro-environment. Through switching genes on and off cells can 
survive or undergo programmed cell death. The switching of genes on or off is 
regulated by epigenetic processes.  
In humans, there are epigenetic mechanisms that control how the DNA is 
packaged in the nucleus of the cell and which genes are accessible to 
transcription machinery and post-transcription there is a mechanism for inhibiting 
translation of the mRNA molecules into protein, microRNAs. Epigenetic regulation 
mechanisms are described in detail in the following sections:    44  
   
1.6.6.1.1 Histone Modification 
In order to form chromatin 146 basepairs of DNA is wrapped twice around an 
octamer of proteins containing two copies of H2A, H2B, H3 and H4 histones, this 
arrangement forms a nucleosome and is repeated along the DNA in the cell 
nucleus. Linker histones (H1) and other proteins interact with the nucleosomes 
and package them in to higher-order chromatin. The N-terminal tail of histones can 
carry post-translational modifications that alter DNA-histone interactions within and 
between nucleosomes. These modifications alter higher–order chromatin 
structures by collaborating with cellular processes such as transcription, DNA 
repair and replication and cell cycle progression.
253 The types of histone 
modification are described below: 
•  Histone Acetylation: Acetylation of lysine residues on the four core histones 
by HATs (Histone acetyltransferases) change histone-DNA interactions and 
create a more open chromatin structure, facilitating activation of gene 
expression as transcriptional machinery has access to genes at that site. 
Open chromatin structures can be closed by histone deacetylation which is 
performed by HDACs (histone deacetyltransferases) enzymes. H3 
acetylation is associated with genome stability (DNA repair) and H4 
acetylation with transcription.
254, 255  
•  Histone Methylation: Histones H3 and H4 can be methylated on lysine and 
arginine residues by histone methyltransferases creating an open or closed 
chromatin structure.
256 Histone methyltransferases appear to be more 
specific about their targets than HATs and it is likely that each enzyme can 
regulate different genes or cellular processes. 
•  Histone Phosphorylation: Histones are often phosphorylated at specific 
sites during cell division and can be induced by DNA-damage signalling 
pathways. Phosphorylation is catalysed by several kinase enzymes and 
appears to have a conserved role for compaction of chromatin during germ 
cell development.(reviewed by Wendt et al, 2006)
257 
•  Histone Ubiquitination: Udiquitination of histone residues (H2A & H2B) 
correlates with active transcription. This relationship is more complex than a 
straight positive correlation with transcription as histone ubiqutination of   45  
   
histone H2B can signal for the methylation of other histones through a 
“histone crosstalk” pathway.
258 
1.6.6.1.2 DNA Methylation 
DNA methylation negatively regulates gene transcription by stopping transcription 
factor binding or by the modification of chromatin structure. DNA methylation is 
important in normal development and cellular differentiation by altering the gene 
expression pattern. DNA methylation is the addition of a methyl group to the 5
th 
carbon atom of a cytosine pyrimidine ring (see figure 1.4). Methylated Cytosine 
bases are grouped together forming CpG islands in the promoter of methylated 
genes. Methylation patterns in imprinted genes are inherited from either the 
maternal or paternal germ line.
259   
 
Figure 1-4: DNA Methylation.  
The maintenance of methylated cytosine bases is due to the action of DNA methyltransferases 
(DNMT) which add the universal methyl donor S-adensyl-L-methionine (SAM-CH3) to cytosine.  
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1.7  Aims of Research 
The pathogenesis of asthma and COPD is complex and heterogeneous in nature. 
Much of the research into asthma has focussed on the immunological component 
of the disease. While this research had lead to a greater understanding and 
generation of effective treatment regimes, there has been no cure and the origins 
of the disease is still not fully understood. Recent evidence from studies of the 
developmental origins of chronic adulthood disease (e.g. cardiovascular disease) 
has shown that exposures during in utero development and early life are important 
factors in the manifestations of disease in offspring.
228 Exposure to excessive 
levels of oxidative stress and impaired nutritional status during pregnancy may be 
detrimental to or alter the trajectory of lung development predisposing offspring to 
a greater risk of respiratory disease, namely asthma in childhood and the 
development of COPD in later life.
260, 261 
The first part of this thesis examines the effect of genetic polymorphism in 
important antioxidant genes in asthmatic children when exposed to parental 
tobacco smoke in early life (Chapter 4). For the genetic association study, a copy 
number variation real-time PCR genotyping methodology was developed and is 
described in chapter 3. 
The second part of this thesis investigates whether an established animal model of 
maternal protein-restriction (Southampton Protein-Restriction Rat Model
262) 
developed for the study of the developmental origins of hypertension is suitable for 
the study of the developmental origins of respiratory disease. Gene expression 
analysis was performed on rat lung tissue to examine whether maternal protein 
restriction during pregnancy results in persistent changes to the expression profile 
of key genes involved in metabolism, lung growth, lung development and 
antioxidant protection (Chapter 5). MicroRNAs have an important role in lung 
development by modulating developmental timing, cell fate determination, 
apoptosis and growth but little is known about microRNAs expression in response 
to protein-restriction in utero. Chapter 6 investigates whether rat lung microRNA 
expression is altered by maternal protein-restriction during pregnancy.  47 
2  Chapter 2: General Materials and Methods 
2.1  Materials  
All reagents were stored at room temperature, unless otherwise stated. All 
chemicals were molecular Biology or Biotechnology grade. 
Table 2-1: Reagents 
Reagent  Cat no:  Supplier 
Absolute Ethanol  51976  Sigma 
DEPC treated water  N/A  N/A 
2xQPCR Mastermix (PD)  Mastermix-R  Primerdesign ltd 
2xQPCR Mastermix for probes (E)  RT-QP2X-03  Eurogentec, SA 
PCR grade water  04 909 631 001  Roche diagnostics, UK 
Iso-propanol  I-0398  Sigma 
Sodium dodecyl sulphate  S/P530NC/48  Fisher Biochemicals 
Sodium Hydroxide  S-8045  Sigma 
Guanidine hydrochloride  G-3272  Sigma 
Sodium Citrate  S-4641  Sigma 
Chloroform  BP1145-1  Fisher BioChemicals 
TRIzol Reagent  15596-026  Invitrogen 
Agarose   EP-0010-05  Eurogentec, SA 
Smartladder  MW-1700-10  Eurogentec, SA 
50bp Ladder  N3236  New England Biolabs (NEB) 
Blue-Orange Loading Buffer  G109A  Promega, UK 
Ethidium Bromide  E-1510  Sigma 
Diethyl Pyrocarbonate  D-5758  Sigma 
10 x TBE Buffer  EC-860  National Diagnostics 
 
Table 2-2: Enzymes and Buffers 
Enzyme  Cat no:  Supplier 
AmpliTaq Gold  4311816  Applied Biosystems, Foster City, CA, USA 
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Table 2-3: TaqMan Probe Assays for qPCR 
Gene  Ref 
sequence  
Forward Primer 
sequence (5’-3’) 
Reverse Primer 
sequence (5’-3’)  Probe sequence (5’-3’)   Oligo Conc
n 
ALBUMIN  M12523  CTGTCATCTCTTGTGGGCTGTAA  GGCATGACAGGTTTTGCAATATT  VIC-CATCGTCTAGGCTTAAGAG-MGB-NFQ 
GSTM1: 
900 / 600 / 150 nM 
GSTT1: 
450 / 300 / 150 nM 
GSTM1  X68676  GACTCTTGCATCCTGCACACA  GGAAAGCACTTGGAGGATGAAT 
6FAM-TGGTCTTAAGTCCCTGGTAC-MGB-
NFQ 
600 / 900 / 150 nM 
GSTT1  af240786  CAGGTGAACCCCCTCAAGAA  GTCCCAGTTACCTCTCCGTCAA  6FAM-CAGCCTTGAAGGACGG-MGB-NFQ  675 / 450 / 150 nM 
Nr3c1 
(GR) 
NM_012576  TGCATGTATGACCAATGTAAACACA  CCTTCCTTAGGAACTGAGGAGAGAA 
TCCTCTGAATTACAAAGATTGCAGGTATCC
TATGAAGA 
900 / 900 / 200 nM 
Actb  NM_031144  CGTGAAAAGATGACCCAGATCA  CACAGCCTGGATGGCTACGT  TTTGAGACCTTCAACACCCCAGCCAT  900 / 900 / 200 nM 
B2m  NM_012512  ACTCTGAAGGAGCCCAAAACC  TCCAGATGATTCAGAGCTCCATAG  CACCTGGGACCGAGACATGTAATCAAGC  900 / 900 / 200 nM 
Ubc  NM_017314  CGTACCTTTCTCACCACAGTATCTAGA  GAAAACTAAGACACCTCCCCATCA  AGAGCCCTTCTTGTGCTTGTTCTTGGGT  900 / 900 / 200 nM 
 
Table 2-4: UPL Probe or miRNA Assays for qPCR 
Gene  Ref 
sequence 
Forward Primer sequence 
(5’-3’) 
Reverse Primer sequence 
(5’-3’) 
Allele 1 Probe 
sequence (5’-3’) or 
part no. 
Oligo Conc
n 
Adam33  XM_001079402.1  TAGTGGCCCTGCACAGTCT  TGGTAGTAGCACCAGGCTAGG  UPL #74 
CAT NO: 04688970001 
900 / 900 / 200 nM 
Pcdh1  NM_225997.4 & 
NM_001066229.1 
CAAATACCCCAGCAAGCAGT  CTGTGCTGTGATGGATCCTG  UPL #49  
CAT NO: 04688104001 
900 / 900 / 200 nM 
5S rRNA  NA  Unknown  Unknown  Exiqon: 201509 
Qiagen: MS00007574 
manufacturers 
recommended 
conditions 
rno-miR-
22* 
miRBase v13  Unknown  Unknown  Exiqon: 202827 
 
manufacturers 
recommended 
conditions 
rno-miR-
126 
miRBase v13  Unknown  Unknown  Exiqon: 202141 
Qiagen: MS00005607 
manufacturers 
recommended 
conditions 
rno-miR-
140 
miRBase v13  Unknown  Unknown  Qiagen: MS00005635  manufacturers 
recommended 
conditions 
rno-miR-
153 
miRBase v13  Unknown  Unknown  Exiqon: 202160 
 
manufacturers 
recommended 
conditions 
rno-miR-
181a* 
miRBase v13  Unknown  Unknown  Exiqon: 204110 
 
manufacturers 
recommended 
conditions 
rno-miR-
186 
miRBase v13  Unknown  Unknown  Exiqon: 202167 
Qiagen: MS0000511 
manufacturers 
recommended 
conditions 
rno-miR-
365 
miRBase v13  Unknown  Unknown  Exiqon: 204622 
 
manufacturers 
recommended 
conditions 
rno-miR-
674 
miRBase v13  Unknown  Unknown  Qiagen: MS000013797  manufacturers 
recommended 
conditions 
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Table 2-5: SYBRgreen Assays for qPCR 
Gene 
Ref sequence 
(Position; bp)  Forward Primer sequence (5’-3’)  Reverse Primer sequence (5’-3’)  Oligo Conc
n 
Atp1a1  NM_012504.1  TGGATCAATGATGTGGAGGA  CAATATTCCTCTGCTCGTAGG  600 / 600 nM 
Atp1a2  NM_012505.1  GACCTCATCATTTGCAAGACC  CTAGCAGCCCAAAAATCAGG  600 / 600 nM 
Hsd11b1  NM_017080.2  TGTCCTCGGCTTCATAGACA  GCGCAGAACTGTGCCTTT  600 / 600 nM 
Hsd11b2  NM_017081.1  GGGGTATCAAGGTCAGCATC  TCCCAGAGGTTCACATTAGTCA  600 / 600 nM 
Gstm1  NM_017014.1  TGTTACAACCCCGACTTTGA  TCTTCTCAGGGATGGTCTTCA  600 / 600 nM 
Gstp1  NM_012577.1  TGGTACCCTCATCTACACTAACTATGA  CAGCAGGGTCTCAAAAGGTT  600 / 600 nM 
Gstt1  NM_053293.2  CCTGGCTGACGTGGTAGC  GACGCCCTTCAAAGACTGG  600 / 600 nM 
Igf1  NM_178866.2  CGGCCTCATAATACCCACTC  AAGACGACATGATGTGTATCTTTATTG  600 / 600 nM 
Igf2  NM_031511.1  CGCTTCAGTTTGTCTGTTCG  GCAGCAACTCTTCCACGATG  600 / 600 nM 
Nr3c2 (MR)  NM_013131.1  CCTGGCAGCGAAACAGAT  TCCTCGAGAGGCAAGTTTTT  600 / 600 nM 
Tp53  NM_030989.1  GAGAGCACTGCCCACCAG  AACATCTCGAAGCGCTCAC  600 / 600 nM 
Ucp2  NM_019354.1  GACTCTGTAAAGCAGTTCTACACCAA  GGGCACCTGTGGTGCTAC  600 / 600 nM 
 
Table 2-6: DNA Cohorts and Human Random Control DNA Samples 
Study Name  Study type  No. of 
individuals  Concentration   Notes: 
Southampton asthma 
study  Family-based  1508  1, 5, 10 or 100 ng/$l 
Originally described in 
Van Eerdewegh et al. 
Nature 2002
121 
Refer to chapter 4. 
ECACC  Human Random Control 
Panel 
96  10 ng/ $l  HRC panel 1 
(www.ecacc.org.uk) 
Pooled control gDNA  Human Random Control 
Panel  96  1 or 10 ng/ $l 
Pooled  gDNA 
template from the 
ECACC dna samples 
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Table 2-7: Protein Restriction Rat Lung Tissue Samples.  
Frozen archived lung tissue was provided by Dr. Christopher Torrens.   
Study  Generation  Treatment group  No. of samples  Sex  Age (days)  Reference 
DohaD Rat PR study
 a  F1  PR  11  Male  120  Torrens et al.
263 
  F1  Control  7  Male  120   
  F1  PR  6  Male  225  Torrens et al.
263 
  F1  Control  6  Male  225   
  F2  PR  13  Male  80  Burdge et al.
264 
  F2  Control  13  Male  80   
a Liver RNA isolates were also available for the same 120 day old F1 generation offspring.    
 
Table 2-8: Commercial Laboratory Kits 
Kit   Cat no:  Supplier 
ImPromII™ - Reverse Transcription Kit  A3800  Promega, Southampton, UK 
SYBRgreen™ Core qPCR Mastermix Kit  RT-SN10-05  Eurogentec, SA 
DNAfree Kit  AM1906  Ambion, USA 
 
Table 2-9: Plasticware 
Plastic ware  Cat no:  Supplier 
ABgene 96 well V-Bottomed storage plates  AB-1058  ABgene, UK 
ABgene Thermo-Fast 384 well plates  TF-0384  ABgene, UK  
Universal tubes  CW3900  Alpha Laboratories 
Bijoux Tubes  -  Alpha Laboratories 
15ml, 25ml & 50ml Falcon Centrifuge tubes  LW1120/LW3078  Alpha Laboratories 
1.5ml Tubes  616201  Greiner Bio-one 
0.5ml Tubes  LT2172  Alpha Laboratories 
0.2ml Tubes  LW2130  Alpha Laboratories 
0.2ml Tube strips  LW2500  Alpha Laboratories 
10ul Pipette tips  771288  Greiner Bio-one 
100, 200, 1000ul Pipette tips  772288/739288/740288  Greiner Bio-one 
10ml & 25 ml Serological Pipettes  607180/760160  Greiner Bio-one 
Petri dishes  633102  Greiner Bio-one 
2ml Screw cap tubes  CP5320WL  Alpha Laboratories 51 
Table 2-10: Apparatus 
Apparatus  Serial no:  Location  Supplier 
Lightcycler480™ real-time PCR 
machine  1230  Asthma Genetics Lab  Roche diagnostics, UK. 
Nano-drop absorbance 
spectrophotometer  unknown  Lab 18, Human Genetics  Nano-drop technologies, USA 
7900ht ABI Prism Sequence 
detection System 
500722  Molecular Pathology lab,   Applied Biosystems, Foster City, 
CA, USA 
MJ Research DNA engine Tetrad 
Thermal cycler  TD002380  Asthma Genetics Lab  BioRad, USA 
Labofuge 400 Plate Centrifuge  40340180  Asthma Genetics Lab  Heraeus, Germany 
Biomek™ 3000 Robotic Liquid 
Handling Platform  9861200140  Asthma Genetics Lab  Beckman-Coulter, UK. 
ABgene Plate Heat-sealer  951/2563  Asthma Genetics Lab  ABgene, UK. 
BioPulverizer  59014H (cat no)  Asthma Genetics Lab  BioSpec Inc, US 
DigiDoc-it UV trans-illuminator  -  Lab 18, Human Genetics  UVP, LLC. Upland, CA, US 
RiboLyser  -  Brook Lab  Thermo Fisher Scientific Inc 
UV PCR Cabinet  MC 0239  Asthma Genetics Lab  Lab-Caire, UK 
M-240R bench-top centrifuge  0000138-02-00  Asthma Genetics Lab  BOECO, Germany 
AB54-S Balance  1120133255  Asthma Genetics Lab  Mettler-Toledo, USA 
 
Table 2-11: Software 
Program  Version  Supplier  Web-link 
SPSS  14.0  SPSS Inc  www.spss.com 
LinRegPCR
265  7.5  N/A  Requested by email  
Roche Lightcycler480 Relative 
Expression Module  1.2  Roche Diagnosics, 
UK  www.roche-applied-science.com 
Roche Lightcycler Basic Software  1.2  Roche Diagnosics, 
UK  www.roche-applied-science.com 
FBAT and PBAT  1.4 & 1.0  N/A  http://www.biostat.harvard.edu/~fbat/default.html 
SDS (ABI 7900ht Real-time PCR 
machine software)  2.1  Applied Biosystems  www.appliedbiosystems.com 
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Table 2-12: Miscellaneous 
Description  Supplier 
Foil  N/A 
ABgene clear seal Diamond plate seals  ABgene, UK 
ABgene clear seal Strong  ABgene, UK 
Nalgene glass bottles  Fisher Scientific 
Parafilm  Fisher Scientific 
Scalpel & blades  - 
Liquid Nitrogen Dewar  - 
Metal spatulas  - 
Sterile tweezers  - 
RNAzap  Ambion, USA 
RNAzap wipes  Ambion, USA 53 
2.2  Methods 
2.2.1  Gel electrophoresis of PCR Products 
PCR products were electrophoresised on either a 2 or 3% w/v Agarose gel. A 3% 
w/v agarose gel was used for PCR products less than 100 bp in length.  2 or 3 
grams of Agarose (Eurogentec, SA) was weighed and dissolved in 100 mls of 1 x 
TBE buffer by heating in the microwave.  The agarose solution was allowed to cool 
to ~40°C before pouring into the mini-gel former and left to set. 5 $l of the PCR 
product was mixed with 1 $l of the blue-orange loading buffer (x 6 Concentration; 
Promega, UK) and loaded on to the gel. 5 $l of either the Smart-ladder (200 bp -10 
kb; Eurogentec, SA) or 50 bp Ladder (Promega, UK) was loaded to the first and 
last lane of the gel to size the products. The PCR products were electrophoresed 
for 30-40 mins dependant of the size of the PCR products. The gel was post-
stained with Ethidium Bromide (EtBr) by submerging the gel in 100 mls of 1 x TBE 
buffer containing EtBr (0.5 $g/ml) for 15 mins and de-stained in 100 mls of water 
for 15 minutes before visualisation on the DigiDoc-it™ system (UVP, LLC. Upland, 
CA, US). 
2.2.2  Nucleic Acid Quantification 
2.2.2.1  Nano-drop Absorbance Spectrophotometer 
RNA and DNA quantification was performed on a Nanodrop D-1000 (Nandrop 
Technologies, US) absorbance spectrophotometer; only 1-2 $l of an undiluted 
nucleic acid solution aliquot is required to accurately quantify nucleic acids over a 
large linear range (2 to 3700 ng/$l of dsDNA). This methodology conserves 
precious samples by only using a small quantity of sample that is recoverable and 
is faster than cuvette spectrophotometers.  
2.2.2.2  Nano-drop DNA/RNA Quantification Protocol 
1.5 $l of water was loaded onto the pedestal and used as a reference to initialise 
the spectrophotometer; after a successful initialisation the pedestal was cleaned 
by wiping the bottom and top sample pedestal 5 times with a clean soft tissue. The 
machine is ‘blanked’ before the 1
st and after the 10
th nucleic acid sample using 1.5 
$l of water to check the baseline and sample carry-over.  54 
1.5 $l of DNA or RNA is also used for each sample reading and between samples 
the pedestal was cleaned as before.  DNA and RNA samples were quantified in 
ng/$l and the 260/230, 260/280 ratios recorded for determining DNA/RNA quality. 
RNA samples were considered to be ‘pure’ when the 260/230 (Abs of DNA/Abs of 
Salts, Solvents & Protein) and 260/280 ratios (Abs of DNA/Abs of Proteins 
containing tryptophan) were between 1.8 - 2.2 and ~2.0, respectively. For DNA 
samples the ranges were between 1.8 - 2.2 and ~1.8. RNA samples were then 
normalised (0.5 $g/$l) and frozen at 
-80°C, ready of use as RT-PCR templates. 
2.2.3  Total RNA, DNA and Protein Isolation using TRIzol™ Reagent 
2.2.3.1  RNA Work GLP 
To maintain the integrity of the RNA isolate it is necessary to work on ice at all 
times and refrigerate the samples during centrifugation. Also, to protect the RNA 
samples from RNase degradation all plasticware, glassware, work-surfaces and 
equipment was either certified as RNase-free (in the case of plastic-ware) or 
treated/wiped down with RNAzap spray or wipes (Ambion, US) and gloves were 
worn at all times. Where applicable, all isolation steps were performed in the UV 
PCR extraction hood (Lab-Caire Systems Ltd, UK); filter tips and a designated set 
of RNA pipettes were used at all times. Appendix 10.1 details the preparation of 
reagents used in the TRIzol™ protocol. 
2.2.3.2  RNA Stabilisation Treatments 
In order to maintain RNA integrity during the lengthy tissue processing steps, it 
was necessary to evaluate the effectiveness of the two most commonly used RNA 
stabilisation treatments in combination with a tissue homogenisation protocol: 
2.2.3.2.1 Liquid Nitrogen-Bio-Pulverizer Method 
The mortar of the Bio-Pulverizer (BioSpec Products Inc, US) and one of the 
spatulas were placed in to a liquid nitrogen dewar. Once the liquid nitrogen had 
ceased to bubble the mortar was removed and placed on to the bench-top work 
surface. A 0.5 cm
3 section of lung tissue was cut using a sterile scalpel blade on a 
foil covered Petri dish top, weighed and quickly transferred to the liquid nitrogen 
remaining in the mortar.  55 
While the liquid nitrogen was freezing the tissue and evaporating away, the 
hammer plate was introduced into the liquid nitrogen to cool. After the liquid 
nitrogen had evaporated the hammer plate was centred over the mortar, pressed 
down into position and the spring-loaded hammer trigger was depressed three 
times reducing the tissue section into a fine powder. Using the cold spatula the 
powder was scraped into a Lysing Matrix-D tube and 1.0 ml of TRIzol was added. 
The capped tube was mixed by inversion and stored in the 
-20°C freezer ready for 
immediate homogenisation in the Ribolyser machine. The mortar, hammer plate 
and spatula were cleaned using UHQ water and RNaseZap wipes before 
repeating the process for more tissue samples. 
2.2.3.2.2 RNALater-ICE RNA Stabilisation Treatment 
In advance, 10 volumes (ie: 1 ml for 100 mg tissue) of RNALater-ICE regent (Cat 
no: 7030, Ambion) were pre-chilled to 
-80°C for each lung sample. A piece of lung 
tissue (0.5 cm
3) was sectioned on a foil covered petri dish lid using a sterile scalpel 
blade and the weight was recorded on an accurate balance. The tissue sample 
had to be >5 cm in one dimension to ensure uniform permeation of the RNA 
stabilising reagent. The reagent contains a blue dye to identify treated samples 
and to see how far the reagent has permeated into the tissue. Working on dry-ice, 
the tissue section was place into 1 ml of the pre-chilled RNALater-ICE in a 1.5 ml 
tube. The tube was capped and inverted several times to mix. The tissue was 
soaked in RNALater-ICE at 
-20°C overnight; ready for tissue homogenisation in 
the Ribolyser machine. At this temperature the tissue sample can be stored for up 
to 6 months. The next day, the treated lung section was finely chopped on an 
RNase-free petri dish lid using a sterile scalpel and transferred to a labelled Lysing 
matrix-D tube containing 1ml of TRIzol reagent. The samples were then stored on 
ice ready for tissue homogenisation in the Ribolyser machine (see table 2.10). 56 
2.2.3.3  Tissue Homogenisation Protocol 
The Ribolyser machine (Thermo Fisher Scientific Inc.) was programmed to run at 
speed 4.0 for 40 seconds. The lysing matrix-D tubes containing the lung sample in 
1 ml of TRIzol were transferred to the Ribolyser machine, balanced and locked 
into place. After the each of the two runs the tubes were removed from the 
Ribolyser and placed on ice to cool for 2 mins. After the second incubation on ice 
the samples was checked for complete tissue homogenisation; if required the 
Ribolyser run program was repeated until samples were homogenous. The 
homogenised samples were incubated for 5mins at room temperature; then 
transferred to a 
-20°C freezer for storage until the RNA isolation step. The tissue 
homogenate in TRIzol can be stored at 
-70°C for up to one month protected from 
RNase degradation. 
2.2.3.4  RNA Isolation 
The homogenate was carefully transferred from the Lysing Matrix-D tubes into 
clean 1.5 ml micro-centrifuge tubes. The lysing Matrix tubes were retained at          
-80°C. 0.2 ml of chloroform was added to the 1.5 ml tube and shaken vigorously by 
hand for 15 seconds; this was then incubated at room temperature for 3 mins and 
then centrifuged at 12,000 x g (11,100 RPM) for 15 mins at 4°C. The upper 
aqueous layer that contains the RNA was carefully transferred to a fresh 1.5 ml 
tube. The remaining interphase and organic layer for DNA and Protein 
precipitation was saved and stored on ice (this preparation can be stored overnight 
at 4°C). The RNA was precipitated by mixing in 0.5 ml of chilled iso-propanol. The 
RNA precipitate in iso-propanol can be stored at 4°C for up to one week or 
-20°C 
for up to one year. The RNA precipitates were incubated at room temperature for 
10 mins; then samples were centrifuged at 12,000 x g for 10 mins at 4°C, with the 
tube hinges facing out from the centre of the rotor. The RNA pellet forms on the 
hinge side and bottom of the tube. The supernatant was carefully removed from 
the tube (in 200 $l aliquots) without disturbing the pellet. The pellet was washed 
once with 1.3 mls of 75% ethanol. The pellet was mixed by vortex and then 
centrifuged at no more than 7,500 x g for 5 mins at 4°C. Most of the ethanol above 
the pellet was carefully removed and the pellet was air-dried for 5 - 10 mins to 
remove the excess ethanol ready for DNase treatment.  57 
2.2.3.5  DNase Treatment of RNA Isolates and Storage 
20 $l of the Ambion DNA-free™ master mix, containing 2 $l of 10 x DNase I Buffer 
1ul rDNase I (2 U/$l), 17 $l RNase-free water was added to each tube and RNA 
pellet was dissolved by gentle aspiration. The samples were incubated at 37°C for 
1 hour on the DNA engine tetrad thermalcycler (MJ Research, US). 2 $l of the 
DNase inactivation reagent was then added, mixed by vortex and then incubated 
at room temperature for 2 mins with occasional mixing. The sample was then 
centrifuged at 10,000 x g for 1.5 mins at 4°C to pellet the inactivation reagent. The 
RNA solution was transferred to a fresh 0.2 ml RNase-free tube and 30 $l of 
RNase-free water was added and mixed gently by pipette aspiration. 25 $l of the 
RNA solution was then aliquoted into another 0.2 ml RNase-free tube and both 
aliquots stored at 
-80°C. 
2.2.3.6  DNA Isolation and Storage 
Any remaining aqueous phase left over the interphase (retained from the RNA 
isolation step) was carefully removed. 0.3 ml of 100% ethanol was added to the 
top of the interphase and the samples were mixed by inversion. The samples were 
then incubated at room temperature for 3 mins and then centrifuged at 2000 x g 
for 5 mins at 4°C to pellet the DNA. The phenol-ethanol supernatant was removed 
and transferred to a clean 1.5 ml tube and left on ice ready for the protein isolation 
step. The DNA pellet was washed twice in 1 ml of 0.1 M Sodium Citrate in 10% 
Ethanol. After the addition of each wash, the sample was incubated 30 mins at 
room temperature with periodic mixing and centrifuged at 2,000 x g for 5 mins at 
4°C. The pellet was suspended in 1.5 ml of 75% ethanol and incubated at room 
temperature for 15 mins with periodic mixing and then centrifuged at 2,000 x g for 
5 mins at 4°C. The 75% ethanol was carefully removed from above the pellet and 
air dried for 5-15 minutes in the open tube. The pellet was dissolved in 100-300 $l 
of TE solution (for 2 hours or overnight at room temperature). Any insoluble 
material was removed by centrifugation at 12,000 x g for 10 mins and the clear 
DNA supernatant was transferred to a new tube. 58 
2.2.3.7  Protein Isolation and Storage 
The phenol-ethanol supernatant retained at the DNA isolation stage was aliquoted 
in equal volumes into two pre-labelled 2.0 ml screw-cap tubes and treated in 
parallel for the rest of the protein isolation procedure as if 0.5 ml of TRIzol reagent 
was used initially.  The proteins were precipitated from the phenol-ethanol 
supernatant with 750 $l of chilled iso-propanol. The precipitates were stored for 10 
mins at room temperature and sedimented by centrifugation at 12,000 x g for 10 
mins at 4°C. The supernatant was removed and the pellet was washed 3 times in 
1 ml of 0.3 M Guanidine hydrochloride in 95% ethanol preparation. During each 
wash, the samples were incubated for 20 minutes at room temperature and 
centrifuged at 7,500 x g for 5 mins at 4°C. Following addition of the third wash, the 
pellet was snap-frozen in liquid nitrogen and stored at 
-80°C. 
 
2.2.4  Reverse Transcription 
2.2.4.1  RNA Work GLP 
Refer to methods section 2.2.3.1 
2.2.4.2  Reverse Transcription Primer Reaction Setup 
Reverse Transcription (RT) was performed on 1 $g of total RNA isolate using the 
Improm™II kit (Promega, UK). All RT reaction set-ups contained positive 
(Kanamycin RNA), Reverse Transcription negative (RT-ve) and water controls 
(No-template control) to control for reagent failure, internal and external gDNA 
contamination respectively. Firstly, the RNA template and primers were mixed as 
in table 2.13 in 0.2 ml PCR tubes and denatured at 70°C for 5 mins on a 
thermalcycler to remove secondary RNA structures, facilitating random/Oligo dT 
primer annealing. At the end of the denaturing step the sample tubes were 
immediately placed on ice. 59 
Table 2-13: RT Primer Reaction Setup 
Reagents  Positive control Reaction 
Negative (No-template)  
Control Reaction 
Experimental/ 
RT-ve reaction 
1.2kb Kanamycin Positive control RNA (1 $g)  2 $l  -  - 
Experimental RNA (1 $g/reaction)    -  -  2 $l 
Oligo(dT)15 Primer (0.5 $g/reaction)    1 $l  -  - 
Random Primer (0.5 ng/reaction)  -  1 $l  1 $l 
Nuclease-Free Water  2 $l  4 $l  2 $l 
Final Volume  5 $l  5 $l  5 $l 
 
2.2.4.3  RT Master Mix Setup 
15 $l RT master mixes were made up as follows (table 2.14) and added to the 5 $l 
Primer/template mixes; mixed by flicking the tubes and spun down in a bench-top 
mini-centrifuge. 
Table 2-14: RT Master Mix Setup 
Reagents 
Positive Control 
Reaction 
 
No RT Control 
Reaction 
(RT-ve) 
Experimental/ 
No-template Control 
Reaction 
Nuclease-Free water (to a final volume of 15 $l)  4.2 $l  8.8 $l  7.3 $l 
5 x ImPromII™ Reaction buffer  4.0 $l  4.0 $l  4.0 $l 
MgCl2 (Final conc 1.5 mM)    4.8 $l  1.2 $l  1.2 $l 
dNTP mix   1.0 $l  1.0 $l  1.0 $l 
RNasin Ribonuclease Inhibitor (20 U)    0.0 $l  0.0 $l  0.5 $l 
ImPromII™ RTase    1.0 $l  0.0 $l  1.0 $l 
Final Volume    15 $l  15 $l  15 $l 
 
The tubes were transferred to the themalcycler and heated to 25°C for 5 mins, 
42°C for 1 hr, 70°C for 15 mins and then finally cooled and held at 20°C. The 
cDNA samples were then stored at 
-20°C ready for use as templates in real-time 
PCR reactions. 60 
2.2.5  Quantitative PCR:  
2.2.5.1  Assay Design 
PCR primers and TaqMan Probes were designed using PrimerExpress (version 
2.0; Applied Biosystems) software and online Universal Probe Library assay 
design centre (www.roche-applied-science.com/sis/rtpcr/upl/index.jsp) for UPL 
probe assays.  
Where possible, mRNA assays were designed over a splice site common to all 
known transcripts, where possible. The CNV assay sequences were BLAST SNP 
searched (www.ncbi.nlm.nih.gov/SNP/snp_blastByOrg.cgi) and all known 
polymorphism was avoided. To ascertain assay specificity the amplicon, the 
primer and probe sequences were also BLAST searched online. 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) 
2.2.5.2  Assay Optimisation 
2.2.5.2.1 Primer Concentration Titrations 
Asymmetrical primer concentration titrations were performed for all assays and the 
concentration combination with the lowest Crossing threshold (Ct) or Crossing 
point (Cp) value was chosen (see table 2.15).  
Table 2-15: Primer Concentrations Utilised in Optimisation Reactions 
Reverse Primer [FINAL] 
  300 nM  600 nM  900 nM 
300 nM  Reaction Set 1  Reaction Set 2  Reaction Set 3 
600 nM  Reaction Set 4  Reaction Set 5  Reaction Set 6 
F
o
r
w
a
r
d
 
P
r
i
m
e
r
 
[
F
I
N
A
L
]
 
900 nM  Reaction Set 7  Reaction Set 8  Reaction Set 9 61 
The quantitative PCR (qPCR) master mix cocktail was made as follows (see table 
2.16); each primer combination was run in triplicate wells using the thermalcycling 
programs in (see appendix 10.3). An absolute quantification analysis was 
performed on the real-time data and the concentration with the lowest average Ct 
or Cp value was considered to be the optimal primer concentrations.  
Table 2-16: Master Mix Setup Tables for Primer Titration Reactions.  
The left tables were used for probe based assays and the right tables for SYBRgreen assays. 
Primers diluted in 1 x TE buffer to stock concentrations of 3.33, 6.66 & 10 !M gave final reaction 
concentrations of 300, 600 & 900 nM respectively. 
Master Mix SYBRgreen  x1  x37 
2 x QPCR Mix  5.0  185 
SYBRgreen dye  0.3  11.1 
DNA (1 ng/$l)  2.0  74 
dH2O  0.9  33.3 
Total Volume ($l)  8.2  303.4 
 
Primer Reaction Sets 1-9  x1  x4 
Master Mix SYBR green  8.2  32.8 
Forward Primer  
[3.33, 6.66 or 10 $M] 
0.9  3.6 
Reverse Primer 
[3.33, 6.66 or 10 $M] 
0.9  3.6 
Total Volume ($l)  10  40 
 
2.2.5.2.2 Melting Curve Analysis 
Assay specificity was determined by post PCR melting curve analysis (see 
appendix 10.3). SYBRgreen assays are melted immediately after the PCR run 
while the probe based assays were spiked with SYBRgreen dye to a final 3% v/v 
concentration before being analysed. 
Master Mix Probes  x1  x37 
2 x QPCR Mix  5.0  185 
10uM probe [100 nM]  0.1  3.7 
DNA (1 ng/$l)  2.0  74 
dH2O  1.1  40.7 
Total Volume ($l)  8.2  303.4 
 
Primer Reaction Sets 1-9  x1  x4 
Master Mix Probes  8.2  32.8 
Forward Primer  
[3.33, 6.66 or 10 $M] 
0.9  3.6 
Reverse Primer 
[3.33, 6.66 or 10 $M] 
0.9  3.6 
Total Volume ($l)  10  40 62 
2.2.5.2.3 Probe Concentration Titrations 
Using the optimised primer concentrations a subsequent probe concentration 
titration experiment revealed the lowest probe concentration to use without 
sacrificing assay sensitivity (see table 2.17).  
Table 2-17: Final Probe Concentrations Used in Probe Titration Optimisation.  
Probes diluted in 1 x TE buffer to stock concentrations of 2, 4, 8 & 10 !M gave final reaction 
concentrations of 50, 100, 150 & 200 nM respectively. 
Probe Reaction Set  1  2  3  4 
Probe [Final]  200 nM  150 nM  100 nM  50 nM 
Probe [Stock]  8 $M  6 $M  4 $M  2 $M 
Volume ($l)/10$l reaction  0.25  0.25  0.25  0.25 
 
The qPCR mastermix cocktail was made as follows (see table 2.18); each probe 
concentration was run in triplicate wells using the required thermalcycling program 
in appendix 10.3. An absolute quantification analysis was performed on the real-
time data and the optimal concentration was determined by choosing the lowest 
probe concentration that produced similar real-time amplification curves to the 
highest concentration reactions. 
Table 2-18: Master Mix Setup Tables for Probe Titration Reactions 
 
 
Master Mix Probes  x1  X4 
2 x QPCR Mix  5.0  20 
Forward Primer  
[3.33, 6.66 or 10 $M] 
0.9  3.6 
Forward Primer  
[3.33, 6.66 or 10 $M] 
0.9  3.6 
2 $M - 8 $M Probe  0.25  1.0 
DNA (1 ng/$l)  2.0  8.0 
dH2O  0.95  3.8 
Total Volume ($l)  8.2  40 63 
2.2.5.3  Assay Validation 
Standard curves were performed to test the linear range, sensitivity and determine 
the PCR efficiency of the qPCR assays (see tables 2.19 – 2.21). Each step of the 
serial dilution was run in triplicate wells on a 384 well PCR reaction plates using 
reaction volumes of 5 $l (CNV assays) or 10 $l (mRNA assays). Serial dilutions 
were made up on the day of the qPCR thermalcycling run in 0.2 ml PCR tubes 
(mixing by gentle vortex at each dilution step) and scaled up in volume if testing 
multiple assays on the same plate. Data was analysed according to appendix 
10.3.   
Table 2-19: Two-Fold Serial Dilution of Pooled gDNA Template (ECACC HRC1 DNA Panel) 
for the GST Copy Number Variation Assays.  
a1 !l of each standard per reaction well 
Table 2-20: Four-Fold Serial Dilution of cDNA Template for mRNA or miRNA Assays.  
a1 !l of each standard per reaction well 
Table 2-21: Ten-Fold Serial Dilution of cDNA Template of the mRNA or miRNA Assays. 
 
 
 
 
a1 !l of each standard per reaction well 
Serial dilution
a 
(DNA/reaction) 
20 ng  10 ng  5 ng  2.5 ng  1.25 ng  0.625 ng  0.3125 ng  0.156 ng 
No 
DNA 
Pooled DNA  
(10 ng/2$l) 
20  10  10  10  10  10  10  10  0 
H20  0  10  10  10  10  10  10  10  10 
 
Serial dilution
a (cDNA/reaction) 
4
0  4
-1  4
-2  4
-3  4
-4  4
-5  4
-6  4
-7  No cDNA 
Pooled cDNA (~25 ng/$l)  18.0  4.5  4.5  4.5  4.5  4.5  4.5  4.5  0 
H20  0.0  13.5  13.5  13.5  13.5  13.5  13.5  13.5  13.5 
Serial dilution
a (cDNA/reaction)  10
0  10
-1  10
-2  10
-3  10
-4  10
-5  No cDNA 
Pooled cDNA (~25 ng/$l)  14  1  1  1  1  1  0 
H20  0  13  13  13  13  13  13 64 
2.2.5.4  Reaction Plate Setup and Analysis 
2.2.5.4.1 Copy Number Variation Reaction Plate Setup 
2.0 $l of gDNA (1 ng/$l) was transferred to duplicate wells on a 384 well reaction 
plate (see figure 2.1) using an electronic multi-channel pipette (Biohit, 0.5-10 $l) or 
the Biomek robot (appendix 10.2).  
 
Figure 2-1: Example 384 Well Reaction Plate Layout.  
The first 96 well DNA was duplicated on to the blue rows (i.e. first sample occupies wells A1 and 
A2). The second 96 well DNA plate was duplicated on to the green rows (i.e. first sample occupies 
wells B1 and B2) 
Each 384 well plate contained negative control wells known as No Template 
Controls (NTCs) and positive control DNA (see table 2.22).  
Table 2-22: ECACC Genomic Control Sample Names Used as Positive Controls for the GST 
CNV Assays 
Copy number  GSTT1  GSTM1 
2  C0858 & C0901  C0145 & C0150 
1  C0906 & C0722  C0027 & C0088 
0  C0007 & C0960  C0073 & C0202 
The DNA template was dried down by heating the DNA solution to 80°C for 10 
minutes in the DNA engine tetrad thermalcycler (Genetic Research Inc, US). To 
each sample well on the plate 5 $l of CNV master mix (see table 2.23) was added 
using a multichannel electronic Pipette (Matrix Technologies, US). The plates were 
sealed, then spun down in a plate centrifuge for 1 min at 3000 rpm and incubated 
at 4°C for 1 hr before PCR thermalcycling (see section 2.2.5.4.1.1). 65 
Table 2-23: CNV Master Mix Setup.  
Primer/Probe premixes were made up in large batches in advance to minimise batch to catch 
variability. CNV Master Mixes were made up in excess for pipetting (420 reaction volumes of CNV 
master mix were required for each 384 well plate) 
 
GSTM1 CNV Master Mix 
 
x1  x420   
  GSTM1 Primer/Probe Premix  x1  x420  [FINAL]  
2xQPCR Mix  2.5  1050    100 $M ALB MGB Forward Primer  0.045  18.9  900 nM 
        100 $M ALB MGB Reverse Primer  0.03  12.6  600 nM  
Primer/Probe Mix per 5 $l 
rxn  0.165  69.3    100 $M GSTM1 MGB Forward Primer  0.03  12.6  600 nM 
        100 $M GSTM1 MGB Reverse Primer  0.045  18.9  900 nM 
H20  2.335  980.7    100 $M ALB MGB Probe  0.0075  3.15  150 nM 
        100 $M GSTM1 MGB Probe  0.0075  3.15  150 nM 
               
Total Volume (!l)  5  2100    Total Volume ($l)  0.165  69.3   
 
 
GSTT1 CNV Master Mix 
 
x1  x420   
  GSTT1 Primer/Probe Premix  x1  x420  [FINAL]  
2xQPCR Mix  2.5  1050    100 $M ALB MGB Forward Primer  0.0113  4.73  225 nM 
        100 $M ALB MGB Reverse Primer  0.0075  3.15  150 nM 
Primer/Probe Mix per 5 $l 
rxn  0.064  26.8    100 $M GSTT1 MGB Forward Primer  0.0225  9.45  450 nM 
        100 $M GSTT1 MGB Reverse Primer  0.015  6.3  300 nM 
H20  2.436  1023    100 $M ALB MGB Probe  0.0038  1.58  75 nM 
        100 $M GSTT1 MGB Probe  0.0038  1.58  75 nM 
               
Total Volume (!l)  5  2100    Total Volume (ul)  0.06375  26.8   
2.2.5.4.1.1  Thermalcycling Reaction Profile 
PCR amplification and real-time fluorescent data collection was performed on the 
ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Thermal 
cycling conditions were 95°C for 10 minutes then 40 cycles of 95°C for 15 seconds 
and 60°C for 60 seconds without 9600 emulated temperature-ramping. 
Fluorescent data was collected at the 60°C annealing/extension cycles and Ct 
values were calculated using the automatic Ct analysis settings on an absolute 
quantification run (SDS v2.1, Applied Biosystems). 
2.2.5.4.1.2   Copy Number Variation Analysis 
See section 3.3.7 in chapter 3. 66 
2.2.5.4.2  mRNA Relative Expression Reaction Plate Setup and Analysis 
9 $l of mRNA expression master mix was transferred to duplicate wells in 384 well 
reaction plates, standard curves and NTCs required triplicate wells. Each qPCR 
assay grouping on the plate also includes extra control wells for RT-PCR 
negatives (RT -ve), extraction negatives (Ex -ve) and calibrator cDNA template. 
The plate was temporally sealed and spun down in the plate centrifuge. Working 
on ice, 1 $l of cDNA template, calibrator, RT -ve, Ex -ve or standard curve serial 
dilution cDNA was added to each well using an electronic multi-channel pipette 
(using clean tips for each assay grouping).  The plate was sealed, mixed, spun 
down and then run on the Lightcycler 480 real-time PCR machine according to 
appendix 10.3.  
Note: qPCR assays were grouped by type (Probe or SYBRgreen dye) and ran on 
the same 384 well reaction plates. 
2.2.5.4.2.1  Thermalcycling Reaction Profile 
The profile used depended on the type of qPCR assay used (i.e. TaqMan™, UPL 
probes or SYBRgreen dye); see appendix 10.3 for a detailed description of each 
thermalcycling profile. 
2.2.5.4.2.2   PCR Efficiency Determination by LinRegPCR Analysis 
PCR efficiency estimates were performed on amplification plot data text files 
exported from the LightCycler480 system software. LinRegPCR analyses were 
performed in line with LinRegPCR user’s manual;
265 fitting the regression line with 
4-6 data points and best correlation. All regression lines were visually checked and 
the fit was corrected as necessary to ensure accurate estimates of PCR efficiency. 
See appendix 10.4 for a detailed description of the LinRegPCR program.  
2.2.5.4.2.3  Relative Expression Using Multiple Reference Genes Analysis Protocol 
Relative expression values were calculated for each target/reference gene 
combination in the Lightcycler480 relative expression module (appendices 10.3 
and 10.4). When the standard curve range did not include all sample 
concentrations, LinRegPCR efficiency values were determined and relative 
expression values were calculated in Microsoft® Excel spreadsheets using the 
Roche E-method.
266 The geometric mean of values from each target/reference 
gene  combination was then used for all further data analysis.  67 
3  Chapter 3: Optimisation and Validation of Glutathione 
S-Transferase Copy Number Variation Assays  
3.1  Introduction  
The advent of microarray-based comparative genomic hybridisation (array CGH) 
technologies and whole genome sequencing has enabled the detection of 
unexpectedly heterogeneous structural variation (deletions, duplications, 
inversions and translocations) in the human genome.
267-269 These variations may 
have a greater effect on disease susceptibility than previously thought; therefore it 
is important for any genetic study to consider the presence of structural variations 
in the region of interest and have suitable technologies to detect them.
270 Current 
technologies such as array-CGH and MLPA (Multiplex ligation-dependant probe 
amplification; HRC Holland) facilitate the detection of structural variation across 
the genome or a smaller chromosomal region respectively.
271, 272  
In order to examine glutathione s-transferase gene polymorphism in the 
Southampton asthma cohort (table 2.6) it was necessary to develop a high-
throughput genotyping technology capable of providing gene dosage information. 
Previous work in the genetics of asthma has shown that deletions of these genes 
increase the risk of developing asthma and interact with environmental oxidative 
stress exposures (section 4.1.4).   
GSTT1 and GSTM1 gross gene deletions were created by separate equal or un-
equal recombination cross-over events between two highly homologous repeat 
regions flanking each gene.
194, 195 The separate recombination events result in 
deletion junction regions spanning up to several kilobases with very high homology 
(>98%) to the flanking repeat regions on chromosomes containing the genes. This 
phenomenon severely restricts unique priming sequences for standard PCR 
methods to identify the presence of a deletion.  68 
Sprenger et al. described a multiplex PCR method using unique priming sites in 
the GSTT1 deletion junction.
194 This method appears to have limited suitability in 
large scale genetic epidemiological studies as it involves two-steps with PCR 
amplification followed by agarose gel electrophoresis being required to visualise 
the 1.46 kb deletion junction and 466 bp gene specific PCR products. Unbiased, 
co-amplification of products differing this much in size can be problematic 
(especially when DNA quality is variable) as preferential amplification of the 
product with the higher PCR efficiency (most likely the smaller product) may 
occur.
273 
Brasch-Andersen et al.
274 have shown that it is possible to utilise the increased 
sensitivity of real-time PCR assays to provide dosage of GSTT1 and GSTM1.
274 
This method can distinguish between individuals with two, one or zero copies of a 
gene. As GSTT1 or GSTM1 copy number variations (also known as, ‘gene 
dosage’) are correlated with altered enzyme activity, 
194, 199 analysis in a dose-
dependant manner would best describe any disease outcome association.  
The principle of applying real-time PCR to copy number variation genotyping is 
relatively simple, each copy number variation will require two sets of primers and 
fluorescent probes, the first set being specific to the gene of interest (i.e. variable 
copy number gene) and the second set specific for a stable reference gene (i.e. 
single copy number gene). The fluorescent signal generated by PCR amplification 
of the variable copy number gene can be normalised to the fluorescent signal from 
the stable reference PCR reaction. When these PCR reactions are combined in a 
single well (‘multiplexed’), the reference gene PCR assay controls for the starting 
amount of template DNA in each PCR reaction and permits the calculation of copy 
number (i.e. no gene present, 1 copy, 2 copies, 3 copies…etc) expressed either as 
a concentration ratio of or difference from the reference gene Ct/Cp value (see 
figure 3.1). 
This Chapter describes the real-time PCR assay design, optimisation, validation 
and novel data analysis software required to generate a high-throughput 
genotyping technology for assaying common GST gene deletion polymorphisms. 69 
 
Figure 3-1: Determining Gene Dosage by Real-Time PCR.  
The level of target gene amplification signal is normalised for starting DNA template concentration 
by the reference gene amplification signal. Ct values are derived from the point at which the 
fluorescent signal crosses the threshold. The resulting "Ct values are used to determine the gene 
copy number in that DNA sample. In this example, samples with no target gene have large "Ct 
values (i.e. no amplification of target gene, therefore the reaction end point of 40 is substituted into 
the equation); in samples with one copy of the target gene the "Ct value is determined to be 
approximately zero. Samples with two copies of the target gene have a "Ct value of about -1 as 
the target gene amplification signal has crossed the threshold before the signal from the reference 
gene. 70 
3.2  Aims 
The aim of this work was to: 
•  Design real-time PCR based copy number variation assays for the 
GSTM1 and GSTT1 genes. 
•  Optimise and validate the use of multiplex real-time PCR assays for 
high-throughput Copy Number Variation genotyping of the GSTM1 
and GSTT1 genes.  
•  Design a custom analysis program for processing high-throughput 
real-time Copy Number Variation data. 71 
3.3  Methods 
3.3.1  Principles of the TaqMan Probe Based Real-Time PCR Assay  
TaqMan Probe based real-time PCR detection is achieved via the 5’ nuclease 
activity of Taq polymerase.
275 Hybridisation of a sequence specific fluorescent 
oligonucleotide probe to template DNA or PCR product is achieved using stringent 
PCR conditions that favour cleavage of a correctly matched probe during 
extension by the Taq polymerase. Upon cleavage the fluorochrome molecule is 
separated from the quencher molecule and releases light that can be detected by 
the real-time machine.  
3.3.1.1  TaqMan PCR Reaction 
At the start of the PCR reaction (step 1 in figure 3.2), Uracil-N-Glycosylase (UNG) 
is activated at 50°C for two minutes; this enzyme degrades any DNA containing 
the Uracil base and therefore stops the amplification of any PCR product that may 
be contaminating the reaction well. Step 2, activates the hot-start Taq polymerase 
enzyme by breaking the synthetic peptide bond covering the active site. Activation 
of the Taq polymerase enzyme at a high temperature ensures that no non-specific 
amplification can occur and interfere with the PCR reaction. Step 3, denatures the 
DNA template into single strands and breaks any secondary structure in the 
probes and primers ready for the first cycle of PCR. Step 4, cools the reaction from 
95°C to 60°C; this cooling step allows the annealing of the correctly matched 
probe to the sequence of interest and then the primers anneal to their respective 
priming sites. The Taq polymerase activity extends the 3’ end of the primer and 
cleaves the probe in the 5’ to 3’ direction releasing the fluorescent dye from the 
close proximity of the quencher molecule. This results in the break down of 
Förster-type resonance energy transfer (FRET) between the two molecules 
allowing for the reporter fluorescence to be visible when excited by the excitation 
light source.
276 Steps 3 and 4, are repeated up to 44 times generating a two-fold 
increase in PCR product  at each cycle and the amplified reporter fluorescence 
signal is detected at the end of each cycle of PCR. A hybridised mis-matched 
probe will be displaced by the Taq polymerase rather than cleaved by the 5’ 
nuclease activity.  72 
Up to 45 Cycles 
The probe Melting temperatures are designed so that the annealing temperature 
of the reaction allows for the binding and cleaving of only the correctly matched 
probe (point A in figure 3.2). The melting temperature (Tm) of a miss-matched 
probe is lower than the annealing temperature of the reaction (Point B), so any 
partial hybridisation of a mis-matched probe will lead to displacement of the probe 
strand by the Taq polymerase, with no release of reporter fluorescence.  
Figure 3-2: TaqMan PCR Thermalcycling Reaction.  
The diagram demonstrates that through stringent assay design and constrained thermalcycling 
parameters the hybridisation of a mis-matched probe is virtually impossible as the melting 
temperature of a miss-matched probe/template duplex is lower than the annealing temperature of 
the thermalcycling reaction. Therefore, the fluorescent probe signal is highly specific to the target 
region only. 
 
Key 
1.  UNG activation 
2.  AmpliTaq Gold Activation  
3.  Denaturing of DNA  
4.  Annealing and extension Stage 
A.  Melting Temperature (Tm) of a hybridised match probe 
B.  Melting Temperature (Tm) of a hybridised miss-matched probe 73 
3.3.1.2  TaqMan® Probe Designs 
There are two designs of TaqMan® probes. A Tamra™ probe (See figure 3.3) 
consists of a reporter dye and the Tamra™ quencher (Tamra™ is a fluorescence 
dye which can quench FAM or VIC reporter dye signals by absorbing the released 
energy and emitting its light at a higher wavelength). The Tm of a Tamra™ probe 
is totally dependant on the melting temperature of the sequence. The MGB probe 
is similar to the Tamra™ probe except for the addition of a DNA Minor Groove 
Binding (MGB) moiety that increases the Tm of the probe and the use of a non-
fluorescent quencher (releases energy as heat). The stabilisation effect of the 
minor groove binder allows for shorter probes to be designed (increases signal 
strength), and the probing of AT rich sequence regions (low Tm regions) in the 
genome.   
 
Figure 3-3: TaqMan Probe Designs.  
There are two forms of the TaqMan hydrolysis probe; both probes have a reporter dye on a linker 
arm attached to the 5’ end of the oligonucleotide probe and a quencher molecule on the 3’ end of 
the probe. The MGB moiety is a crescent shaped molecule that fits into the minor groove of the 
DNA, whereby stabilising the shorter TaqMan MGB probe:DNA duplex. 74 
3.3.2  Copy Number Variation qPCR Assay Design  
Real-time PCR TaqMan® MGB probe assays were designed as previously 
described in the general methods section 2.2.7.1 for the GSTM1, GSTT1  and 
ALBUMIN (ALB) gene which acts a reference to normalise out differences in the 
starting DNA template concentrations between samples. As the PrimerExpress 
v2.0 software designs up to 200 assays for each gene; the optimum assay designs 
were chosen as follows: 
•  Lowest Penalty score (automatically generated by software,  assays 
are ranked by closeness to optimum TaqMan® assay design 
parameters) 
•  Matched amplicon size to ALB assay 
•  Primers lie over an exon-intron boundary 
•  Primers do not form excessive dimers under multiplex PCR 
conditions (Performed using the primer test analysis in 
PrimerExpress software v2.0) 
The GSTM1 and GSTT1 TaqMan® MGB probes were 5’ labelled with a 6-FAM 
reporter dye and the ALB probe with VIC™ (refer to table 2.3).  
3.3.3  Optimisation of Copy Number Variation Assays 
Using a pooled ECACC Human Random Control (HRC1) DNA samples as 
template (10 ng/reaction), asymmetric primer concentration PCR reactions were 
performed for all three assays as detailed in the general method section 2.2.5.2.1 
to optimise priming conditions. Probe concentration titration reaction cocktails 
(section 2.2.5.2.3) were then made up using the primer concentrations determined 
from the previous experiment. Once the optimal concentrations of primers and 
probe were determined for each assay extra PCR product was generated and 
spiked post-PCR with SYBRgreen dye and a meltcurve analysis was performed 
according to the general methods section (section 2.2.5.2.2.) to test the primer 
specificity for each gene target. Single (e.g. GSTT1, GSTM1 or ALB) and multiplex 
(e.g. GSTT1 & ALB or GSTM1 & ALB) two-fold serial dilution standard curves 
were constructed  according to general methods section 2.2.5.3 and used to 
determined the PCR efficiencies of each probe assay. 75 
3.3.4  Validation of Copy Number Variation Assays 
ECACC Human Random Control (HRC1) DNA samples (www.ecacc.org.uk) were 
used to optimise reaction conditions, determine reaction plate storage stability and 
validated subsequent experiments as positive controls. Table 2.22 details the 
ECACC HRC1 DNA samples used as genomic controls after their genotypes were 
confirmed using the Brasch-Andersen GSTT1/M1 TaqMan assays.
274 
All GST copy number variation reaction mixture cocktails were made up, aliquotted 
to 384 well reaction plates and thermalcycled according to the general methods 
section 2.2.5.4.1. Inter-plate and intra-plate duplicate reactions and Inheritance 
checks (using FBAT v1.4
277) were performed on the Southampton family-based 
asthma cohort (table 2.6) to determine genotyping accuracy.  
3.3.4.1  Hardy-Weinberg Equilibrium Calculations  
Hardy-Weinberg calculations were performed on the parents genotypes using the 
online version of the Definetti program
278 (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl) A 
Pearson’s p value of less than 0.05 was considered to be a significant deviation of 
genotype frequency from Hardy-Weinberg Equilibrium. 
3.3.5  Copy Number Variation Stability Tests 
Assay plate stability trials were performed at 0 hr, 12 hr, 24 hr and 48 hr time 
intervals using the ECACC HRC1 DNA panel (table 2.6) as template for PCR. The 
four identical plates were set up at the same time. The first plate was run 
immediately on the ABI Prism 7900ht sequence detection system, the remaining 
three plates were stored at room temperature (21°C) and ran at 12, 24 and 48 
hour time points.   
3.3.6  Performance of GST CNV Assays on Other Real-Time PCR 
Machines 
One reaction plate using the ECACC HRC1 DNA panel (see table 2.6) as template 
was set up according to the general methods section 2.2.5.4.1 and was 
thermalcycled on the Roche Lightcycler 480 real-time PCR machine (see 
apparatus table 2.10 and appendix 10.3). The reaction plate was thermalcycled 
according to section 2.2.5.4.1.1, a colour comparison was performed and the data 
was analysed according to appendix 10.3. 76 
3.3.7  Design of Copy Number Variation Analysis Spreadsheet 
A macro-based Microsoft® Excel spreadsheet was designed for the analysis of 
gene dosage real-time PCR data. The results and clipped data files generated by 
the SDS v2.1 software (Applied Biosystems) for each plate run can imported into 
the spreadsheet and each duplicate data point can be visualised in a ranked XY 
scatter graph (%Ct versus %Ct ranked sample position; see figure 3.4).  
 
Figure 3-4: Copy Number Variation Ranked XY Scattergraph.  
This is a screenshot of the ranked XY scattergraph from the analysis spreadsheet. A blue diamond 
data point corresponds to the mean "Ct value for one sample. The vertical dashed bars can be 
moved by the user to determine the start and end "Ct values for each genotype group. At this 
zoom level it is relatively easy to distinguish between 0 copy and gene present (1 or 2 copies) 
samples. 
 
The %Ct value for each duplicate can be compared directly to the real-time 
amplification curve plots generated by each sample well grouping (see figure 3.5). 
The interactive sliding rules allow the researcher to semi-automatically assign 
genotype groups and outliers on the basis of %Ct value grouping on the ranked XY 
scatter graph.  
 
0 copies 
2 copies 
1 copy 77 
 
Figure 3-5: Zoomed Copy Number Variation Ranked XY Scattergraph.  
This is a screenshot of the ranked XY scattergraph zoomed into focus on gene present data points 
only. A blue diamond data point corresponds to the mean "Ct value for one sample. The vertical 
dashed bars (labelled ‘A’) can be moved by the user to determine the start and end "Ct values for 
each genotype group. The purple solid bar (labelled ‘B’) can also be controlled by the user; this bar 
displays the real-time amplification data used to calculate the "Ct data point. At this zoom level it is 
relatively easy to distinguish between 1 copy, 2 copy samples and abnormal data points that can 
be manually excluded from genotype assignment by examining the amplification plots directly. 
 
Importantly, interrogation of the real-time amplification curve plots allows the 
researcher to rapidly determine the validity of any genotype call and correct 
manually. The spreadsheet automatically calculates copy number variation and 
gene present/absent frequencies, deviation from Hardy-Weinberg equilibrium and 
several quality control parameters (i.e. mean %Ct value and SD of each copy 
number group). Figure 3.6 displays a full screenshot of the analysis spreadsheet 
user interface.  
B  A  A 
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Figure 3-6: Full Screenshot of the Copy Number Variation Analysis Spreadsheet User 
Interface.  
Data importing is controlled by three mouse reactive control buttons, one to import all plate data, 
and two to import the first or second 96 well DNA array data (1
st button column in the left blue box); 
at this point DNA array names can be typed in (left green box). Users can assign genotype groups 
on the ranked XY scattergraph (top left chart) using sliding control buttons for each genotype group 
(4
th button column in the left blue box), zoom into the gene present results (3
rd button column in the 
left blue box) and simultaneously examine amplification plots (top right chart) using scrolling 
buttons (right blue box). After examining the amplification plot data, any manual genotype calls or 
exclusions are performed using drop down list boxes (right green box). Genotype frequencies, 
Hardy-Weinberg calculations and "Ct value statistics are also displayed in this interface (red box). 
Analysed copy number variation data is then exported in a database format using the three export 
data buttons (2
nd button column in the left blue box). 79 80 
In addition, the interactive and colour-coded 384 and 96 well plate layout arrays 
generated by the macro allow the well position of any genotype call (with 
corresponding %CV of target and reference Ct values between each sample pair), 
water control or failure to be visualised post-analysis; this utility enables the 
researcher to monitor any problematic samples, experimental controls and identify 
any possible plate-edge effects on data quality (see figure 3.7).   
   
Figure 3-7:  Colour Coded 384 & 96 Well Plate Layout Arrays for Data Quality Control.  
The well position of any genotype call (Left panel: left array column; 0 copies in red, 1 copy in 
yellow and 2 copies in green) can be visualised by pressing genotype control button (blue box in 
left panel). Water controls and genotyping failures (Right panel: left array column) are highlighted in 
green and red respectively by pressing the QC control button (blue box in right panel). %CV of Ct 
values for each sample well duplicate is displayed on the right array column in both panels. 
 
Finally, the macro exports all analysed data to a new sheet in the spreadsheet in a 
database compatible format (Microsoft® Access).  
 
 
 
 81 
3.4  Results  
3.4.1  Assay Optimisation 
The sensitivity of the qPCR assays were substantially improved by utilising the 
asymmetric primer concentrations listed in table 2.3; these conditions reduced Ct 
values by up to 1.38 Ct values. Probe concentration titrations (figure 3.8) revealed 
that a 150 nM or 75 nM final concentration of probe for each assay (GSTM1 or 
GSTT1 respectively) could be used in a reaction without any significant decrease 
in signal strength (i.e. lower signal to noise ratio) or sensitivity (increase in Ct 
value). SYBRgreen melt curve analysis revealed single melting peaks for all 
assays.  
 
Figure 3-8: GSTM1 Real-Time Amplification Plots in Reactions with a Decreasing Probe 
Concentration.  
It is clear from the amplification plot data that 150 nM of probe can be used without any change in 
Ct value or significant decrease in fluorescence signal magnitude compared to the highest probe 
concentration (200 nM); thus the use of 150 nM of probe in reactions is a probe cost saving of 
25%. 82 
3.4.2  Assay Validation 
3.4.2.1  Standard Curve Analysis 
Under multiplex conditions all assays performed well using the optimised 
asymmetric primer and probe concentrations described above. The standard 
curves in figures 3.9 and 3.10 demonstrate that the multiplex reactions are 
capable of linear amplification over the full range of DNA template concentrations.  
Over the 20 – 0.156 ng DNA template dilution range all PCR reaction efficiency 
values (E = 10 
1/s -1; where s is the slope of the standard curve) were between 
1.95 and 1.99; which are close to the maximum theoretical value (E = 2.0) where a 
1 Ct value is equal to a doubling of PCR product at each cycle of PCR. The inter-
assay PCR efficiency variation was less than 1% in both multiplexes (EGSTM1 - 
EALBUMIN = 0.65%; EGSTT1 & EALBUMIN = 0.01%) confirming that both PCR products 
in the multiplex are amplifying at almost the same rate.  
 
Figure 3-9: GSTM1 Standard Curve Analysis.  
Standard curves generated using pooled ECACC DNA template in a GSTM1 (!) + ALBUMIN (") 
multiplex reaction. Each data point is the mean of three duplicate wells, errors bars = 95% CI. DNA 
concentration range 0.156 – 20 ng/well. The PCR efficiencies (E) are almost the same in both PCR 
reactions and the linear regression coefficients are > 0.997. 83 
 
 
Figure 3-10: GSTT1 Standard Curve.  
Standard curves generated using pooled ECACC DNA template in a GSTT1 (!) + ALBUMIN (#) 
multiplex reaction. Each data point is the mean of three duplicate wells, errors bars = 95% CI. DNA 
concentration range 0.156 – 20 ng/well. The PCR efficiencies (E) are virtually identical in both PCR 
reactions and the linear regression coefficients are > 0.999. 
 
Any experimental variation in the !CT (!CT = CTtarget – CTreference) value used to 
determine the gene of interest copy number can be estimated by the %CV 
(Percentage Coefficient of Variation) of the mean of the !Ct values determined at 
each DNA dilution point along the standard Curve. Over the full dilution range (20-
0.156 ng DNA) there is 13.34 %CV and 13.92 %CV in !CT values for the GSTM1 
and GSTT1 assays respectively.  
3.4.2.2  !Ct Variation by Genotype 
Initial genotyping of 192 DNA samples for both genes demonstrated that the mean 
"Ct values (± 1 SD) for 0 copy individuals were 12.9 ± 1.14 for GSTM1, 14.15 ± 
1.77 for GSTT1; 2, and 1 copy individuals for GSTM1 were -1.25 ± 0.09 and -0.22 
± 0.16 respectively. For GSTT1, individuals with 2 copies have mean "Ct values of 
-1.83 ± 0.21 and -0.74 ± 0.18 for 1 copy of the gene.  84 
The "Ct2copies – "Ct1copy difference was initially determined to be 1.03 and 1.08 for 
GSTM1 and GSTT1; this value is very close to the theoretical 1 Ct value 
associated with a doubling in concentration (i.e. one extra copy of the gene). In 
practise, this value varies slightly between plate runs (0.85-1.20); this variation 
does not impact genotyping accuracy as data from each plate is analysed 
independently in the analysis spreadsheet. 
3.4.2.3  Genoytyping Success and Accuracy 
Table 3.1 shows the full cohort and parent genotype frequencies for both gene 
copy number variations and non-significant Pearson test results for deviation from 
Hardy-Weinberg Equilibrium. Undetermined copy number variation call rates (e.g. 
2, 1, and 0 copies) were 4 and 9% for GSTM1 and GSTT1 genes respectively; and 
2% and 3% for the gene absent/present call. 
Genotyping accuracy of the GSTM1 (99.87%) and GSTT1 (99.46%) assays was 
determined by subtracting the number of non-Mendelian inheritances detected by 
the FBAT program from the number of child genotypes (GSTM1 n = 770; GSTT1 n 
= 735). All of the non-Mendelian inheritances (GSTM1 n = 1; GSTT1 n = 4) 
resulted from child ‘2 copy’ genotype calls when the parental genotype 
combination permitted only 0 or 1 copy offspring.  Duplicate genotyping of 6% of 
the cohort demonstrated 100% concordance of genotype calls between plate runs 
and analyses. 
Table 3-1: GST CNV Genotype Frequencies in the Southampton Asthma Cohort.  
Hardy-Weinberg calculations were only performed to the parent samples to avoid any potential 
confounding by related individuals.  
Copy Number Variation Frequencies n (%) 
Group  Gene  2 copies  1 copy  O copies  HWE P value 
All cohort 
GSTT1 
GSTM1 
415 (31) 
98 (7) 
690 (51) 
534 (38) 
247 (18) 
786 (55) 
N/A 
N/A 
Parents only 
GSTT1 
GSTM1 
193 (31) 
42 (6) 
321 (52) 
250 (39) 
103 (17) 
356 (55) 
0.117 
0.831 
 85 
3.4.3  Stability Trials 
All plates were analysed using the copy number variation analysis spreadsheet 
and genotypes were assigned to the three later time point plates based on the 
genotype results from the first plate (time = 0). The reported Ct values for each 
genotype were then compared to determine the maximum length of storage 
without loss of data quality (figure 3.11). The assay plate stability trial results 
determined that sealed reaction plates can be stored protected from light at room 
temperature for up to 24 hours before the real-time PCR thermalcycling run 
without any degradation in the real-time data quality. 
 
Figure 3-11: Matrix Histograms of the Assay Stability Trial.  
Left panel: histogram matrix of "Ct values by GSTM1 genotype (WT = 2 copies, HET = 1 copy, 
NULL = 0 copies) at four time points (0, 12, 24, 28 hours). Right panel: histogram matrix of "Ct 
values by GSTT1 genotype at the four time points (0, 12, 24, 28 hours). It is apparent from the 
distinct distribution of "Ct values for each genotype that the master mix remains stable up to 24 
hours after plating out. 86 
3.4.4  Performance of GST CNV Assays on Other Real-Time PCR 
Machines 
The analysed GST CNV results from the Lightcycler 480 real-time PCR machine 
show that the assays perform well on other real-time PCR platforms without any 
further optimisation or validation. All of the genotype assigned to the ECACC 
HRC1 DNA panel on the Lightcycler 480 machine matched the genotypes 
determined previously on the ABI Prism 7900HT sequence detection system. The 
GSTT1 XY scatter graph generated in excel directly from the relative quantification 
concentration ratios shows that sample data points can be discriminated into 
individuals with 0, 1 and 2 copies of the GSTT1 genes (see figure 3.12). The data 
from the GSTM1 XY scatter graph was very similar and clustered into each of the 
three possible genotypes (data not shown).    
 
Figure 3-12: GSTT1 CNV Scatter graph from the Roche Lightcycler 480 Machine.  
As the Lightcycler relative quantification software module calculates the difference between the 
target and reference gene using a ratio (ConcTarget/ConcReference); a 0 copy genotype has a 
concentration value of 0 and 1 & 2 copy genotypes have respective concentration values of about 1 
& 2.  It is clear from the distribution of the data that this assay performs well on other real-time PCR 
platforms without further optimisation. 87 
3.5  Discussion 
This new methodology provides a significant advance in enabling the study of 
gene copy number variation in large sample numbers required by genetic 
association studies. This is not the first application of real-time PCR to assay 
GSTM1 and GSTT1 copy number variation; several other protocols have been 
described in the literature.
274, 279 Unfortunately, these methods do not have true 
high-throughput capability because of low sample density on reaction plates due to 
triplicate wells and large reaction volumes (# 5 $l) resulting in high costs per 
sample. With this method 96 samples can be genotyped in duplicate wells for 2 
copy number variations on 1 reaction plate (or 192 samples for 1 copy number 
variation) in under two hours with a proportional cost saving of 66% in 2 x qPCR 
master mix and 25% in probe costs. The protocol presented in this thesis has true 
high-throughput capability as it is compatible with standard laboratory liquid 
handling robotic platforms for DNA aliquoting, reaction plate setup and real-time 
PCR machine plate loading. Assay stability trials have shown that 12 x 384 well 
reaction plates can be processed with in a 24 hour period with out any degradation 
of real-time PCR data quality.  
The analysis methodology described in the Brasch-Anderson paper
274 requires 
substantial post-run data processing and analysis by Probit/Rankit plots. Whereas, 
the macro-driven analysis spreadsheet described in this chapter provides 
automation to the data analysis procedure and allows for the examination of real-
time amplification plots for every well on each reaction plate while assigning 
genotypes to each "Ct value. The analysis spreadsheet provides non-experienced 
and experienced real-time PCR users alike a complete analysis, quality control, 
troubleshooting and data handling solution to copy number variation genotyping on 
the ABI 7900ht sequence detection machine. This Microsoft Excel® spreadsheet 
removes the considerable bottleneck of processing real-time PCR data and can be 
applied to real-time data from other copy number variations. Initial experimentation 
on the Lightcycler 480® Real-time PCR machine (Roche Diagnostics, UK) 
demonstrated the portability of these assays without further optimisation of 
reaction or run conditions. This system is readily adaptable to study other copy 
number variations in the human genome. 88 
3.6  Concluding Remarks and Future Work 
Two multiplex copy number variation real-time PCR assays have been 
successfully designed and tested. These assays provide full gene dosage 
information for common gene deletion polymorphisms in the GSTM1 and GSTT1 
genes. The assays have been optimised down to small volumes (2 x 5 $l per DNA 
sample) enabling true high-throughput capability by providing substantial 
economic savings 66% of master mix and 25% of probe cost) and returning 96 - 
99% of results on the first round of genotyping. In order to speed up data analysis, 
an excel macro-driven analysis package has been designed to process the 
numerous data handling and calculation steps required to generate copy number 
genotypes from the raw real-time PCR data. Streamlining the process in this way, 
with a semi-automatic system has removed the considerable bottleneck of data 
analysis.   
Further developments would include the generation of a standalone software 
application to analyse real-time PCR copy number variation data, with support for 
other real-time PCR platforms currently available on the commercial market. This 
technology could also be applied to other copy number variation polymorphism 
and the assay design, optimisation and validation protocol described in this 
chapter should aid in this. In the case of further study into GSTM1 polymorphism it 
would be interesting to determine if the assay has the capabilities to detect the 
GSTM1 gene duplication (> 2 copies) that had previously been described in a 
Arabic population.
199 Doing so, would require fine tuning of the genotype cut-off 
windows in the analysis spreadsheet as analysis would be performed on the 
extreme end of the data range, where inaccuracy and imprecision is at its 
maximum. This would provide the opportunity to test and implement a procedure 
for automatic genotype assignment, either by a linear regression or statistical 
method. These improvements could also increase the overall successful genotype 
call rate on first round of genotyping.  89 
4  Chapter 4: Environmental Tobacco Smoke, 
Glutathione S-Transferase Gene Polymorphisms and 
Childhood Asthma 
4.1  Introduction 
Asthma is mediated by inflammation in lung tissue, reactive oxygen species (ROS) 
can be formed as a result of inflammatory processes and from environmental 
exposures. Glutathione is a tripeptide that protects cells from ROS damage 
through conjugation with reactive substances (section 1.5.1). Glutathione S-
transferases catalyse the conjugation of glutathione to reactive substances (see 
section 1.5.2). Therefore, glutathione S-transferase enzymes are potent 
antioxidants and play an important role protecting against cellular damage caused 
by oxidative stress. GST genes are highly polymorphic and polymorphisms that 
reduce enzyme activity have been associated with increased risk from numerous 
cancers,
204, 280, 281 Reduced GST activity can increase cancer risk by increasing 
cellular sensitivity to environmental toxins and carcinogens and by modifying the 
efficacy and toxicity of certain anti-cancer treatments.
282, 283 
4.1.1  Oxidative Stress in the Lung 
The potential for oxidative stress mediated damage in the lung is high as a 
consequence of breathing air. The pathology of respiratory diseases such as 
cystic fibrosis, COPD and asthma are characterised by an imbalance between 
reactive oxygen species and antioxidant defences (reviewed in Kelly, 1999).
284 In 
the lung, ROS arise from endogenous sources such the influx of inflammatory 
cells and exogenous sources such as air pollution and cigarette smoke.
284 Chronic 
inflammation, a characteristic of asthma, can be induced in the lung through a 
continuing imbalance between increased ROS levels and/or inadequate 
antioxidant defence mechanisms.
285 The lung has a range of antioxidant defences 
to protect tissue from damage by oxidative stress, employing either enzymatic or 
non-enzymatic mechanisms (See table 4.1).  90 
Table 4-1: Antioxidant Defences in the Lung. 
Adapted from Kirkham et al, 2006.
286 
Enzymatic antioxidants  Location in lung 
Catalase  Fibroblasts, macrophages, 
pneumocytes 
Cu,ZnSOD 
Bronchial & alveolar epithelium, 
macrophages, neutrophils, vascular 
walls, pneumocytes 
EC-SOD 
Bronchial epithelium, macrophages, 
neutrophils, vascular walls, 
pneumocytes 
Glutamate cysteine  ligase  Alveolar, bronchical epithelium, 
macrophages 
Glutathione Peroxidase  ELF cells, epithelium, macrophages 
and other lung cells 
Glutathione S-transferases 
Bronchial & alveolar epithelium, 
clara cells, avelolar macrophages, 
pneumocytes
287 
Heme Oxygenase 1 
Alveolar, bronchical epithelium, 
macrophages, inflammatory cells of 
the lung 
Mn,SOD 
Bronchial epithelium, macrophages, 
neutrophils, vascular walls, 
pneumocytes 
Thioredoxin  Bronchial epithelium, macrophages 
4.1.1.1  Antioxidant Vitamins in the Lung 
Vitamin C (L-ascorbic acid) is an essential nutrient for humans and must be 
obtained from the diet, it is a potent antioxidant that is recycled back into its 
reduced state by glutathione; vitamin C is also required for the synthesis of 
collagen (reviewed by Linster et al, 2007).
288 Deficiency of this vitamin in humans 
causes scurvy. Vitamin C is present in the extracellular fluid lining of the lung and 
low intake of this vitamin has been associated with lower lung function and 
respiratory symptons.
289 Vitamin E is the generic term for eight related tocopherols 
and tocotrienols, that are antioxidant lipid soluble vitamins. These molecules are 
thought to protect membranes from oxidation by reacting with lipid radicals 
produced by lipid peroxidation (reviewed by Wang et al, 1999).
290 In the lung, 
vitamin E is actively secreted with surfactant lipids by type II pneumocytes and is 
considered to be the most important lipophilic antioxidant molecule protecting the 
lung surfactant lipid layer.
291 
Non-enzymatic  
antioxidants 
Concentration in 
lung epithelium 
lining fluid ($M) 
Albumin-SH  70 
Ascorbic acid  100 
%-Carotene  - 
Glutathione  100 
&-Tocopherol  2.5 
Uric Acid  90 91 
4.1.1.2  Measuring Oxidative Stress 
In cells, reactive oxygen species degrade lipids forming Malondialdehyde (MDA), 
this molecule is highly reactive and causes toxic stress in cells by forming protein 
adducts and reacts with bases in DNA to form mutagenic DNA adducts.
292 MDA is 
widely used as a biomarker to measure the level of oxidative stress in an organism 
or disease state.(Reviewed by Rio et al)
293 The level of MDA a biological sample 
can be determined by a colorimetric assay using thiobarbituric acid.
294 
4.1.1.3  Oxidative Stress from Tobacco Smoke 
Cigarette smoke contains thousands of reactive chemical species that have 
damaging effects on lung tissue. (reviewed by Yoshida et al, 2007)
295 Nitric oxide 
(NO) is highly abundant in the gas phase of tobacco smoke and the tar phase 
contains reactive oxygen and nitrogen species (ROS & RNS), quinones and 
phenol. At physiological levels, nitric oxide acts as a key signalling molecule in 
virtually every cell and organ in the body, controlling signal transduction and 
regulation of gene expression.
296 At higher levels, nitric oxide is a highly 
deleterious and cytotoxic free radical.
297 Nicotine components from tobacco smoke 
have been shown to activate NF-'B signalling in several cell lines
298 and long-term 
exposure to nicotine leads to thickening of the airway wall in chronic bronchitis 
because of an imbalance between apoptosis and cell proliferation.
299 
4.1.1.4  Glutathione in the Lung 
The antioxidant, glutathione is present in the intracellular, and vasculature systems 
and in respiratory tract lining fluid (RTLF).
300 Glutathione (GSH) is a key 
intracellular antioxidant in the lung, that is maintained at high concentrations in 
RTLF and levels are higher in smokers and asthmatics, and lower in people with 
CF, HIV and idiopathic pulmonary fibrosis (reviewed by Kelly, 1999).
284 It is clear 
that low levels of GSH in the RTLF will leave the surface of the lung more 
susceptible to damage from exogenous and endogenous sources (see figure 4.1).  
However, is not known if GSH status is the cause or a consequence in these 
conditions.
284 It is thought that reduced GSH levels in the RTLF could lead to 
inactivation of the antiproteolytic screen in the airways, leaving the lung epithelium 
more susceptible to proteolytic attack.
284  92 
The GSH redox status of the airways plays a key role in the regulation of the 
inflammatory response in the lung to stimuli via NF-'B signalling, inducing 
transcription of pro-inflammatory genes (reviewed by Rahman et al, 2006).
301  
 
 
Figure 4-1: Mechanism of Cigarette Smoke Mediated Lung Injury by Glutathione Depletion  
Reactive components of cigarette smoke are thought to overwhelm antioxidant defences, namely 
by depleting glutathione levels, whereby unbound ROS are free to damage cells and initiate airway 
remodelling mechanisms.    
4.1.2  Reactive Oxygen Species in Asthma 
ROS generation can induce many of the pathological features of asthma such as, 
increased arachidonic acid release, airways smooth muscle contraction, airways 
reactivity, secretions, vascular permeability, and synthesis of chemoattractants 
(reviewed in Kirkman et al, 2006).
286 Triggers for asthma exacerbations include 
ozone (O3), environmental tobacco smoke and viral infections (see section 1.2). 
Malondialdehyde, NO and H2O2 can be used as markers of oxidative stress in the 
lung and are found to be increased in breath condensate from asthmatics.
302 ROS 
can stimulate histamine release from mast cells and increases mucus production 
by airways epithelial cells.
303 Inflammation has been shown to be driven by 
oxidative stress in asthmatics.
304 Inflammatory and immune cells such as, 
macrophages, neutrophils and eosinophils release increased amounts of ROS in 
asthmatic individuals.
305 Finally, ROS can directly damage epithelial cells and 
cause cell shedding.
306 93 
4.1.3  Environmental Tobacco Smoke Exposure in Early Life 
Environmental tobacco smoke is a major risk factor for respiratory disease in 
children.
307, 308 Exposure from maternal smoking during pregnancy and the first 
years of life in the home has consistently been found to affect the respiratory 
system and is associated with symptoms such as wheezing, cough, bronchitis and 
development of asthma.
58, 309-311 The impact of ETS appears to be strongest 
during foetal development and in the first years of life, affecting intrauterine 
growth, lung development and lung function growth.
57, 312-314 The results from 
studies examining the effect of ETS exposure on atopy are not as consistent as 
those focussing on wheeze and asthma, indicating that non-immune related 
mechanisms may be more important in determining susceptibility.
315, 316 The 
increasing prevalence of respiratory symptoms in recent years is thought to be due 
to a genetic predisposition in individuals exposed to detrimental environmental 
exposures. Maternal smoking during pregnancy is the largest avoidable exposure 
and can be tackled through awareness programs aimed at expectant mothers.   
4.1.4  GST Polymorphism and Risk of Asthma 
The majority of genetic epidemiological studies of GST polymorphism (GSTP1, M1 
and T1) provide supporting evidence for an association with increased asthma 
susceptibility in children and adults. In addition, these polymorphisms, as might be 
expected from their function, interact with environmental oxidative stress 
exposures such as ETS and air pollution. 
In Danish atopic families the presence of GSTM1 and GSTT1 gene deletions are a 
risk factor for the development of asthma in a dose response manner.
274 Other 
studies of asthma have also confirmed GSTM/T1 gene deletion as a risk factor for 
asthma development.
279 GSTM1/T1 polymorphism and ETS interactions have also 
been shown to contribute to the development of childhood asthma
317 and may 
leave asthmatic children more susceptible to the deleterious effects of ozone.
84 
Gilliland et al.
318 showed that GSTM1 and GSTP1 polymorphism appears to 
modify the adjuvant effect of diesel exhaust particles on allergic inflammation,
318 
and children with GSTM1 deletions have also been shown to have decreased lung 
function growth.
319  
A recent meta-analysis of GST polymorphism in adult asthma involving 14 studies 
(2292 asthma patients and 5718 controls) reported an overall asthma risk of 1.20 
(95% CI: .08-1.35) with the GSTM1 null genotype.
320 When stratified for age and 94 
smoking status this risk increased to 1.56 (95% CI: 1.25-1.94) and 1.95 (95% CI: 
1.21-3.13) in non-smokers. The GSTT1 null genotype was also associated with 
asthma risk in non-smoking adults (OR = 2.06, 95% CI: 1.21-3.71). Further 
analysis with combined GST genotypes revealed that individuals with both GSTM1 
and GSTT1 null genotypes were at a significantly higher risk of developing asthma 
(2.15, 95% CI: 1.39-3.33). The authors concluded that GSTM1 and GSTT1 genes 
do not protect against the development of asthma in adults with a positive history 
of smoking, because chronic smoking carries such a high dose of toxins into the 
body that it overloads the capacity of either GSTM1 or GSTT1 detoxification 
system.
320   
Findings from GSTP1 association studies are not so consistent. The variant 
GSTP1 Val105 allele, that is associated with decreased glutathione activity,
321 has 
been shown to be protective against asthma,
202 atopy
322 and reduced airway 
responsiveness.
323 Carroll et al.
324 observed increased lung function in children 
carrying the GSTP1 Val105  allele.
324  Furthermore, the same group also observed 
that mothers who are homozygous for GSTP1 Val105 have children who are more 
likely to have increased lung function, decreased atopy and airways 
hyperresponsiveness.
325,326  An eleven year follow up study in the SAPALDIA 
cohort,
327 found there was an increased risk of progression of BHR to adult onset 
asthma in the Swiss general population who are homozygous for GSTP1 Ile105.
328 
The GSTP1 Val105
 genotype has been shown to interact with a high EPHX1 
(Microsomal epoxide hydrolase) phenotype, increasing the risk of lifetime asthma, 
in children who lived within 75 metres of a major road.
329 In a relatively small study 
of isocyanate-induced occupational asthma in 131 individuals exposed for over 10 
years, a protective effect of homozygosity for the GSTP1 Val105 allele was 
observed; Val105 carriers experienced milder airways responsiveness and the 
protective effect increased in proportion to the duration of exposure to toluene 
diisocyanate.
330 However, in the published literature there are several findings that 
contrast with these reports; the Val105 allele has also been associated with risk of 
asthma,
279 increased environmental tobacco smoke effects on lung function
331 and 
ozone induced breathing difficulties.
332 Furthermore, several publications have 
also found no association between GSTP1 Val105 genotype and asthma.
274,333 95 
In the last year, studies have tried to address these contrasting findings by 
performing comprehensive GSTP1 haplotyping studies examining gene-
environmental interactions with risk factors. GSTP1 haplotypes have been 
associated with respiratory illness-related absence, decreased risk of exercise 
associated asthma in high ozone and particular haplotypes have been shown to 
modulate the association of in utero maternal smoking on asthma/wheezing 
outcomes in shoolchildren.
334-336  
Very few genetic epidemiological studies have been performed on GSTO2 
polymorphism, and the ones that have been done, generally focus on arsenic 
exposure and cancer risk.
337 To date there have been no studies performed that 
examine the role of GSTO2 polymorphism in asthma susceptibility. However, the 
results from a recent large genome-wide association study of population based 
lung function found two GSTO2 single nucleotide polymorphisms (rs156697 and 
rs156699) to be strongly associated with mean FVC and FEV1 values.
338 A recent 
study of susceptibility to chronic obstructive pulmonary disease (COPD) failed to 
replicate the lung function findings from the genome-wide association study, but 
did find that the GSTO2 polymorphism, rs156697 was associated with increased 
risk of developing COPD.
339  96 
4.1.5  Hypotheses 
It is proposed that: 
‘Glutathione S-transferase gene polymorphisms modulate the susceptibility to, and 
subsequent severity of, childhood asthma when exposed to environmental tobacco 
smoke in pregnancy and/or early life’. 
The work presented in this chapter attempts to test the above hypothesis by 
utilising the novel real-time PCR based copy number variation technique 
presented in Chapter 3 and further GST SNP genotyping described in this chapter. 
GSTM1, GSTT1 CNV genotyping and GSTO2 and GSTP1 SNP genotyping was 
performed on DNA from a large UK family-based study of childhood asthma. 
Family based association tests were used to investigate whether GST 
polymorphism modulated the risk or severity of asthma and if a gene-environment 
interaction exists between GST genotype and tobacco smoke exposure in early 
life.      
4.2  Aims 
The aim of this work was to: 
•  Perform gene-only association analysis of GST gene polymorphism 
with asthma phenotypes in the Southampton asthma family cohort.  
•  Perform gene-environment interaction association analysis of GST 
gene polymorphism and asthma phenotypes from asthmatic siblings 
stratified by parent smoking status during pregnancy or early 
childhood. 97 
4.3  Methods  
4.3.1  Study Population 
Recruitment to the Southampton asthma study began in 1997 by the Asthma 
Genetics group at the University of Southampton in collaboration with Genome 
Therapeutics Corporation (Waltham, MA, USA). In the UK, families were recruited 
into the study from the Southampton area, with multi-centre sites in Southampton, 
Portsmouth, Bournemouth and the Isle of Wight. Potential candidates were 
identified by general practitioners and the families were contacted in writing. 
Families were entered into the study if there were two siblings (5 to 21 years old) 
diagnosed with asthma and currently using asthma medication. Families were 
excluded if both parents were affected with asthma. Data was collected from 341 
families, comprising 1,508 individuals. In 2002, a genome-wide linkage analysis of 
this study population identified a novel asthma susceptibility gene called 
ADAM33.
121 
4.3.2  Study Questionnaire 
The case report form included questions on demographics, medical history 
including medication, a health survey on the incidence and frequency of asthma, 
wheezing, eczema, hay fever, nasal problems, smoking and home environment.
121 
4.3.3  Preparation of DNA samples 
DNA was previously isolated from peripheral blood samples collected from the 
participants at recruitment and archived in the laboratory for future analysis.  
1 ng/$l working concentration DNA arrays were aliquoted from the archived 100 
ng/ul stock DNA arrays stored at 
-80°C using the Biomek 3000 liquid handling 
system. (See appendix 10.2) 98 
4.3.4  Asthma Phenotypes 
All of the phenotype measurements were performed at recruitment. Numerous 
measurements were made but only six phenotypes were used in the GST CNV 
FBAT analysis:  
•  Asthma diagnosis 
•  Log age corrected total IgE levels 
•  BHR 
•  % Predicted FEV1 
•  Positive atopy severity score 
•  Positive asthma severity score 
4.3.4.1  Asthma Diagnosis 
The criteria for being affected with asthma in this study required a physician’s 
diagnosis of asthma and current asthma medication use. 
4.3.4.2  Atopy Measurement 
Total and specific IgE levels (house dust mite, cat, dog, grass) were measured 
from the blood samples by the ImmunoCAP™ system (Pharmacia Diagnostics). 
Asthmatic individuals were dichotomised using an age-specific cut-off for elevated 
total IgE levels (age 5–9 yr, >52 kilounits (kU) l
-1; age 10–14, >63 kUl
-1; age 15–
18, >75 kUl
-1; age # 19, >81 kUl
-1). An individual was assigned a positive specific 
IgE value if his/her level was positive (to grass or tree) or elevated (#0.35 kUl
-1for 
cat, dog, Dermatophagoides pteronyssinus, D. farinae, Alternaria, ragweed) for at 
least one such measure.
121 Skin prick tests using the same allergens were also 
performed.
121 99 
4.3.4.3  Bronchial Hyperresponsiveness 
Bronchial hyperresponsiveness was measured using a methacholine challenge 
(section 1.1.4.1.1). Bronchial responsiveness was only measured in participants 
with a baseline forced expired volume in 1 second (FEV1) of #70% predicted. 
Doubling methacholine concentrations (0.06 – 16.0 mg/ml) were administered in 
continuous 5 minute durations until a 20% reduction in FEV1 or the highest 
concentration has been reached. FEV1 values were recorded 30 seconds after 
each dose and continued at 1 minute intervals thereafter. A linear model was then 
fitted to the recorded FEV1 values and corresponding cumulative dose received. 
The least squares slope value could then be derived and used in the following 
equation, to provide a measure of each participant’s bronchial responsiveness. 
Equation 5: Calculation of BHR Variable 
 
The reciprocal transformation was used to improve uniformity of variance, while 
the constant value of 30 was added to avoid negative values. Furthermore, 
multiplying by the constant 1000 avoided the need for three decimal places. This 
BHR variable has a negative correlation with BHR (i.e. larger value = less BHR). 
4.3.4.4  Lung Function Measurements 
A baseline FEV1 measurement was established by monitoring the participant’s 
performance in pulmonary function tests at 60 second intervals. Percentage 
predicted FEV1 were calculated using the formula and the population-based 
sample used to calculate the Predicted FEV1 values is described in section 
1.1.4.1.2.  100 
4.3.4.5  Atopy Severity Score 
Each patient’s atopy score was derived via an equation involving the following 
components: 
1.  The 1st principal component (PC) for mean wheal diameter from the skin 
prick test. This represents the magnitude of the response. 
2.  The numbers of positive skin prick responses representing the range of the 
response. If the mean wheal diameter was greater than or equal to 3mm 
then that particular test was considered positive. 
3.  The level of specific IgE response as measured by the 1st PC of specific 
IgE’s. This represents the magnitude of the response. 
4.  The number of positive responses to specific IgE. This represented the 
range of the response. 
An appropriate constant value was added to the severity score to ensure all values 
were positive. 
4.3.4.6  Asthma Severity Score 
Each patient’s asthma score was calculated via an equation involving three 
components: 
1.   
2.  A treatment score, representing a value assigned to each patient according 
to the British Thoracic Society’s guidelines. This was dependent on the type 
of medication they were receiving. A high treatment score indicates the 
patient is being treated for severe asthma. 
3.  A symptom score, derived from ten questions regarding asthma on the 
health survey questionnaire. The score was calculated by assigning a 
weight indicating the degree of importance to each question. These weights 
were based on the opinion of experienced professionals, namely GP’s, 
chest physicians, paediatricians with a respiratory interest and respiratory 
nurse specialists. 
A high asthma severity score implied the patient had severe asthma. A constant 
value was added to all scores to ensure all values were positive. 101 
4.3.5  Environmental Tobacco Smoke Exposure 
Children were classified as smoke exposed when the mother reported that one or 
more of the following situations occurred:  
•  the mother had smoked during pregnancy  
•  the mother had smoked during early childhood  
•  the father had smoked during early childhood 
4.3.6  Genotyping Methodologies 
4.3.6.1  Copy Number Variation Genotyping 
GSTT1 and GSTM1 CNV genotyping of the Southampton asthma cohort is 
described section 3.3.4.  
4.3.6.2  SNP Genotyping by High Resolution Melting Curves  
The GSTP1 (rs1695 & rs1138272) and GSTO2 (rs156697 & rs156699) SNPs 
were genotyped by High Resolution Melting Curve Analysis
340 (HRM-PCR) after 
PCR amplification on the Lightcycler 480 real-time PCR machine.  
4.3.6.2.1 Principles of high-resolution melting curve analysis 
This SNP genotyping technique incorporates a saturating dsDNA intercalating 
florescent dye (SYTO9, Invitrogen) into a PCR reaction (see table 4.2). Once 
bound to the PCR product it fluoresces greatly compared to the unbound form of 
the dye molecule. During the post-PCR dissociation stage (when the thermalcycler 
ramps slowly from 60 to 95ºC) the double stranded PCR product begins to 
separate and the dye dissociates losing fluorescence. The rate of decline in 
fluorescence is dependant on the length of the PCR product and base 
composition, and can be detected by the real-time PCR machine optics (melting 
curve analysis). A single base pair change in the product can result in a change in 
the rate of decline of fluorescence that can be detected by the real-time PCR 
instrument. The presence of a SNP in the PCR product will form a melting curve 
shape unique to that genotype (see figure 4.2).   102 
Table 4-2: Advantages and Disadvantages of SNP Genotyping by High-Resolution Melting 
Curve Analysis 
Advantages of HRM-PCR  Disadvantages of HRM-PCR 
Cheap. Only requires primers and fluorescence dye. 
No expensive probes. 
Can detect multiple or unknown mutations in a PCR 
amplicon. 
Resolution of the assay is affected by the type of basepair 
transition. i.e. for A>T changes the difference in melting 
temperature can be indistinguishable. However, this can be 
resolved by creating artificial heterozygotes by spiking PCR 
reactions with wild type (AA) DNA template. AA samples will 
generate AA melting curves and TT samples will generate 
heteroduplexes and therefore will present as AT melting curves. 
 
 
Figure 4-2: Principles of SNP Genotyping by High Resolution Melting Curve Analysis 
The presence of a different single nucleotide in the short PCR amplicon (left panel) can have a 
profound effect on the melting temperature (top right panel). DNA with a heterozygote SNP form 
heteroduplex products containing a basepair mismatch that decreases the melting temperature 
further, allowing all three genotypes to be discriminated based on shape and temperature of 
melting curves (bottom right panel).   
4.3.6.2.2 High-Resolution Melting Curve Genotyping Assay Design and Validation 
GSTO2 and GSTP1 SNP assays were designed using the Primer3 website 
(http://frodo.wi.mit.edu/primer3/) setting the design parameters for a PCR product 
size of less than 100 basepairs, primer length ( 27 basepairs with a melting 
temperature of 60°C. Primer sequences are shown in table 4.3. Assays were 
validated by comparing HRM-derived genotypes of commercially available human 
control DNA samples (www.coriell.org/) to publically available individual SNP 
genotype datasets (http://www.ncbi.nlm.nih.gov/projects/SNP/).  
CC 
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Where there was no individual SNP genotype for the human control DNA samples 
in the database; all three genotypes were confirmed by sequence validation. 
Table 4-3: GSTO2 and GSTP1 HRM Primers 
Gene 
Ref sequence 
(Position; bp)  Forward Primer sequence (5’-3’)  Reverse Primer sequence (5’-3’)  Oligo Conc
n 
GSTP1  rs1695  AGCCCTGGTGGACATGGTGA  GCCCAACCCTGGTGCAGAT  600 / 600 nM 
GSTP1  rs1138272  TGGGAGGGATGAGAGTAGGA  GGGCAGTGCCTTCACATAGT  600 / 600 nM 
GSTO2  rs156697  ACCTCTTCCAGGTTGCTGAA  GCCTGGTAGCGTTGAGATGT  600 / 600 nM 
GSTO2  rs156699  CCGGTTTGCACTGGAACTAA  TTGAATGACACAGGGTTGACA  600 / 600 nM 
4.3.6.2.3 HRM Genotyping Experiment Setup 
1.5 $l of DNA template was pipeted into each well on 384 well reaction plates and 
dried down according to section 2.2.5.4.1. Each reaction plate included a minimum 
of three negative and 3 genomic DNA controls (Corriell samples; one of each SNP 
genotype). The HRM-PCR reaction mixture was made up in bulk volumes (see 
table 4.4 below), and 10 $l was transferred to each well using a multi-channel 
electronic pipette. The plates were sealed, spun down and incubated at room 
temperature for 20 minutes with occasional mixing. 
Table 4-4: HRM-PCR Reagent Master Mix Setup 
HRM mastermix  X1  
2xQPCR mix (Eurogentec)  5.0   
Forward Primer (10 $M)  0.6 
Reverse Primer (10 $M)  0.6 
SYTO9 dye (Invitrogen)  1.0 
DNA (10 ng/ul; dried)  --   
dH20  2.8 
Total  10 $l 
4.3.6.2.4 HRM-PCR Thermalcycling Reaction 
The Lightcycler 480 real-time PCR machine thermalcycling conditions for HRM-
PCR were as follows: Taq Activation: 95°C for 10 mins. 45 cycles of PCR: 95°C for 
15 secs, 62°C for 30 secs and 72°C for 30 secs. Directly after the PCR reaction 
the post-PCR dissociation profile was performed: 95°C for 1 min, 55°C for 1 min, 
60 °C for 1 sec, ramping from 60 to 95°C with 25 data acquisitions per °C/s. 104 
4.3.6.2.5 HRM-PCR Data Analysis 
Analysis of the data was performed using the Lightcycler 480 gene scanning 
software module v1.5 (Roche Diagnostics). The SYTO9 dye fluorescent signal 
intensity generated by each reaction well is normalised (vertical adjustment) and 
temperature-shifted (horizontal adjustment) to generate groups of melting curve 
shapes (see figure 4.3). Each group of melting curve data corresponds to a SNP 
genotype and is automatically compared to the in-run genomic DNA control 
samples by the analysis software. At this stage, dubious genotype calls or 
abnormal melting curve data can be identified and excluded.  
 105 
 
Figure 4-3: Normalisation and Temperature-Shifting of HRM Data. 
Before genotype assignment can be performed the fluorescent data signals from all reactions in an 
experiment requires normalisation to the same intensity (Panel A). Normalised data (Panel B) is 
then temperature-shifted, this allows the software to distinguish any differences in the shape of the 
melting curves (Panel C) and assign the correct genotype. 
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4.3.7  Preliminary Analysis 
4.3.7.1   Data Processing, Genotype Frequency and Hardy-Weinberg Equilibrium 
The genotype results were imported into a database directly from the GST CNV 
analysis spreadsheet and duplicate sample and control DNA results were filtered 
from the final data set. An exclusion variable was then applied to the data set to 
remove excluded individuals (e.g. identical twins or those withdrawn from the 
study) from any further analysis. The genotypes were then recoded in to the FBAT 
program pedigree file format.
277, 341 The genotype frequencies for each gene were 
counted and Hardy-Weinberg Equilibrium was tested according to section 3.3.4.1 
in the parents only. 
4.3.7.2  Inheritance Checks 
Mendelian inheritance checks are automatically performed by the FBAT program 
when the pedigree file is loaded into the software. Families with any inheritance 
errors are immediately recoded by the program and are excluded from any further 
FBAT analysis. 
4.3.8  Family Based Association Tests 
This section details the Family Based Association Test (FBAT) method that was 
used to analyse GST copy number variation genotypes and the asthma 
phenotypes described in the last section. The FBAT software also facilitates the 
exploration of any relationship between the smoking status of the parents, GST 
polymorphism and asthma in their children. 
The FBAT association and regression analyses described in this chapter were 
performed with the assistance of Mr. Jake Kashani and Ms. Sheila Barton.  
4.3.8.1  Principles of Transmission Disequilibrium Test  
A transmission disequilibrium test (TDT) uses genotype data from families with at 
least one affected child and evaluates the transmission of the associated marker 
allele from an informative parent to an affected offspring. TDT tests can detect 
linkage between the marker locus and the disease locus only if association (due to 
linkage disequilibrium) is present.  107 
As the test compares the number of times a heterozygous parent transmits the 
associated marker to an affected offspring to the number of times they transmit the 
alternate marker allele within the family pedigree, this test is not affected by the 
presence of population stratification.
342 
4.3.8.2  The FBAT Software 
FBAT version 1.4 (table 2.11 for details) is a computer program designed by 
Rabinowitz and Laird,
277, 341 that builds on the TDT method
342 and integrates tests 
of different genetic models, sample designs, disease phenotypes, missing parents 
and tests of different null hypotheses.  
4.3.8.2.1 Regression Analysis Using the FBAT Software 
FBAT can be modified to include environmental covariates through a covariate-
adjusted phenotype defined as the continuous or dichotomous covariate 
subtracted from the dichotomous indicator of affection status.
343 It is possible to 
develop a susceptibility score using residuals derived from a logistic regression 
model of affection status as a function of only known environmental predictors 
(see table 4.5). 
Table 4-5: FBAT Regression Analysis Outcomes 
Residual values  Inference 
Highly positive   Affected with low environmental risk = Strong Genetic predisposition  
Close to zero  Environmental risk predicts the outcome. Therefore it is unlikely that 
genotype information would provide additional information to the 
association test.   
Highly negative  Unaffected with high environmental risk = No genetic predisposition 
In this analysis, instead of modelling affection status the residuals were derived 
from a linear regression model of the phenotype variables as functions of 
exposure to smoke. Pearson/Standardised residuals were calculated from the 
asthma phenotype measures (dependant variables) and exposure to smoke was 
expressed as a dichotomy (independent variable). 
The advantage of using the regression approach is that the power of the statistical 
tests is often improved because the number of informative families present at each 
stage of the analysis remained relatively large, whilst taking account of the 
differences in exposure to cigarette smoke. 108 
4.3.8.3  Haplotype Based Association Tests (HBAT) Using the FBAT Software 
An extension of the FBAT analysis program is the ability to test for linkage and 
association between a haplotype and a disease susceptibility locus.
277 In the 
presence of multiple tightly linked SNP markers a FBAT test using haplotypes may 
be more beneficial than using the markers one by one as in the standard FBAT 
test procedure as less statistical tests are performed.  
The GSTP1 and GSTO2 SNPs are close together on their respective genes and 
form bi-allelic haplotypes. Therefore, these SNPs were analysed under the HBAT 
protocol.
344 GSTP1 and GSTO2 haplotypes are constructed by the FBAT program 
using an EM algorithm.(See Section 1.4.1.5 regarding EM algorithms) 
4.3.8.4  FBAT Association Analysis Plan 
This study aims to determine whether there is an association between the asthma 
phenotypes described in section 4.3.4 and GST genotype status, stratified by 
whether the parents smoked during pregnancy or early childhood. 
The analysis plan is broken down as follows: 
1.  Perform gene only association tests under a null hypothesis of no linkage 
and no association. Association analysis for the diagnosis of asthma was 
performed on asthmatic and non-asthmatic individuals (siblings); while the 
remaining asthma phenotypes were tested for association in asthmatic 
siblings only. 
2.  Gene-environment analysis: Stratify the genotype and phenotype data for 
the asthmatic siblings by parental smoking status during pregnancy and 
early childhood and perform and compare the association analysis results 
for the smoke exposed and unexposed asthmatic siblings. Note: some 
families may have appeared in each group as the parents smoking status 
may have changed during different pregnancies.  
3.  Finally, perform regression analysis using FBAT using the smoking variable 
as a covariate in the series of regression models for each of the five asthma 
phenotypes (Log age corrected total IgE levels, BHR, %Predicted FEV1, 
Positive atopy severity score, Positive asthma severity score) using SPLUS 
version 6.2 Professional (www.insightful.com/products/splus/default). 109 
FBAT test hypotheses were as follows: 
H1 = association between the presence or absence of the gene and the asthma 
phenotype 
H0 = ‘no association and no linkage’ between the presence or absence of the gene 
and the asthma phenotype  
As there is more than one affected sibling in some families the null hypothesis was 
set to ‘no association and no linkage’ so that the family pedigree can be broken 
down into nuclear families that can be treated as independent. 
4.3.9  Post-Hoc PBAT Power Analysis 
PBAT is an integrated FBAT and study design software package that has 
conditional power calculation functions for virtually any type of family based study 
design.
345, 346 The program can handle different types of traits (dichotomous/binary 
or continuous), family structures and genetic models and all power calculation 
results can be verified by Monte-Carlo simulations. As this study is a retrospective 
study of asthma susceptibility and examines a gene-environment interaction, two 
estimates of power are required. The first calculation estimates the power of the 
study to detect a gene only association with the primary outcome (asthma 
diagnosis) and the second estimates the power to detect an association with 
asthma diagnosis in smoke exposed individuals. PBAT power calculation settings 
were as follows:   110 
Table 4-6: PBAT Power Calculation Settings 
Parameters  Gene only  
Smoke Exposed  
(30 % of families)  
Study Design: 
no. of siblings per family = 
no. of missing parents = 
no. of families =  
ascertainment condition for proband 1 = 
ascertainment condition for proband 1 = 
 
2 
0 
341 
1 
1 
 
2 
0 
102  
1 
1 
Genetic Model: 
Allele freq. of disease gene = 
Increment in allele freq. Per iteration = 
Mode Of Inheritance =   
Odds Ratio of disease allele = 
Is disease locus = Marker locus 
 
0.53/0.17
† 
0  
0 (Additive) 
1.20/1.36
a 
1 (Yes) 
 
0.53/0.17
† 
0 
0 (Additive) 
1.6/unknown
a 
1 (Yes) 
Statistical Parameters: 
Significance level = 
Offset value =  
Sigificance level =  
 
0.05 
0 (default) 
0.05 
 
0.05 
0 (default) 
0.05 
Power Calculation option: 
1 = Numerical integration;  
2 = Approximation; 3= Simulation (Monte carlo) 
2  2 
†(GSTM1/GSTT1). 
aOdds ratios from a published meta-analysis of GST polymorphism, smoke 
exposure and asthma. (Saadat et al 2007)
347 
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4.4  Results 
4.4.1  Preliminary Genotype Analysis Results  
Table 4.7 shows the CNV genotype frequencies of the final data set of 1456 
individuals available for FBAT analysis after merging the pedigree and phenotype 
data files.    
Table 4-7: GST Copy Number Variation Genotype Frequencies in the Final Data Set 
Gene  2 copies of gene n 
(%) 
1 copy of gene     
n (%) 
0 copies of gene n 
(%) 
Total number of 
genotypes            
n (%) 
Undetermined 
genotypes            
n (%) 
GSTM1  97 (6.7)  528 (36.3)  773 (53.1)  1398 (96.0)  58 (4.0) 
GSTT1  407 (30.0)  683 (47.0)  242 (16.6)  1332 (91.5)  128 (8.5) 
The FBAT program identified a number of non-mendelian inheritances within 
families in the final data set. The number and type of non-mendelian inheritances 
present are described in section 3.4.2.3; in order to proceed with the FBAT 
analysis all samples from the affected family were excluded from the data set. 
Hardy-Weinberg equilibrium calculations were performed on the parent subset as 
described in section 3.3.4.1 and both GST CNV genotype frequencies did not 
deviate from the expected distribution. 
Table 4.8 shows the genotype frequencies of the final data set for the GSTO2 and 
GSTP1 SNPs, the number of undetermined alleles were less than 5%.  As with the 
CNV genotypes, a number of non-mendelian inheritances were present within 
some families. Data from these families were excluded prior to FBAT analysis. 
Table 4-8: GSTO2 and GSTP1 SNP Allele Frequencies 
Gene  SNP (allele1>allele2) 
Allele 1  
n (%) 
Allele 2 
n (%) 
Total number of Alleles  
n (%) 
Undetermined alleles   
n (%) 
rs156697 (T>C)  1945 (68)  905 (32)  2850 (96.5)  52 (3.5) 
GST02 
rs156699 (T>C)  2048 (72)  796 (28)  2844 (96.3)  55 (3.7) 
rs1695 (A>G)  2030 (70)  880 (30)  2910 (98.5)  22 (1.5) 
GSTP1 
rs1138272 (C>T)  2606 (90)  274 (10)  2880 (97.5)  37 (2.5) 
 112 
4.4.1.1  GSTO2 and GSTP1 Haplotype Frequencies  
Haplotype frequencies for the GSTO2 SNPs are shown in table 4.9 and were 
different to previously published frequencies from the HapMap database.
147 
Table 4-9: GSTO2 FBAT Haplotype Frequencies 
GSTO2 Haplotype  Alleles (rs156697 rs156699)  Frequency  Published Freq. 
h1  T  T  0.65    0.59 
h2  C  C  0.23      0.36 
h3  C  T  0.07      0.04 
h4  T  C  0.04    -- 
Haplotype frequencies for the GSTP1 SNPs are shown in table 4.10 and were 
similar to previously published frequencies from population-based case-control 
studies conducted in Sweden, southeast England, Denmark, and Finland.
348 
Table 4-10: GSTP1 FBAT Haplotype Frequencies 
GSTP1 Haplotype  Alleles (rs1695 rs1138272)  Frequency  Published Freq 
h1  A  C  0.67      0.65 
h2  G  C  0.24     0.27 
h3  G  T  0.08      0.08 
h4  A   T  0.01  -- 
 
4.4.2  Environmental Tobacco Smoke Exposure 
Out of a total of 781 siblings who participated in the study 93 were exposed to 
smoke during pregnancy, 192 were exposed to their mother smoking during 
childhood, and 124 were exposed to their father smoking during childhood.  In total 
of 240 siblings (30.7%) were defined as being exposed to cigarette smoke in early 
life. 113 
4.4.3  FBAT Analysis Results 
4.4.3.1  Gene Only Association Analyses 
4.4.3.1.1 Diagnosis of Asthma 
There is no significant association at the 5% level between diagnosis of asthma 
and the GST CNV genotypes (see table 4.11). Comparison of the test statistic (S) 
against the expected test statistic (E(S)) for both genes reveals that there are 
more null alleles (0 copy) present than expected under the null hypothesis. 
Table 4-11: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and the Diagnosis of Asthma.  
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S
a  E(S)  Var(S)  Z  P 
1  0.262  199  252  260.8  110.8  -0.839  0.401 
GSTM1 
0  0.738  199  508  499.2  110.8  0.839  0.401 
1  0.573  224  450  468.7  146.2  -1.544  0.123 
GSTT1 
0  0.427  224  414  395.3  146.2  1.544  0.123 
aWhere S is the test statistic; E(S) and Var(S) are the expected value and variance of the test 
statistic under H0; Z and P are the Z statistic (S normalized using E(S) and Var(S)) and its 
corresponding p-value. 
There is a rare GSTO2 haplotype (h4; freq = 0.04) that is significantly associated 
(uncorrected P-value = 0.046) with the diagnosis of asthma phenotype (see table 
4.12). Comparison of the test statistic (S) against the expected test statistic (E(S)) 
for the GSTO2 h4 haplotype shows that there are less h4 haplotypes present than 
expected under the null hypothesis. 
Table 4-12: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and the Diagnosis of Asthma.  
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.669  146  381.990  362.309  156.901  1.571  0.116 
h2  0.239  127  157.010  167.858  141.421  -0.912  0.361 
h3  0.081  60  61.990  70.076  59.303  -1.050  0.293 
GSTP1 
h4  0.012  16  14.010  14.758  9.372  -0.244  0.807 
h1  0.652  115  322.701  312.567  110.296  0.965  0.334 
h2  0.230  101  122.701  125.174  97.507  -0.250  0.802 
h3  0.075  43  52.299  49.524  43.059  0.423  0.672 
GSTO2 
h4  0.043  26  18.299  28.735  27.426  -1.993  0.046 114 
 
4.4.3.1.2 Log Age-Corrected Total IgE Levels 
There is no significant association at the 5% between log age-corrected total IgE 
levels in siblings diagnosed with asthma. Inspection of the test statistic (see table 
4.13) indicates that individuals with at least one copy of a GST gene have lower 
total IgE levels compared to the expected values under the null hypothesis.  
Table 4-13: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and the Log Age-Corrected Total IgE Levels in Asthmatic Siblings.  
Marker  No. of 
Copies 
Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
1  0.262  208  496.8  527.8  545.4  -1.327  0.185 
GSTM1 
0  0.738  208  981.1  950.1  545.4  1.327  0.185 
1  0.571  229  870.1  901.7  770.7  -1.136  0.256 
GSTT1 
0  0.429  229  817.5  785.9  770.7  1.136  0.256 
There is a rare GSTO2 haplotype (h4; freq = 0.04) that is significantly associated 
(uncorrected P-value = 0.01) with log age-corrected total IgE levels in siblings 
diagnosed with asthma (see table 4.14). Inspection of the FBAT test statistic 
indicates that individuals with a GSTO2 h4 haplotype have lower total IgE levels 
compared to the expected values under the null hypothesis. 
Table 4-14: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and the Log Age-Corrected Total IgE Levels in Asthmatic Siblings 
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.669  213  1128.968  1080.413  945.247  1.579  0.114 
h2  0.239  197  438.045  474.181  805.373  -1.273  0.202 
h3  0.081  96  194.263  205.237  344.714  -0.591  0.554 
GSTP1 
h4  0.012  20  21.788  23.233  34.389  -0.246  0.805 
h1  0.652  182  1034.040  1008.784  620.825  1.014  0.311 
h2  0.23  168  386.747  400.462  543.412  -0.588  0.556 
h3  0.075  61  185.570  162.303  279.048  1.393  0.163 
GSTO2 
h4  0.043  39  61.306  96.113  180.381  -2.592  0.010 
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4.4.3.1.3 Bronchial Hyperresponsiveness 
Association analysis of the bronchial hyperresponsiveness variable was non-
significant at the 5% level. Examination of the test statistic revealed no discernable 
trend compared to the expected test statistic under the null hypothesis (see table 
4.15 & 4.16). 
Table 4-15: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and the Measure of BHR on the Asthmatic Siblings.  
Marker  No. of 
Copies 
Allelic 
Frequency 
No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
1  0.262  206  3726.1  3643.7  31267.2  0.467  0.641 
GSTM1 
0  0.738  206  6099.2  6181.7  31267.2  -0.467  0.641 
1  0.571  227  5693.0  6021.7  41501.4  -1.614  0.107 
GSTT1 
0  0.429  227  5195.2  4866.4  41501.4  1.614  0.107 
Table 4-16: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and the Measure of BHR on the Asthmatic Siblings. 
Marker  Haplotype  Frequency 
No. of 
Informative 
Families 
S  E(S)  Var(S)  Z  P 
h1  0.669  214  9043.048  8676.365  52782.440  1.596  0.110 
h2  0.239  197  3936.955  4221.142  48037.139  -1.297  0.194 
h3  0.081  96  1566.882  1658.404  20521.335  -0.639  0.522 
GSTP1 
h4  0.012  21  265.092  256.067  3471.073  0.153  0.878 
h1  0.652  183  8267.687  7996.126  47388.469  1.247  0.212 
h2  0.23  170  3438.961  3634.717  46778.193  -0.905  0.365 
h3  0.075  61  1236.262  1211.921  20504.296  0.170  0.865 
GSTO2 
h4  0.043  40  663.595  763.741  6530.893  -1.239  0.215 
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4.4.3.1.4 Percentage Predicted FEV1 Values 
Association analysis using the percent predicted FEV1 phenotype shows a strong 
non-significant trend (P = 0.068) towards the presence of a copy of the GSTT1 
gene being associated with a lower percentage predicted FEV1 value (worse lung 
function) than expected under the null hypothesis (see table 4.17; smaller S value 
than expected E(S)).  
Table 4-17: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and Percentage Predicted FEV1 Values on Asthmatic Siblings.  
Marker  No. of 
Copies 
Allelic 
Frequency 
No. of 
Informative 
Families 
S  E(S)  Var(S)  Z  P 
1  0.262  209  25933  26876.5  1003691.8  -0.942  0.346 
GSTM1 
0  0.738  209  50851  49907.5  1003691.8  0.942  0.346 
1  0.571  230  44261  46361.0  1325268.0  -1.824  0.068 
GSTT1 
0  0.429  230  41147  39047.0  1325268.0  1.824  0.068 
Association analysis using the percent predicted FEV1 phenotype shows a 
significant association (uncorrected P value = 0.038) towards a GSTO2 h4 
haplotype being associated with a lower percentage predicted FEV1 value (worse 
lung function) than expected under the null hypothesis (see table 4.18; smaller S 
value than expected E(S)).  
Table 4-18: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and Percentage Predicted FEV1 Values on Asthmatic Siblings. 
Marker  Haplotype  Frequency 
No. of 
Informative 
Families 
S  E(S)  Var(S)  Z  P 
h1  0.669  214  60930.179  59356.212  1670589.513  1.218  0.223 
h2  0.239  196  26647.821  27474.455  1541932.247  -0.666  0.505 
h3  0.081  97  10868.179  11601.078  600675.041  -0.946  0.344 
GSTP1 
h4  0.012  21  1499.821  1514.255  85322.529  -0.049  0.960 
h1  0.652  183  56179.845  54491.765  1233602.038  1.520  0.128 
h2  0.23  169  22361.845  23518.537  1112849.537  -1.096  0.272 
h3  0.075  61  8671.155  8065.866  557730.342  0.810  0.417 
GSTO2 
h4  0.043  40  3866.155  5002.831  301345.059  -2.071  0.038 
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4.4.3.1.5 Atopy Severity Score 
There is no significant association at the 5% level between the atopy severity 
score phenotype and GST polymorphism (see tables 4.19 & 4.20) in the gene-only 
analyses.  
Table 4-19: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and Atopy Severity Scores on Asthmatic Siblings. 
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
1  0.262  187  317.0  336.4  272.1  -1.180  0.238 
GSTM1 
0  0.738  187  617.6  598.1  272.1  1.180  0.238 
1  0.571  207  600.6  620.1  420.8  -0.951  0.341 
GSTT1 
0  0.429  207  531.9  512.4  420.8  0.951  0.341 
Table 4-20: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and Atopy Severity Scores on Asthmatic Siblings. 
Marker  Haplotype  Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
h1  0.669  199  762.698  730.210  461.643  1.512  0.130 
h2  0.239  181  277.697  293.311  370.212  -0.811  0.417 
h3  0.081  89  103.076  120.376  177.551  -1.298  0.194 
GSTP1 
h4  0.012  20  14.886  14.461  14.687  0.111  0.911 
h1  0.652  169  608.658  613.204  272.360  -0.275  0.782 
h2  0.23  158  250.980  243.633  231.726  0.483  0.629 
h3  0.075  55  105.709  93.379  115.299  1.148  0.250 
GSTO2 
h4  0.043  39  41.959  57.090  78.175  -1.711  0.087 
 
4.4.3.1.6 Asthma Severity Score 
A highly significant association exists between the GSTT1 CNV genotype and the 
asthma severity score phenotype (P = 0.015; table 4.21). It appears from the test 
statistic that the asthma severity score variable is higher in asthmatic siblings with 
no copies of the GSTT1 gene (0 copy genotype) than expected under the null 
hypothesis (S = 1631.7 vs E(S) = 1513.4). Therefore, it would appear that 
inheritance of one or more copies of the GSTT1 gene would protect against the 
development of more severe asthma in this cohort.  118 
 
Table 4-21: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and Asthma Severity Scores on Asthmatic Siblings.  
Marker  No. of 
Copies 
Allelic 
Frequency 
No. of 
Informative 
Families 
S  E(S)  Var(S)  Z  P 
1  0.262  201  1027.4  1076.8  1873.3  -1.142  0.254 
GSTM1 
0  0.738  201  2059.1  2009.7  1873.3  1.142  0.254 
1  0.571  217  1705.1  1823.5  2351.4  -2.441  0.015 
GSTT1 
0  0.429  217  1631.7  1513.4  2351.4  2.441  0.015 
A significant association exists between the GSTP1 h1 haplotype and the asthma 
severity score phenotype (P = 0.047; see table 4.22). It appears from the test 
statistic that the asthma severity score variable is higher in asthmatic siblings with 
a GSTP1 h1 haplotype than expected under the null hypothesis Therefore, it 
would appear that inheritance of a GSTP1 h1 haplotype would protect against the 
development of more severe asthma in this cohort.  
Table 4-22: FBAT Results from Association Analysis involving GSTO2 and GSTP1 
Haplotypes and Asthma Severity Scores on Asthmatic Siblings. 
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.669  211  2351.772  2244.730  2906.641  1.985  0.047 
h2  0.239  197  992.810  1060.992  2675.141  -1.318  0.187 
h3  0.081  95  402.109  436.905  1150.247  -1.026  0.304 
GSTP1 
h4  0.012  21  60.813  64.877  155.648  -0.326  0.744 
h1  0.652  182  2110.397  2065.569  1999.401  1.003  0.316 
h2  0.23  169  868.217  903.698  1740.319  -0.851  0.395 
h3  0.075  61  323.201  308.839  739.305  0.528  0.597 
GSTO2 
h4  0.043  40  153.709  177.419  315.779  -1.334  0.182 
 
4.4.3.2  FBAT Analysis Adjusted for Smoke Exposure  
Note: Only summary tables for significant or suggestive results are presented in 
this results section. The full FBAT result output of the smoke exposure analysis 
can be found in appendix 10.5. 
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4.4.3.2.1 Smoke Exposed Individuals 
There is no significant association at the 5% level between GST CNV genotypes 
and the diagnosis of asthma (table 4.23), BHR, percentage predicted FEV1 or 
atopy severity score phenotypes in smoke exposed individuals.  It is clear from 
table 4.23, that the number of informative families has been substantially reduced 
as the majority of the siblings were not exposed to tobacco smoke during 
pregnancy or early childhood. This will obviously reduce the power of any 
association tests to detect any significant differences between genotypes in the 
smoke exposed data subset. 
Table 4-23: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and the Diagnosis of Asthma on Smoke Exposed Individuals.  
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
1  0.262  62  74  73  30.5  0.181  0.856 
GSTM1 
0  0.728  62  140  141  30.5  -0.181  0.856 
1  0.571  73  127  136  45.3  -1.412  0.158 
GSTT1 
0  0.429  73  133  123  45.3  1.412  0.158 
Even with reduced statistical power due to a small sample size, a significant 
association was detected between log age-corrected total IgE levels and the 
GSTT1 CNV genotype (P = 0.041).  On examination of the test statistic (S) from 
table 4.24, it is apparent that the presence of a copy of the GSTT1 gene 
associates with lower log age-corrected IgE levels in smoke exposed individuals 
compared to the expected test statistic (E(S)) under the null hypothesis.  
Table 4-24: FBAT Results from Association Analysis Involving GSTT1 CNV Genotypes and 
the Log Age-Corrected Total IgE Levels on Smoke Exposed Individuals.  
Marker  No. of 
Copies 
Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
1  0.571  81  258.3  289.6  234.1  -2.048  0.041 
GSTT1 
0  0.429  81  287.8  256.5  234.1  2.048  0.041 
There is a suggestive trend towards significance at the 5% level between the 
asthma severity score phenotype variable and the GSTT1 CNV genotype (table 
4.25). Examination of the test statistic values suggests that the presence of a copy 
of the GSTT1 gene is protective against the development of more severe asthma 
than predicted by the null hypothesis test statistic.  120 
 
Table 4-25: FBAT Results from Association Analysis Involving GSTT1 CNV Genotypes and 
Asthma Severity Scores on Smoke Exposed Individuals.  
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
1  0.571  76  535.5  584.4  807.5  -1.719  0.086 
GSTT1 
0  0.429  76  596.4  547.5  807.5  1.719  0.086 
There is no significant association at the 5% level between GSTP1 and GSTO2 
haploypes and the diagnosis of asthma, log age corrected IgE levels, BHR, 
percentage predicted FEV1 or atopy severity score phenotypes in smoke exposed 
individuals. In some of HBAT tests there are less than ten informative families for 
the GSTP1 h4 haplotype; this is the sample size cut off for calculating a reliable 
HBAT test statistic and indicates a substantial reduction in power when stratifying 
by smoke exposure. 
 
4.4.3.2.2 Unexposed Individuals 
There is no significant association at the 5% level between GST CNV genotypes 
and the diagnosis of asthma (table 4.26), log age-corrected IgE levels, BHR, 
percentage predicted FEV1 or atopy severity score phenotypes in unexposed 
individuals.  
Table 4-26: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and the Diagnosis of Asthma on Individuals Unexposed to Smoke.  
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
1  0.262  140  172  182.5  78.3  -1.187  0.235 
GSTM1 
0  0.738  152  358  347.5  78.3  1.187  0.235 
1  0.571  152  307  315.0  96.5  -0.814  0.415 
GSTT1 
0  0.429  152  261  253.0  96.5  0.814  0.415 
There is a rare GSTO2 haplotype (h4; freq = 0.04) that is significantly associated 
(uncorrected P-value = 0.03) with the diagnosis of asthma phenotype in 
unexposed siblings (see table 4.27). Comparison of the test statistic (S) against 
the expected test statistic (E(S)) for the GSTO2 h4 haplotype shows that there are 
less h4 haplotypes present than expected under the null hypothesis. 
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Table 4-27: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and the Diagnosis of Asthma on Individuals Unexposed to Smoke. 
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.666  109  255.439  244.932  106.755  1.017  0.309 
h2  0.237  90  113.561  117.734  95.634  -0.427  0.669 
h3  0.085  47  46.439  53.366  41.392  -1.077  0.281 
GSTP1 
h4  0.011  11  10.561  9.968  5.102  0.263  0.792 
h1  0.655  89  236.521  226.546  83.407  1.092  0.274 
h2  0.241  78  87.521  92.379  70.465  -0.579  0.562 
h3  0.065  29  36.479  32.787  29.890  0.675  0.499 
GSTO2 
h4  0.039  15  6.479  15.287  16.427  -2.173  0.029 
The GSTO2 h4 haplotype is significantly associated (uncorrected P value = 0.017; 
see table 4.28) with log age-corrected total IgE levels in unexposed siblings 
diagnosed with asthma. Inspection of the FBAT test statistic indicates that 
individuals with a GSTO2 h4 haplotype have lower total IgE levels compared to 
the expected values under the null hypothesis 
Table 4-28: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and Log Age-Corrected IgE Levels in Individuals Unexposed to Smoke. 
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.669  155  776.733  735.765  665.723  1.588  0.112 
h2  0.239  141  294.872  332.293  563.825  -1.576  0.115 
h3  0.081  73  155.072  159.110  266.567  -0.247  0.804 
GSTP1 
h4  0.012  12  17.786  17.296  27.858  0.093  0.926 
h1  0.652  129  696.135  672.247  441.729  1.137  0.255 
h2  0.23  123  268.213  287.347  393.406  -0.965  0.334 
h3  0.075  39  111.502  91.438  167.192  1.552  0.120 
GSTO2 
h4  0.043  23  28.222  53.041  107.453  -2.394  0.017 
Association analysis in the unexposed asthmatic siblings, using the percent 
predicted FEV1 phenotype shows a significant association (uncorrected P value = 
0.041) towards a GSTO2 h4 haplotype associating with a lower percentage 
predicted FEV1 value (worse lung function) than expected under the null 
hypothesis (see table 4.29). 122 
Table 4-29: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and Percentage Predicted FEV1 in Individuals Unexposed to Smoke. 
Marker  Haplotype  Frequency 
No. of 
Informative 
Families 
S  E(S)  Var(S)  Z  P 
h1  0.669  153  40208.419  39176.305  1093976.398  0.987  0.323 
h2  0.239  139  18713.581  19027.362  1015761.125  -0.311  0.755 
h3  0.081  73  7748.419  8542.338  392043.780  -1.268  0.204 
GSTP1 
h4  0.012  12  1067.581  991.995  51541.776  0.333  0.739 
h1  0.652  128  37768.353  36189.472  931511.378  1.636  0.101 
h2  0.23  122  14941.353  16388.472  823730.751  -1.594  0.110 
h3  0.075  38  5515.647  4742.528  396095.732  1.228  0.219 
GSTO2 
h4  0.043  23  1922.647  2827.528  196475.953  -2.041  0.041 
Association analysis in the unexposed asthmatic siblings, using the atopy severity 
score shows a significant association (uncorrected P value = 0.038) towards a 
GSTO2 h4 haplotype associating with a lower positive atopy severity score (less 
atopic) than expected under the null hypothesis (see table 4.30).  
Table 4-30: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and Atopy Severity Score in Individuals Unexposed to Smoke. 
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.669  142  525.096  496.779  306.430  1.618  0.105 
h2  0.239  132  183.842  203.121  235.699  -1.256  0.209 
h3  0.081  68  83.262  94.289  144.796  -0.916  0.359 
GSTP1 
h4  0.012  12  12.874  10.885  12.166  0.570  0.568 
h1  0.652  120  404.091  403.926  185.138  0.012  0.990 
h2  0.23  114  171.281  168.649  159.406  0.208  0.834 
h3  0.075  35  60.025  49.639  56.671  1.380  0.167 
GSTO2 
h4  0.043  22  18.444  31.626  35.573  -2.210  0.027 
The asthma severity score phenotype association analysis result for unexposed 
individuals provided a suggestive trend towards significance with GSTT1 CNV 
genotype (table 4.31). This suggestive result mirrors the significant association 
result from the gene only analyses where presence of a GSTT1 gene is protective 
against the development of severe asthma.  
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Table 4-31: FBAT Results from Association Analysis Involving GSTT1 CNV Genotypes and 
the Asthma Severity Scores on Individuals Unexposed to Smoke. 
Marker  No. of 
Copies 
Allelic 
Frequency 
No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
1  0.571  153  1169.5  1239.1  1558.1  -1.761  0.078 
GSTT1 
0  0.429  153  1053.4  965.9  1558.1  1.761  0.078 
 
4.4.3.3  Regression Analysis: Smoke Exposure as a Covariate 
4.4.3.3.1 Log Age-Corrected Total IgE Levels 
No significant association was detected between the GST CNV genotypes and 
total IgE levels from the model involving the log age-corrected total IgE levels as a 
function of the sibling’s exposure to cigarette smoke (table 4.32). 
Table 4-32: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and the Log Age-Corrected Total IgE Levels on Asthmatic Siblings Using Smoke 
Exposure as a Covariate.  
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
1  0.262  209  -6.6  3.6  174.5  -0.769  0.442 
GSTM1 
0  0.738  209  -14.1  -24.3  174.5  0.769  0.442 
1  0.571  230  5.8  4.8  246.0  0.063  0.950 
GSTT1 
0  0.429  230  25.1  26.1  246.0  -0.063  0.950 
No significant association was detected between the GSTP1 and GSTO2 
haplotypes and total IgE levels from the model involving the log age-corrected total 
IgE levels as a function of the sibling’s exposure to cigarette smoke (see table 
4.33). 124 
Table 4-33: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and the Log Age-Corrected Total IgE Levels on Asthmatic Siblings Using Smoke 
Exposure as a Covariate. 
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.669  215  12.177  -3.571  256.046  0.984  0.325 
h2  0.239  198  -41.516  -26.399  214.664  -1.032  0.302 
h3  0.081  97  -10.825  -11.107  106.278  0.027  0.978 
GSTP1 
h4  0.012  20  -6.856  -5.943  15.818  -0.230  0.818 
h1  0.652  182  0.758  6.422  188.608  -0.412  0.680 
h2  0.23  168  -14.221  -20.039  163.597  0.455  0.649 
h3  0.075  61  18.734  10.713  64.628  0.998  0.318 
GSTO2 
h4  0.043  39  1.746  9.921  36.461  -1.354  0.175 
 
4.4.3.3.2 Bronchial Hyperresponsiveness 
Association analysis using the residuals from the model using the bronchial 
hyperresponsiveness measure as a function of the sibling’s exposure to cigarette 
smoke revealed a suggestive result (P < 0.1) that an association may exist with 
GSTM1 CNV genotypes (table 4.34).  
Table 4-34: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and the Measure of BHR on Asthmatic Siblings Using Smoke Exposure as a 
Covariate. 
Marker  No. of 
Copies 
Allelic 
Frequency 
No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
1  0.262  206  303.9  103.1  13279.5  1.743  0.081 
GSTM1 
0  0.738  206  -517.3  -316.5  13279.5  -1.743  0.081 
1  0.571  227  -13.5  -8.9  18189.3  -0.034  0.973 
GSTT1 
0  0.429  227  -171.5  -176.1  18189.3  0.034  0.973 
As the test statistic is greater than the expected statistic (E(S)) under the null 
hypothesis, it is possible that larger BHR slope values are associated with the 
presence of a copy of the GSTM1 gene in individuals, after taking into account 
their smoke exposure in early life. As the slope variable negatively correlates with 
the degree of BHR, the presence of a GSTM1 gene could be protective against 
BHR, therefore having more normal airway reactivity.    
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No significant association was detected between the GSTP1 and GSTO2 
haplotypes and bronchial hyperresponsiveness variable from the model involving 
the log age-corrected total IgE levels as a function of the sibling’s exposure to 
cigarette smoke (see table 4.35). 
Table 4-35: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and the Measure of BHR on Asthmatic Siblings Using Smoke Exposure as a 
Covariate. 
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.669  212  143.773  42.341  20925.609  0.701  0.483 
h2  0.239  196  184.111  248.991  18031.322  -0.483  0.628 
h3  0.081  95  -85.476  -45.745  6590.921  -0.489  0.624 
GSTP1 
h4  0.012  21  41.692  38.512  788.209  0.113  0.909 
h1  0.652  181  206.925  163.000  14523.570  0.364  0.715 
h2  0.23  168  195.282  191.258  13965.503  0.034  0.972 
h3  0.075  61  -106.110  -13.334  3686.413  -1.528  0.126 
GSTO2 
h4  0.043  40  73.979  29.151  2230.251  0.949  0.342 
 
4.4.3.3.3 Percentage Predicted FEV1 Values 
The results in table 4.36 are suggestive (P < 0.1) of an association between the 
presence of a copy of the GSTT1 and lower percentage predicted FEV1 value in 
sibling’s after accommodating for cigarette smoke exposure. It would appear from 
the highly insignificant P values that there is no association with the GSTM1 CNV 
genotype 
Table 4-36: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and Percent Predicted FEV1 Values on Asthmatic Siblings Using Smoke 
Exposure as a Covariate. 
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
1  0.262  209  -28.1  19.3  23128.6  -0.311  0.756 
GSTM1 
0  0.738  209  205.3  158.0  23128.6  0.311  0.756 
1  0.571  230  -410.5  -75.0  33592.7  -1.830  0.067 
GSTT1 
0  0.429  230  238.6  -96.9  33592.7  1.830  0.067 
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No significant association was detected between the GSTP1 and GSTO2 
haplotypes and percent predicted FEV1 phenotype from the model involving the 
log age-corrected total IgE levels as a function of the sibling’s exposure to 
cigarette smoke (see table 4.37). 
Table 4-37: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and Percent Predicted FEV1 Values on Asthmatic Siblings Using Smoke 
Exposure as a Covariate. 
Marker  Haplotype  Frequency 
No. of 
Informative 
Families 
S  E(S)  Var(S)  Z  P 
h1  0.669  214  -206.042  -90.315  32992.910  -0.637  0.524 
h2  0.239  196  301.720  142.500  30532.270  0.911  0.362 
h3  0.081  97  -216.577  -162.669  9122.720  -0.564  0.572 
GSTP1 
h4  0.012  21  25.094  14.680  1416.009  0.277  0.781 
h1  0.652  181  -126.132  -228.609  25917.665  0.637  0.524 
h2  0.23  166  -194.613  -46.265  22771.015  -0.983  0.325 
h3  0.075  60  228.880  113.814  7007.174  1.375  0.169 
GSTO2 
h4  0.043  40  73.668  142.863  5917.196  -0.900  0.368 
 
4.4.3.3.4 Atopy Severity Scores 
No significant association was detected between the GST CNV genotypes and 
atopy severity scores as a function of the sibling’s exposure to cigarette smoke as 
the P values are non-significant (table 4.38). 
Table 4-38: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and Atopy Severity Scores on Asthmatic Siblings Using Smoke Exposure as a 
Covariate. 
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
1  0.262  208  -7.1  0.2  123.6  -0.656  0.512 
GSTM1 
0  0.738  208  -24.3  -31.6  123.6  0.656  0.512 
1  0.571  229  34.5  33.2  182.5  0.098  0.922 
GSTT1 
0  0.429  229  16.8  18.2  182.5  -0.098  0.922 
Association analysis using the atopy severity score residual shows a significant 
association (uncorrected P value = 0.045) towards the GSTO2 h1 haplotype 
associating with a lower positive atopy severity score (less atopic) than expected 
under the null hypothesis (see table 4.39). 127 
 
Table 4-39:  FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and Atopy Severity Scores on Asthmatic Siblings Using Smoke Exposure as a 
Covariate. 
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.669  214  59.442  50.588  189.996  0.642  0.520 
h2  0.239  194  -14.783  -12.086  155.612  -0.216  0.828 
h3  0.081  95  -17.280  -10.353  71.734  -0.818  0.413 
GSTP1 
h4  0.012  21  -4.022  -4.791  8.711  0.261  0.794 
h1  0.652  177  -11.315  10.917  123.433  -2.001  0.045 
h2  0.23  164  7.136  -11.153  112.480  1.725  0.084 
h3  0.075  59  10.721  6.050  45.197  0.695  0.487 
GSTO2 
h4  0.043  40  3.890  4.619  26.127  -0.143  0.886 
 
4.4.3.3.5 Asthma Severity Scores 
All P values from the asthma severity score association analysis using residuals 
from the regression model as a function of the sibling’s exposure to cigarette 
smoke are outside the limit for suggestive results (P < 0.1; see table 4.40).  
Table 4-40: FBAT Results from Association Analysis Involving GSTM1, GSTT1 CNV 
Genotypes and Asthma Severity Scores on Asthmatic Siblings Using Smoke Exposure as a 
Covariate. 
Marker  No. of 
Copies 
Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
1  0.262  201  -9.8  3.4  64.7  -1.640  0.101 
GSTM1 
0  0.738  201  29.1  15.9  64.7  1.640  0.101 
1  0.571  217  -0.5  12.7  79.5  -1.479  0.139 
GSTT1 
0  0.429  217  10.2  -3.0  79.5  1.479  0.139 
Therefore it is unlikely that GST CNV genotypes associate with asthma severity 
scores. By comparing the test statistic to the expected statistic for the null 
hypothesis it could be inferred that the presence of either gene is protective 
against the development of severe asthma. This observation mirrors the findings in 
the gene only and smoke exposure analyses. No significant association was 
detected between the GSTP1 and GSTO2 haplotypes and the asthma severity 
score phenotype from the model involving positive asthma severity scores as a 
function of the sibling’s exposure to cigarette smoke (see table 4.41). 128 
Table 4-41: FBAT Results from Association Analysis Involving GSTO2 and GSTP1 
Haplotypes and Asthma Severity Scores on Asthmatic Siblings Using Smoke Exposure as a 
Covariate. 
Marker  Haplotype  Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
h1  0.669  205  3.446  -0.569  78.743  0.452  0.650 
h2  0.239  193  -9.225  -5.411  69.589  -0.457  0.647 
h3  0.081  93  3.458  1.622  29.573  0.338  0.735 
GSTP1 
h4  0.012  21  -3.425  -1.389  1.794  -1.520  0.128 
h1  0.652  175  1.234  -3.559  60.555  0.616  0.537 
h2  0.23  164  -4.792  1.732  56.233  -0.870  0.384 
h3  0.075  60  0.004  1.024  16.572  -0.251  0.802 
GSTO2 
h4  0.043  39  -0.391  -3.142  11.223  0.821  0.411 
 
4.4.4  Post-hoc PBAT power analysis results 
Power calculations were performed using odds ratios associated with GSTM1 and 
GSTT1 deletion alleles in a comprehensive meta-analysis of GST polymorphism, 
smoke-exposure and asthma.
347 The meta-analysis of 2292 asthma patients, 5718 
controls in smokers and non-smokers determined that the risk associated with a 
GSTM1 and GSTT1 null deletion allele and asthma was 1.2 (95 % CI: 1.08 – 1.35) 
and 1.36 (95 % CI: 1.11 – 1.63) respectively. When accounting for smoking status 
the asthma risk increased to 1.6 (95 % CI: 1.25 – 1.94) for only the GSTM1 
deletion allele. Based on these odds ratios, the GSTM1 and GSTT1 gene only and 
gene-environment analyses in this study are underpowered (50 ( 79 % power) to 
detect an association between asthma and a risk allele with an odds ratio between 
1.20 and 1.60. If the GSTP1 and GSTO2 risk alleles confer similar odds ratios 
then it would be likely that the GSTP1 and GSTO2 haplotype analyses will also be 
underpowered in this study. 129 
4.4.5  Summary of Results 
Table 4.42 provides a summary of the significant association analyses results 
previously described in this chapter. 
 
Table 4-42: Summary of the FBAT Association and Regression Analyses 
Marker  Individuals tested/ Method  Phenotype 
Risk Allele/ 
Haplotype 
Uncorrected  
P-value 
GSTP1  Asthmatic Individuals  ) Asthma Severity Score  h1 (0.67)  0.047 
*Affection  h4 (0.04)  0.046 
*  Log Age-Corrected IgE Levels  h4 (0.04)  0.01 
Asthmatic Individuals 
* % Predicted FEV1  h4 (0.04)  0.04 
*Affection  h4 (0.04)  0.03 
* Log Age-Corrected IgE Levels  h4 (0.04)  0.02 
* % Predicted FEV1  h4 (0.04)  0.04 
Asthmatic Individuals not 
exposed to cigarette smoke 
*  Atopy Severity Score  h4 (0.04)  0.03 
GSTO2 
Regression  * Atopy Severity Score  h1 (0.65)  0.045 
GSTM1  -  -  -  - 
Asthmatic Individuals  ) Asthma Severity Score  GSTT1*0  0.02  GSTT1 
Asthmatic Individuals Exposed 
to Cigarette Smoke  ) Log Age-Corrected Total IgE Levels  GSTT1*0  0.04 130 
4.5  Discussion 
In the majority, previous studies of GST polymorphism in asthma have shown that 
inheritance of a gene variant (or gene deletion) with reduced or no enzyme activity 
is associated with increased risk of developing asthma. Specifically, whole gene 
deletions of GSTM1 and GSTT1 have been linked with decreased lung function 
growth and appear to modulate gene-environment interactions including exposure 
to environmental tobacco smoke, ozone and diesel exhaust in children with 
asthma. In this chapter, GST gene dosage information was determined by real-
time PCR (see chapter 3) in an established UK childhood asthma family cohort 
and analysed accounting for ETS exposure in early life.  
Gene only and smoke exposure adjusted analysis using FBAT revealed no 
association with physician diagnosed asthma for GSTM1 GSTP1 or GSTT1 
polymorphisms. A rare GSTO2 haplotype h4 (freq = 0.04, rs156697 C/rs156699 T: 
Asp142/intron5) may be protective against the development of asthma (P = 0.046) 
and was more strongly associated in individuals not exposed to cigarette smoke (P 
= 0.03). As described earlier, GSTM1 and GSTT1 gene deletions have been 
previously associated with increased susceptibility to childhood asthma worldwide. 
Thus, it would appear that GSTM1 or GSTT1 gene deletions do not alter 
susceptibility to asthma in this UK population sample. These findings are in line 
with a recent HuGE review meta analysis of GST polymorphism and asthma 
phenotypes which included the GSTM1 and GSTT1 data from this study.
349 The 
review found little evidence for substantial role of GST genes alone in the 
development of asthma, BHR or wheezing and found considerable heterogeneity 
in the results, indicating extensive publication bias. Therefore, it is probable that 
other GST genetic loci, such as GSTO2, are more important in the development of 
asthma in this population.  
Glutathione s-transferase Omega 2 detoxifies arsenic compounds from cigarette 
smoke,
350 recent studies have found GSTO2 haplotypes, containing the Asp142 
residue, are associated with increased Chronic Obstructive Pulmonary Disease 
(COPD) susceptibility and reductions in adult lung function.
338, 339  131 
The discovery of a protective GSTO2 haplotype against asthma development in 
this study is a novel finding, indicating that GSTO2 polymorphism could be 
important in the development of an asthmatic phenotype regardless of exposure to 
tobacco smoke exposure in early life. This finding warrants further investigation in 
other genetic studies of childhood asthma with more comprehensive measures of 
maternal and environmental tobacco smoke exposure.    
Several studies have shown lack of association of GST gene deletion with 
childhood asthma, admittedly some of these studies may lack sufficient power to 
detect an association because of small sample sizes.
351 Recent work performed at 
the University of Southampton (in collaboration with University of Bristol and 
Imperial College London), examining GST polymorphism in the Avon Longitudinal 
Study of Parents and Children (a large (n > 10,000) population-based birth cohort), 
has also reported a lack of association of GST gene deletion genotypes with 
childhood asthma at age 7 - 9.
352 However, GST gene deletion was shown to be 
associated with deficits in lung function when individuals were exposed to 
maternal smoking and were also found to modify the risk of childhood asthma 
associated with prenatal paracetamol exposure.
353, 354 Therefore, it is likely that 
GST genes interact with environmental factors modulating the asthma risk in 
susceptible individuals. 
A meta-analysis of 14 studies has reported that adults with a combined GSTM1 
and GSTT1 null genotype were at a significantly higher risk of asthma (OR = 2.15, 
95% CI: 1.21-3.71) and that smoking overloads the capacity of either GSTM1 or 
GSTT1 detoxification systems.
320 A combined genotype analysis was not 
performed in this study, as neither gene was independently associated with the 
diagnosis of asthma. It is interesting to note that both genes are lowly expressed 
or absent (based on genotype) in lung tissue, whereas GSTP1 is highly expressed 
and reduced activity is associated with lower asthma risk, and airways 
responsiveness (see section 4.1.4). Saadat et al.
320 commented that glutathione 
S-transferases have overlapping substrate specificities, and a deficiency in one 
form may be compensated by another. Therefore, a simultaneous determination of 
all GST genotypes appears to be necessary for reliable interpretation of the role of 
GST enzymes in asthma.  132 
Thus, it would be very interesting in the future, for example, to examine a profile of 
gene polymorphism that alters the expression or function of GSTP1, GSTO2 and 
in conjunction with GSTM1/T1 gene deletion polymorphisms.  
A priori power calculations were not performed because further recruitment in this 
study, was not possible.  Post-hoc power calculations, based on adult odds ratios 
for GST genes, were performed in PBAT
344 and it is possible that low power is 
responsible for the lack of association of with asthma risk in this study.  However, 
the rare GSTO2 haplotype h4 was found to be protective against asthma and 
several asthma intermediate phenotypes were associated with GST 
polymorphisms. So, the current estimation of the power of this study may be too 
conservative and these findings may reflect a stronger genetic effect of particular 
GSTs on asthma in early life. Significant P values described in this chapter were 
not adjusted for multiple testing by Bonferroni correction as this correction would 
be too conservative and gene-environment interactions may be missed.
355 
However, type 1 error must be considered as a possible explanation of these 
results. 
Log age-corrected total IgE levels were not significantly associated with GSTM1, 
GSTT1 or GSTP1 polymorphism in the gene only, linear regression or tobacco 
smoke unexposed group analyses. A rare GSTO2 haplotype h4 was significantly 
associated with decreased log age-corrected IgE in asthmatic children before and 
after adjusting for individuals unexposed to cigarette smoke (P = 0.01 - 0.02). 
Interestingly, total IgE levels were found to be significantly higher in asthmatic 
children possessing a GSTT1 gene deletion when exposed to familial tobacco 
smoke (P = 0.041). It is intriguing to find an associaton between GSTO2 
haplotypes and atopy and a novel gene-environment interaction between the 
presence of GSTT1 and protection from atopy when exposed to cigarette smoke 
at a young age. 
Atopy severity scores (a specific serum IgE dependant score) lacked any 
association with GSTM1, GSTP1 and GSTT1 polymorphism in relation to asthma 
and/or smoke exposure. Mirroring the total IgE results, decreased atopy severity 
scores were associated with GSTO2 h4 haplotype in asthmatic children not 
exposed to cigarette smoke (P = 0.03). In the regression analysis the common 
GSTO2 h1 haplotype (rs156697 T/rs156699 T, freq = 0.65) was found to be 
weakly associated with decreased atopy severity scores in asthmatic children 
exposed to cigarette smoke (P = 0.045).  133 
Total IgE levels can be affected by viral infection and cigarette smoke 
exposure.
356, 357 Therefore, the FBAT analysis controlled for any confounding 
parental smoke effect on total IgE levels by performing separate exposure 
analyses. However, confounding from viral infection in study participants at the 
time of recruitment cannot be ruled out.  
The exact mechanism by which GSTs can directly affect IgE levels or atopy 
severity is unclear as the formation of IgE is complex and involves many 
processes. Interestingly, other studies have found similar associations to this 
study, for example, individuals with a low antioxidant capacity have been shown to 
be at an increased risk of developing allergic asthma
358 and GSTP1 genotypes 
have been found to be associated with atopic indices such as, skin test positivity 
and IgE levels in atopic and non-atopic subjects.
322 Also, a randomised, placebo 
controlled cross-over study found that deficits in GST anti-oxidant capacity (due to  
genetic polymorphism) can result in allergic individuals having a more robust 
increase in IgE levels when exposed to an allergen in combination with diesel 
exhaust particles, than allergen alone.
318 
The methacholine challenge measure of bronchial hyperresponsiveness (BHR) 
was not significantly associated with any GST genotype in the gene only, 
exposure or regression analysis. However, from the regression analysis there is a 
suggestive trend (P = 0.081) with the presence of a GSTM1 gene and reduced 
BHR in smoke exposed children. This trend was not replicated in the separate 
exposure analyses, most likely because of reduced statistical power from the 
smaller sample size (208 vs. 147 families). Interestingly, a recent study found that 
GSTM1 null variants (homozygous gene deletion) were associated with asthma 
and greater airflow obstruction in a sub-group analysis of 50 children (10% of the 
cohort) exposed to intrauterine smoke exposure.
359 Therefore, it is likely that 
maternal smoking during pregnancy is a greater risk factor for the development of 
asthma phenotypes in children without a GSTM1 gene.  
In the fetus, normal lung development proceedes through the balanced interplay of 
cell proliferation and apoptotic events and reactive oxygen species can be 
transmitted from the mother to the fetus via the placenta.
16, 360 Maternal smoking 
may overwhelm the fetus’ antioxidant capacity, leading to a depletion of fetal GSH, 
increased cellular damage by ROS.
361  134 
High levels of ROS have also been shown to dysregulate the ligandin function of 
certain GST enzymes (GSTP1 & GSTM1) leading to loss of the negative 
regulatory feedback loop involving JNK1 and ASK1, thus activating cellular 
signalling pathways involved in cell proliferation and apoptosis (through MAPK 
signalling) in response to oxidative stress.
362-364  
These pathways are critical for the normal course of lung development and growth 
and therefore deficits in GST enzyme function may not only have direct 
consequences via protection from cellular damage by ROS (due to maternal 
smoking), but also indirect consequences resulting from insufficient free cytosolic 
GSTs to function as ligandins. In early life, exposure to high levels of ROS could 
alter Th1/Th2 responses, as in mice, glutathione depletion in antigen-presenting 
cells has been shown to generate more Th2 like response patterns.
365 
GSTP1 genotypes (GSTP1 Ile105) have previously been associated with 
increased airways reactivity,
323 although results from other studies provide 
conflicting evidence.
333 Therefore, the results from this study either contribute to 
the literature by providing evidence for no association with GST gene 
polymorphism and BHR. Or, alternatively the data set could lack sufficient power 
to detect a gene or gene-environment interaction with BHR in smoke exposed 
asthmatic children, as only 30.7% of individuals were classified as smoke 
exposed.  
As with BHR, previously published studies have provided evidence for reduced 
lung function in asthmatic children with particular GST genotypes and exposure to 
ozone in Mexico city (GSTP1 Ile105).
84 Reductions in MMEF (Maximum Mid 
Expiratory Flow) correlate with GST gene deletion and are more pronounced in 
children exposed to ETS in utero.
317  No GSTM1, GSTP1 or GSTT1 genotype was 
found to be associated with a reduction in % predicted FEV1 at the 5 % 
significance level in the current study. There was however, an association 
between the rare GSTO2 haplotype h4 and decreased % predicted FEV1 values in 
asthmatic children and after adjusting for individuals unexposed to cigarette smoke 
(P = 0.04). This observation replicates the finding, from the Framingham Heart 
Study genome-wide association of population-based pulmonary function 
measures, that GSTO2 genotypes (rs156697 & rs156699) strongly associate with 
FEV1 and FVC.
338 In the current study, the GSTO2 h4 haplotype associations have 
produced conflicting results, it was found to be protective against asthma and 135 
atopy phenotypes as well as being a risk haplotype for lower lung function in 
asthmatic children.  
It is likely that the h4 haplotype captures information on distant causal 
polymorphisms that have different roles in asthma pathogenesis and the exact role 
of GSTO2 polymorphism may be fully elucidated by extensive haplotype analysis 
of the GSTO2 gene region, in conjunction with more comprehensive ETS 
exposure measures. Nevertheless, the association of GSTO2 haplotypes with 
asthma, atopy and lung function phenotypes in asthmatic children remains a novel 
and interesting preliminary finding because GSTO2 detoxifies arsenic compounds 
found in cigarette smoke and deficits in adult lung function correlate with GSTO2 
genotypes.
337, 338 
The gene only analyses involving the asthma severity score phenotype provided 
the strongest evidence for a role for GST gene deletion polymorphism. Increased 
asthma severity scores were significantly associated with asthmatic children 
carrying a GSTT1 gene deletion (P = 0.015). In this study, presence of a GSTT1 
gene is protective against the development of severe asthma regardless of 
exposure to tobacco smoke in the home during pregnancy and early life.  
Adjusting for parental smoke exposure did not reveal a more significant 
association (exposed, P = 0.086; unexposed, P = 0.078). Therefore, the protective 
effect of GSTT1 in this study does not appear to be modulated or made stronger 
by tobacco smoke exposure in early life, this is in line with the hypothesis that ETS 
exposure can overwhelm endogenous anti-oxidant defences or other GSTs 
compensate for deficiencies in other genes.
320 The common GSTP1 haplotype h1 
(rs1695 A/rs1138272 C: Ile105/Ala114: GSTP1*A) was associated with increased 
asthma severity scores (P = 0.02); this result reflects studies that found the Val105 
allele to be associated with milder asthma phenotypes.
202,322,323  
Taken together the strongest associations in this study provide evidence that 
GSTT1 and GSTP1 gene polymorphism may be more important in the 
development of a severe asthma phenotype in susceptible individuals, than in 
asthma susceptibility per se and a rare GSTO2 haplotype may mark causal 
polymorphisms that independently associate with decreased IgE levels and lung 
function (FEV1) in asthmatic children.  136 
4.6  Concluding Remarks and Future Work 
To summarise, maternal smoking is a known risk factor for childhood asthma, 
gene polymorphism in detoxifying GST enzymes has been associated with asthma 
phenotypes and interact with ETS exposures. This work described in this chapter 
has demonstrated that GSTT1, GSTP1 and GSTO2 polymorphism is associated 
with IgE levels, which may be modified by smoke exposure, and asthma severity 
phenotypes in a family based study of childhood asthma. The exact biological 
processes involved remain unclear. However, it is likely that there is a critical time 
window in prenatal or early post-natal life where maternal smoking or ETS 
exposure has the strongest detrimental effects on lung health. In humans, ETS 
exposure (especially maternal smoking) is notoriously difficult to quantify 
accurately, partly due to recall bias and lack of the ability to monitor levels 
transmitted to the fetus.  
Glutathione (GSH) is the major endogenous antioxidant molecule protecting 
cellular systems from ROS. Fetal GSH levels decrease during gestation, leaving 
the fetus particularly sensitive to ROS. During gestation the fetal nutritional 
requirements must be met entirely by the mother and poor maternal diets have 
been associated with increased asthma risk. Therefore, it is probable that future 
lung health in smoke exposed children will depend on the interplay of balanced 
maternal nutrition, to maintain fetal GSH levels, and interaction between the 
mothers and fetus’ antioxidant capacity to deal with ROS transmitted to the 
developing lung. 
 
This relationship has the potential to be modelled in animals, where the level and 
timing of maternal smoking can be tightly controlled and offspring lung tissue can 
directly examined using morphological and molecular biological techniques at time 
points throughout development and post-natal life. The remainder of the thesis 
seeks to establish the suitability of a Developmental Origins of Health and Disease 
rat model of maternal protein-restriction during pregnancy (Southampton protein-
restriction rat model
262) to model the effects of maternal smoke exposure on 
offspring lung.  137 
In this model, maternal protein-restriction has been shown to have consequences 
for offspring organ function and produces many of the phenotypes associated with 
common adult disease (e.g. hypertension). This model has shown that disease 
phenotypes may be epigenetically programmed, as they can be transmitted to 
future generations, this is interesting as there is some evidence to suggest that 
grand-maternal smoking is associated with increased asthma risk.
366 Before this 
animal model can be utilised, it is necessary to determine what effects, if any, 
maternal protein-restriction (PR) has on the lung. Therefore, the research in the 
following chapters have sought to begin to examine lung physiology, gene and 
miRNA expression in PR exposed and unexposed control animals.  138 
5  Chapter 5: Protein-Restricted Rat Lung: Gene 
Expression Analysis 
5.1  Introduction  
Evidence from epidemiological studies have shown that a sub-optimal intrauterine 
environment can have long term effects on offspring lung function and may 
increase susceptibility to future respiratory illnesses such as asthma and COPD 
(reviewed in Maritz et al, 2005).
367 Low birth weight is associated with respiratory 
symptoms in children up to 7 years of age and increased asthma risk.
368, 369  
COPD mortality in the Hertfordshire 1911 – 1939 birth cohort was associated with 
low birth weight and weight at one year.
370, 371 Considering that a foetus can also 
mount immune responses in the womb; that maternal smoking and paracetamol 
intake is associated with increased asthma risk potentially through a mechanism of 
increased oxidative stress;
372,354 and that the active EMTU seen in asthmatics is a 
lung remodelling process similar to embryonic lung development. It is intriguing to 
think asthma or respiratory disease in general may result, at least in part, from the 
transmission of maternal environmental risk factors to the fetus that lead to altered 
immunological and lung development or growth in utero. Thus, it would appear 
that the role of the intrauterine environment may be critical in modulating the risk 
of developing respiratory illness in later life. 
5.1.1  Rational 
In humans, maternal diet and environmental exposures are associated with 
increased risk of respiratory disease. Reduced birth weight (a marker for poor 
maternal nutrition during pregnancy) is associated with increased risk of asthma in 
childhood and COPD in later life. Measuring maternal or offspring exposures in 
humans are notoriously difficult, time consuming, expensive and cannot be altered 
due to ethical issues.  Animal models are routinely used in the study of the 
developmental origins of health and disease (DOHaD) as they are closed 
experimental systems, where exposures can be altered and tightly controlled and 
the effects on offspring phenotype can be rapidly determined due to their shorter 
life span.  139 
Adaption of an established DOHaD rat model of maternal protein-restriction 
(Southampton protein-restriction rat model) to include a cigarette smoke exposure 
would provide a system to examine offspring lung health into old age. However, 
before this model can be used it is necessary to determine the consequence of 
maternal protein-restriction alone on offspring lung physiology, metabolism and 
homeostasis. This work presented in this chapter examines lung gene expression 
profiles in protein-restricted and control offspring.     
5.1.2  Immunological Evidence for Developmental Origins of Asthma 
There is a growing body of evidence that asthma originates in early life and even 
during foetal development. The hygiene hypothesis (see section 1.3.1.1) supports 
the protective effect of exposure to infection at a critical time window in early life 
against atopy and asthma. It is apparent that this exposure to bacterial endotoxin 
is critical to switch the TH1/TH2 balance towards a TH1 phenotype, whereby 
reducing/ablating IgE mediated responses to allergens.  
Recently, it is becoming clear that a new born baby is not immunologically naïve
373 
and atopic children have altered immune responses at birth,
374 there is evidence 
they can even mount immune responses in the womb.
375 Therefore, this critical 
time window could extend into neonatal life and maternal environment exposures 
during pregnancy are important in the development of allergy. Immune cells in the 
foetus can be seen as early as 9 weeks and lymphocytes can be detected in the 
lung at 14 weeks.
375 The neonate is known to be able to mount antibody 
responses after exposure of the mother during pregnancy to tetanus toxoid.
376 
Swallowing of amniotic fluid is the obvious route for exposure to maternal allergen 
and this action has probably evolved to provide protection to the foetus against 
any parasitic infection in the mother.
377 There is a shared genetic susceptibility 
with in atopic families, but increased circulating IgE levels in mothers’ correlate 
more strongly with raised IgE levels and increased allergic sensitisation in the child 
than with the fathers IgE level.
378 The foetus is exposed to maternal IgG antibodies 
during development
379 and this may explain why maternal allergy is a stronger 
predictor of allergy in the child rather than allergy in the father. This reinforces the 
role of the environment (i.e. the mother’s womb) in the development of allergy in 
genetically susceptible neonates. 140 
5.1.3  Genetic Evidence for the Developmental Origins of Respiratory 
Disease Concept 
At present, there is not much known about the genetic contribution to the 
developmental origins of asthma and COPD. Detailed below are examples of 
possible genes that may directly modify fetal lung development or maternal genes 
variants that alter fetal exposure to harmful chemicals from tobacco smoke. 
5.1.3.1  ADAM33  
ADAM33 (Gene ID: 80332; MIM: 607114) was positionally cloned from a genomic 
wide linkage scan in 460 Caucasian US and UK families (affected sib-pairs) in 
2002 and was the first asthma gene identified through this approach.
121 Strongest 
genetic linkage at 20p13 was seen with a combined asthma and BHR phenotype 
(LOD, 3.93) and the D20S482 microsatellite with a 35% excess allele sharing. 
Analysis of polymorphisms in the linkage region revealed that the strongest 
association was in the region of a novel gene, ADAM33. 
ADAM33 (a disintergrin and metalloproteinase 33) is part of the ADAM gene family 
that is a sub-group of a super-family of zinc-dependant metalloproteinases that 
possess proteolytic activity.
380 Other known functions of ADAMs are to promote 
myogenic fusion and in the release of proliferative growth factors
381, 382 ADAM 
members have also been shown to have roles in fertilization, muscle development 
and neurogenesis.
383-386 ADAM33 is expressed in mesenchymal cells such as sub-
epithelial fibroblasts and smooth muscle cells but not in respiratory epithelium or in 
cells of the immune system.
387 The association of ADAM33 polymorphism with 
asthma, BHR and related phenotypes has been studied in several different ethnic 
populations. The majority have found significant association with ADAM33 
polymorphisms, albeit with different SNPs or haplotypes.
134-141, 388 Non-replication 
of ADAM33 association may be explained by differences in population and/or 
environmental exposures.
389-391  
A meta-analysis of ADAM33 association data has shown that variation in this gene 
could account for 50,000 excess asthma cases in the UK alone.
392 Genetic 
variants of ADAM33 are associated with asthma, BHR and reduced lung function 
in early life (age 3 & 5).
393  141 
ADAM33 protein is known to be expressed in asthmatic airways and in human 
embryonic lungs
394 and recent study has shown increasing expression of ADAM33 
in mild to severe asthmatics.
395 This gene may also play a role in the decline in 
lung function in later life and in susceptibility to chronic obstructive pulmonary 
disease (COPD).
396, 397  
5.1.3.2  Maternal GSTP1 Genotype Modulates Oxidative Stress Experienced by 
the Developing Fetus 
The chromosomal region (Chr 11q13) containing the GSTP1 gene has 
demonstrated strong linkage with asthma phenotypes.
398, 399 During pregnancy the 
foetus is dependant on the mother to meet its physiological requirements; nutrient 
delivery and toxin removal is dependant on placental function and maternal 
factors, such as antioxidant defence mechanisms. GSTP1 is highly expressed in 
the lung and maternal genotype (GSTP1 Val105/ Val105
 or Ala114/Val114) has 
been shown to be predictive of better lung function in asthmatic children.
325 This 
association is independent of transmission of alleles to the child, maternal ETS 
exposure and atopy and is stronger than the paternal genotype effect. The authors 
concluded that this suggested an intrauterine effect of maternal GSTP1 genotype 
and hypothesised that the mother’s antioxidant defence mechanisms can 
modulate the transmission of oxidative stress to the foetus. 
5.1.4  Nutritional Programming of Respiratory Disease 
There is evidence to suggest that measures of restricted growth at birth correlate 
with reduced lung function in later life.
400 It is thought that restricted growth, altered 
lung development and a genetic susceptibility to oxidative stress may be a driving 
force behind the development of respiratory disease in later life. During 
development, the overriding external environmental cue for the neonate is 
nutritional intake from the mother via the placenta. Thus, poor maternal nutrition 
during pregnancy could increase the risk of developing asthma and COPD in late 
life by nutritional programming (section 1.6.3) during gestation that alters the 
trajectory of normal lung development and growth. 142 
5.1.4.1  Birth Weight and Lung Function 
Prematurely born infants with intrauterine growth restriction (birth weight below 
10th percentile for gestational age) are at increased rick of impaired lung function 
(Raw  - airways resistance measure) at follow up, aged 6 -24 months.
401 
Observations in infants born small at # 37 weeks gestation have shown that lower 
rates of fetal growth and higher rates of early infancy weight gain are associated 
with impaired lung development at 5 – 14 weeks of age.
402 At school age, in utero 
growth restricted children born at term have been shown to have impaired lung 
function and increased incidence of respiratory symptoms.
403, 404 Independent of 
birth size and respiratory symptoms, poor airway function (lower quartile for 
VmaxFRC) in early infancy tracks with lower FEV1/FVC ratios up to age 22.
405 In 
adulthood, low birth weight and weight gain in the first year of life predict lower 
adult lung function and worse response to environmental exposures (smoking) that 
lower lung function.
406 Therefore, IUGR is linked with impaired lung function at 
birth, infancy childhood and poor lung function in early life tracks into adulthood. 
Thus, impaired lung development in foetal life could have implications for future 
development of COPD as these individuals are more likely to develop airways 
obstruction.
370 
5.1.5  Lung Development in DOHaD Animal Models  
Intrauterine growth restriction (IUGR) can induce immediate and long term 
changes to structure and function of many organs including the lung. Early 
nutritional, oxygen and endocrine environment may be important for the entire life 
cycle of the lung. In humans, reduced fetal breathing movements are associated 
with IUGR, these movements are essential for lung expansion and normal lung 
growth.
407 Restriction of nutrient supply during fetal life can alter lung architecture, 
although lung/body weight ratios may not be altered.
367 The timing, severity and 
type of nutritional restriction determine the nature of alteration in the lungs (see 
table 5.1).  
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Table 5-1: Milestones in Human Lung Development. 
Changes to lung architecture that have been found in DOHaD animal models  
  Week  Lung development 
stage 
Milestones in 
development  Type of IUGR  Effect of IUGR on 
lung architecture 
3 - 9  Embryonic  Organogenesis 
5 - 16  Pseudoglandular 
Formation of major 
airways, bronchial tree, 
portions of respiratory 
parenchyma and birth of 
acinus 
16 – 26  Canalicular  Air-blood barrier formed. 
Epithelial differentiation 
and last generations of 
lung periphery formed 
60% Nutrient 
restriction in 
sheep.
408 
No reduction in 
lung weight. 
Up regulation of 
Glucocorticoid 
receptor mRNA 
expression.
408 
24 - 38  Saccular  
(start of Surfactant 
production) 
Expansion of air spaces. 
Surfactant is detectable in 
amniotic fluid  
Differentiation 
36 - 39  Alveolar  Secondary septation 
Starvation in 
rats.
409 
Umbilico-
placental 
embolisation in 
sheep.
410, 411 
Decrease in 
number of alveoli
409 
Enlarged alveoli 
with thicker 
walls
410, 411 
 
Post-natal  37 - >  Early life growth and 
lung maturation 
Maturation  of 
microvascular  and late 
alveolarisation (ceases by 
yr 2-3) 
Under nutrition 
in rats by 
increasing litter 
size.
412 
Cell division 
reduced in 
bronchiolar 
epithelium
412 
 
5.1.6  Southampton Protein Restriction Rat Model 
The Southampton protein restriction rat model utilises a 50 % reduction in the 
protein content of feed fed to pregnant rat for the whole of gestation (section 
5.3.1). This model has been used to study hypertension, endothelial dysfunction 
and insulin resistance.
263, 413 A protein-restriction diet during pregnancy has 
adverse effects on glucose homeostasis in the first generation, second and third 
generation offspring, without further exposure to the PR diet.
414 Alterations in DNA 
methylation patterns in hepatic gene promoters in these rats correlate with 
changes to gene expression and are transmitted up to second generation 
offspring.
264 It is thought that this is a mechanism for the transmission of a 
predictive adaptive phenotype between generations.  144 
5.1.7  Maternal Protein-Restriction During Pregnancy 
Animal models of under-nutrition recapitulate many of the phenotypes associated 
with chronic human disease in adulthood, i.e. CVD and diabetes. Milder nutritional 
manipulations such as a 50% reduction in the protein content of an isocaloric diet 
fed to mothers during pregnancy results in increased blood pressure in offspring in 
later life, this is the hallmark phenotype of hypertension.
235, 262 Other alterations in 
protein-restricted offspring (and in subsequent later generations without further 
exposure) include, changes to gene promoter DNA methylation levels in the liver, 
reduced nefron numbers in the kidney and endothelial dysfunction.
263, 264, 415  
A protein-restricted diet will potentially reduce the availability of amino acids and 
the mother may not be able to meet the developing fetus’ requirements during 
pregnancy. Amino acids are critical for life and have variety of roles in 
metabolism.(reviewed by Wu, 2009)
416 The maternal-fetal-placental unit is the 
interface between the mother and fetus.(reviewed by Cetin et al., 2009)
417 A study 
into the effect of maternal protein restriction on amino acid transfer to the fetus 
showed that at day 19 the total free fetal amino acids did not change in 
concentration, apart from a decrease in threonine to 45% of the control values; this 
reduction was not limiting protein synthesis as fetal growth did not appear to be 
affected.
418 It is thought that fetal amino acid levels were supplemented by the 
mobilisation of maternal protein, but availability of threonine may influence growth 
in late stages of development as it is metabolised to produce glycine.
418 Glycine is 
important for the synthesis of DNA, DNA methylation and is also important in the 
synthesis of many compounds required for growth (collagen, haem and 
glutathione).
419 
In rats, a cross-fostering study of maternal protein-restriction (60 % reduction in 
casein) during pregnancy and in lactation, demonstrated reduced offspring lung 
weights at post-natal day 21 and that the lungs were greater in size in proportion 
to body weight, when compared to controls.
420 In this study, a switch to maternal 
protein-restriction in lactation alone was sufficient to reduce offspring lung weight. 
However, these effects were not permanent as at 11 months of age (330 days) the 
lung weights in offspring were similar to control animals.  145 
5.1.8  Rat and Human Lung Development 
Apart from the obvious differences between new-born humans and rats e.g. rats 
are born to large litters, blind and hairless; there are also differences in the timing 
of stages of lung development, lung architecture and bronchoconstriction 
response.
421, 422 However, non-primate models, including rodents, are relevant to 
human disease and are routinely used in the study of asthma and COPD.
422, 423 
Figure 5.1 shows the milestones in human lung development. Full-term rats are 
born with their lungs in the saccular phase of development (equivalent to human 
lung at 26–28 wk of gestation), where thinning of interstitium, flattening of 
epithelium has occurred, alveolar ducts and air sacs are formed and surfactant 
production is started. In the rat, unlike humans, alveolarisation takes place 
postnatally in two phases; the first phase corresponds to week 35-40 of gestation 
in human fetal lung. The second phase includes, maturation  of microvasculature  
and late alveolarisation and can continue up to post natal day 60 (young adulthood 
in the rat).
424 This difference in the timing of late lung development into postnatal 
life in the rat provides the opportunity to expose young rats to strict challenges 
when the lung is still in a phase of developmental plasticity (see section 1.6.4). 
5.1.9  Altered Gene Expression in DOHaD Animal Models 
As stated earlier in this chapter (section 5.1.1) it is necessary to establish the 
effect of maternal protein restriction on offspring lung gene expression before we 
can utilise the Southampton protein-restriction rat model to study the consequence 
of maternal cigarette smoke exposure on offspring lung health. Previous studies of 
intrauterine growth restriction (IUGR) in rat and sheep have shown that exposed 
offspring have altered expression of genes involved in growth and metabolism 
compared to control offspring. IUGR offspring have shown changes in the 
expression of growth factors (Insulin-like Growth Factor (IGF1 and IGF2), 
receptors for steroid hormones (glucocorticoid receptor, GR and mineralcorticoid 
receptor, MR), enzymes regulating steroid synthesis (11%-dehydroxysteroid 
dehydrogenase-1 and 2 (HSD11B1 & HSD11B2) and glucocorticoid responsive 
ATPase’s (ATP1A1 & ATP1A2). Alterations in gene expression have been found 
in different tissues (including lung, liver, kidney, thymus and hypothalamus) at 
several time points during gestation, early life and in some cases these changes in 
gene expression can persist far into adulthood.
425-428  146 
Furthermore, it has been shown that these changes in gene expression can be 
programmed at the epigenetic level, through changes in the DNA methylation 
pattern of gene promoters, and passed on to the next generation of offspring.
429 
The genes chosen for gene expression analysis in this chapter are as follows: 
5.1.9.1.1 Atp1a1 & 2 and Atp1b1 
Sodium/Potassium adenosine triphosphatase subunit gene expression is 
regulated by corticosteroids and 11%-hydrosteroid dehydrogenase activity. Atp1a1, 
2 and b1 mediate Sodium and potassium transport and may have roles in 
controlling blood pressure, maintaining electrochemical gradient across plasma 
membrane and oxygen homeostasis.
430 In an IUGR rat model (maternal low 
protein diet; MLP) examining the in utero programming of hypertension increased 
levels of Atp1a1 and b1 mRNA expression was associated with significantly higher 
levels of glucocorticoid receptor GR mRNA and protein in kidney, liver, lung and 
brain in the MLP offspring at 12 weeks.
428    
5.1.9.1.2 Igf1 & 2 
Insulin-like growth factors (IGFs) are cytokines that modulate cell proliferation and 
differentiation during embryogenesis through interactions with the IGF cell surface 
receptor (IGFR1). Late gestation (last trimester) maternal under-nutrition in rats 
resulted in significantly lower lung/body weight ratios of the IUGR offspring on 
postnatal days 7 and 14 and increased expression of IGF1 and 2 at postnatal days 
1 and 28.
425  
5.1.9.1.3 Nr3c1(GR), Nr3c2 (MR),  Hsd11b1 & 2 
Glucocorticoid and mineralcorticoid hormone levels in the lung are regulated by 
expression of the glucocorticoid receptor (GR) or  mineralcorticoid receptor (MR) 
and isoforms of 11%-dehydroxysteroid dehydrogenases (Hsd11b1 & Hsd11b2) at 
the levels of gene transcription. Mice with disrupted glucocorticoid receptor genes 
die shortly after birth with severe lung atelectasis (non-inflated lungs); the action of 
the glucocorticoid hormone is critical for lung maturation and surfactant 
production.
431 Mineralcorticoid receptors are found in epithelium in fetal lung and 
are thought to play an important role in lung liquid re-absorption at birth.
432  147 
In IUGR fetal ovine lung the mRNA levels of Hsd11b1 and GR were at their most 
abundant at 140 days gestation, although dietary restriction had no effect on lung 
weight.
427 In an IUGR rat model (maternal low protein diet; MLP) examining the in 
utero programming of hypertension significantly higher levels of GR mRNA and 
protein were found in kidney, liver, lung and brain in the MLP offspring up to 12 
weeks postnatal age; whereas MR levels remained the same.
428 Conversely, the 
levels of Hsd11b2 were significantly reduced in placenta (14 & 20 days gestation), 
foetal lung (d20 gestation) and in kidney from new born offspring up to 12 weeks 
postnatal age.
428 Changes to GR promoter DNA methylation in the liver of protein-
restricted rat offspring correlated with differential gene expression and were found 
to be transmitted to the next generation of offspring without further protein 
restriction.
264     
5.1.9.1.4 Tp53 
The transcription factor p53 is a key factor involved in determining cellular 
response to stress by affecting apoptosis, cell cycle regulation and angiogenesis. 
It has been hypothesised that changes in p53 expression due to IUGR alters the 
lung apoptotic /cell proliferation balance during alveolar development resulting in a 
lung more susceptible to injury and chronic lung disease in later life. An IUGR rat 
model has demonstrated that IUGR results in decreased localised p53 serine-15P 
associated with distal lung alveolar septum thickening in neonatal lungs.
433  
5.1.9.1.5 Ucp2 
Uncoupling protein 2 is an inner mitochondrial membrane carrier that is highly 
abundant in the lung, this gene has postulated roles in energy balance, reactive 
oxygen species production, apoptosis and macrophage mediated immunity.
434 
Genetic polymorphism in the UCP2 gene have been associated with obesity and 
diabetes risk in children and adolescents.
435, 436 In the ovine lung, increased UCP2 
expression has been shown to peak in offspring, from ewes assigned to the 60% 
nutrient restricted diet during early to mid gestation compared to the ‘feed to 
appetite’ control diet, at 1 day of age then decreasing at each later sampling age 
(7, 30 and 180 days) but being still detectable at 6 months (180 days).
427  In 
offspring from ewes with nutrient restriction in late gestation increased UCP2 
expression persisted until 30 days postnatal age.
427 148 
5.1.9.2  Oxidative Stress Genes: Glutathione S-Transferases 
The expression of glutathione s-transferases will also be examined as; GSTM1, 
GSTP1 and GSTT1 polymorphisms have been associated with asthma and 
COPD. In school children, GSTM1 and GSTP1 genotypes are associated with 
deficits in lung function growth.
319 Children suffering from severe malnutrition have 
consistently been found to have oxidative stress induced cellular damage and 
impaired synthesis of the antioxidant glutathione.
437 Under-nutrition in rats during 
gestation and up to day 21 of life produced a 61% decrease in microsomal 
glutathione s-transferase activity in lung tissue at day 90 of life. A recovery diet of 
ad libitum feed from day 45 to 90 failed to bring GST activities in line with the 
activity seen in control animals.
438  
5.1.9.3  Candidate Human Asthma Genes: Adam33 & Pcdh1 
Two human candidate asthma genes where included in the panel of genes for 
expression analysis because of their involvement in asthma in early life: 
5.1.9.3.1 Adam33 
ADAM33 polymorphism has been shown to be important in determining early-life 
lung function
393 and in the regulation of fetal lung morphogenesis
394 which could 
affected by IUGR. Although the exact control mechanism that regulates ADAM33 
expression is not known, promoter methylation does occur in a tissue specific 
manner.
387 and has shown to be responsible for the suppression of ADAM33 
expression in epithelial cells.
439  
5.1.9.3.2 Pcdh1 
Protocadherin 1 (PCDH1) polymorphism has also been associated with bronchial 
hyperresponsiveness in asthma
440 but the exact function of this calcium dependant 
cell-cell adhesion membrane molecule in the pathogenesis of asthma is unknown. 
However, it is likely that it may mediate early life development of asthma as there 
appears to be synergistic interaction between exposure to environmental tobacco 
smoke in utero or first years of life and genetic polymorphism of PCDH1 in 
determining asthma susceptibility. 149 
5.1.10  Hypotheses 
It is proposed that: 
‘Maternal protein-restriction during pregnancy leads to altered lung growth and 
alterations in gene expression that persist into adulthood alter the susceptibility to 
respiratory disease.’  
And that: 
‘DNA methylation and miRNA expression are the epigenetic mechanisms that 
control persistent changes to lung gene expression in the offspring of mothers who 
experienced protein-restriction during pregnancy.’  
 
The work presented in this chapter attempts to establish the validity of the 
Southampton protein restriction rat model to test the above hypotheses. A panel of 
genes were selected from a review of the literature and mRNA expression was 
assayed in archived lung tissue from first (F1) and second generation (F2) animals 
by qPCR. Altered gene expression in adult F1 offspring lung tissue will indicate that 
maternal protein restriction during pregnancy in this model produces persistent 
changes in gene expression that have been previously observed in animal models 
designed to  study the effect of maternal under-nutrition on lung development. 
Differential gene expression in the F2 generation may indicate that epigenetic 
mechanisms such as DNA methylation are controlling the alterations in gene 
expression in lung tissue from rats exposed to protein-restriction in the F1 
generation. 150 
5.2  Aims 
The aim of this work was to: 
•  Perform morphometric analyses of lung weight and volume to 
determine whether maternal protein restriction during pregnancy 
affects organ size.  
•  Validate the suitability of a TRIzol™ based simultaneous  RNA, DNA 
and Protein isolation protocol for rat lung tissue samples 
•  Design, optimise and validate real-time PCR assays for mRNA 
transcripts expressed in rat lung tissue, including a panel of target 
genes known to be differentially expressed in animal models of 
intrauterine growth restriction and the Glutathione S-transferases 
genes Gstm1, Gstp1 and Gstt1.  
•  Test the suitability of three reference genes (Actb, B2m and Ubc) for 
use as endogenous controls for real-time PCR in the rat lung.  
•  Perform relative quantification analysis on F1 & F2 generation protein 
restricted and control rat lungs and show whether the chosen target 
genes are differentially expressed in lung tissue and whether this 
persists in the F2 generation animals, as this would indicate the 
presence of epigenetically controlled transmission of programmed 
lung gene expression due to ancestral maternal protein-restriction. 151 
5.3  Methods 
5.3.1  Protein Restriction Rat Model 
The lung samples used in the following experiments are from an established 
model of maternal protein-restriction during pregnancy. The lung samples were 
collected from animals that were part of an ongoing study of endothelial 
dysfunction at the DoHaD Division (School of Medicine, University of 
Southampton).
441 All animal handling and harvesting of lungs was performed by 
Dr. Christopher Torrens and his team. All of the qPCR experiments were 
performed by myself and the lung morphometry experiments with the assistance of 
Dr. Christopher Torrens, his team and Miss Shelley Davis (fellow PhD student in 
the Respiratory Genetics laboratory). The HO project license number for this 
investigation is 70/6457. 
5.3.1.1  Experimental Study Design 
Female Wister rats (F0 generation) were mated and then fed either a Control (C) 
containing 180g/kg (w/w) casein or an isocaloric Protein Restriction (PR) diet 
containing 90g/kg (w/w) as described by Langley & Jackson.
262 (cited in Burdge et 
al)
264 At delivery, the litters were standardised to eight pups (4 male & 4 female). 
After delivery the dams and pups were fed standard chow (pups were weaned on 
to the standard chow 28 days after birth). Male offspring (F1) were killed on 
postnatal day 120. Lungs were removed immediately, frozen in liquid Nitrogen and 
stored at 80°C. Figure 5.1 displays the study design for the F0 & F1 generation 
animals. Female F1 generation offspring (selected by random removal from cage) 
were mated on postnatal day 125 with males from the control diet litters. At all 
times the mated F1 generation females and offspring (F2 generation) were fed 
standard chow. Again, the litters were reduced to eight animals. Male offspring (F2) 
were killed on day 80 and the lungs harvested and frozen. Lungs from one 
offspring from each litter were studied.  152 
 
Figure 5-1: Protein Restriction Study Design. 
On confirmation of pregnancy by the presence of a vaginal plug expectant mothers are placed on 
either the protein-restricted or control chow diet. After birth protein-restricted mothers are 
immediately returned to the original chow diet and litter sizes are standardised. Male offspring are 
sacrificed at different time points and some of the female offspring are mated at 125 days of age to 
produce the F2 generation.   
5.3.1.1.1 F1 Generation Lung Samples  
qPCR experiments were performed on RNA isolated from the first generation 
Protein restricted or control offspring lung samples that were sacrificed on day 120 
and 225. Eleven control and seven protein restricted lungs from 120 day old 
animals were provided by Dr. Christopher Torrens (table 2.7). Six protein-
restricted and six control lungs were collected from 225 day old animals that were 
available at the time of this study.  
5.3.1.1.2 F2 Generation Lung Samples 
qPCR experiments were performed on lung RNA isolated from second generation 
offspring that were sacrificed on day 80. Thirteen frozen lung samples from both 
groups were provided by Dr. Christopher Torrens (table 2.7).  
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5.3.2  Lung Morphometry 
At the time of this study it was only possible to perform lung morphometry 
experiments on 225 day old F1 offspring. 
5.3.2.1  Lung Samples 
Pregnant Wistar rats were allocated to either control (C, 18% casein) or protein 
restricted (PR, 9% casein) diet for the duration of the pregnancy. Lung tissue was 
harvested from F1 male offspring from separate litters at 225 day of age. Six lungs 
from each diet were available for lung volume measurements.  
5.3.2.2  Lung Volume Measurements 
Lungs (left lobe) were fixed by tracheal instillation of formalin under fixed pressure  
and left lobe volumes were calculated by volume displacement.
442 Left lobe 
volumes were extrapolated to estimate a total lung volume (Equation 6) and this 
value was used to calculate lung weight and volume indices for comparison 
between the PR and control groups (Equation 7 & 8). 
Equation 6: Total Lung Volume Extrapolation 
=    
Equation 7: Lung Weight Index
443 
=    
Equation 8: Lung Volume Index
443 
=  
5.3.2.2.1 Lung Fixation Protocol 
Whole lungs were dissected free from the animal and excess connective tissue 
and trachea was removed. The whole lung was weighed, then the left bronchial 
tube was cut close to the left lung and the weight of the left lung was recorded. A 
small gauge hypodermic needle on the end of a plastic tube connected to the 
formalin was inserted into the left bronchial tube and secured with cotton thread 
(figure 5.2). The value on the formalin reservoir was opened and ran for two 
minutes to fully inflate and fix the lung tissue. After two minutes the needle was 
removed from the lung and the cotton thread was used to gently lower the fixed 
lung into a tared universal tube containing 5 mls of formalin and weight taken. 154 
 
Figure 5-2: Lung Fixation Apparatus 
Working on a bench top the base of the syringe of formalin was suspended at the correct height to 
achieve the correct pressure to inflate and fix the left lung lobe resting in a petri dish. 
5.3.2.3  Calculation of Lung Fixing Perfusion Pressure 
Instillation of 10 % formalin into the left lung lobe was performed at a fixed 
pressure of 25 cm of H2O. This was achieved by calculating the required height of 
the formalin reservoir as follows:   
Perfusion pressure from Chen et a
442l:  = 25 cm of H2O (1.36 cm of H2O is equivalent to 1 mmHg) 
= 18.4 mmHg   (1 mmHg is equivalent to 133 Pa) 
= 2447.2 Pa 
 
Calculation of Hydrostatic pressure [Pa]: = !gh      
 
Therefore: 
2447.2  = 1030 + 9.81 + h 
h  = 2447.2 ÷ 10104.3 
h  = 0.242 m  
= 24.2 cm 
5.3.2.4  Statistical Analysis 
Significant differences in lung weight and volume indices were determined using 
Mann-Whitney U tests in SPSS v15. 
24.2 cm 
50 ml Syringe of 10 % 
formalin 
Lung 
Cotton Thread 
Petri dish 
Where: g is gravity at 9.81 m/s
2 , h is height (m)
 and ! 
is practical gravity of fluid (the practical gravity for 10% 
formalin is 1030 kg/m
3) 155 
5.3.3  Total RNA, DNA and Protein Isolation Using TRIzol™ Reagent 
5.3.3.1  Principle of TRIzol™ Reagent Isolation Procedure 
As described in section 2.2.3, TRIzol™ reagent allows for the rapid isolation of 
Nucleic Acids (RNA and DNA) and proteins from the same tissue biopsy. RNA 
expression and protein level results can be normalised to DNA quantity; allowing 
for direct comparison of alterations in the genome, transcriptome and proteome. 
TRIzol™ is a mono-phasic solution of phenol and guanidine isothiocyanate that 
has been improved from the single step RNA isolation method developed by 
Chomczynski and Sacchi.
444 The reagent maintains the integrity of the RNA during 
sample homogenization and cell lysis. This technique performs well on small (50-
100 mg) and large (# 1 grm) quantities of tissue and isolates a variety of RNA 
species of large and small molecular weights suitable for use in northern blots, 
PCR reactions and other RNA analysis techniques. Figure 5.3 shows an overview 
of the isolation procedure using TRIzol™. The entire isolation protocol can be 
completed with in three days with several stages in each isolation procedure 
where the sample can be conveniently stored.  Frequently, issues with low RNA 
quality are due to active endogenous RNase or contamination that rapidly 
degrades RNA molecules. It is necessary to control or ablate RNase activity so 
that any analysis yields relevant and meaningful results.  Traditionally, maintaining 
the tissue at -80°C or lower during storage and homogenisation ensures that any 
RNase activity is kept to a minimum. TRIzol™ can protect the RNA molecules 
during the homogenisation step and can be used in conjunction with traditional 
liquid nitrogen snap-freezing, pulverisation and mechanical cell lysis. 
Biotechnology companies offer convenient proprietary solutions (such as 
RNALater-ICE, Ambion) that penetrate the tissue and stabilise RNA molecules by 
chemically inactivating any RNases while allowing for sample storage at -20°C and 
handling at room temperature for short period. 
 
Figure 5-3: TRIzol™ Workflow Diagram.  
Firstly RNA is isolated from the aqueous layer then DNA can be precipitated with ethanol from the 
interphase and finally proteins can be pelleted from the phenol-ethanol phase and purified by 
successive washes or dialysis. 156 
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5.3.3.2  Optimisation of the TRIzol Isolation Procedure 
In order to maintain RNA integrity prior to isolation two RNA stabilisation methods 
were initially compared in parallel (see figure 5.4 and section 5.3.3.1). To 
maximise the nucleic acid and protein yield from each biopsy, a tissue 
homogenisation step was inserted before the start of the isolation procedure 
(section 2.2.3.3). No further alterations were made to the manufacturers 
recommended RNA (section 2.2.3.4), DNA (section 2.2.3.6), protein (section 
2.2.3.7) procedures and good laboratory procedures were followed throughout the 
isolation procedure (section 2.2.3.1).   
5.3.3.3  Validation of the RNA Stabilisation Methods 
The suitability of the RNA stabilisation methods was examined by qPCR analysis 
(section 2.2.7.5.2) of Adam33 expression (normalised by Actb expression) in three 
control rat lung samples (2 biopsies per lung) that were stabilised by either the 
Liquid Nitrogen-Bio-Pulverizer method or the RNALater-ICE stabilisation treatment 
(section 2.2.3.2) prior to RNA isolation (2.2.3.4), DNase treatment (section 2.2.3.5) 
and RT-PCR (section  2.2.4).  
5.3.3.4  Isolation of Nucleic Acids and Protein from Lung Samples  
Where possible, ~100 mg biopsies were taken from the right lung. In some cases 
the harvested lungs had been damaged in cold storage and the right lung could 
not be identified. RNA stabilisation was performed according to section 2.2.3.2.1, 
the lung tissue was homogenised according to section 2.2.3.3 and RNA (section 
2.2.3.4), DNA (section 2.2.3.6) and protein (section 2.2.3.7) isolated from the 
same lung biopsy. RNA and DNA concentration was measured according to 
section 2.2.2. 158 
5.3.4  Reverse-Transcription PCR 
5.3.4.1  Principle of Reverse-Transcription PCR 
Before the RNA can be used as a template in a real-time PCR reaction to measure 
relative transcript expression levels between the different tissue biopsies, the 
single stranded molecules must under go a first strand compliment reaction 
catalysed by a viral reverse-transcriptase. 
In this experiment a commercially available reverse-transcriptase kit was used to 
generate the first strand complimentary DNA (cDNA). cDNA is not susceptible to 
RNase degradation and is more stable at room temperature than RNA molecules 
that can be rapidly degraded resulting in altered relative expression levels that will 
not be representative of any treatment or biological phenotype.  
5.3.4.2  Choice of Reverse-Transcription System 
The Improm-II™ RT system (Promega, UK) has been proven by the manufacturer 
to efficiently reverse transcribe both long (up to 8.9 kb) and rare RNA molecules 
and produces cDNA from up to 1 $g of RNA template per reaction that is suitable 
for use in real-time PCR (Table 2.8). These qualities where deemed to be 
advantageous as the experiments will require the amplification of numerous 
mRNA targets from a single cDNA sample. 
5.3.4.3  Improm-II™ Reverse-Transcription System Protocol 
All RNA samples were DNase treated (section 2.2.3.5), normalised to 0.5 $g/$l 
according to section 2.2.2.2, and all RT-PCR reactions were set up according to 
section 2.2.4. 159 
5.3.5  mRNA qPCR Assay Design 
All target gene assays were designed according to section 2.2.5.1. Table 5.2 
details the qPCR assay technologies used for the target and reference genes.  
Table 5-2: mRNA qPCR Assay Designs 
Section 5.3.4.1 explains how mRNA abundance was determined. N.D. = Not Determined. 
Gene Name  Target or reference  Assay Type 
Intron 
Spanning? 
Adjusted for  
PCR efficiency 
Abundance 
Adam33  Target (IUGR marker)  UPL  Yes  E-method  Medium 
Atp1a1  Target (IUGR marker)  SYBR green  Yes  E-method  High 
Atp1a2  Target (IUGR marker)  SYBR green  Yes  LinRegPCR  Medium 
GR  Target (IUGR marker)  TaqMan  Yes  E-method  Medium 
Gstm1  Target (oxidative stress marker)  SYBR green  Yes  E-method  N.D. 
Gstp1  Target (oxidative stress marker)  SYBR green  Yes  E-method  N.D. 
Gstt1  Target (oxidative stress marker)  SYBR green  Yes  E-method  N.D. 
Hsd11b1  Target (IUGR marker)  SYBR green  Yes  LinRegPCR  High 
Hsd11b2  Target (IUGR marker)  SYBR green  Yes  LinRegPCR  Medium 
Igf1  Target (IUGR marker)  SYBR green  Yes  LinRegPCR  Medium 
Igf2  Target (IUGR marker)  SYBR green  Yes  LinRegPCR  Low 
MR  Target (IUGR marker)  SYBR green  Yes  E-method  Medium 
Pcdh1  Target (IUGR marker)  UPL  Yes  LinRegPCR  Medium 
Tp53  Target (IUGR marker)  SYBR green  Yes  LinRegPCR  Medium 
Ucp2  Target (IUGR marker)  SYBR green  Yes  LinRegPCR  Low 
Actb  Reference (endogenous control)  TaqMan  Yes  E-method  High 
B2m  Reference (endogenous control)  TaqMan  Yes  E-method  High 
Ubc  Reference (endogenous control)  TaqMan  No  E-method  Medium 
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5.3.5.1  Target mRNA Abundance 
Relative target mRNA abundance (e.g. high, medium and low expression) was 
determined by running all target gene assay reaction mixes spiked with the same 
cDNA template and grouping the target amplification plots by Cp values. Figure 
5.4 shows that the target gene amplification plots can placed into three groups 
based on Cp values alone, Cp values < 24 were designated as high abundance, 
26-29 Cp values as medium and >30 as low abundance.  
 
Figure 5-4: Relative Abundance of Target Genes.  
Amplification plots of Atp1a1 (yellow lines), Atp1a2 (green), Hsd11b1 (light blue), Hsd11b2 
(purple), Igf1 (brown), Igf2 (red), Pcdh1 (violet), Tp53 (dark blue) and Ucp2 (grey) 
5.3.6  Optimisation of mRNA qPCR Assays 
All mRNA qPCR assay conditions were optimised by performing primer and probe 
titrations (probe based assays only) and checked for primer specificity by melting 
curve analysis according to section 2.2.5.2.2. 
5.3.7  Validation of mRNA Assays 
Standard curve dilutions were performed for all assays (section 2.2.5.3) and the 
mRNA qPCR reactions plates were setup according to section 2.2.5.4.2. All 
reaction plates were thermal cycled according to section 2.2.5.4.2.1 and analysed 
on the Lightcycler 480 real-time PCR machine (appendix 10.3). Where there was 
an insufficient standard curve range to estimate PCR efficiency a LinRegPCR 
analysis was performed (section 2.2.5.4.2.2). 161 
5.3.8  Choice of Reference Gene Assays 
A minimum of two reference genes are required to determine any variation in 
reference gene expression between treatment and control group;
445 therefore it 
was determined to be prudent to include a third gene, just in case one of the 
chosen reference genes is unsuitable for relative quantification qPCR analysis. 
B2m and Actb were in the top five recommended reference genes for numerous 
rat tissues when examined by TaqMan® low density arrays.
446 Ubc was chosen as 
the third reference gene and all the genes were validated according to section 
5.3.7.  The Actb assay had been previously designed by Dr Fred Anthony (DoHaD 
Division, School of Medicine, University of Southampton). See table 2.3 for the 
TaqMan assay designs for Actb, B2m and Ubc. 
5.3.9  mRNA qPCR Experiments 
5.3.9.1  F1 Generation Rat Lungs 
Three qPCR reaction plates were set up for all the samples described in section 
5.3.1.1.1 for all of the target genes in table 5.2 and the three reference genes 
according to methods section 2.2.5.4.2.  
The 225 day lungs were obtained after the first qPCR experiment using the 120 
day lung samples. Therefore, in order to reduce reagent costs only the qPCR 
assays of mRNA transcripts demonstrating different levels between the PR and 
control lungs were ran on these samples. 
5.3.9.2  F2 Generation Rat Lungs 
Three qPCR reaction plates were set up for all the samples described in section 
5.3.1.1.2 for the following target genes as these genes were differentially 
expressed in the F1 generation lungs:  
•  GR 
•  Hsd11b1 
•  Hsd11b2 
•  Igf1 
•  Igf2 
•  Pcdh1 
•  Tp53 
•  rUCP 
And the oxidative stress genes (Gstm1, Gstp1 and Gstt1) and the three reference 
genes according to methods section 2.2.5.4.2.  162 
5.3.10  mRNA qPCR Data Analysis 
5.3.10.1  Determining the Minimum Detectable Difference in Expression 
Between Treatment and Control Samples 
When using multiple reference genes it is possible to estimate the minimum 
detectable difference in expression between the protein-restricted and control RNA 
samples by calculating the ratio of the geometric means of normalised 
concentration ratios from each reference gene pairing. For example, when using 
two reference genes you can estimate the minimum detectable difference as 
follows: 
Equation 9: Formula for Calculating the Minimum Detectable Difference in Expression. 
 
Therefore, if the normalised concentration for the treatment group equals the 
normalised concentration ratio for the control group the minimum detectable 
difference ratio would be one fold, i.e. you can be relatively certain that a doubling 
or 50% decrease in expression between the treatment and control group is real as 
there is no variation between the expression levels of reference genes for the two 
groups. The minimum detectable difference estimate was calculated in Microsoft® 
Excel™ for the reference gene combinations used to normalise the F1 and F2 
generation lung qPCR experiments. 
5.3.10.2  Relative Quantification Analysis 
Relative quantification analysis was performed according to section 2.2.5.4.2.3 for 
all target gene reference gene combinations.  
5.3.10.3  Statistical Analysis of qPCR Data 
Non-parametric Mann-Whitney U tests were performed on the normalised 
expression data using SPSS 15.0 (SPSS Inc, US). Expression levels were 
considered to be significantly different at the 5% level (2-tailed P values). 163 
5.4  Results 
5.4.1  Lung Morphometry 
It is apparent from the comparison of body weights that the PR offspring tend to be 
smaller than the control animals at 225 day of age (see figure 5.5). However, this 
reduction in body mass is not statistically significant. Conversely, although the 
weight of the lungs is similar between the groups, when body weight is accounted 
for, the lung weight index tends to be larger in PR offspring; a similar observation 
is also seen with the lung volume index.  
 
Figure 5-5: Boxplots of F1 225 Day Old Lung Measurements.  
(a) body weight in grams (b) total lung weight (c) lung weight index (d) lung volume index of PR (n 
= 6; green boxes) and control (n = 6; blue boxes) animals. None of the measurements were 
significantly different at the 5 % level.  
The trend of increased lung weight and volume indices in the PR animals was not 
statistically significant. It is probable that due to the small sample size this 
experiment lacks sufficient power.        
a  b 
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5.4.2  Validation of the RNA Stabilisation Methods: qPCR Results 
The results of the qPCR experiment from section 5.3.3.3 show that Liquid 
Nitrogen-Bio-Pulverizer method of RNA stabilisation out-performed the RNALater-
ICE stabilisation treatment for maintaining mRNA integrity during the tissue 
processing stage of the TRIzol mRNA isolation procedure. Actb and Adam33 
amplification of the cDNA template from the Liquid Nitrogen-Bio-Pulverizer method 
occurred a full 3-4 Cp values before the RNALater-ICE treated cDNA template 
indicating an approximate 10 fold increase (~3.33 Cp values = 10 fold change in 
concentration) in reverse-transcribed cDNA template from the same weight of 
isolated RNA transcripts (Figure 5.6). 
 
Figure 5-6: Validation of mRNA Stabilisation Methods Amplification Plots.  
Blue plots = Liquid Nitrogen-Bio-Pulverizer treatment, Green plots = RNALater-ICE treatment, Red 
plots = Standard curve analysis, Black plots = negative control reactions. Y-axis is the change in 
fluorescence and x-axis is the PCR cycle number (Cp value). The Liquid Nitrogen-Bio-Pulverizer 
treated samples are consistently amplifying earlier than the RNALater-ICE treated samples for both 
the Actb (left panel) and Adam33 (right panel) genes.  
 
Between mRNA stabilisation treatment groups the Adam33 relative quantification 
ratios differed by up to 6 fold in concentration when comparing biopsies from the 
same lung (Figure 5.7); and the Inter-sample variability in concentration with in 
groups is less in the Liquid Nitrogen-Bio-Pulverizer treated samples, 1.05 ± 0.158 
(mean ± std error) with 26 %CV; than in the RNALater-ICE treated cDNA template, 
4.75 ± 1.37 (mean ± std error) with 51 %CV. 
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Figure 5-7: Validation of mRNA Stabilisation Methods Relative Expression Chart.  
Light blue bars are the calibrator normalised concentration values used to determine the relative 
quantification of Adam33 to Actb. Y-axis is the log10 concentration ratios and each result set is 
shown on the x-axis. It is clear to see the small change in relative concentration values of ADAM33 
in the Liquid Nitrogen-Bio-Pulverizer treated (Liquid N2) lung biopsy group compared to the 
RNALater-ICE
® treated samples. 
 
From these results it is apparent that the Liquid Nitrogen-Bio-Pulverizer method is 
superior in maintaining RNA integrity consistently between tissue samples so that 
any result by qPCR should be a true reflection of transcript expression levels 
within rat lung.  
 
5.4.3  RNA, DNA and Protein Yields 
RNA isolates were obtained from all lung biopsies. RNA yield was from 7 to 100 
$g, with 260/280 ratios of 1.97 to 2.11.  DNA isolates were obtained from all lung 
biopsies and stored at -80°C ready for future analysis. DNA yield was from 22 to 
160 $g, with 260/280 ratios of 1.7 to 2.0. Large protein pellets (~1 cm diameter) 
were obtained from all lung biopsy samples. All pellets were frozen in liquid 
nitrogen according to section 2.2.3.7 ready for future analysis. 166 
5.4.4  Optimisation & Validation of the mRNA qPCR Assays 
5.4.4.1  Optimisation of mRNA qPCR Assays 
All SYBR green assays were successfully optimised according to section 5.3.6; 
the optimal primer concentration was determined to be 600 nM for both the 
forward and reverse primers. The TaqMan® and UPL based probe assay optimal 
concentrations were 900 nM and 200 nM for the primers and probe, respectively. 
None of the SYBR green primer sets amplified excessive primer dimer products 
(figure 5.8) only two assays (Atp1a1 and Atp1a2) were found to generate small 
amounts of primer dimer product. In order to remove any primer dimer contribution 
to the SYBR green signal the Lightcycler 480 machine was programmed to 
acquire the SYBR green data during a short 80°C extension step at each PCR 
cycle. At this temperature the primer dimer product (max Tm = 78°C) is melted in to 
single stranded DNA, thus SYBR green molecules cannot bind and fluoresce.  
 
 
Figure 5-8: SYBRgreen Melting Curve Analysis.  
Atp1a2 (left panel, green curve) and IGF1 (right panel, red curve) melting peaks from the 
Lightcycler 480 machine. It is clear from these melting plots that the Igf1primers forms a single 
product peak with no primer dimer production in either the cDNA reactions or water control reaction 
(black curves). While in the Atp1a2 melting plot a primer dimer product peak can be clearly seen in 
the water control, but it is less pronounced in the cDNA reactions. The red dashed line indicates 
the temperature at which SYBR green fluorescence is acquired by the Lightcycler 480 machine, to 
remove any primer dimer contribution to the signal. 167 
5.4.4.2  Validation of mRNA qPCR Assays 
Standard curves were performed for all assays as described in section 5.3.7 (see 
figure 5.9).  
 
Figure 5-9: Gstp1 Standard Curve Analysis.  
This figure provides an example of a successful standard curve analysis. Each dilution step (4
0 – 4
-
7) was performed in triplicate 10 $l reactions. The linear range of this assay extends over a 4
0 – 4
-5 
dilution of cDNA template with a high PCR efficiency of 94% before the triplicate wells are no 
longer reproducible because of the low copy number of template cDNA present in the 4
-6 & 4
-7 
dilution reactions.   
Table 5.3 shows which assays were successfully validated by standard curve 
analysis, (which generates a PCR efficiency estimate from the slope of the curve) 
and the other assays that did not generate a standard curve over the required 
minimum three dilution steps. It would appear that more cDNA template is required 
to generate an acceptable standard curve for the majority of the SYBR green 
assays.    
 
Efficiency =1.94 
Error = 0.03 
4 fold serial dilution 168 
Table 5-3: PCR Efficiency Determination  
Standard curve or LinRegPCR derived calibrator sample PCR efficiency values. 
Gene Name  Assay Type 
Adjusted for  
PCR efficiency 
PCR efficiency estimate 
E (dilution range , std error) 
Adam33  UPL  Standard curve  1.98 (4 dil, error 0.013) 
Atp1a1  SYBR green  Standard curve  2.03 (4 dil, error 0.009) 
Atp1a2  SYBR green  LinRegPCR  1.82  
GR  TaqMan  Standard curve  1.83 (5 dil, error 0.06) 
Gstm1  SYBR green  Standard curve      1.98 (6 dil, error 0.04) 
Gstp1  SYBR green  Standard curve  1.94 (6 dils, error 0.027) 
Gstt1  SYBR green  Standard curve  1.92 
Hsd11b1  SYBR green  LinRegPCR  1.86 
Hsd11b2  SYBR green  LinRegPCR  1.94 
Igf1  SYBR green  LinRegPCR  1.85 
MR  SYBR green  LinRegPCR  2.0* assumed 
Igf2  SYBR green  LinRegPCR  1.81 
Pcdh1  UPL  LinRegPCR  1.94 
Tp53  SYBR green  LinRegPCR  1.87 
rUCP  SYBR green  LinRegPCR  2.0* assumed 
Actb  TaqMan  Standard curve  1.96 (4dil, error 0.03) 
B2m  TaqMan  Standard curve  1.85 (6 dil, error 0.015) 
Ubc  TaqMan  Standard curve  1.89 (5 dil, error 0.01) 
 
Unfortunately, the amount of cDNA template spiked into each reaction is already 
at the recommended 10% of the final reaction volume. It is well established that 
>10% volumes of cDNA template has a negative impact on the performance of the 
PCR reaction. Furthermore, to increase the volume of the cDNA template it would 
be necessary to use 20 $l reaction volumes and that would double the cost of 
each reaction setup. Therefore, to maintain performance and minimise cost these 
assays  had  to  use  the  LinRegPCR  method  of  PCR  efficiency  estimation  for 
relative quantification by qPCR. 169 
5.4.4.3  Minimum Detectable Difference in Expression between Treatment and 
Control Samples  
The minimum detectable difference in expression between treatment groups was 
calculated using the F1 generation result data set for the three reference genes, 
according to section 5.3.10.1. Table 5.4 shows the difference as the geometric 
mean of expression levels of the three possible reference gene combinations 
between treatment groups. Immediately, it is apparent that the expression of the 
three reference genes is similar in magnitude but not exactly the same. Therefore, 
it would not be correct to assume that a difference in the target genes between the 
groups is due to the treatment alone; because this difference could actually be 
caused by variation in the reference genes between the treatment and control 
group samples.  
Table 5-4: Fold Expression for all Reference Gene Combinations for the F1 Generation Lung 
mRNA Samples.  
These values are used to estimate the minimum detectable difference in expression between the 
sample groups. 
 Group  Geometric mean of expression  SD (std error) 
Protein Restriction  5.9  1.5 (0.57) 
Control  4.7  1.85 (0.56) 
 
The minimum detectable difference between treatment groups is calculated by 
simply dividing the expression value of the protein restriction group by the control 
group: 
>1.25 ± 0.81 (fold expression ± SD)  
At first glance, it is clear that a 25% or less change in expression in the target 
gene is most likely to be due variation in the reference genes. The standard 
deviation for the minimum detectable difference is relatively high; therefore it 
would be prudent to adjust the difference value by the addition of three standard 
deviations (covering 99 % of the normal distribution of reference gene variation). 
With this highly conservative adjustment, the minimum detectable difference 
between the treatment groups would be a 3.7 fold change in expression. 170 
5.4.5  mRNA qPCR Data Analysis   
5.4.5.1  qPCR Performance of 120 Day Old F1 Generation Lung Samples 
IUGR marker results from three out of the eleven 120 day RNA isolates from the 
control group had to be excluded from analysis because of poor quality qPCR 
data; all result sets from the seven protein restriction lung isolates were used in 
data analysis. For the oxidative stress marker panel results from all 120 day lung 
samples were suitable for data analysis.  All of the qPCR data from the 225 day 
old lungs were suitable for analysis and all control negative controls (RT 
negatives, water controls, TRIzol™ extraction negatives) from all qPCR runs were 
free from contamination.  
5.4.5.2  IUGR Marker and Candidate Asthma Gene Analysis in 120 Day F1 
Generation Lungs 
Figure 5.10 displays the distribution of relative quantification normalised ratios 
between the protein-restricted and control groups for all of the genes assayed in 
this experiment. Examination of the chart shows there are only three outlying data 
points and the inter-sample variability within groups is acceptable for the majority 
of the genes, with the possible exception of the Hsd11b1 control group data. Any 
results for this gene should be interpreted with caution and may need to be 
repeated in the future to increase confidence in the reported Hsd11b1 normalised 
ratio values for the control group.   171 
 
Figure 5-10: 120 Day F1 Generation Rat Lung qPCR mRNA Expression Results.  
Box and whisker plot of the geometric mean of normalised concentration ratio (y-axis) for the IUGR 
marker genes (x-axis). Boxes display the 25%-75% percentile range, whiskers the 0% & 100% 
percentiles and the horizontal lines are the median value for the protein-restricted (green boxes) 
and control lung groups (blue boxes). 
 
Statistical analysis of this data revealed that relative quantification values for 5 
genes were significantly higher in the protein-restricted rat lung samples 
(Hsd11b2, Igf1 & 2, Pcdh1 and Tp53); the Ucp2 gene also showed a suggestive 
trend (P = 0.08) towards increased values (see figure 5.11).  172 
 
Figure 5-11: 120 Day F1 Generation Rat Lung qPCR mRNA Differential Expression Results.  
Box and whisker plot of the geometric mean of normalised concentration ratio (y-axis) for the IUGR 
marker genes (x-axis). Boxes display the 25%-75% percentile range, whiskers the 0% & 100% 
percentiles and the horizontal lines are the median value for the protein-restricted (green boxes) 
and control lung groups (blue boxes).  
 
The fold difference (i.e. ratio of PR over Control) of median relative quantification 
values between the two groups is clearly shown in figure 5.12, it is apparent from 
this chart that Hsd11b1 could also be increased in the protein-restricted group but 
this failed to reach statistical significance (P = 0.247). 173 
 
 
Figure 5-12: Fold Difference in Median Relative Quantification Values.   
Minimum detectable difference of 1.25 fold (pink dashed line) and the more conservative 
adjustment of 3.7 fold (1.25 +3SD; red dashed line). All of the genes with differential mRNA 
expression levels are above the minimum detectable difference of 1.25 fold (increase greater than 
25%). 
 
From figures 5.10 and 5.11 it is clear to see that although Hsd11b2 appears to be 
less abundant than other transcripts (i.e. small normalised ratio values compared 
to other genes) it has the highest level of differential expression between groups 
and it is possible that this gene is tightly regulated (small distribution of normalised 
ratio values). 
Table 5-5: Fold Expression Levels in F1 Generation Lung mRNA Isolates   
  Hsd11b2  Igf1  Igf2  Pcdh1  Tp53 
IUGR 
CONTROL 
6.3  2.4  2.0  2.7  1.5 
 
Hsd11b2 has the largest fold difference (6.3 fold) between the two groups and is 
the only gene to remain above the threshold for the most conservative minimum 
detectable difference adjustment of >3.7 fold (see figure 5.12 and table 5.5). 174 
5.4.5.3  IUGR Marker Gene Analysis in 225 Day F1 Generation Lungs 
Hsd11b2, Igf1, Igf2 and Tp53 mRNA levels in 120 day old rat lung were found to 
be significantly increased in PR offspring. Therefore, those transcripts (including 
Hsd11b1) were assayed in the 225 day lung RNA samples in order to replicate the 
120 day lung findings at a later sampling time point.  
 
Figure 5-13: IUGR mRNA Expression in 225 Day F1 Generation Rat Lung 
Box and whisker plot of the geometric mean of normalised concentration ratio (y-axis) for the IUGR 
marker genes (x-axis). Boxes display the 25%-75% percentile range, whiskers the 0% & 100% 
percentiles and the horizontal lines are the median value for the protein-restricted (green boxes) 
and control lung groups (blue boxes). PR lung, n =6. C lung , n = 6. 
 
Figure 5.13 shows that at 225 days of age mRNA levels are similar between PR 
and control lung for Hsd11b1 & 2, Igf2 and Tp53. Furthermore, Igf1 mRNA levels 
appear to be lower in control compared to PR lungs, this is the opposite to the 120 
day findings where Igf1 levels were significantly increased 2.4 fold in the PR 
group.  175 
5.4.5.4  Oxidative Stress Marker Analysis in 120 Day F1 Generation Lungs 
Relative quantification levels of the glutathione s-transferase genes were not 
significantly different between the F1 generation protein-restricted and control rat 
lungs when examined by a Mann-Whitney test (see figure 5.14). The box and 
whisker plot displays several outlying data points in the Gstm1 and Gstp1 data that 
are not representative of each group and may be caused by qPCR data of 
borderline quality. The outliers should not impact the statistical test as ranked 
values are used to test for differences; therefore the outlying data was not 
excluded from analysis.  Although, statistically non-significant (P = 0.15), the 
geometric mean of Gstp1 in the protein-restricted group is slightly lower and the 
inter-sample variability of Gstp1 is much less when compared to the control lung 
group; this could indicate that expression of this gene is tightly controlled and 
slightly down regulated in response to protein restriction.   
 
Figure 5-14: GST mRNA Expression in 120 Day F1 Generation Rat Lung.  
Box and whisker plot of the geometric mean of normalised ratio (y-axis) for the Gstm1, Gstp1 & 
Gstt1 genes (x-axis). Boxes display the 25%-75% percentile range, whiskers the 0% & 100% 
percentiles and the horizontal lines are the median value for the protein-restricted (green boxes) 
and control lung groups (blue boxes). 176 
5.4.5.5  qPCR Performance of F2 Generation Lungs 
IUGR marker results from two out of the thirteen RNA isolates from protein 
restricted lung group had to be excluded from analysis because of poor quality 
qPCR data. Similarly, three control lung data sets had to be excluded from the 
IUGR marker analysis. For the oxidative stress marker panel results from all 
samples were suitable for data analysis. All control negative controls (RT 
negatives, water controls, TRIzol™ extraction negatives) were free from 
contamination.  
5.4.5.6  IUGR Marker & Candidate Asthma Gene Analysis of 80 Day F2 
Generation Lungs 
Statistical analysis of the IUGR marker data for the F2 generation lung samples 
revealed no significant difference in relative quantification levels between groups 
in 7 out of the 8 genes that were assayed by qPCR (see figure 5.15). Median 
Hsd11b1 relative quantification levels were significantly lower in the protein-
restricted group (0.89, range = 0.06 – 3.30) compared to the control group, where 
the median level was 3.01 (0.27 – 7.59). In the F1 generation lungs, this gene was 
significantly higher in the protein-restricted group (6.3 fold increase).  
The small numbers of outlying sample data points were not excluded from the 
analysis, as they are unlikely to generate spurious significant results in a non-
parametric statistical test. The disproportionately large inter-quartile ranges of the 
Igf2 and Tp53 geometric mean normalised concentration ratios for both sample 
groups could indicate a lack of reproducibility of the qPCR data and the results for 
these genes should be interpreted with caution. 177 
 
Figure 5-15: F2 Generation Rat Lung qPCR mRNA Expression Results.  
Box and whisker plot of the geometric mean of normalised concentration ratio (y-axis) for the IUGR 
marker genes(x-axis). Boxes display the 25%-75% percentile range, whiskers the 0% & 100% 
percentiles and the horizontal lines are the median value for the protein-restricted (green boxes) 
and control lung groups (blue boxes). 
 
5.4.5.7  Oxidative Stress Marker Analysis of 80 Day F2 Generation Lungs 
Relative quantification levels of the glutathione s-transferase genes were not 
significantly different between the F2 generation protein-restricted and control rat 
lungs when examined by a Mann-Whitney test (data not shown).  
The non-significant trend towards lower levels of Gstp1 mRNA transcripts in the 
120 day F1 generation PR lung samples (see section 5.4.5.4) was not evident in 
the second generation samples. 178 
5.4.5.8  Replication of 120 F1 Generation Lung Results 
The observation of altered mRNA levels in 120 day F1 PR lung was not replicated 
in 225 day F1 PR lung or in 80 day F2 PR lung. In order to demonstrate the 
reproducibility of the findings in 120 day lung, the qPCR experiment was repeated 
using pooled cDNA templates (i.e. PR or Control) from two further cDNA synthesis 
reactions. Pooling the cDNA template by treatment helped to reduce reagent 
costs.  
 
Figure 5-16: Ratio of PR Versus Control mRNA Levels from Pooled 120 Day Lung and Liver 
cDNA Templates.   
The ratios of PR versus control expression do not reflect the original findings in 120d PR lung (see 
table 5.4) and there are considerable differences in ratios between subsequent cDNA syntheses. 
Lu1 = 1
st lung cDNA pool. Lu1 = 2
nd lung cDNA pool. Liver = liver cDNA pool. rGR 3’UT = GR 
3’UTR. GR1-10 = GR transcript containing variable exon 1-10.  
Lu 1  Lu 2  Liver  Lu 1  Lu 2  Liver  Lu 1  Lu 2  Liver  Lu 1  Lu 2  Liver 
Pooled cDNA templates 179 
As liver RNA was available for the same 120 day animals and liver GR expression 
had been previously found to be increased 300% by PR in 6 day old pups;
426  it 
was reverse-transcribed and included in this experiment.  
Figure 5.16 demonstrates the variability in PR/control ratio levels between two 
separate cDNA syntheses and highlights a substantial lack of replication of the 
original findings from the same RNA samples. The original 120 day findings that 
have been marginally reproduced by this experiment, were Igf1 (ratio of 1.4 & 1.3) 
and the Tp53 and Ucp2 ratios, but only in one out of the two cDNA templates 
used. Interestingly, MR ratios are higher in both pooled lung cDNA templates (ratio 
of 1.3 & 1.6). The MR transcript was not assayed in the original experiment due to 
delays in assay validation. Previous work using this rat model had demonstrated 
that the expression of GR was increased 3 fold in 6 day old PR liver,
426 however 
our results do not replicate those findings.  
5.4.6  Summary of Gene Expression Results 
Table 5.6 presents a summary of the statistically significant results from the qPCR 
experiments performed on the F1 and F2 generation rat lung mRNA isolates.  
Table 5-6: Summary of Gene Expression Results 
Panel  Gene  Generation 
Expression in 
PR vs control 
Fold change  
in expression 
P value 
Asthma candidate   Pcdh1  F1 
F2 
UP 
- 
2.7 
- 
0.04 
- 
IUGR marker  Hsd11b1  F1 
F2 
- 
DOWN 
- 
3.4 
- 
0.02 
  Hsd11b2  F1 
F2 
UP 
- 
6.3 
- 
0.01 
- 
  Igf1  F1 
F2 
UP 
- 
2.4 
- 
0.01 
- 
  Igf2  F1 
F2 
UP 
- 
2.0 
- 
0.03 
- 
  Tp53  F1 
F2 
UP 
- 
1.5 
- 
0.02 
- 
  rUCP  F1 
F2 
UP 
- 
1.9 
- 
0.08 
- 
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5.5  Discussion 
5.5.1  Lung Morphometry 
Previous studies of protein restricted offspring have found that at birth, body 
weight and certain organ sizes are reduced in comparison to the control 
offspring,
232, 237 although other studies have found no change.
447 As the protein 
restricted offspring age, there appears to be catch up growth with body weight and 
organ size similar between PR offspring and controls.
420 No significant differences 
in body weight or lung weight or lung volume between protein restricted and 
control offspring were observed in 225 day old offspring in the current study. 
These findings support previous studies that found no change in the lung weights 
of older protein restricted offspring.
420 However, some studies have shown 
reductions in offspring lung size and volume by using more severe deficits in 
maternal nutrition or altering the time of exposure to protein restriction. A study of 
maternal under-nutrition in rats (50% reduction in food availability) showed 
reductions in lung weight/body weight and lung volume/body weight ratios in 42 
day old offspring when compared to controls.
442 In 1996 Desai et al. found reduced 
lung weights in 21 day old rat offspring from dams that were fed a protein-
restricted diet during pregnancy and weaning or weaning alone suggesting that 
post-natal nutrition is important for normal lung growth.
420 
5.5.2  Optimisation & Validation of the TRIzol™ Isolation Protocol 
RNA, DNA and protein isolates were successfully obtained from all biopsies. DNA 
and RNA purity was in the acceptable range of each nucleic acid when determined 
by absorbance spectrophotometry (260/280 ratio for DNA , 1.8; RNA , 2.0).
448 
Therefore, contamination of the nucleic acids with protein or solvent is at a 
minimum and will not have a detrimental effect on PCR. In the future, an aliquot of 
all RNA isolations will be processed on an Agilent RNA micro-fluidics chip (Agilent 
Technologies, CA, USA) to determine the integrity of RNA molecules in the 
sample. It is well known that RNA integrity is crucial for accurate mRNA analysis 
by qPCR.
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5.5.2.1  mRNA Stabilisation Methods 
The liquid Nitrogen (N2) Bio-pulverizer mRNA stabilisation method was superior 
compared to the RNAlater-ICE treatment. In general, the liquid N2 Bio-pulverizer 
method improved the sensitivity of the qPCR assays ten fold, by virtue of 
consistent maintenance of RNA integrity. The ultra cold freeze fracture technique 
enabled rapid permeation of the TRIzol reagent into the tissue, whereby 
inactivating any endogenous or exogenous RNase activity. Increased inter-sample 
variability in the RNAlater-ICE treated group and differences in relative 
quantification ratios for Adam33 and Actb between the two stabilisation methods 
indicated that RNA integrity was not consistently maintained in the RNAlater-ICE 
treated biopsies. Differences between the dimensions of each biopsy could 
account for this variation because the rate of permeation into the tissue is 
dependant on the size and composition of each biopsy. RNA integrity numbers 
from future Agilent RNA chip analysis should confirm these conclusions. If RNA 
integrity remains an issue for the validity of gene expression results qPCR assays 
can be designed for the 5’ and 3’ of each transcript of interest and used to 
ascertain any degradation by deviation from a 1:1 ratio in concentration between 
the two assays. 
5.5.3  qPCR Assay Design, Optimisation and Validation 
qPCR assays were successfully designed, optimised and validated by melt curve 
analysis and either standard curve analysis or PCR efficiency estimation by 
LinRegPCR. From the standard curve analysis results (section 5.4.4.2) it is 
apparent that the SYBR green assays did not perform as well as the probe based 
assays. In the future, performance of these assays can be improved by the 
inclusion of a fluorescent probe.
450 As the SYBR green assays were originally 
designed with this in mind, a UPL probe binding site is available in each PCR 
amplicon, and optimisation should be relatively simple.  182 
5.5.4  Minimum Detectable Difference in Gene Expression 
Accurate determination of relative quantification values is limited by variation in 
reference gene expression between biological replicates in the treatment and 
control groups. In theory, reference gene expression should be stable and 
consistent, in practice this may not be the case as experimental treatments may 
have unexpected consequences on reference gene expression. In this study, 
variation in the three reference genes was determined by examination of the 
geometric mean of each gene-pairing in the control and protein-restricted lungs. 
The minimum detectable difference was initially calculated at 1.25 ± 0.81 fold; 
when accounting for 99% of the variation in expression this was adjusted to 3.7 
fold. This value is relatively high when considering the detected fold differences in 
gene expression in the F1 generation lungs (1.5 – 6.3 fold). Therefore, a more 
robust strategy for testing the stability of reference genes is required; a solution is 
the GENORM method as it calculates a pair-wise stability index for up to twelve 
candidate reference genes.
445 In addition to GENORM, inclusion of a panel of 
genes known to be stably expressed in the rat lung may provide a more reliable 
normalisation factor for any further analysis.
446  
5.5.5  Gene Expression in F1 and F2 Generation Lung Tissue 
5.5.5.1  Markers of IUGR 
The expression of six markers of IUGR were significantly increased in the 120 day 
protein restricted lung but not in 225 day F1 or 80 day F2 PR lung, when accounting 
for ~99% of the variation in reference gene expression only Hsd11b2 (6.3 fold 
increase) remained above the 3.7 fold threshold. Therefore, it is likely that 
differential expression of this gene is real and is not an artefact of experimental 
variation. As discussed earlier (sections 5.4.4.3 and 5.4.5.2), the 3.7 fold threshold 
may be too conservative. As the difference in expression between groups for the 
six genes is above the 1.25 fold minimum detectable difference threshold (see 
figure 5.12), the results of all six genes will be assumed to be real and any 
implications of the findings will be discussed here.  183 
5.5.5.1.1 Atp1a1 & 2 
Atp1a1 & 2 gene expression was unaltered by protein restriction and expression 
levels remained the same in the next generation.  Atp1a1 mRNA levels were 
previously associated with higher GR mRNA levels in the lungs of MLP (maternal 
low protein diet) rat offspring at 20 weeks (140 days).
428 As GR levels are also 
unaffected in the current study at day 120, it is likely that either PR has no effect 
on lung expression of Atp1a1 & 2 genes or that any affect is transient, and can 
only be detected at earlier time points. Alternatively, lack of replication with the 
Bertram et al.
428 study mentioned earlier, could indicate a problem with the qPCR 
experiment for these gene targets or animal model itself. As the lung samples 
used in both studies came from the Southampton low protein diet rat model 
housed at the same institution.   
5.5.5.1.2 GR and MR 
Glucocorticoid receptor expression in the lung was also unaffected by protein 
restriction in this experiment. This result was surprising as GR expression has 
been shown to be consistently up-regulated in response to protein restriction in 
several organs and programmed GR expression can be transmitted to the F2 
generation.
264, 428 The GR gene consists of a variable and constant coding region 
that generates tissue-specific splice forms,
451 the decision was made to design a 
common primer set to the 3’ end of the GR mRNA transcript as the most abundant 
GR transcript in lung tissue has not been identified. The previous study used a 
primer set specific for the tenth variable exon (GR110) because it was the most 
widely expressed splice form and is abundant in their target organ, the liver.
264 The 
GR110 exon promoter was then found to have altered DNA methylation status in 
response to PR exposure in the F1 and F2 generation offspring.
264 However, 
profiling GR splice variants expressed in lung tissue in the current work by using a 
primer set was designed to detect the GR110 exon did not discover any alteration 
to GR splice form expression between the PR and control lungs and reflects the 
findings with the 3’UTR assay. 
Unfortunately, validation of MR assay performance was not completed until after 
the 120, 225 and 80 day lung experiments. However, the results from the pooled 
cDNA experiments (testing the reproducibility of real-time PCR data) indicate that 
Mineralcorticoid receptor expression might be sightly increased in 120 day PR 
lung (1.3 - 6 fold; see section 5.4.5.8).  184 
A previous study of low maternal protein in rats found that offspring MR expression 
was unchanged in utero and early life.
428 Mineralcorticoids are thought to stimulate 
lung liquid re-absorption by binding the mineralcorticoid receptor on lung 
epithelium in late-gestation ovine fetal lung and may play a pivotal role in the 
transition from intrauterine to extrauterine life.
432 However, the programming of 
rodent hypothalamic-pituitary-adrenal axis is different to sheep and the 
consequence of increased MR expression in adult PR offspring is unclear.
452 This 
observation awaits confirmation in late gestation fetal and neo-natal rat lung. 
5.5.5.1.3 Hsd11b1 & 2 
Hsd11b1 & 2 have refractory effects on glucocorticoid action; Hsd11b1 catalyses 
the conversion of cortisone to bioactive cortisol, which can activate glucocorticoid 
receptors, whereas Hsd11b2 catalyses the inactivation of cortisol to cortisone and 
maintains the aldesterone specificity of the minerocorticoid receptor.
453, 454 The 
programming of hypertension and dysregulation of glucose metabolism are 
thought to be mediated by inhibition of placental Hsd11b2 activity.
455 However, the 
consequence of altered glucocorticoid action in the lung by protein restriction is not 
well understood.  
In 2001, Bertram et al.
428 investigated the mechanism of glucocorticoid action the 
same rat PR model as the current study, reporting that Hsd11b1 expression was 
not changed by PR and that Hsd11b2 mRNA expression was significantly reduced 
in foetal lung at day 20 of gestation (term = 22days).
428 They also found that 
Hsd11b2 mRNA was undetectable in post-natal lung tissue by northern blot 
analysis.
428 In the current study, Hsd11b2 expression was significantly increased 
in the 120 day F1 generation PR lung (6.3 fold), but not at 225 days of age or  in 
the F2 generation, where Hsd11b1 was found to be down regulated 3.4 fold 
compared to control animals. The decreased Hsd11b1 mRNA levels in the PR F2 
generation lung tissue in the current study are intriguing. However, they require 
clarification by further experimentation as no change was observed in the F1 
generation, in fact levels tended to be higher in the F1 PR group. Utilisation of real-
time PCR in the current study has demonstrated that not only is Hsd11b2 
expressed in the post-natal lung, there appears to be a programmed up-regulation 
of mRNA levels in response to in utero protein restriction. Hsd11b2 has been 
found to be present in human airways by immunological staining and is localised 
to vascular endothelial cells in the lamina propria and bronchial epithelium.
456, 457 185 
In 2003, Susuki et al.
457 concluded that human bronchial epithelial cells possess a 
putative autoregulatory system for natural and synthetic glucocorticoids and 
control their own bioactive levels by inducing the expression of Hsd11b2.
457 
Therefore, an up-regulation of expression could potentially increase the capacity of 
Hsd11b2 to down regulate glucocorticoid action in the lung. However, it has been 
suggested that Hsd11b2 can act as a oxidoreductase and reactivate synthetic 
glucocorticoids such as dexamethasone.
458 Furthermore, it has been suggested 
that Hsd11b2 may modulate the efficacy of systemic glucocorticoids given 
therapeutically and that steroid resistance in asthmatics could be caused by an 
adverse balance in metabolism.
456  Therefore, the results from this study suggest 
that in utero protein restriction alters the balance between levels of Hsd11b1 & 2 
and this could affect the control of glucocorticoid action in lung tissue and may be 
clinically relevant to inhaled corticosteroid treatment in humans. Further 
examination of GR, MR Hsd11b1 & 2 mRNA levels in earlier time points will clarify 
the effect of PR on the control of glucocorticoid action in the lung.  
5.5.5.1.4 Igf1 & 2 
Both Insulin-like growth factor genes were up regulated in response to PR in 120 
day first generation animals and increased Igf1 levels were confirmed by the 
reproducibility experiment (see section 5.4.5.8). However, expression of Igf1 
appeared to be lower in 225 day F1 PR lung and similar in the F2 animals. There is 
limited understanding of the consequences of IUGR on the IGF system in lung. 
Chen et al.
425 reported that increased lung Igf1 mRNA expression can be detected 
up to postnatal day 28 in rats exposed to maternal under nutrition (50% total 
nutrient restriction) during the last trimester of pregnancy. Results from this study 
show that in a rat protein restriction model Igf1 mRNA expression is still up 
regulated (2 – 2.4 fold) 120 days after birth but not at 225 days; this is much later 
than in the previous study. Growth factors like the IGFs are important for the 
regulation of cell proliferation during lung development. Increased IGF gene 
expression was significantly up regulated in ovine models of accelerated postnatal 
lung growth.
459 Deletion of the Igf1 & 2 genes in mice caused growth retardation 
and impairments in lung function at birth.
460, 461 and the IGF 1 receptor has been 
found to be important for lung vascular development in rat embryonic lung 
explants.
462 186 
5.5.5.1.5 Tp53 
p53 is a transcription factor that plays a pivotal role in determining cellular 
response to stress and was found to be expressed 1.5 fold more in the 120 day F1 
generation PR lungs compared to controls, and increased Tp53 levels were 
confirmed in one out of the two extra cDNA templates in the reproducibility 
experiment (see section 5.4.5.8) but not at 225 days of age, nor in the F2 lungs. 
p53 is involved in alveolar development by regulation of cellular apoptosis. 
Increased alveolar cell apoptosis is seen in the emphysemic lung and p53 protein 
levels in lung parenchyma cells are significantly higher in subjects with 
emphysema.
463  
Uteroplacental insufficiency in rats has revealed an epigenetic programming 
mechanism through reduced CpG DNA methylation of the p53 gene promoter, 
resulting in increased p53 expression that correlates with key apoptosis related 
proteins, renal apoptosis, and reduced glomeruli number in the IUGR kidney.
464 
Therefore, the Tp53 gene is a potential candidate to test whether, the change in 
gene expression observed in the F1 PR lung, is programmed by altered gene 
promoter DNA methylation. It is unlikely that the programmed adaptation is 
maintained in subsequent generations as the F2 generation Tp53 expression was 
unaltered and its expression levels may alter with age as Tp53 levels were similar 
in the 225 day F1 lungs. Programmed adaptations to p53 expression in response 
to IUGR may impact COPD susceptibility and modulate disease severity. Smokers 
expose their lung to excessive levels of oxidative stress and an amplified p53 
response in an IUGR individual could leave them predisposed to accelerated 
alveolar cell apoptosis and by extension, earlier onset or increased severity of 
emphysema in later life.   
5.5.5.1.6 Ucp2 
There is a suggestive trend (1.9 fold; P = 0.08) to increased uncoupling protein 2 
mRNA levels in the 120 day F1 generation PR lung but not at 225 days of age or in 
the F2 generation. It has been suggested by Gnanalingham et al, 2005.
427 who also 
found increased Ucp2 expression in response to IUGR in sheep, that increased 
Ucp2 abundance in later life could have deleterious consequences in lung function 
and enhanced susceptibility to infection. Ucp2 deficient mice have an amplified 
immune response with greater macrophage phagocytic activity and increased 
ROS production, one of the phenotypes of these mice is a striking resistance to 187 
infectious microorganisms.
465 These results provide suggestive evidence that 
programmed up-regulation of Ucp2 expression by in utero protein restriction could 
result in a dampened immune response in offspring and increased incidence of 
infection during life. Infection during childhood may impair lung growth and make 
these individuals more vulnerable to developing COPD on exposure to additional 
injurious agents (reviewed by Sethi, 2000).
466 Therefore, it would be of interest to 
examine role of Ucp2 genetic polymorphism in susceptibility to COPD and asthma.  
5.5.5.2  Oxidative Stress Genes 
All three GST gene transcripts were present in 120 day old rat lung and the 
abundance of transcripts was in the following increasing order, Gstt1 > Gstm1 > 
Gstp1 in the F1 generation. Interestingly, Gstp1 expression was slightly less 
abundant than Gstm1 expression in the F2 generation samples and Gstt1 
transcript was detectable in rat lung; whereas some studies have suggested that 
GSTT1 is not expressed in human lung,
467 whilst others have found it at low 
levels.
188, 190  
In both generations, there was no significant difference in expression levels of 
rGST transcripts between protein-restricted and control groups. Thus, it appears 
that there is no evidence of alterations in expression of anti-oxidant glutathione s-
transferase genes in the lung tissue from animals exposed to protein-restriction 
during gestation. mRNA expression is not always representative of protein levels, 
without evidence to suggest that this is the case in this model, the GST expression 
results could reflect that both the PR and control animals have similar oxidative 
stress in the lung at 120 days of life. GSTO1 (Glutathione S-Transferase Omega 
1) has recently been found to be expressed in alveolar macrophages, airway and 
alveolar epithelium and airways secretions.
468 In COPD patients, sputum and lung 
homogenate levels of GSTO1 have been found to be lower when compared to 
non-smokers.
468 Again, as with the IUGR marker genes it would be very 
interesting to monitor GST gene expression profiles (including GSTO1) over time,  
including earlier and later sample time points (birth (day 0) and old age (day 300)) 
to determine if response to oxidative stress is affected by protein-restriction in 
early life. Ideally, incorporation of controlled tobacco smoke exposure into the rat 
PR model would facilitate the understanding of the effect of an imprudent maternal 
lifestyle (i.e. maternal ETS and poor nutrition during pregnancy) on risk of 
respiratory disease in her offspring.     188 
5.5.5.3  Candidate Asthma Genes 
As Adam33 expression was not found to be differentially expressed in the PR F1 
generation lungs at 120 days of life, this gene was not assayed in the F2 
generation samples. ADAM33 is thought to be important in the developing foetal 
lung but these results suggest that if PR did alter expression, these effects are 
transient and are not apparent at 120 days of life. In humans, ADAM33 is more 
abundant in the embryonic lung, clustering around developing embryonic bronchi 
and in smooth muscle bundles, hence involvement of this gene in remodelling and 
bronchial hyper responsiveness.
394 Expression of mRNA splice variants and 
immunostaining of normal and asthmatic bronchial biopsies revealed no significant 
differences.
394 A knockout mouse study found that ADAM33 is not essential for 
growth, development or allergic asthma.
469 Recent work has shown that DNA 
methylation of the ADAM33 promoter controls its expression in a cell type-specific 
manner
439 and that the soluble form released from cell membranes of damaged 
lung epithelium cell results in a disease-related gain of function, that is 
independent of inflammation.
470 It is now thought that ADAM33 has a functional 
role in airway remodelling by the promotion of  angiogenesis.
470 Therefore, it would 
be of interest to examine expression of this gene in earlier sample time points, 
such as at birth (day 0) or earlier to determine if PR does have any affect on 
ADAM33 expression during lung development in utero, because of the extensive 
remodelling of the foetal lung during development. 
Pcdh1 expression was significantly increased in the 120 day old PR group (2.7 
fold; P = 0.04) in the F1 but not in the F2 generation. Protocadherin 1 is involved in 
the maintenance of cell junctions and is expressed in airway epithelial cells and 
therefore may be important epithelial barrier function.
440 The expression of Pcdh1 
in PR lungs may indicate that there is increased angiogenesis and lung 
remodelling in these animals into adulthood (120 days). The findings with Pcdh1 
were not replicated in the F2 generation lungs, suggesting that epigenetic 
mechanisms are not transmitting enhanced Pcdh1 expression to the next 
generation in absence of a protein-restricted environment during pregnancy. In 
order to test this conclusion, results need to be confirmed by replication in more 
samples and changes to the expression of key angiogenic genes (e.g. VEGF) 
would provide extra evidence for alterations to the lung vasculature. Morphological 
analysis and staining of serial sections of PR rat lung tissue would confirm the 
presence of increased vascularisation.  189 
5.5.5.4  Reproducibility of 120 Day PR Lung mRNA Expression Results 
Attempts to replicate the 120 day PR lung mRNA expression results met with 
limited success with only the levels of Igf1, MR, Tp53 and Ucp2 in either two or all 
three of the cDNA templates generated from the same RNA isolate. The poor 
reproducibility of the results reflects the fact that in qPCR reverse-transcription of 
RNA into cDNA is technically the most variable step in any real-time PCR 
experiment.
471 As the observed changes in gene expression in this rat model are 
relatively small in comparison to the inherent experimental variability (e.g. variation 
in reference gene, mRNA stability and between cDNA templates), it is in some 
respects, unsurprising that some of the observations are hard to replicate with a 
small sample size at all sampling time points (i.e. 225 day lung).  
Therefore, the gene expression findings presented in this chapter should be 
interpreted with caution until they are confirmed by further experiments utilising 
larger sample sizes across a range of sampling time points, with improvements in 
establishing a reference gene normalisation factor with less background variation  
(e.g. GENORM normalisation software can use up to twelve reference genes)
445 
and using multiple cDNA templates (minimum of two replicates per biological 
sample) for real-time PCR to account for variation in the efficiency of the RT-PCR 
step.    190 
5.6  Concluding Remarks and Future Work 
In conclusion, the purpose of this work was to determine whether maternal PR 
alters lung growth and expression of key genes in lung development, establishing 
a ‘baseline’ of lung physiology and gene expression, with the ultimate aim of 
combining this model with an extra maternal exposure, such as tobacco smoke 
during pregnancy in future studies and monitor offspring respiratory phenotypes. 
The work presented in this chapter provides supporting evidence for programmed 
expression of key genes involved in hypertension, dysregulation of glucose 
metabolism, and mitochondrial energy balance and organ development in the 
lung, in response to in utero protein restriction in the F1 generation at 120 days of 
age but not in older animals (225 days). The expression of genes involved in 
antioxidant defences are unaltered by in utero protein restriction and there is no 
evidence for the trans-generational programming of gene expression in lung. In 
the rat at 255 days of age there is no evidence to suggest that PR during 
development has resulted in permanent retardation to organ size or to respiratory 
function (lung volume). 
At the start of this chapter two hypotheses were proposed (section 5.1.10) analysis 
of mRNA levels by qPCR has revealed that in a rat model of hypertension, a 
maternal low protein diet during pregnancy has programmed changes in gene 
expression that could alter the course of normal lung development, 
vascularisation, growth and later lung function (Hsd11b2, Tp53, Pcdh1, Igf1 &2 
and Ucp2) and even dampen immune responses in the offspring (Ucp2).  
Importantly, up-regulation of these genes, programmed in utero, have persisted in 
to adulthood (up to 120 days in the rat) and therefore could have implications for 
susceptibility to respiratory disease in later life (COPD) as well as in childhood 
(asthma). The mRNA levels of three key anti-oxidant GST genes are unaltered in 
120 day old PR lung, indicating that protein-restriction does not appear to program 
the expression of cytosolic GST enzymes. In order to fully understand these 
findings, it is necessary to validate these findings in more sample time points 
during the life of the PR rats.  
Gene expression analysis in other sample time points (time points could include, 
foetal (20 days gestation), birth (day 0), after weaning (day 21) and old age (day 
300) would produce a gene expression profile from development until old age that 
could be used to examine the consequence of alterations to gene expression at 191 
critical windows of lung development and help understand how gene expression 
changes as the animals age.  
It is thought that epigenetic mechanisms (DNA methylation) could potentially 
control nutritional programming, but the F2 gene expression results do not provide 
any evidence that these candidate genes are under the influence of trans-
generational programming at 80 days of age. However, investigation of the 
epigenetic programming of other genes in PR lung could be performed by gene 
promoter DNA methylation analysis by real-time PCR melt-curves
472 or by 
pyrosequencing. The lung DNA, RNA and protein isolations collect in this study 
would prove to be very useful as any DNA methylation finding could be directly 
related to mRNA and protein levels from the same sample.  
A more detailed approach to the analysis of lung morphology would determine if 
there are structural changes to the tissue, such as a reductions in alveolar 
abundance/size and alveolar capillary bed vascularity, which could be detrimental 
to normal lung function by reducing the gas exchange potential of the organ. 
Examination of lung tissue morphology by stereological methods would determine 
if exposure to protein restriction in utero alters airways size and number, airways 
wall thickness, smooth muscle/myofibroblast content or vascularity. 
Other areas to address in future work include improvements to the quality control 
measures for qPCR, such as, accounting for the efficiency of reverse transcription 
step (by utilising multiple cDNA templates for each biological sample). RNA 
integrity could be determined by Agilent RNA micro-fluidic chips and confirmed by 
5’ & 3’ mRNA qPCR primer sets. Conversion of the SYBRgreen based primer sets 
into probe based assays will improve specificity and performance of the assays in 
standard curve analysis. The selection of reference genes could be improved by 
performing pair-wise assessments using the GENORM method
445 to find the most 
stably expressed reference genes in the experimental model. 192 
6  Protein-Restricted Rat Lung: micro RNA Expression 
Analysis 
6.1  Introduction 
The lung undergoes several stages of development, extending into early life, that 
are sensitive to alterations in the developmental environment. microRNAs 
(miRNA) are short nucleotides that can regulate the expression of individual and 
pathways of genes at the post-transcriptional level. They have an important role in 
lung development and are differentially expressed during development, to 
modulate developmental timing, cell fate determination and apoptosis. Currently, 
little is known about the regulation of miRNA expression. However, dietary 
components, such as folate have been shown to alter miRNA expression
473 and 
epigenetic mechanisms, including DNA methylation are known to play an 
important role in the regulation of miRNA precursor expression.
474 
Therefore, miRNAs responding to fetal nutrition or epigenetically controlled miRNA 
expression represent novel mechanisms by which predictive adaptive responses 
can made by the foetus to predict the post-natal nutritional environment and 
program the lung accordingly during windows of developmental plasticity that 
continue into early life. The Southampton protein-restriction rat model provides an 
opportunity to determine whether ‘nutritional programming’ by maternal protein-
restriction during pregnancy alters offspring lung miRNA expression. Furthermore, 
miRNA target gene predictions, by bio-informatics approaches, should highlight 
metabolic pathways under the influence of miRNAs.  
6.1.1  miRNA Biogenesis and Function 
Micro RNA molecules (miRNA) are short molecules (15-25 bp) that are not 
translated into protein but silence/reduce gene expression by binding to the 3’ end 
of the mRNA gene transcript as part of a RNA-induced Silencing Complex (RISC). 
(Figure 6.1) This triggers degradation of the mRNA or translationally represses 
expression of the gene. The degree of miRNA complementary to the mRNA 
sequence determining whether the target mRNA is cleaved or not. Mature miRNA 
show near complementarity to the 3’ untranslated (3’UTR) region of target mRNA. 
The complementarity is in the form of a ‘seed’ sequence of about 7 nucleotides at 193 
the 5’ end of the miRNA molecule to bind the 3’UTR mRNA sequence. The seed 
sequence is essential to confer regulation of the mRNA target.  
 
Figure 6-1: microRNA Biogenesis. 
The pri-miRNAs are processed into ~70bp pre-miRNAs by Drosha in the nucleus. Exportin 5 
transports the pre-miRNA into the cytoplasm, where Dicer processes them into miRNA:miRNA 
duplexes. Dicer can also process long dsRNA molecules into short interfering RNA (siRNA). One 
strand of the miRNA:miRNA duplex is assembled into the RNA Induced Silencing Complex(RISC) 
and the other miRNA strand is targeted for degradation. The miRNA acts on its target by either 
translational repression or mRNA cleavage; this is dependant on the miRNA complementarily to 
the target sequence. 
The process of miRNA maturation from, (1) polymerase II transcribed Pri-miRNA 
(2) Cleavage into precursor miRNA (pre-miRNA) by the endonuclease Drosha in 
the nucleus (3) The importing of pre-miRNA into the cytoplasm by exportin 5 (4) 
Cleavage of cytoplasmic pre-miRNA by Dicer into miRNA:miRNA duplexes, is 
tightly regulated at each step.  
A recent study of miRNA turnover in Caenorhabditis elegans reported degradation 
of fully processed mature miRNAs by the 5’-3’ exoribonuclease XRN-2; these 
results suggest the presence of additional layer of regulation of miRNA activity.
475 
The authors suggested that regulation of mature miRNA turnover may be 
important for rapid changes in miRNA expression profiles during developmental 
transitions and in the homeostasis of miRNA levels. Little is known about how 
miRNAs are transcribed and what promoter elements control expression. The 
limited analysis of miRNA promoters has shown they are likely to be under control 194 
of transcription factors, enhancers, silencing elements and chromatin modifications 
such as DNA methylation, much like any protein-expressing gene (reviewed by 
Breving et al, 2009).
476 To date, it has been accepted that miRNA species repress 
gene expression. However, emerging data has shown in some circumstances 
miRNAs can activate genes by stimulating protein translational activation
477
 and 
the promote expression of genes with complementary promoter sequences.
478 
Therefore, as our understanding of this group of short RNA molecules grows, it is 
likely that more interesting functions of miRNAs will emerge. 
6.1.2  Genomics of miRNA 
In the human or rat genome about 50% of the miRNA genes are found in clusters 
on all chromosomes except for the Y chromosome (see Table 6.1). miRNAs in the 
same cluster are transcribed as a polycistronic transcript. miRNAs in a cluster are 
often related to each other, possibly as a result of gene duplication of the cluster. 
Clustered miRNA genes are functionally related and could act on the same gene 
or gene pathway and many miRNAs target genes are involved in development. 
The majority of mammalian miRNA genes are located in transcribed units (TUs), 
consisting of three types; intronic miRNA in protein coding TUs (61%), intronic 
miRNA in non-coding TUs (18%), and exonic miRNA in non-coding TUs (20%).
479 
Table 6-1: Rattus Norvegicus miRNA Gene Clusters. 
Chromosome 
(strand)  miRNA gene clusters
a (rno-mir-xxx cluster 1 | rno-mir-xxx cluster 2…)
 
Chr X (+) :   rno-mir-222 rno-mir-221 
Chr X (-) :   rno-mir-421 rno-mir-374 | rno-mir-363 rno-mir-92-2 rno-mir-19b-2 rno-mir-20b | rno-
mir-503 rno-mir-322 
Chr 1 (+) :   rno-mir-99b rno-let-7e rno-mir-125a | rno-mir-194-2 rno-mir-192 
Chr 1 (-) :   rno-mir-292 rno-mir-291 rno-mir-290 
Chr 2 (+) :   rno-mir-15b rno-mir-16 
Chr 3 (-) :   rno-mir-296 rno-mir-298 
Chr 4 (-) :   rno-mir-96 rno-mir-183 | rno-mir-29a rno-mir-29b-1 | rno-mir-141 rno-mir-200c 
Chr 6 (+) :   rno-mir-337 rno-mir-540 | rno-mir-376b rno-mir-376a rno-mir-300 | rno-mir-381 rno-
mir-487b | rno-mir-382 rno-mir-134 | rno-mir-409 rno-mir-412 rno-mir-369 
Chr 7 (+) :   rno-let-7c-2 rno-let-7b 
Chr 8 (-) :   rno-mir-34c rno-mir-34b 
Chr 10 (+) :   rno-mir-497 rno-mir-195 | rno-mir-212 rno-mir-132 | rno-mir-144 rno-mir-451 
Chr 12 (-) :   rno-mir-25 rno-mir-93 rno-mir-106b 
Chr 13 (+) :   rno-mir-181a-1 rno-mir-181b-1 | rno-mir-194-1 rno-mir-215 | rno-mir-29b-2 rno-mir-
29c 
Chr 15 (+) :   rno-mir-17 rno-mir-18 rno-mir-19a rno-mir-20a rno-mir-19b-1 rno-mir-92-1 
Chr 17 (+) :   rno-let-7a-1 rno-let-7f-1 
Chr 17 (-) :   rno-mir-24-1 rno-mir-27b rno-mir-23b 
Chr 19 (-) :   rno-mir-24-2 rno-mir-27a rno-mir-23a 
aInter-miRNA  clustering  distance  = 5 0 0 b p .   red =  g e n i c  c l u s t e r . D a t a  f r o m  m i R G e n  d a t a b a s e  
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6.1.3  Methylation and Epigenetically Controlled miRNA Expression  
It is thought that 5-10% of mammalian miRNA genes are epigenetically regulated 
(reviewed by Breving et al, 2009)
476 and with 47% of miRNA genes reported as 
being associated with CpG islands.
480 The predicted targets of some miRNAs 
have included transcripts from genes involved in chromatin regulation (miR-520 
cluster in human embryonic stem cells)
481 and DNA methylation (miR-29 and 
DNMT3a &b).
482 Therefore, miRNAs are in a unique position of being subjected to 
epigenetic control but can also regulate the very same processes, forming a 
regulatory feedback loop.
483 Miss-expression of miRNAs due to promoter 
dysregulation by changes in DNA methylation levels is seen in human disease and 
will be discussed in the next section. 
6.1.4  miRNAs in Disease 
The over and under-expression of miRNAs has been observed in various 
diseases, included numerous cancers,
484-486 and many human miRNA genes are 
located in cancer-associated regions and in gene deletion/amplification and 
mutation hotspots (reviewed by Rossi et al, 2008).
487 It is thought that miRNA 
dysregulation is important in cancer because miRNAs are key regulators of cell 
growth, apoptosis, proliferation and differentiation. 
In cancer cell culture and animal model studies, many miRNAs have been shown 
to have tumour-promoting or suppressive activities, for example miR-21 is over 
expressed in many cancers and inhibition of miR-21 in HeLa cervical cancer cells 
reduces tumour cell profileration.
488 The enforced expression of miR-29 in lung 
cancer cell lines restored normal patterns of DNA methylation (by targeting DNA 
methyltransferases 3A and 3B), this lead to re-expression of methylation-silenced 
tumour suppressor genes (FHIT & WWOX) and inhibited tumorigenicity in vitro 
and in vivo.
482 In breast cancer, abberrant DNA hypermethylation occurs early on 
in tumour development and hypermethylation of CpG islands near miRNA genes is 
thought to be another mechanism of gene inactivation.
489 In fact, miRNA 
expression profiles have been demonstrated to be more accurate in predicting 
poorly differentiated cancer than mRNA expression profiles in the same group of 
patients.
490 miRNAs have a therapeutic potential in cancer treatment for example, 
miRNAs with tumour promoting activities could be targeted by miRNA silencing, 
antisense blocking and miRNA modification (reviewed by Li et al, 2009).
491  
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There are now emerging roles for miRNA in other diseases such as, cardiac and 
vascular malignancies, diabetes, obesity, metabolic syndrome and infection. 
miRNAs are important regulators of normal vascular development and function, 
studies in mice with Dicer deletions have demonstrated impairments in blood 
vessel formation of the developing embryo and altered expression of the 
angiogenic regulators.
492 miR-126 has been shown to inhibit the expression of 
vascular cell adhesion molecule1 (VCAM1) an important component of leukocyte 
adhesion to endothelial cells in the early development of atherosclerotic lesions.
493   
Several miRNA species have been indentified as having roles in insulin secretion, 
islet development, B cell differentiation and can indirectly control glucose and lipid 
metabolism.(reviewed by Tang et al, 2008)
494 Expression profiling in diabetic 
animal models have demonstrated altered miRNA levels which have predicted 
targets in glucose, lipid metabolism and over-expression of miR-29s lead to insulin 
resistance in adipocytes.
495, 496 Furthermore, the miRNAs expressed in islets, liver 
and adipose tissue share significant changes in response to genetic obesity in 
diabetes-susceptible mice.
497 
It is likely that miRNAs can also have direct antiviral effects as one study has 
demonstrated that IFN-% can modulate the expression of cellular miRNAs that 
have predicted targets in the hepatitis C virus genome.
498 However, the direct 
interaction between host miRNA machinery and virus genomes is still not fully 
understood.  
6.1.5  Role of miRNAs in Development  
miRNAs were originally indentified in Caenorhabditis elegans as genes that were 
required for the timed regulation of developmental events.
499, 500 Now, hundreds of 
microRNAs have been characterised and are thought to regulate the expression of 
20-30% of human genes, many of which are involved in development and 
homeostasis.
501 The role of miRNAs in human development are still not fully 
understood, however forward and reverse genetic experiments in worms, flies, fish 
and mice have provided insights into the developmental stages where miRNAs are 
essential for viable life. The most studied miRNAs are lin-4 and let-7, these 
miRNAs are involved in controlling early and late developmental timing in worms 
(reviewed by Wienholds et al, 2005).
502 Again, in worms, lsy-6 and mir-273 were 
found to control left/right neuronal asymmetry. In flies, programmed cell death was 
found to be regulated by miR-14.  197 
In zebrafish, miR-7 was found to regulate Notch signalling which is essential for 
proper patterning and development of all multicellular organisms and miR-430 was 
found to be important in brain morphogenesis. (reviewed by Wienholds et al, 
2005)
502  
In 2006, Strauss and colleagues used mouse embryonic stem cells as a model 
system for the early mammalian embryo and reported the miRNA expression 
signature against mature heart, lung, liver, kidney and brain tissue miRNA 
signatures.
503 They observed an overall trend of increasing miRNA complexity 
from immature embryonic stem cells to mature tissues. The most complex 
signature came from more functionally complex tissues (brain to liver being least 
complex). They hypothesed that the interaction between the miRNAs and 
messenger RNA determines a finely tuned set of mature mRNA for each tissue at 
the end of development. 
6.1.5.1  Lung Development  
The role of miRNAs during fetal lung development is not fully understood. In 2007 
Williams et al. published miRNA expression profiles of fetal and adult lung in 
humans and mouse.
504 They found miRNA profiles between humans and mouse 
to be very similar, both species possessing a maternally imprinted miRNA cluster 
(miR-154 and miR-335 families) and up-regulation of a subset of miRNAs 
expressed in adult (miR-26b, 29a, 29b, 142-3p and 187) compared to fetal lung 
(miR-134, 154, 214, 296, 299, 323, 337 and 370). There were also differences in 
the spatial expression of miRNAs, with miR-26a and miR-29a localising to airway 
and alveolar epithelia and miR-154 present in fetal stoma but not in adult lung. In 
2008, Ventura et al. demonstrated that mice deficient for the miR-17~92 cluster die 
after birth with lung hypoplasia and defects in heart and B cells.
505 The authors 
noted that a previously published work on the over expression of the cluster had 
demonstrated increased cell proliferation and inhibition of differentiation of  the 
lung epithelium (Lu et al, 2007. Cited in Ventura et al)
505 and concluded that this 
miRNA cluster played an important role in the control of the proliferation or survival 
of lung cells. 
In rat, microarray analysis of miRNA expression revealed 21 miRNA species that 
changed during development and that the miRNA could be placed into 4 groups 
based on the timing of their expression.
506 (see table 6.2)  198 
The authors noted that cluster 1 contained miRNAs that controlled developmental 
timing (let-7), proliferation and differentiation of cells (miR-195). Cluster 2 and 3 
expressed miRNA species from the miR-17~92 cluster that, as stated earlier, 
could promote proliferation and differentiation of lung epithelial cells.  
miRNAs in cluster 4 (miR-127 and miR-351), were shown by In situ hybridisation 
to shift from the mesenchymal compartment of the developing lung to epithelial 
cells. This lead the authors to conclude that these miRNAs may have role in 
cellular reorganisation. Finally, the over expression of miR-127 at an earlier stage, 
embryonic day 14, in fetal lung cultures caused defects in lung branching 
morphogenesis, resulting in larger and fewer terminal buds than untreated 
cultures.
506 This finding indicates that the timed expression of miRNAs is important 
for normal lung development to occur. 
Table 6-2: Rat Lung Developmental Stages and miRNA Expression.   
miRNA Cluster
a 
  Days  Lung development stage  Milestones in development 
1  2  3  4 
E1 
* 
E13 
Embryonic  lobar division 
?  ?  ?  ? 
Organogenesis 
E13 
* 
E18 
Pseudoglandular  epithelial tubes of air 
passage form (no lumen) 
L  H  H  L 
E18 
* 
E20 
Canalicular  Bronchioles are producted 
and lumen is found in 
many tubules  L  H  L  L 
Differentiation 
E20 
* 
full term 
Saccular  
 
Thinning of interstition, 
flattening of epithelium, 
alveolar ducts and air sacs 
are formed.  
Start of Surfactant 
production 
L  L  L  H 
H  Post-natal  birth (P0) 
* 
adult 
Alveolar  true alveolar formation 
H  L  L 
L 
a miRNA Cluster 1:let-7b, miR-29a, 23a, 22, 195. Cluster 2: miR-298, 341, 130b, 92. Cluster 3: 
miR-17, 214, 106b, 93, 290, 20a, 17-5p, 18. Cluster 4: miR-127, 210, 19b, 351. Data adapted from 
Bhaskaran et al 2009.
506  L = low expression, H= high expression 199 
6.1.6  Hypotheses 
It is proposed that: 
‘Maternal protein-restriction during pregnancy leads to altered lung miRNA gene 
expression in offspring.’ 
6.2  Aims 
We hypothesised that restricting the amount of protein available to the developing 
fetus will result in alterations to lung miRNA expression. We aim to test this 
hypothesis by determining miRNA gene expression levels, by microarray, in lungs 
from 120 day old protein-restricted and control F1 generation rat offspring. 
Furthermore, we will validate any differentially expressed miRNA genes identified 
by microarray with real-time PCR.  We will then perform miRNA gene cluster and 
miRNA gene target bioinformatics to ascertain whether alterations to miRNA gene 
expression is independent of shared miRNA gene promoter regions and identify 
potential gene targets to understand which biological pathways may be under the 
influence of altered miRNA expression. 200 
6.3  Methods 
6.3.1  miRNA Isolation and Purification  
Total RNA from lung tissue was extracted using a modified trizol RNA isolation 
protocol (section 2.2.3). Extractions were carried out utilising 
-20°C isopropanol 
with 50 mg of glycogen and stored overnight at 
-80°C to precipitate small RNA 
molecules. RNA quantification was performed according to section 2.2.2.2. For the 
microarray experiments lung tissue biopsies were sent to Miltenyi Biotec for 
isolation by standardised in-house protocols.  
6.3.2  miRNA Microarray 
PIQOR™ miRXplore Microarrays were used to assess global miRNA expression 
in the lung tissue. Mac Molecular Genomic Services (Miltenyi Biotec GmbH) 
provided the service and performed the entire tissue processing, total RNA 
isolation, RNA labeling, microarray hybridization steps and performed quality 
control analyses for the microarray data. 379 rat miRNA species were targeted on 
the PIQOR™ miRXplore Microarray (miRNA sequences according to miRBase 
version 10.0). All oligonucleotides were spotted in quadruplicate. 
Controls included on the miRXplore Microarray were: 
• 13 Negative mismatch controls 
• 36 Positive controls 
• 5 Hybridization controls 
• 18 Calibration controls 
6.3.2.1  Total RNA Samples on the Microarray 
7 Protein-restricted and 7 control 120 day F1 lung samples (from section 5.3.1) 
were analysed by microarray. The total RNA isolates were pooled into two groups 
(Pool 1 = Protein-restricted; Pool 2 = Control) and labelled with Hy5 dye; then 
hybridized on to two microarrays, respectively.  201 
6.3.2.2  Microarray Data Normalisation 
All Hy5 signals were normalized to a Hy3 labelled miRExplore™ universal 
reference of synthetic microRNA molecules (supplied by Miltenyi Biotec GmbH) 
before calculation of the ratio values (RNA Pool 1/ RNA Pool 2) for the miRNA 
species of interest.  
6.3.2.3  Microarray Data Quality Control 
As an additional quality filtering step, only hybridisation spots with signals or higher 
than the 75% percentile of the background signal intensities were used in the 
calculation of the Hy5/Hy3 ratio. This discriminated questionable results from 
relevant miRNA results because they were flagged as having very low signal 
intensities and removed from the final data set. The cut-off value for putative up or 
down-regulated miRNA expression was determined as a ( 1.7 fold change in 
signal intensity. 
6.3.3  Real-Time PCR validation 
Real-time PCR miRNA quantification was performed to validate the microarray 
results. Initially, the miScript system (Qiagen) was chosen to validate the top two 
over and under-expressed miRNA species. This system utilises a single cDNA 
synthesis step to generate template for all miRNA species in a single sample. The 
second real-time PCR miRNA system (miRcury, Exiqon) was used to confirm 
initial real-time PCR findings from the miScript system and subsequently replaced 
it as the real-time PCR miRNA system of choice. All miRNA gene quantification 
levels generated by real-time PCR were normalised to an endogenous control 
siRNA gene, rRNA 5S. 
6.3.3.1  Qiagen miScript System 
6.3.3.1.1 Overview 
This system combines SYBRgreen dye detection with validated miRNA primer 
assays to provide rapid determination of hundreds of miRNA molecules from a 
single cDNA synthesis (Figure 6.2).  
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Figure 6-2: Principles of miScript miRNA Real-Time PCR System.  
In step 1, the reverse-transcription reaction, miRNAs have a poly(A) tail added to the 3’ end of the 
molecule, prior to hybridisation to a oligo dT primer with a universal tagging sequence to generate 
cDNA template. In step 2, real-time PCR reaction, the miRNA cDNA template is PCR amplified by 
a miRNA specific primer and a universal PCR primer. Accumulation of PCR product is detected by 
hybridisation of the fluorescent SYBRgreen dye to the double-stranded PCR product.  
6.3.3.1.2 cDNA Synthesis 
cDNA synthesis was performed for each lung sample according to the 
manufacturers protocol.  
6.3.3.1.3 Real-time PCR Setup 
PCR reactions were setup in master mixes for miRNAs (RNO-MIR-126, 140, 186 
and 674) and the endogenous control gene rRNA 5S as follows: 
Table 6-3: miScript MicroRNA PCR Reaction Master Mix. 
miRNA/rRNA 5S Control  Master mix  x1 
miScript SYBRgreen Master mix  10.0 $l 
Universal Primer  2.0 $l 
microRNA Primer assay  2.0 $l 
Water  5.0 $l 
cDNA (no dilution)  1.0 $l 
Total Volume  20 $l 203 
PCR was performed in triplicate wells and each 384 well reaction plate contained 
negative control reactions (NTC and RT-ve) and standard curves (section 2.2.5.3). 
6.3.3.2  Exiqon miRNA miRcury System 
6.3.3.2.1 Overview 
This system combines SYBRgreen dye detection with validated mature miRNA 
primer assays to provide determination of a single miRNA species from a gene-
specific cDNA synthesis (Figure 6.3).  
 
Figure 6-3: Principles of miRcury miRNA Real-Time PCR System. 
Mature miRNAs are hybridised to miRNA specific RT primers, which have a universal priming 
sequence overhang at the 5’ end, during cDNA synthesis. In step 2, the cDNA template contains 
the mature miRNA sequence attached to the universal priming sequence which is targeted for PCR 
amplification by the Locked Nucleic Acid (LNA) PCR primer and a universal PCR primer. 
Accumulation of PCR product is detected by hybridisation of the fluorescent SYBRgreen dye to the 
double-stranded PCR product.  
6.3.3.2.2 cDNA synthesis 
cDNA synthesis was performed for each of the miRNA species (rno-miR-22*, 126, 
153, 181a*, 186, 365 and endogenous control gene rRNA 5S) in duplicate for each 
of the lung samples according to the manufacturers protocol.  204 
6.3.3.2.3 Real-Time PCR Setup 
PCR reactions were setup in master mixes as follows: 
Table 6-4: miRcury MicroRNA Real-Time PCR Reaction Master Mixes. 
miRNA Master mix  x1 
SYBRgreen Master mix  10.0 $l 
Universal Primer for PCR  1.0 $l 
microRNA LNA PCR primer  1.0 $l 
Water  4.0 $l 
cDNA (1:10 dilution)  4.0 $l 
Total Volume  20 $l 
 
Real-time PCR was performed in duplicate wells and each 384 well reaction plate 
contained negative control reactions (NTC and RT-ve) and standard curves 
(section 2.2.5.3).  
6.3.4  miRNA Genomics and Gene Cluster Analysis 
All miRNAs identified by microarray were searched against the miRbase genome 
database (www.diana.pcbi.upenn.edu/miRGen/v3/miRGen.html).
507 Changes in 
putative up or down-regulation (from the microarray data) were correlated to 
miRNA gene cluster locations to determine if altered miRNA expression could be 
controlled by cis-elements acting at shared promoter regions or whether there is 
post-transcriptional regulation of miRNA maturation. Also, similar expression levels 
with in a miRNA cluster could also act as a way to internally validate the 
microarray data. In this study, a miRNA gene cluster was defined as two or more 
miRNA genes less than 500bp apart in non-genic regions, and therefore likely to 
be a polycistronic transcript, by using Rattus norvegicus chromosomal coordinates 
(Genome assembly: RGSC3.4) of microRNA genes from miRBase sequence 
version 13.0 (www.mirbase.org).
508 This search also identified miRNAs located in 
protein coding gene. 
rRNA 5S Control Master mix  x1 
SYBRgreen Master mix  10.0 $l 
Control PCR primers  2.0 $l 
Water  4.0 $l 
cDNA (1:10 dilution)  4.0 $l 
Total Volume  20 $l 205 
6.3.5  miRNA Target Gene Prediction Analysis 
Computational methods are used to predict miRNA targets by scoring base pair 
matches (Watson-Crick pairing) to gene locations in the genome and there are 
many websites hosting miRNA target prediction database tools (reviewed by Li et 
al, 2009).
491 Target predictions have high false positive rates and predicted targets 
can vary between prediction databases. One method to strengthen a prediction is 
to compare the results from several databases.  
In this study, miRNA target gene predictions were made using the miRNApath 
database.
509 miRNApath (http://lgmb.fmrp.usp.br/mirnapath/query_mirna.php) is 
an integration of the miRNA sequence database (miRbase, www.mirbase.org), 
miRNA target gene database (miRgen, 
www.diana.pcbi.upenn.edu/miRGen/v3/miRGen.html) and a gene pathway 
database (KEGG database, www.genome.jp/kegg/pathway.html). miRNApath can 
interrogate multiple miRNAs simultaneously and produce a list of shared target 
gene predictions and metabolic pathways. 206 
6.4  Results 
6.4.1  miRNA Isolation and Purification  
All lung samples yielded high quality total RNA enriched for miRNAs and the total 
miRNA isolates used on the microarray passed all of the Miltenyi BioTec quality 
control checks (performed using Agilent 2100 Bioanalyzer RNA microfluidic chips).  
6.4.2  miRNA Microarray Results 
The lung RNA pools contained 163 miRNA species that returned valid results (See 
figure 6.4). After normalising the signal intensities for each spot grouping to the 
synthetic universal reference RNA (ratio values), then dividing the ratio values of 
RNA pool 1 (protein restricted) by pool 2 (control diet) a total of 43 miRNA species 
were identified as being different between the two groups. The scatter plot of ratio 
values revealed 15 miRNA species that were up (1.7 > 16 fold) and 13 miRNA 
species down (1.7 > 14 fold) in the protein-restricted lung compared to the control 
lungs. A further 9 miRNA species were found to be only present in the PR lung 
and 6 miRNAs were only found in the control lung sample pool.  
 
 
Figure 6-4: Double-Log Scatter Plot of Re-Ratio Values from the Microarray Experiment.  
The signal intensities of each spot/miRNA that passed the quality filtering are shown in a double-
logarithmic scale, represented by a dot. X-axis: Hy3 signal intensity, y-axis: Hy5 signal intensity. 
Dashed diagonal lines define the areas of x-fold differential signal intensities. Red circles identify 
the first four miRNA genes chosen for real-time PCR validation. 207 
Table 6.5 displays all of the miRNA species that are present in lung tissue from 
both groups but at different levels, and table 6.6 shows miRNA species that were 
only detected in one group. 
Table 6-5: Putative Up or Down Regulated miRNA Species in Protein-Restricted Offspring 
Lung Tissue. 
miRNA name  Increased in PR lung
a    miRNA name  Decreased in PR lung
a 
 RNO-MIR-186  16.14    RNO-MIR-122  0.56 
RNO-MIR-126*  12.96    RNO-MIR-101B  0.56 
RNO-MIR-218  10.22    RNO-MIR-362-3P  0.53 
RNO-MIR-142-3P  7.61    RNO-MIR-181B  0.50 
RNO-MIR-22*  4.69    RNO-MIR-151*  0.48 
RNO-MIR-347  4.63    RNO-MIR-301A  0.45 
RNO-MIR-33;  3.80    RNO-MIR-99A  0.31 
RNO-MIR-484  3.26    RNO-MIR-98  0.30 
RNO-MIR-130B  3.26    RNO-MIR-23A  0.28 
RNO-MIR-124  3.04    RNO-MIR-17-3P  0.19 
RNO-MIR-450A-2  3.03    RNO-MIR-181A*  0.18 
RNO-MIR-494  2.35    RNO-MIR-674-3P  0.09 
RNO-MIR-100  2.15    RNO-MIR-140*  0.07 
RNO-MIR-92B  1.90       
RNO-MIR-24-1*  1.78       
a microarray reratio values =  fold change in PR lung miRNA levels when compared to control lung 
data.  
 
Table 6-6: miRNA Species Found Only in Protein-Restricted or Control Diet Offspring Lung 
Tissue. 
Grouping  miRNA name (rno-miR-xxx) 
PR only  LET-7D*, 10B, 20A, 142-5P, 331-5P, 340*, 365, 450A-1, 664 
Control only  9*, 129*, 153, 190, 378*, 384-3P 
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6.4.3  Real-Time PCR Validation 
Two real-time PCR systems were used to generate miRNA relative quantification 
results against the endogenous control gene, rRNA 5S. The real-time PCR relative 
quantifications results were then compared to the microarray data, corroboration of 
results would validate the observation.   
6.4.3.1  Qiagen miScript miRNA Real-Time PCR System Validation 
The top two over and under-expressed miRNA species identified by microarray 
were assayed using this system. Trizol™ derived total miRNA isolates enriched for 
miRNAs (isolation carried out in our laboratory) failed to replicate the microarray 
data (see figure 6.5). All four miRNA species were detected at almost equal levels 
in the protein-restricted and control diet offspring lung. Assuming that the 
microarray data is a true reflection of miRNA levels in the tissue of the two groups, 
this result could indicate a problem with the Trizol™ extraction procedure 
performed in our laboratory. 
 
Figure 6-5: miScript miRNA Real-Time PCR Validation Using Trizol™ Total RNA Isolates 
Enriched for miRNAs.  
Real-time PCR miRNA levels are similar between the PR (green columns) and control lungs (blue 
columns). 209 
Therefore, the experiment was repeated on cDNA template generated from the 
miRNA isolations returned from Miltenyi BioTec (preparations used on the 
microarray). Figure 6.6 displays real-time PCR data from the microarray RNA 
preparations, these results are very similar to the data generated by the RNA 
preparations carried out in our laboratory and do not reflect the original microarray 
observations.  
 
Figure 6-6: miScript miRNA Real-Time PCR Validation Using Miltenyi Biotec RNA Isolates.  
Real-time PCR miRNA levels are similar between the PR (green columns) and control lungs (blue 
columns). 
The lack of replication of microarray-based miRNA levels between the two groups, 
even when utilising the original microarray RNA preparations, lead to the trial of 
another real-time PCR system. Lack of replication from a different real-time PCR 
system would throw the microarray data into question.  
6.4.3.2  Exiqon miRNA miRcury Real-Time PCR System Validation 
The miRcury real-time PCR system utilises a miRNA species specific cDNA 
synthesis step, this is unlike the miScript system which generates a cDNA pool of 
all miRNA species. Unfortunately, at the time of this work Exiqon Inc. did not have 
a primer assay library containing of all of the miRNA species from the first 
experiment. Therefore, in this experiment only rno-miR-126 and 186 (both up in 
PR lung) were quantified by this system. Four extra miRNA species were also 
quantified by this system, they included rno-miR -22* (up in PR lung; 4.7 fold), 153 
(Control lung only), 181a* (down in PR lung; 5.6 fold) and 365 (PR lung only).  210 
Figure 6.7 shows the miRcury real-time quantification results alongside the 
microarray data; rno-miR -22*, 153 and 181a* did not demonstrate similar levels 
and in two cases (rno-miR -153 and 181a*) showed a reciprocal fold difference in 
expression in comparison to the microarray data.  
 
Figure 6-7: miRcury miRNA Real-Time PCR Validation Using Miltenyi Biotec RNA Isolates.  
Using the total RNA isolates from the microarray experiment, three miRNA species (red boxes) 
demonstrated real-time PCR miRNA levels (purple columns) similar to the microarray results (blue 
columns). Error Bars represent  ± Std Error.  
However, the remaining three miRNA species results were more encouraging (see 
table 6.7); with rno-miR-365 being closely replicated by real-time PCR 
quantification, followed by rno-miR-186 and 126 fold differences that are in the 
same direction, if not the same magnitude as the microarray results.   
Table 6-7: miRNA Species Validated by Real-Time PCR 
miRNA species 
microarray vs real-time PCR 
fold difference 
rno-miR-365  5.2 vs. 7.5 
rno-miR-186  16.1 vs. 6.2 
rno-miR-126  13.0 vs. 2.7 
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6.4.4  miRNA Genomics and Gene cluster Results 
Six miRNA genes are located in the introns of protein coding genes and therefore 
their expression may be controlled by the host gene promoter. (See table 6.8)  
Table 6-8: miRNAs in Protein Coding Genes 
miRNA name  level in lung  Gene   Role of gene 
rno-miR-33  up in PR lung  Srebf2, intron16 
Sterol regulatory element binding transcription 
factor 2. This gene encodes a ubiquitously 
expressed transcription factor that controls 
cholesterol homeostasis by stimulating 
transcription of sterol-regulated genes. Cellular 
cholesterol homeostasis is controlled by Srebf2 
and SCAP.
510 
rno-mir-101b  down in PR lung  Rcl1, intron 8  RNA terminal phosphate cyclase-like 1. function 
in pre-rRNA processing and with U3 -snoRNA  is 
thought to control an early step in ribosome 
biogenesis.  
rno-mir-126
a  up in PR lung  Egfl7, intron 7  Epidermal growth factor like domain 7. Important 
in vascular tubulogenesis. Methylation of host 
gene promoter controls expression of miR-126 
(tumour suppressor) in cancer.
511  
rno-mir-186
a  up in PR lung  Zfp265; intron 8 
 
zinc finger protein 265. is a novel component of 
spliceosomes 
 
rno-nir-153  present in control lung only  Ptpra2, intron 19  protein tyrosine phosphatase, receptor type, N 
polypeptide 2. may play a role in secretory 
granule biogenesis and organization or 
exocytosis 
rno-mir-301  down in PR lung  RGD1307084, intron1  Protein coding, function unknown 
a validated by real-time PCR 
 
Another four of the miRNA species identified by microarray are part of a miRNA 
cluster (<500bp between genes). miR-181a1 and -181b1 form a cluster of miRNAs 
on chromosome 13 (+), within 270 bp of each other, and both species had lower 
levels in the PR lungs (5.6 and 2.0 fold) compared to controls.(see figure 6.8) 212 
 
Figure 6-8: miRNA Gene Expression by Chromosome. 
This chart shows that the levels (y-axis) of miRNA genes altered in the PR animals are found 
across the rat genome (Chromsome number on x-axis). Green boxes identify miRNA gene clusters 
with differential expression. Light blue arrows and columns are the miRNA species validated by 
real-time PCR.  
In the miR-17~92 cluster on Chr 15(+) only miR-17-1 (down in PR lung; 5.3 fold) 
and 20a (in PR lungs only) were found to be at different levels. This is an 
interesting observation as the miR-17~92 gene cluster is known to be expressed 
as a polycistronic transcript. These results indicate that in the PR lungs miR-17-1 
may be negatively regulated post pri-miRNA transcription, as it has to be 
transcribed as part of the polycistronic transcript along with the other members of 
the gene cluster. This observation is supported by the fact that the other miRNAs 
(mir-18, 19a, 19b, 92) in the miR-17~92 cluster have similar levels in both lung 
groups. Furthermore, as miR-20a is only expressed in PR lung this miRNA must 
be positively regulated or selected after transcription of the miR-17~92 pri-miRNA. 
In a different miRNA gene cluster on chromosome 19(-), miR-23a was down in PR 
compared to control lung (3.6 fold), this gene is part of miRNA gene cluster: mir-
24-2, 27a and 23a.  All of the miRNA genes in this cluster are found in a region of 
388 bp and therefore, are likely to be expressed as a polycistronic transcript. Post 
pri-miRNA transcriptional regulation could also explain the difference in miRNA 
levels in this gene cluster. 213 
6.4.5  miRNA Gene Target Results 
Three miRNApath analyses were performed using: 1) a list of all of the miRNAs 
species identified by microarray that were increased or present in PR lung. 2) a list 
of all or decreased/absent (i.e. up/present in control lung) in the PR lung. 3) The 
miRNA species successfully validated by real-time PCR (miR-126, 186 and 365 all 
up in PR lung).  
The miRNApath analysis results from the increased/ present miRNA list had 
predicted target genes that are involved in 55 metabolic and 45 pathways were 
predicted to contain genes targeted in the decreased/absent miRNA list. The top 
two pathways (i.e. which pathway has the most part of the genes targeted by the 
miRNAs) for each miRNA list will be presented here.  
In the increased/present list in PR lung, 5 miRNA species (let-7d, mir-33, 92, 186, 
365) targeted 5 genes (Atp2b2, Camk2d, Itpr2, P2rx3, Gna14) in the Calcium 
signalling pathway and four miRNAs (miR-33, 100, 331, 664) targeted 4 genes 
(Casp3, Cacnb4, Mapk8ip3, Elk1) in the MAPK signalling pathway. In the 
decreased/absent list, 4 miRNAs (miR-98, 99A, 101B, 151) targeted 3 genes 
(Cacnb4, Mapk8ip3, Elk1) in the MAPK signalling pathway and 4 miRNAs (miR-
23A, 98, 181A, 153) targeted 2 genes (Cox7a2 & Ndufs2) in the oxidative 
phosphorylation pathway. 
6.4.5.1  miRNApath Analyis for the Validated miRNAs 
Tables 6.9 shows the predicted gene targets and metabolic pathways in the PR 
lung, which could be under the influence from increased expression of the three 
validated miRNA species, miR-126, 186 and 365. 214 
Table 6-9: Predicted Target Genes for rno-mir-126, 186 and 365 
miR name  Gene Symbol   Location  Description  Pathways 
rno-mir-126  Glul   13q22  glutamate-ammonia ligase (glutamine synthase)  Glutamate metabolism 
        Peptidoglycan biosynthesis 
        Nitrogen metabolism  
  Psma2   17q12.1  proteasome (prosome, macropain) subunit, alpha type 2  Proteasome  
   Plk1   1q36  polo-like kinase 1 (Drosophila)  Cell cycle  
rno-miR-186  Mat1a   16p14  methionine adenosyltransferase I, alpha  Methionine metabolism 
        Selenoamino acid metabolism 
  Polm   14q21  polymerase (DNA directed), mu  DNA polymerase 
  Rpl24   11q12  ribosomal protein L24  Ribosome 
  Gabra4   14p11  gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4  Neuroactive ligand-receptor interaction  
   Atp2b2   4q41.3-  ATPase, Ca++ transporting, plasma membrane 2  Calcium signaling pathway 
rno-miR-365  Itpr2   4q44  inositol 1,4,5-triphosphate receptor 2  Calcium signaling pathway  
        Phosphatidylinositol signaling system  
        Gap junction  
        Long-term potentiation  
        Long-term depression  
        GnRH signaling pathway  
  Cldn16   11q22  claudin 16  Cell adhesion molecules (CAMs)  
        Tight junction  
        Leukocyte transendothelial migration  
  Prkg1   1q43  protein kinase, cGMP-dependent, type 1 (mapped)  Gap junction  
        Long-term depression  
        Olfactory transduction  
  Grap2   7q34  GRB2-related adaptor protein 2  T cell receptor signaling pathway  
   Psma2   17q12.1  proteasome (prosome, macropain) subunit, alpha type 2  Proteasome  215 
6.5  Discussion 
6.5.1  Validation of miRNA Microarray Data 
Validation was performed using two commercially available real-time PCR miRNA 
systems. The miScript system failed to reproduce microarray data for the two most 
over and under-represented miRNA species, while the miRcury system validated 3 
out of 6 miRNA species assayed. The validation success rate stands at only 50 % 
of the miRNA genes identified by microarray. Data from microarrays is not always 
reliable; therefore some of the miRNA signals could be false positive results. 
Furthermore, miRNA are difficult to quantify as the short nucleotide sequences can 
present problems in maintaining the specificity of hybridisation sequences.
512  
Differences in the real-time PCR system technology can help to explain the failure 
of one system to replicate any microarray observations. The miScript system uses 
a global miRNA cDNA synthesis step and does not always target mature miRNA 
sequence during PCR (personal communication, Qiagen technical support), while 
the miRcury system amplifies only one miRNA species in duplicate RT-PCR 
reactions using gene-specific RT-PCR primers and LNA PCR primers that 
hybridise to the mature miRNA sequence. Reverse transcription is the most 
variable experimental step in real-time PCR based quantification, gene specific 
RT-PCRs have been shown to increase sensitivity and duplicate RT-PCR 
reactions help to estimate reproducibility. (reviewed by Nolan et al, 2006)
449 The 
locked nucleic acid (LNA) primer technology is also beneficial when using short 
primer hybridisation sequences as LNA bases have increased binding affinity over 
standard DNA bases.
513 
6.5.2  Validated miRNA Transcripts 
The following three miRNAs were validated by real-time PCR and had increased 
levels in PR lung tissue. 
6.5.2.1  rno-mir-126 
miR-126 is the intronic product of the epidermal growth factor like domain 7 
(EGFL7) gene
514 and this miRNA has been shown to inhibit tumour invasion in 
lung cancer.
515 miR-126 has also been shown to regulate vascular integrity, 
developmental angiogenesis
516, 517 and provide control of vascular inflammation by 
inhibiting VCAM1 expression (VCAM1 mediates leukocyte adherence to 216 
endothelial cells) from TNF! activated endothelial cells.
493 In breast cancer, miR-
126 was shown to inhibited cell growth by targeting insulin receptor substrate 1 
(IRS1).
518  
In this rat model, the increased miR-126 levels could be promoting lung blood 
vessel formation by repressing the expression of SPRED1, an intracellular inhibitor 
of angiogenic signaling, thereby increasing the pro-angiogenic actions of VEGF 
and FGF.
517 However, this is speculation based on current knowledge of miR-126 
action and will have to be assessed by functional studies and morphometric 
analysis of lung vasculature. 
6.5.2.2  rno-mir-186 
The function of miR-186 is not fully understood. However, along with mir-150 it has 
been demonstrated to down regulate the expression of the pro-apoptotic 
purinergic P2X7 receptor in cancer epithelial cells.
519 In another publication, three 
miRNAs, including miR-186 were predicted to target over 50% of all lupus genes, 
indicating that miRNA miR-186 may target immune transcripts.
520 P2X receptors 
are widely expressed in cells of the immune system with varying functions
521 and 
can be used as biomarkers for alveolar epithelial type I and type II cells.
522 
Therefore, increased levels of miR-186 in PR lung could result in reduced 
apoptosis of alveolar epithelial cells. In a small study of asthma, attenuated P2X7 
pore function has been identified as a risk factor for virus-induced loss of asthma 
control.
523 
6.5.2.3  rno-mir-365 
Even less is known about the function of miR-365, one study has reported 
changes to miRNA signatures, including miR-365, in different growth arrest states 
in WI-38 lung fibroblasts.
524 miR-365 appeared to be a key regulator of cell cycle 
inhibitors, senescence and inverse correlations with p16, p21 and PTEN indicated 
that it may play an important role in the regulation of cell proliferation and survival 
axis.
524 Therefore, increased levels of miR-365 may indicate that there is 
increased cell survival and proliferation in PR lung compared to control lung 
samples.  217 
6.5.3  Gene Cluster Analysis 
Five intronic miRNA genes had altered levels in the rat PR lungs (see table 6.8); 
this is potentially interesting because as miRNA genomic location is well 
conserved between species, the relationship between the host gene and miRNA 
must be functionally important. For example, the host gene of miR-33 (up in PR 
lung) is SREBF2 a sterol-sensitive transcription factor that controls cellular 
cholesterol homeostasis, if miR-33 is co-expressed with the host gene, then 
activation of SREBF2 transcription will increase miR-33 levels repressing its 
predicted target gene ABCA1. ABCA1 is a cholesterol efflux pump in the cellular 
lipid removal pathway so targeting by miR-33 could increase cellular lipid levels. In 
the lung, ABCA1 is involved in basolateral transport of surfactant
525 and knockout 
studies in mice show major morphological abnormalities (foamy type II 
pneumocytes, macrophages and cholesterol clefts) that increase in severity with 
age.
526 It was suggested that this accumulation of foamy cell represented a 
protective phagocytic response but could also causes chronic stress and impair 
cellular functions, resulting in the production of cytokines and extracellular 
degrading enzymes that could injure lung cells.
526 Alternatively, under normal 
homeostasis miR-33 can act as part of a negative feedback loop to ‘fine-tune’ the 
expression of ABCA1 which can be initiated by its host gene, SREBF2.
527 The 
relationship between miR-126 and EGFL7 is also interesting and is discussed later 
as an opportunity for future work (Section 6.7). 
miRNA genes within 500 base pairs of each other are likely to be expressed as a 
single polycistronic transcript. Although based on microarray results from whole 
lung preparations, lower levels of all mature miRNAs from a single polycistronic 
transcript or switching on or off an isolated miRNA gene could indicate that the 
expression of the pri-miRNA is down-regulated by transcription factors or silenced 
by DNA methylation. Alternatively, the maturation of all miRNAs within a cluster 
could be regulated to the same extent by post-transcriptional mechanisms. Lower 
levels of a single or several, but not all miRNAs from a polycistronic transcript 
could indicate that the maturation of specific miRNA is regulated by post-
transcriptional mechanisms. Cluster analysis of the miRNA genes identified a one 
cluster that could be transcriptionally regulated or reduced by DNA methylation, as 
both miRNA genes in the miR-181a1~181b1 cluster were found at lower levels in 
PR lung.  218 
Observations in two other miRNA gene clusters (miR-17~92 and miR-24-2~23a) 
indicate that post-transcriptional mechanisms are most likely to control the 
maturation of particular miRNAs from a polycistronic transcript and target others 
for degradation. Any conclusion drawn from these observations awaits 
confirmation by detailed functional molecular studies; but it is likely that lung 
miRNA profiles will vary by tissue/cell type under the control of a complex 
interaction of epigenetic, transcriptional and post-transcriptional mechanisms.  
6.5.4  Predicted miRNA Target Genes and Pathways 
The miRNApath analysis predicted that groups of up to five of the differentially 
expressed miRNA could target multiple genes in the calcium signalling, MAPK 
signalling and oxidative phosphorylation pathways. Calcium signalling is a major 
pathway, involved in membrane depolarisation and acts as a secondary 
messenger in muscle contraction, cellular motility, enzyme activity and ion pumps 
(reviewed by Petersen, 2005).
528 Mitogen Activated Protein Kinase (MAPK) 
signalling is involved in action of most of the non-nuclear oncogenes and mediate 
cellular responses to growth factors.(reviewed by Pearson et al, 2001)
529 For 
example, the predicted miRNA target gene MAPK8ip3 interacts with MAPK8 (a 
member of the stress-activated c-Jun N-terminal kinases, JNKs). MAPK8ip3 acts 
as a scaffolding protein to enhance activation of the signalling pathway.
530 The 
downstream pro-apoptotic molecule, Caspase3 is also a predicted target of some 
the miRNAs and another predicted target is ELK1, this gene is the nuclear target 
of ras-raf-MAPK signalling leading to cell proliferation and differentiation.(reviewed 
by Sharrocks, 2002)
531 Oxidative phosphorylation is the mitochondrial metabolic 
pathway releasing energy from oxidation of nutrients to produce ATP by the 
electron transport chain and reactive oxygen species are produced as a by-
product (reviewed by Lesnefsky et al, 2006).
532  
Focussing on the some of predicted targets genes of validated miRNAs (miR-126, 
186 and 365 up in PR) provides more intriguing insights into the action of miRNAs 
in the lung. Predicted targets of miR-126 include Glutamine synthetase (Glul), this 
is an enzyme with an essential role in the metabolism of nitrogen and Glul mRNA 
is present in the embryonic day 17 mouse lung bronchioli.
533 Glutamine synthetase 
catalyses the condensation of glutamate and ammonia to form glutamine, an 
amino acid essential for growth.
534  219 
If miR-126 does target glutamine synthetase, then it will provide the first evidence 
for miRNA involvement in protein metabolism (catabolism) in a DOHaD animal 
model of maternal protein restriction. In this model, protein-restriction was defined 
by a 50% reduction in caesin protein as part of an isocaloric diet fed during 
pregnancy.
262 Caesin accounts for 80% of the protein in cow’s milk, and milk is a 
source of exogenous L-glutamine.
535, 536 Fetal uptake of maternal glutamine across 
the placenta is the highest of any amino acid and in fetal sheep there is no uptake 
of maternal glutamate.  
Therefore, expectant mothers on the protein-restricted diet could have less 
glutamine to supply to the fetus via the maternal-fetal-placental unit, although 
there is some evidence to suggest that the deficit could be made up by the 
mobilisation of maternal protein.
418 During pregnancy, glutamate requirements 
must be met by the fetal conversion of glutamine to glutamate by the liver enzyme 
glutaminase. Fifty percent of the fetal glutamate is sent back to the placenta for 
conversion into glutamine adding to the placental glutamine pool destined for the 
fetus. Therefore, is lung glutamine synthetase targeted by miR-126 in order to 
protect fetal lung glutamate for essential nitrogen signalling and lung growth in 
development?  
Differences in organ weights at birth in a study of maternal protein-restriction 
indicate that this could be the case as lung growth is not as severely affected (i.e. 
lung weight is in proportion to body weight) unlike other organs such as pancreas, 
liver, muscle and spleen demonstrating significantly lower weights in PR animals 
when compared to control offspring.
420 Affected organs, such liver, do go on to 
have a period of catch up growth but hepatic function is profoundly affected as a 
result of maternal protein restriction during pregnancy (cited in Desai et al, 
1996).
420 Indicating that although restricted growth may be transient, organ 
function can be compromised. In humans, premature and intrauterine growth 
restricted (lower 10th percentile of size for gestational age) infants have poor 
respiratory function at birth, pulmonary structural abnormalities and go on to 
experience poorer respiratory function in adulthood. (Reviewed in Maritz et al, 
2005)
367 ‘Brain-sparing’ is an accepted phenomenon in PR models and protects 
essential neurological functions, is the lung ‘spared’ as well?  
Furthermore, should the timing of exposure to maternal protein-restriction also be 
considered before interpreting a potential role for miRNA?  Rat lung development 
continues from birth to the first few weeks of life, therefore it is logical that post-220 
natal maternal diet during lactation could have an effect on offspring lung growth. 
The observation of significantly lower offspring lung weights from mothers on a low 
protein diet during the weaning period, indicates that the timing of exposure is 
important.
420 Therefore, it would be interesting to compare miRNA expression 
profiles in offspring experiencing exposure to maternal protein-restriction at 
different times during pregnancy and the weaning period.  
The expression of miR-126 in other organs affected by maternal protein restriction 
awaits determination, however levels of glutamine synthetase enzyme activity 
have been shown to be increased in the hippocampus, hypothalamus and 
cerebellum in weanling rats exposed to maternal protein-restriction
262 indicating 
that gluamine synthetase is sensitive to this exposure and miR-126 could be a way 
to fine-tune expression of this gene in a tissue-specific manner.  
Why are there increased levels of miR-126 in offspring lung 120 days after 
exposure to maternal protein restriction and are changes in DNA methylation 
responsible? Understanding the relationship between miR-126 and its host 
protein-coding gene Egfl7 could help to answer this question, as in human cancer, 
the miR-126 transcripts are processed from certain EGFL7 mRNA splice forms 
and EGFL7 expression is known to be controlled by promoter DNA methylation.
511 
Other miR-126 targets include, Psma2 a sub-unit of the proteosome and Plk1. 
Plk1, a potential target for cancer drugs, is known to interact with proteosome sub-
units PSMA3-7 and is a regulator of proteosome activity that is involved in the 
regulation of cellular division and genomic stability.
537, 538  
miR-186 target genes that are expressed in lung include a neuro-active ligand 
receptor, Gabra4; polymorphism in this gene has been associated with nicotine 
dependence in humans
539 and the Atp2b2 gene that is a key membrane protein in 
the maintenance of intracellular calcium homeostasis.
540 Mat1a is also predicted to 
be a target of miR-186 but this molecule is only expressed in adult liver because of 
tissue specific DNA hypomethylation.
541 If this miRNA is found to be differentially 
expressed in PR liver then it could provide a role for miRNA influence on the one-
carbon pathway and substrate availability (S-adenosylmethionine) for DNA 
methyltransferases, potentially leading to alterations to DNA methylation levels.
542  
miR-365 target genes include Itpr2 and Prkg1 and Grap2. Itpr2 is a key molecule 
in mobilising calcium from storage organelles and in the regulation of cell 
proliferation and Prkg1 is known to interact with Itpr1, an inositol trisphosphate 221 
receptor similar to Itpr2.
543-545 Grap2 is a leukocyte specific protein-tyrosine kinase 
that interacts with CD8 and through the co-stimulatory pathway activates T 
cells,
546 this molecule contains a glutamine rich linker region with a caspase 3 
cleavage site.
547 
6.5.5  Pattern of miRNA Expression 
It is tempting to focus on specific predicted gene targets of the differentially 
expressed miRNA species found in PR lung and qualify gene candidates by a 
priori hypotheses based on potential roles in development, maturation and 
pathophysioological conditions, without further confirmation by functional studies. 
The fact that miRNA profiles will differ in time, by cell type and could have many 
modes of action in numerous pathways that can interact in complex mechanisms, 
must be taken into account. A more general overview of the significance of altered 
miRNA expression in lung can be proposed by grouping miRNA expression into 
patterns. 
Irrespective of miRNA target genes and pathways there are three distinct miRNA 
expression patterns. Group one, consists of miRNAs that were found in both PR 
and control lungs but at different levels. Group two, consists of miRNAs that were 
only found in PR lung and the third group are miRNAs found only in control lung. 
As the exposure (maternal protein-restriction) occurred during fetal development 
and yet miRNA expression is altered in adulthood (120 days), this poses the 
question:   
‘Are miRNA expression profiles altered as a consequence of PR or in response to 
dysregulation of processes sensitive to PR?’ 
In short, the pattern of miRNA expression suggests that both have occurred to 
some extent. Group one must consist of some miRNA genes that are essential for 
normal organ function (as they are found in PR and control lungs) and alteration of 
miRNA levels in this group could reflect the miRNA response to dysregulation of 
gene processes due to PR exposure in development (i.e. compensatory or ‘fine 
tuning’ of expressed protein coding gene profiles).  
miRNA gene expression from development to adulthood is temporal, and many 
miRNAs are switched on or off, thereby regulating events such as developmental 
timing and growth. Group two and three are interesting in this respect as they are 
found in either PR or control lungs, but not in both.  222 
For example, the presence of let-7d and miR-365 in PR lungs indicates that let-7d 
could be still regulating events that should have finished in late development and 
miR-365 could be regulating cell proliferation and survival.  
Another factor to take in to consideration when interpreting these results is the role 
of miRNAs in the aging process.
548 In worms, let-7 expression decreases with age 
and in mice a maternal protein-restricted diet during pregnancy has been 
associated with altered offspring longevity.
549 Therefore, miRNA profiles are only 
likely to provide a snap-shot of miRNA gene regulation at that time, and possibly of 
events upto that period of life. Also, the role of certain miRNAs may change as the 
animal ages, further confounding our interpretation of miRNA function.  
6.6  Conclusion 
In conclusion, this work has demonstrated altered miRNA levels in whole lung 
preparations from 120 day old offspring of mothers exposed to a protein-restricted 
diet in pregnancy. The regulation of miRNA gene expression is unknown but is 
likely to involve, DNA methylation, transcriptional and post-transcriptional 
regulatory mechanisms. Target gene predictions revealed numerous pathways 
that could be under the influence of the miRNA, including cellular metabolism 
(protein metabolism by the glutamate pathway), calcium, nitrogen, MAPK 
signalling and oxidative phosphorylation. Expression patterns revealed that a set 
of miRNAs, thought to be important for lung homeostasis, were likely to be altered 
in response to protein-restriction and two further groups that may have been 
switched on or off as a consequence of the maternal exposure, these miRNA may 
regulate developmental timing, cell proliferation and survival. However, these 
results should be interpreted with caution as miRNA expression at 120 days 
unlikely to reflect the miRNA profile at birth and in the first weeks of life, where a 
window of lung developmental plasticity exists.    223 
6.7  Future Work 
Only three miRNA species have been validated by real-time PCR. Therefore, 
further validation work is required for the remaining 37 species identified by 
microarray. It would be prudent to replicate the miRNA findings in samples from an 
independent animal experiment and at other sampling time-points. miRNA 
expression is known to change temporally (development " growth " adulthood) 
and have tissue specific profiles; none of which was addressed in the current 
work. As other sampling time-points can be obtained from this rat model it would 
be interesting to observe miRNA profiles from birth to old age and see if they alter 
over time. Furthermore, processing of whole lung samples by paraffin-embedding, 
sectioning (of large and small airways) and Laser Capture Micro-dissection (LCM) 
would allow for the determination of tissue/cell specific (e.g. airway epithelium or 
vascular endothelium) expression profiles. Alterations to miRNA profiles in 
adulthood (120d) may not have persisted from birth (i.e. miRNAs directly altered 
by or in response to the exposure may change over time) and could actually reflect 
rescue or maintenance of altered organ homeostasis or function that is 
programmed by other mechanisms; therefore it is essential to compare miRNA 
profiles from birth into later life. 
In other organs, nutritional programming has shown transgenerational 
transmission of phenotypes without further exposure, indicating an epigenetic 
mode of inheritance that may involve changes to DNA methylation. Whether DNA 
methylation controls miRNA expression in the PR lung and is a trans-generational 
epigenetic mark could be determined by future studies, assessing miRNA profiles 
in F2 and F3 generation animals (samples under collection), in parallel with 
genome-wide miRNA gene promoter CpG island DNA methylation analysis by 
microarray. Alternatively or in parallel with the DNA methylation microarray 
analysis, EGFL7 (protein coding gene) and its intra-genic miR-126 could be used 
as a model system to test the role of DNA methylation controlling miRNA 
expression. miR-126 (up-regulated in PR lung) is known to be co-expressed with 
EGFL7 and has previously been shown to have altered DNA methylation in 
disease.
511  224 
The predicted target genes remain that, a prediction. Target gene protein levels 
need to be determined by western-blotting the protein collected from the Trizol™ 
preparations. Reduced protein levels would indicate that further functional studies 
of miRNA action would be warranted; this could be achieved by miRNA gene 
knockdown experiments in vivo.  
The ultimate aim of this work is to use this animal model in combination with 
environmental exposures linked with respiratory disease, such as cigarette smoke. 
Therefore, it is essential that alterations to miRNA expression through nutritional 
programming is characterised well and fully understood before interpreting any 
effects of inhaled risk factors on lung miRNA expression profiles. 225 
7  General Discussion 
Chronic non-transmittable human disease, such as asthma, CVD, diabetes, 
obesity, and COPD are known to have a complex genetic basis that is induced 
through exposure of genetically susceptible individuals to environmental risk 
factors (high fat, high sugar diets and smoking etc.).
169, 550 
Common genetic polymorphism associate with altered disease susceptibility and 
can interact with environmental exposures modifying disease risk. However, 
genetic polymorphism alone cannot explain all of the heritability of common 
disease in families or the recent explosion in the common disease epidemic.
551 
Changes in lifestyle may be more important, but the exact origin or cause of 
chronic human disease remains unclear.
552 
Epidemiological studies of low birth weight have shown associations with 
increased disease risk and mortality in later life.
223-226 This lead to the proposal 
that impaired fetal growth may leave individuals at higher risk of disease in 
adulthood.
553 These observations and work using animal models with altered 
maternal diet have lead to the developmental origins of health and disease 
hypothesis.
230 Where it is thought that maternal exposures during pregnancy may 
alter or ‘program’ the course of fetal development, predisposing offspring to 
increased risk of adulthood disease if the prenatal exposures do not match 
exposures in post-natal life.
429 
In respiratory disease such as, asthma and COPD it is known that low birth 
weight,
370 anthropomorphic measures at birth,
554 and environmental exposures 
(maternal nutrition and ETS)
58 associate with increased disease risk. Common 
genetic polymorphism can predict lung function growth,
319 correlate with decline in 
lung function as the person ages,
406 and deficits in lung function associate with 
genotype and smoking.
338,556 Smoking is a major risk factor for COPD in later 
life.
295 However, not all smokers develop COPD and non-smokers can develop 
COPD.
295 These observations indicate that not everyone is susceptible and certain 
individuals are predisposed to develop disease without exposure to high levels of 
tobacco smoke. 
 226 
Our study began by examining the relationship between important anti-oxidant 
genes known to detoxify tobacco smoke and early life exposure to tobacco smoke 
in children with asthma. In the first part of this thesis we investigated the 
interaction between glutathione s-transferase gene polymorphism, ETS exposure 
and childhood asthma. We developed copy number variation genotyping 
methodology to provide full GSTM1 and GSTT1 gene dosage information for use 
in the genetic association tests. We found that common GST polymorphism was 
associated with increased asthma risk, IgE levels and disease severity scores and 
indentified the presence of a novel G-E interaction between GSTT1*0 (gene 
deletion), ETS exposure and increased IgE levels in asthmatic children.  
As respiratory disease is thought to have developmental origins, we then 
examined whether an established animal model of maternal protein-restriction 
used in the study of the developmental origins of health and disease hypothesis is 
relevant for the study of lung health and disease in general. In the second part of 
the thesis we sought to determine the effect of maternal protein-restriction on 
offspring lung physiology, gene and miRNA expression. With the aim to use this 
established DOHaD animal model to investigate the effect of maternal tobacco 
smoke exposure on offspring lung health. In the DOHaD animal model we found 
that maternal PR alters gene and miRNA expression profiles in F1 adult offspring 
lung tissue. However, these observations were not found in older animals and 
were not transmitted to the next generation. 227 
7.1  Gene-Environment Interactions in the Early Life Origins of 
Asthma 
Asthma is a chronic respiratory disease involving hypersensitivity to airborne 
allergens, inflammation, reversible bronchoconstriction and has its origins in early 
life. Environmental tobacco smoke exposure in early life increases the prevalence 
and severity of asthma and maternal smoking is associated with reduced lung 
function in children.
54, 
58 
Asthma is a complex genetic disease with incomplete penetrance and common 
genetic polymorphism has been shown to alter disease susceptibility. For example 
single nucleotide polymorphisms in HLA-G, GPRA and ADAM33 genes are 
consistently associated with asthma in several populations.
98 
Glutathione S-transferase genes are important antioxidant enzymes that detoxify 
harmful combustible tobacco smoke products and deficiencies in enzyme activity 
due to genetic polymorphism has been associated with increased asthma risk and 
deficits in lung function.
320, 322 
A gene-environment interaction is the phenotypic effect of the interaction between 
the environment and a particular gene allele. Gene-environment interactions can 
explain the inter-individual differences in sensitivity to environmental exposures 
that are risk factors for disease susceptibility. Several studies have shown 
presence of gene-environment interactions between Glutathione S-transferase 
polymorphism and smoke exposure, these interactions can increase the risk of 
developing asthma and modulate the severity of disease phenotypes in asthmatic 
children.
317, 331 
This thesis has found no evidence to suggest that GSTM1, GSTP1 or GSTT1 
polymorphism are associated with asthma susceptibility in the UK sample 
population of families with two asthmatic children. This is in line with recent 
findings from large birth cohorts and meta-analyses of previous studies.
349, 557 
A possible explanation for the disparity in findings in the literature, include 
publication bias in favour of small studies with ‘loose’ phenotype definitions of 
asthma, including wheeze. In our study asthma is clearly defined as doctor 
diagnosed asthma, requiring asthma medication. Therefore, GST polymorphism 
may actually be more important for wheeze in childhood, although some studies 
have found associations with BHR, a hallmark phenotype of asthma.
359, 555, 558, 559 228 
The findings from this thesis suggest that GST polymorphism is associated with 
the development of more severe asthma in children regardless of tobacco smoke 
exposure. This observation fits in with the hypothesis that an inability to efficiently 
detoxify reactive metabolites such as reactive oxygen species, could enhance the 
inflammatory response to toxins, leading to a progressive cycle of lung epithelial 
cell damage, shedding and persistent inflammation.
322 This is relevant, as 
uncontrolled chronic inflammation in asthmatics is associated with more frequent 
and severe exacerbations.
560, 561  
The FBAT association tests did reveal a significant negative association with 
asthma diagnosis, age corrected IgE levels, FEV1 values and a rare GSTO2 
haplotype. This is an intriguing finding as polymorphism in this gene has 
previously been independently associated with lung function and COPD 
susceptibility.
338, 339 Could the GSTO2 gene be a shared genetic susceptibility 
locus via the association with lung function? Further genetic association studies of 
asthma and COPD are required to elucidate this. 
The identification of only two gene-environment interactions between GSTT1*0 
and high IgE levels in smoke exposed asthmatics and the GSTO2 h1 haplotype 
and reduced atopy severity scores in the regression analysis, highlights the lack of 
statistical power in the current study. This probably due to the small number of 
smoke exposed individuals and the fact that the smoke exposure variable lacked 
any quantifiable measure of the level of smoke exposure.  
The significant association with a GSTO2 haplotype provides the first evidence 
that this gene may be important in asthma susceptibility. This finding mirrors 
recent publications that have examined the role of other GST genes in asthma. 
For example, variation in other GST Mu gene family members (GSTM2, GSTM3, 
GSTM4)  have been shown to be determinants of childhood lung function growth 
and interact with maternal smoking during pregnancy.
562   
The genetic association analyses presented in this thesis were limited by the 
poorly defined tobacco smoke exposure measure and lack of statistical power due 
to the small number of exposed individuals. In this study tobacco smoke exposure 
was simply defined as the presence of a parental smoker in childhood.  229 
Therefore, it was not possible to separate out or quantify the level of exposure that 
occurred during pregnancy (in utero) or in early life (environmental second hand 
smoke). Also, bias and confounding could also be a potential issue as there was 
no control over other factors, such as maternal socio-economic status or 
educational attainment, that are associated with both asthma and smoking.
563, 564 
In the future, the study of gene-environment interactions between ETS exposure 
and GST polymorphism in asthma would be facilitated by larger family based, birth 
cohort or case-control sample populations with measures of the level of ETS 
exposure (for example by the number of pack years of smoking). Potential 
confounding by other maternal factors associated with both smoking and asthma 
could be controlled for by performing a ‘propensity to smoke’ adjustment to the 
data analysis.
557 A recent study of childhood asthma was able to confirm, by using 
a propensity score that controlled for 32 confounders, that intrauterine tobacco 
smoke exposure is associated with lower lung function in childhood and that this 
was independent of the mother’s propensity to smoke.
557  
As the GST enzymes have known to have overlapping substrate affinities and a 
deficiency in one gene could be compensated by another gene, this could enable 
an individual to still successfully detoxify tobacco smoke. A conditional logistic 
regression analysis of a prolife of GST gene polymorphism could be utilised to 
determine the presence of any epistatic effects between Glutathione S-transferase 
genes and asthma phenotypes and determine the critical GST genes that modify 
the risk of smoke exposure. 
Finally, we can only fully examine the role of GSTs in the early life origins of 
asthma by, not only carefully measuring early life environment exposures in 
relation to polymorphism in genes, but also considering the role of the epigenome 
all in the same cohort, as prenatal tobacco smoke exposure has been shown to 
affect global and gene-specific DNA methylation.
562 230 
7.2  Modelling the Developmental Origins of Respiratory Disease 
Hypothesis 
The interaction between the in utero - early life environment, genetic and 
epigenetic mechanisms in development are thought to predispose individuals to 
susceptibility to disease in adult life.
228 During development there are critical 
windows of developmental plasticity that are sensitive to programming 
mechanisms. This allows the fetus to adapt it’s phenotype to the expected external 
environment, aiding survival in later life, based on nutritional cues from it’s mother 
during pregnancy. Disease is thought to occur when the offspring’s phenotype 
does not match the external environment in later life.
429  
Exposure to under-nutrition via placental ligation, total nutritional restriction or 
restriction of individual key nutrients such as, protein-restriction during pregnancy, 
in animal models has recapitulated many of the common chronic human disease 
phenotypes. Exposure to nutrient restriction early or late in gestation has 
demonstrated that timing of the exposure is also important, because as the fetus 
develops there are critical windows of developmental plasticity during 
organogenesis, where an exposure can have a greater effect.
565 
Transmission of offspring phenotypes to the next and even third generation, 
without further exposure, have indicated that epigenetic mechanisms, such as 
DNA methylation, have an important role in the programming of these phenotypes 
at the germ line level.
264  
Epidemioloigical studies of humans have demonstrated that lower lung function 
and COPD mortality associates with lower birth weight, a surrogate marker for 
impaired growth during pregnancy. Maternal diets low in vitamins and grand-
maternal and maternal smoking during pregnancy are associated with asthma 
phenotypes in children.
366, 566, 
567 In rats, maternal protein-restriction has been 
shown to alter the expression of genes involved in glucocorticoid hormone action 
and reduce lung size in young offspring.
420, 428 
However, little is known about the role of maternal nutrition on offspring lung 
development, metabolism, homoeostasis and later life function or whether 
offspring are more susceptible to environmental risk factors for lung disease in 
later life. 231 
A DOHaD animal model, such as the Southampton protein-restricted rat, 
represents a convenient experimental system in which to test the developmental 
origins of respiratory disease hypothesis.  The use of an animal model is not 
without precedence as animals are routinely used in study of respiratory disease; 
mainly focussing on allergy, immune responses and effects of environmental 
exposures on lung remodelling processes that underlie the pathogenesis of 
diseases such as asthma and COPD. 
This thesis found that maternal protein restriction did not result in detectable 
alterations to basic lung measurements of size or volume in 225 day adult rat 
offspring. This finding is in line with previous studies of the effect of protein 
restriction or intrauterine growth restriction on organ size in the rat, where 
differences detected in early life (up to day 42) are likely to be transient and not 
seen in much older animals (11 months).
420, 442 Our study did find alterations to 
candidate gene expression and miRNA profiles in 120 day old first generation 
offspring. This is much later on in the life of the offspring, indicating that this 
maternal exposure could have consequences for offspring lung metabolism and 
homeostasis into adulthood. However, there was no evidence to suggest the 
transmission of altered candidate gene expression to the second generation 
offspring. This finding is not unexpected as there is no evidence in the literature to 
suggest a transgenerational transmission of lung phenotypes induced in response 
to maternal protein restriction in DOHaD animal models.  
In humans, grand-maternal smoking is associated with increased asthma risk, 
therefore it would be interesting to examine whether this environmental respiratory 
risk factor induces transgenerational transmission of a lung phenotype to the next 
generation of control diet offspring. As pre-natal cigarette smoke exposure is 
known to alter global DNA methylation levels,
562 future work should consider the 
role of DNA methylation in the epigenetic transmission of phenotypes induced by 
tobacco smoke exposure in early life. 
The discovery of altered lung miRNA profiles in PR offspring is a novel finding in 
this DOHaD animal model and suggests that miRNAs may be important due to 
their role in developmental timing, stages of lung development and can be induced 
in response to environmental stimuli.
502  232 
In cancer, miRNA profiles are more powerful than mRNA profiles in prediction of 
stage of disease.
490 Therefore, assuming that miRNA expression can be 
programmed or dysregulated in some way by early life exposures could organ 
specific miRNA expression profiles predict which individuals are susceptible to 
common disease in adulthood? A disease-associated SNP guided miRNA 
association analysis in 15 common diseases, including hypertension, cardio-
vascular disease and diabetes, revealed that SNPs in genes encoding miRNAs or 
in predicted miRNA binding sties in 3’UTR regions can interfere with the function 
of microRNAs.
568 The findings from this association study reflects our hypothesis 
that dysregulation of miRNA function could lead to increased susceptibility to 
disease. 
The work presented in this thesis has several limitations. We have sought to 
define a role for maternal protein restriction by using a candidate gene approach, 
whereby we chose the genes of interest based on findings from previous studies,  
to investigate lung gene expression in exposed offspring. With this type of study 
design there is always the risk of not choosing the relevant genes. It should also 
be noted that we have only examined gene expression at two adult time points. In 
order to validate these findings and fully understand the implication of the gene 
expression results, it will necessary to examine earlier time points in the offspring 
lung. The implications of altered miRNA expression on predicted target genes is 
also limited as we have not performed any functional characterisation, such as 
gene knockdown experiments, to determine which genes the miRNAs actually 
target.  
In the future, it will be necessary to perform gene-expression analysis in a 
hypothesis independent manner, by using microarrays, to determine global lung 
gene and miRNA gene expression in samples taken from gestation and early life 
through to old age. This is particularly relevant to the miRNA observations and 
should determine whether they are programmed by, or are responding to, effects 
induced by maternal protein-restriction. Assessment of miRNA expression and 
function in the lung and in other organs should indicate whether miRNA 
expression is an important regulatory mechanism that deserves consideration in 
the study of the developmental origins of health and disease hypothesis.  233 
Previous studies using the Southampton rat model have observed structural 
changes in organs (e.g. nephron number in kidneys) that could alter normal 
function and have consequences for disease susceptibility. The lung is a highly 
structured organ by virtue of its function to provide efficient gas exchange that is 
necessary for respiration. Analysis of lung morphometry in protein-restricted lungs 
by stereological techniques should identify the presence of structural alterations 
that could impede normal function and could lead to increased susceptibility to 
pathologies induced by respiratory risk factors, such as cigarette smoke, 
encountered in early or later life. 
Although this thesis did not discover any evidence to suggest the transmission of a 
phenotype to the next generation of offspring, epigenetic mechanisms such as, 
DNA methylation, are likely to be important for programming of the first generation 
phenotype. Therefore, it will be necessary to examine DNA methylation in the 
promoters of programmed genes identified by future microarray experiments and 
in shared promoter regions of miRNA genes, as miRNA expression can also be 
regulated by changes in DNA methylation patterns.
569, 
489 
7.3  Conclusion 
In conclusion, we have shown that GST polymorphism is associated with severity 
of asthma and atopy in children, including GSTO2 gene polymorphism which has 
previously been associated with measures of lung function and COPD may also 
be important for asthma susceptibility. Using an established animal model used in 
study of the developmental origins of health and disease hypothesis we have 
demonstrated that mild maternal protein-restriction during pregnancy results in 
altered lung gene expression and major changes to miRNA expression profiles in 
adult offspring. We propose that this model is suitable for the study of 
environmental respiratory risk factors in relation to the developmental origins of 
respiratory disease hypothesis.   234 
7.4  Future Directions 
The further experimental work required to address the findings from the current 
project have been discussed at length in the individual chapter and general 
discussion sections. However, in addition to these possibilities, the results 
presented in this thesis open up many avenues for further research in other areas 
including: 
•  Given the association of GSTO2 polymorphism with asthma in this thesis. Is 
GSTO2 expression different in primary cell lung airway epithelium explants 
from asthmatic and non-asthmatic patients? Does smoke exposure modify 
GSTO2 expression in cell explant models of asthma and COPD?  
•  Are the changes in gene and miRNA expression in protein-restricted lung 
due to changes in DNA methylation? 
•  Are the changes in miRNA expression that were observed in protein-
restricted lung, tissue specific or not? 
•  Does maternal protein restriction in pregnancy in the rat induce a 
pulmonary hypertension-like phenotype in offspring lung by dysregulation of 
miRNA expression? In the miRNA gene expression work presented in this 
thesis, miR-20a was only found to be present in protein-restricted lung. In 
human cells lines this miRNA has been shown to target bone 
morphogenetic protein receptor type II (BMPR2) mRNA transcripts.
570 
Dysregulated expression of this gene is a pathogenetic hallmark of 
pulmonary hypertension and is thought to lead to remodeling of the 
pulmonary vascular bed.
571 
•  Pcdh1 expression was found to be increased in protein-restricted rat lung. 
In mouse embryogenesis, Pcdh1 expression is especially prominent in 
blood vessels and in both the developing and adult mouse kidney the 
glomeruli stained strongly for Pcdh1 protein.
572 Previous animal studies of 
the programming of hypertension have used maternal protein restriction in 
rats and found reductions in nephron number in offspring kidney.
415  
Given the role of Pcdh1 in kidney development, its expression in adult 
glomeruli and the consequence of maternal protein-restriction on offspring 
kidney structure. Does maternal protein-restriction program Pcdh1 
expression in highly vascularised organs such as, kidney and placenta? 235 
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10.1 Reagent Preparations for Total RNA, DNA and Protein 
Isolation Using TRIzol™ Reagent: 
DEPC treated water preparation: 
Draw 18m# water into an RNase-free glass nalgene bottle Add diethylpyrocarbonate 
(DEPC) to 0.01% v/v. Let stand overnight and autoclave.  
75% Ethanol preparation (in DEPC treated water for RNA isolation): 
Add 75 mls of absolute ethanol to 25 mls of DEPC treated water in a sterile Nalgene glass 
bottle and mix. 
75% Ethanol with glycogen preparation (in DEPC treated water for miRNA 
enrichment): 
Add 75 mls of absolute ethanol to 25 mls of DEPC treated water in a sterile Nalgene glass 
bottle and mix. 
75% Ethanol preparation (For DNA isolation): 
Add 75 mls of absolute ethanol to 25 mls of Ultra high quality water (UHQ water) in a 
sterile Nalgene glass bottle and mix. 
10% Ethanol preparation (For DNA isolation): 
Add 10 mls of absolute ethanol to 90 mls of UHQ water in a sterile Nalgene glass bottle 
and mix. 
0.1M Sodium Citrate in 10% Ethanol preparation (For DNA isolation): 
Weigh out 1.29 grams of Sodium Citrate and add to 50mls of 10% Ethanol in a sterile 
Nalgene glass bottle and mix. 
8mM NaOH preparation (For DNA isolation): 
Add 1.0 gram of NaOH to 100 mls of UHQ water in a Nalgene glass bottle and mix to 
make a 0.25M NaOH solution. Add 3.2 mls of 0.25M NaOH to 96.8 mls of UHQ water in a 
glass Nalgene bottle and mix.  
0.3M Guanidine hydrochloride in 95% ethanol preparation (For Protein isolation): 
NB: Perform solution formulation in a fume hood. 
Add 14.33 grams of Guanidine hydrochloride to 475 mls of absolute ethanol and 25 mls of 
UHQ water in a Nalgene glass bottle and mix; this can be stored at 4°C for up to one 
month. 
1% SDS solution preparation (For Protein isolation): 
Add 1gram of SDS to 100 mls of UHQ water in a Nalgene glass bottle and mix. 269 
10.2 Robotic Liquid Handling Protocols using the Biomek 3000 
Platform 
The Biomek 3000 automated liquid handling system maintains DNA sample integrity and 
facilitates high-throughput genotyping.  
 
Figure 10-1: Biomek 3000 Robot in the Asthma Genetics Laboratory 
Plasticware and Pipette tools 
In this project the following plastic-ware was used to store DNA solutions: 
Table 10-1: Biomek 3000 Plasticware for DNA Arrays 
DNA Array type  Plastic-ware 
Working DNA array (10-1 ng/$l)  96 well V-bottomed storage plates (ABgene) 
Stock DNA array (100 ng/$l)  96 well deep well plates (ABgene) 
To transfer DNA solutions both the 8 channel 200 $l pipette tool (MP200) and the single 
channel 200 $l liquid sensing pipette tool (P200L) was used and pre-calibrated to ensure 
accurate volume transfer. Beckman-coulter P250 and P50 robotic tips were used at all 
times. 
DNA Array Dilutions: This robotic program diluted the 100 ng/$l 96 well DNA stock 
arrays for the GTC cohort, 1 in 10 with water to 10 ng/$l 96 well DNA working arrays using 
the MP200 pipette tool, p250 and p50 tips. These working arrays could then be used to 
create the 1 ng/$l 96 well DNA arrays used to supply the DNA template for the GST CNV 
genotyping assay qPCR reactions.  
DNA Working Arrays to 384 Well Reaction Plates: Using this program the Biomek 3000 
would transfer 2 $l of the 1 ng/$l 96 well DNA working arrays for the CNV genotyping 
assays by multi-dispensing into adjacent wells on the 384 well plates. This method used 
the MP200 pipette tool with p50 tips. By using this robotic method 192 DNA samples 
could be accurately transferred to the 384 plates without error. 270 
10.3 Use of the Lightcycler480™ Real-Time PCR Machine 
All qPCR relative expression experiments were performed on the Lightcycler480™ Real-
time PCR machine (Roche Diagnostics, UK). This platform is a third generation real-time 
PCR machine that has a flexible 96 or the higher-throughput 384 well plate format. The 
machines unique thermal control and superior optical systems provide highly accurate and 
reproducible results. The analysis software modules described below allow for the 
complete analysis of real-time data from copy number variation and mRNA relative 
expression experiments.  
Consumables 
In order to generate reproducible data it is essential to use especially designed plastic-
ware and plate seals for qPCR applications. In accordance with the manufacturers 
instructions all experiments were carried out using Roche lightcycler 384 well reaction 
plates and adhesive plate seals (Roche Diagnostics, UK). 
Real-Time PCR Runs 
All qPCR relative expression experiments were performed on the Lightcycler480™ Real-
time PCR machine (Roche Diagnostics, UK). The TaqMan probe and UPL probe based 
qPCR assays were thermal-cycled and fluorescence data collected according to the 
following program:  
Figure 10-2: Thermalcycling Conditions for TaqMan and UPL Based qPCR Assays 
 
All SYBRgreen based qPCR assays were ran according to the following program: 
Figure 10-3: Thermalcycling Conditions for SYBRgreen Based qPCR Assays 
 
Fluorescent Data was collected at the end of the extension step on a 1 second 80°C hold 
to ensure that any primer-dimer product was single stranded and therefore did not 
contribute to any fluorescent signal.  271 
 
Absolute Quantification Data Analysis 
DNA or cDNA templates can be quantified by real-time PCR via a standard curve of a 
control nucleic acid over a large dynamic range (generally up to 8 orders of magnitude)
573 
Crossing point values (Cp values) are determined by a computer controlled algorithm 
using the second-derivative curve method this produces very reproducible results as Cp 
values are not user-defined.
574 The analysis module plots the sample Cp values against 
the standard curve and calculates the concentration via extrapolation against the 
regression line.    
Relative Expression Data Analysis 
This analysis module utilises the E-method to generate PCR efficiency adjusted relative 
expression results for RNA expression experiments.
266 Using standard curve adjusted 
concentration values for the target and reference genes this module will calculate 
normalised concentration values relative to the calibrator sample.  This allows for 
comparison of expression results between different target and reference genes and 
controls for inter-assay variation. The module calculates the crossing point values of the 
sample target and reference gene assays using the second-derivative curve method
574 
and plots them against their respective standard curves, whereby adjusting the 
concentration values for the PCR efficiency of each assay. Concentration ratios and 
standard deviations are calculated by the software using equation 10.  
Equation 10: Concentration Ratio Formula 
 
Normalised concentration ratios and standard deviations are calculated by dividing the 
sample concentration ratio by the calibrator sample concentration ratio, see equation 11 
below. 
Equation 11: Normalised Ratio Formula 
 
Concentration and Normalised ratio values calculated by the relative quantification 
software module can be exported for further analysis in Microsoft® excel. 
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Post PCR Melting Curve Analysis 
Melting temperature analysis is performed at the end of the PCR thermalcycling program 
in SYBRgreen qPCR experiments and monitors the decrease in SYBRgreen fluorescence 
as the PCR product is heated and denatured (figure 10.4).  Melting curve analysis is used 
to determine that specificity of the SYBRgreen reaction is maintained at all starting DNA 
template concentrations as the SYBRgreen dye will bind to any double-stranded DNA 
molecules. A PCR amplicon will melt at a specific temperature; this is the melting 
temperature (Tm), the point at which 50% of all of the PCR molecules are single-stranded. 
Therefore a specific qPCR assay will only have one melting temperature. This type of 
analysis is generally used to determine the specificity of the primers (i.e. one melting 
curve at the correct Tm) and the presence/absence of primer dimer accumulation at a 
lower Tm that could cause the results to be inaccurate. 
Figure 10-4: SYBRgreen Thermal Melt Program 
 
 
Colour Compensation Analysis 
A colour compensation analysis was performed in accordance with the LightCyler480 
operator’s manual for qPCR multiplex experiments that used reporter dyes with 
overlapping emission spectra. Only one colour compensation analysis was required to 
correct for spectral overlap between the FAM and Yakima Yellow reporter dyes used in 
the copy number variation experiments in chapters 3 and 4. 273 
10.4 Real-Time PCR Data Analysis 
The real-time PCR technique is a well established sensitive fluorescence-based PCR 
method for quantifying nucleic acids. This technique is primarily used to quantify gene 
expression (mRNA) by normalising the target gene concentration to a stably expressed 
reference gene (also known as a ‘Housekeeper Gene’). There are several mathematical 
equations available for calculating normalised gene expression values and all involve 
large amounts of data analysis after the PCR run. It is important for the researcher to 
understand any limitations of the mathematical techniques and correctly handle error 
propagation to produce a valid result data set for analysis.  
PCR Efficiency Corrections 
PCR is an enzyme driven reaction for amplifying DNA,
575 this reaction is not always 100% 
efficient, i.e. 1 cycle of PCR does not always result in a doubling of PCR product. The 
PCR reaction can be described by the following equation: 
Equation 12: PCR Reaction Calculation.  
Where: Xn = number of DNA molecules at cycle n. n = PCR cycle number. Xo = initial number of 
molecules. Ex = efficiency value (Probability value, 0-1.0) 
 
It is impossible to know for certain that there has been a doubling of PCR product at each 
cycle. Therefore, the efficiency value is a measure of probability that estimates the 
reaction efficiency over the entire PCR reaction. Knowing the efficiency of each PCR 
reaction is important for accurate quantification, especially when performing gene 
expression analysis. If the reactions are amplifying at different rates then they cannot be 
directly compared without adjusting for the differences in PCR efficiency first. 274 
PCR Efficiency Estimation Methods 
The efficiency value can be estimated in various ways; the two most common methods 
are: 
1.  From the slope of a standard curve (serial dilution of test DNA or cDNA) 
Figure 10-5: Standard Curve PCR Efficiency (E) Estimation.  
Calculated from an 8 step 4-fold serial dilution of cDNA template; where E = 10 1/s (s is the slope 
of the standard curve). The PCR efficiency for this assay is 93.3±0.005%. 
 
2.  Linear Regression of Fluorescent amplification curve data (LinRegPCR).
265 
Figure 10-6: LinRegPCR Program Screenshot.  
A linear regression line is fitted to the exponential part of the amplification plot and the PCR 
efficiency value is estimated from the slope of the regression line. The PCR efficiency estimate for 
the PCR assay in this reaction well is 106%, indicating the possible presence of amplified primer-
dimer products 
 
Either method produces valid estimates of PCR efficiency and has benefits and 
disadvantages over one another as listed in table 10.2 275 
Table 10-2: Advantages and Disadvantages of the Different PCR Efficiency Estimation 
Methods 
Efficiency Estimation Method  Advantages  Disadvantages 
Standard Curve  Accurate estimate of PCR Efficiency 
Provides information on dynamic range of 
assay 
Sample concentrations can be calculated 
directly from the curve 
Included in many Real-Time PCR machine 
analysis software packages. 
Expensive in both reagents and DNA 
template 
Uses up space on the reaction plate 
Standard curve is required for each assay 
on the plate – time consuming 
Does not provide efficiency value for every 
DNA sample 
Hard to generate a sufficient standard 
curve for low abundance targets 
Linear Regression  Standard curve not required. 
No added reagent costs 
Efficiency value for every well on the 
reaction plate 
 
Intensive external post PCR run data 
analysis 
No information on dynamic range of assay 
Accuracy of PCR efficiency value can 
dependant on quality of PCR amplification 
curve data. 
 
Relative Expression Analysis Using Multiple Reference Genes 
There are several mathematical equations available to perform relative quantification 
analyses (target gene versus reference gene).
576-578 The two most widely used methods 
are as follows: 
1.  Comparative Ct (2
-!!Ct) method: assumption based relative quantification; the 
assumption is that the PCR efficiencies are equal for both the target and reference 
genes in all samples.
576 
2.  Relative standard curve: Standard curve based relative quantification; adjusts for 
differences in PCR efficiency of the target and reference gene assays; PCR 
efficiencies of all samples are not assumed to be equal.
578 
Recent trends in real-time PCR relative quantification practise involves the use of multiple 
reference genes to control for any variation in reference gene concentrations between 
sample treatment groups. Thus, improving the accuracy and reproducibility of results.
445 
Reference gene combinations (pairs, trios or more) are chosen on the basis of a pair-wise 
stability index in both the control and treatment sample groups. The geometric mean of 
the reference gene concentrations can be used as a ‘normalisation factor’ in relative 
quantification calculations described earlier (section 1.6.3.3).  
There will still be some variation in the concentration of the chosen reference genes 
between the treatment and control groups, this variation (V = geometric mean of 
concentration of all possible reference gene combinations with in a group) can be used to 
determine the ‘minimal detectable fold difference’ of target gene between the two sample 
groups (Vtreatment group / Vcontrol group).  276 
Error Propagation in qPCR Relative Expression Analyses 
In order to have confidence in real-time PCR quantification results it is essential to 
determine measurement error, reproducibility (intra/inter-variability) and comparability 
between different PCR runs by using calibrator samples.
579 Normalisation of all 
concentration values to a calibrator sample is an efficient way to compare data between 
runs and measure inter-run variability. Duplicate samples (these can be extraction, RT 
duplicates and/or simple replicate sample well groupings) are used to determine intra-
assay variability accounting for the contribution of all experimental, RT-onwards or 
pipetting and instrument steps respectively.  The way the standard deviation of the result 
for each well grouping is calculated (Equations 13 & 14) is dependant on the relative 
expression calculation method used: 
Equation 13: Comparative Ct Method Standard Deviation.  
Where S1 = standard deviation of target values, S2 = standard deviation of reference values. 
 
Equation 14: Relative Standard Curve Standard Deviation.  
Where CV1 = standard deviation of target value/mean target value and CV2 = standard deviation of 
reference value/mean reference value. 
 277 
10.5 Full FBAT Result Outputs 
Which genes are responsible for asthma? 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  199  252  260.8  110.8  -0.839  0.401 
GSTM1  0  0.738  199  508  499.2  110.8  0.839  0.401 
GSTT1  1  0.573  224  450  468.7  146.2  -1.544  0.123 
GSTT1  0  0.427  224  414  395.3  146.2  1.544  0.123 
Results from Association Analysis Involving the Markers and the Diagnosis of Asthma 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  208  496.8  527.8  545.4  -1.327  0.185 
GSTM1  0  0.738  208  981.1  950.1  545.4  1.327  0.185 
GSTT1  1  0.571  229  870.1  901.7  770.7  -1.136  0.256 
GSTT1  0  0.429  229  817.5  785.9  770.7  1.136  0.256 
Results from Association Analysis Involving the Markers and the log Age-Corrected Total IgE Variable, Involving the 
Asthmatic Siblings 
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  206  3726.1  3643.7  31267.2  0.467  0.641 
GSTM1  0  0.738  206  6099.2  6181.7  31267.2  -0.467  0.641 
GSTT1  1  0.571  227  5693.0  6021.7  41501.4  -1.614  0.107 
GSTT1  0  0.429  227  5195.2  4866.4  41501.4  1.614  0.107 
Results from Association Analysis Involving the Markers and the Measure of Bronchial Responsiveness, Involving the 
Asthmatic Siblings 
Marker  No. of 
Copies  Allelic Frequency 
No. of 
Informative 
Families 
S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  209  25933  26876.5  1003691.8  -0.942  0.346 
GSTM1  0  0.738  209  50851  49907.5  1003691.8  0.942  0.346 
GSTT1  1  0.571  230  44261  46361.0  1325268.0  -1.824  0.068 
GSTT1  0  0.429  230  41147  39047.0  1325268.0  1.824  0.068 
Results from Association Analysis Involving the Markers and Percentage Predicted FEV1 Values, Involving the Asthmatic 
Siblings 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  187  317.0  336.4  272.1  -1.180  0.238 
GSTM1  0  0.738  187  617.6  598.1  272.1  1.180  0.238 
GSTT1  1  0.571  207  600.6  620.1  420.8  -0.951  0.341 
GSTT1  0  0.429  207  531.9  512.4  420.8  0.951  0.341 
Results from Association Analysis Involving the Markers and Atopy Severity Scores, Involving the Asthmatic Siblings 278 
 
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  201  1027.4  1076.8  1873.3  -1.142  0.254 
GSTM1  0  0.738  201  2059.1  2009.7  1873.3  1.142  0.254 
GSTT1  1  0.571  217  1705.1  1823.5  2351.4  -2.441  0.015 
GSTT1  0  0.429  217  1631.7  1513.4  2351.4  2.441  0.015 
Results from Association Analysis Involving the Markers and Asthma Severity Scores, Involving the Asthmatic Siblings 
Does exposure to smoke affect this? The Smoke Exposed Children 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  69  165.7  171.8  145.3  -0.506  0.613 
GSTM1  0  0.738  69  271.0  264.9  145.3  0.506  0.613 
GSTT1  1  0.571  81  258.3  289.6  234.1  -2.048  0.041 
GSTT1  0  0.429  81  287.8  256.5  234.1  2.048  0.041 
Results from Association Analysis Involving the Markers and the log Age-Corrected Total IgE Variable, In Exposed 
Asthmatic Siblings 
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  68  1302.1  1236.2  10220.7  0.651  0.515 
GSTM1  0  0.738  68  1947.5  2013.4  10220.7  -0.651  0.515 
GSTT1  1  0.571  80  1573.6  1685.8  13562.7  -0.963  0.336 
GSTT1  0  0.429  80  1901.2  1789.0  13562.7  0.963  0.336 
Results from Association Analysis Involving the Markers and the Measure of Bronchial Responsiveness, In Exposed 
Asthmatic Siblings 
Marker  No. of 
Copies 
Allelic 
Frequency 
No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  69  8551  8444.5  291184.3  0.197  0.844 
GSTM1  0  0.738  69  14537  14643.5  291184.3  -0.197  0.844 
GSTT1  1  0.571  81  13320  14231.0  432673.5  -1.385  0.166 
GSTT1  0  0.429  81  14560  13649.0  432673.5  1.385  0.166 
Results from Association Analysis Involving the Markers and Percentage Predicted FEV1 Values, In Exposed Asthmatic 
Siblings 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  57  101.5  106.8  78.6  -0.604  0.546 
GSTM1  0  0.738  57  180.7  175.3  78.6  0.604  0.546 
GSTT1  1  0.571  68  186.6  204.5  136.7  -1.533  0.125 
GSTT1  0  0.429  68  188.0  170.0  136.7  1.533  0.125 
Results from Association Analysis Involving the Markers and Atopy Severity Scores, In Exposed Asthmatic Siblings 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  64  316.4  321.1  490.3  -0.211  0.833 
GSTM1  0  0.738  64  548.5  543.8  490.3  0.211  0.833 
GSTT1  1  0.571  76  535.5  584.4  807.5  -1.719  0.086 
GSTT1  0  0.429  76  596.4  547.5  807.5  1.719  0.086 
Results from Association Analysis Involving the Markers and Asthma Severity Scores, In Exposed Asthmatic Siblings 279 
Unexposed 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  150  330.9  355.8  404.6  -1.238  0.216 
GSTM1  0  0.738  150  709.5  684.6  404.6  1.238  0.216 
GSTT1  1  0.571  163  623.8  624.0  544.6  -0.009  0.993 
GSTT1  0  0.429  163  533.7  533.5  544.6  0.009  0.993 
Results from Association Analysis Involving the Markers and the log Age-Corrected Total IgE Variable, In Unexposed 
Asthmatic Siblings 
Marker  No. of 
Copies 
Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  147  2024.1  2407.5  21080.8  0.115  0.909 
GSTM1  0  0.738  147  4151.7  4168.3  21080.8  -0.115  0.909 
GSTT1  1  0.571  159  4119.3  4335.9  27944.1  -1.296  0.195 
GSTT1  0  0.429  159  3294.0  3077.3  27944.1  1.296  0.195 
Results from Association Analysis Involving the Markers and the Measure of Bronchial Responsiveness, In Unexposed 
Asthmatic Siblings 
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  150  17382  18432  723058.5  -1.235  0.217 
GSTM1  0  0.738  150  36314  35264  723058.5  1.235  0.217 
GSTT1  1  0.571  163  30941  32130  899113.5  -1.254  0.210 
GSTT1  0  0.429  163  26587  25398  899113.5  1.254  0.210 
Results from Association Analysis Involving the Markers and Percentage Predicted FEV1 Values, In Unexposed Asthmatic 
Siblings 
Marker  No. of 
Copies 
Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  137  215.5  229.6  195.1  -1.010  0.312 
GSTM1  0  0.738  137  436.9  422.8  195.1  1.010  0.312 
GSTT1  1  0.571  148  414.0  415.5  288.0  -0.093  0.926 
GSTT1  0  0.429  148  344.0  342.3  288.0  0.093  0.926 
Results from Association Analysis Involving the Markers and Atopy Severity Scores, In Unexposed Asthmatic Siblings 
Marker  No. of 
Copies 
Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  145  711.0  755.7  1393.3  -1.199  0.231 
GSTM1  0  0.738  145  1510.7  1465.9  1393.3  1.199  0.231 
GSTT1  1  0.571  153  1169.5  1239.1  1558.1  -1.761  0.078 
GSTT1  0  0.429  153  1053.4  965.9  1558.1  1.761  0.078 
Results from Association Analysis Involving the Markers and Asthma Severity Scores, In Unexposed Asthmatic Siblings 280 
Using Residuals 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  209  -6.6  3.6  174.5  -0.769  0.442 
GSTM1  0  0.738  209  -14.1  -24.3  174.5  0.769  0.442 
GSTT1  1  0.571  230  5.8  4.8  246.0  0.063  0.950 
GSTT1  0  0.429  230  25.1  26.1  246.0  -0.063  0.950 
Results from Association Analysis Involving the Markers and the log Age-Corrected Total IgE Variable Involving the 
Asthmatic Siblings, using Smoking As a Covariate 
Marker  No. of 
Copies 
Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  206  303.9  103.1  13279.5  1.743  0.081 
GSTM1  0  0.738  206  -517.3  -316.5  13279.5  -1.743  0.081 
GSTT1  1  0.571  227  -13.5  -8.9  18189.3  -0.034  0.973 
GSTT1  0  0.429  227  -171.5  -176.1  18189.3  0.034  0.973 
Results from Association Analysis Involving the Markers and the Measure of Bronchial Responsiveness Variable Involving 
the Asthmatic Siblings, using Smoking As a Covariate 
Marker  No. of 
Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  209  -28.1  19.3  23128.6  -0.311  0.756 
GSTM1  0  0.738  209  205.3  158.0  23128.6  0.311  0.756 
GSTT1  1  0.571  230  -410.5  -75.0  33592.7  -1.830  0.067 
GSTT1  0  0.429  230  238.6  -96.9  33592.7  1.830  0.067 
Results from Association Analysis Involving the Markers and Percentage Predicted FEV1 Values Variable Involving the 
Asthmatic Siblings, using Smoking As a Covariate 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families 
S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  208  -7.1  0.2  123.6  -0.656  0.512 
GSTM1  0  0.738  208  -24.3  -31.6  123.6  0.656  0.512 
GSTT1  1  0.571  229  34.5  33.2  182.5  0.098  0.922 
GSTT1  0  0.429  229  16.8  18.2  182.5  -0.098  0.922 
Results from Association Analysis Involving the Markers and Atopy Severity Scores Variable the Involving Asthmatic 
Siblings, using Smoking As a Covariate 
Marker  No. of Copies  Allelic Frequency  No. of Informative 
Families  S  E(S)  Var(S)  Z  P 
GSTM1  1  0.262  201  -9.8  3.4  64.7  -1.640  0.101 
GSTM1  0  0.738  201  29.1  15.9  64.7  1.640  0.101 
GSTT1  1  0.571  217  -0.5  12.7  79.5  -1.479  0.139 
GSTT1  0  0.429  217  10.2  -3.0  79.5  1.479  0.139 
Results from Association Analysis Involving the Markers and Asthma Severity Scores Variable the Involving Asthmatic 
Siblings, using Smoking As a Covariate 281 
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 Copy-Number Variation Genotyping of GSTT1 and
GSTM1 Gene Deletions by Real-Time PCR
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BACKGROUND: Structural variation in the human ge-
nome is increasingly recognized as being highly preva-
lent and having relevance to common human diseases.
Array-based comparative genome-hybridization tech-
nology can be used to determine copy-number varia-
tion (CNV) across entire genomes, and quantitative
PCR (qPCR) can be used to validate de novo variation
orassaysofcommonCNVindisease-associationstud-
ies.AnalysisoflargeqPCRdatasetscanbecomplicated
and time-consuming, however.
METHODS: WedescribeqPCRassaysforGSTM1(gluta-
thione S-transferase mu 1) and GSTT1 (glutathione
S-transferase theta 1) gene deletions that can genotype
up to 192 samples in duplicate 5- L reaction volumes
in 2hontheABIPrism7900HTSequenceDetection
System. To streamline data handling and analysis of
theseCNVsbyqPCR,wedevelopedanovelinteractive,
macro-driven Microsoft Excel  spreadsheet. As proof
ofprinciple,weusedoursoftwaretoanalyzeCNVdata
for 1478 DNA samples from a family-based cohort.
RESULTS: With only 8 ng of DNA template, we assigned
CNV genotypes (i.e., 2, 1, or 0 copies) to either 96%
(GSTM1) or 91% (GSTT1) of all DNA samples in a
single round of PCR amplification. Genotyping accu-
racy, as ascertained by familial inheritance, was
 99.5%, and independent genotype assignments with
replicate real-time PCR runs were 100% concordant.
CONCLUSIONS: The genotyping assay for GSTM1 and
GSTT1genedeletionissuitableforlargegeneticepide-
miologic studies and is a highly effective analysis sys-
temthatisreadilyadaptabletoanalysisofotherCNVs.
© 2009 American Association for Clinical Chemistry
The advent of microarray-based comparative genomic-
hybridization technologies and whole-genome sequenc-
ing has revealed unexpectedly heterogeneous structural
variation (deletions, duplications, inversions, and
translocations) in the human genome (1–3). These
variations may have a greater effect on disease suscep-
tibility than previously thought; therefore, it is impor-
tant for any genetic study to consider the presence of
structural variation in the region of interest and to
havesuitabletechnologiesfordetectingthem(4).Cur-
rent technologies such as microarray-based compara-
tive genomic hybridization and multiplex ligation-
dependent probe amplification facilitate the detection
ofstructuralvariationacrossthegenomeandatsmaller
chromosomal regions, respectively (5, 6). Glutathione
S-transferases (GSTs)
6 (EC 2.5.1.18) are phase II de-
toxification enzymes found free in the cytosol. These
enzymes catalyze the conjugation of glutathione to
many electrophilic substrates (including free radicals,
xenobiotics,andphysiologicalmetabolites),producing
stable and more soluble compounds that can then be
excreted or compartmentalized by phase III enzymes
(7). The families of genes that encode GSTs are highly
polymorphic in the human population (8). Complete
deletion of the GSTM1
7 (glutathione S-transferase mu
1)andGSTT1(glutathioneS-transferasetheta1)genes
occurs in approximately 50% and 20% of Caucasians,
respectively.Copy-numbervariation(CNV)hasados-
age effect on the concentrations of the GSTM1 (MIM
138350) and GSTT1 (MIM 600436) proteins that af-
fects an individual’s ability to detoxify compounds ef-
ficiently and provide protection from oxidative stress
(9, 10).
Polymorphisms for GST gene deletion have con-
sequences for the detoxification of xenobiotics (11).
Single or combined deletions in GST-encoding genes
1 Respiratory Genetics Group, Human Genetics,
2 Infection, Inflammation and
Immunity, and
3 Public Health Sciences and Medical Statistics, Community
Clinical Sciences Divisions, School of Medicine, University of Southampton,
Southampton, UK;
4 Department of Community-Based Medicine, University of
Bristol, Bristol, UK;
5 The National Heart and Lung Institute, Imperial College
London, London, UK.
* Address correspondence to this author at: Respiratory Genetics Group, Human
Genetics Division, University of Southampton, Duthie Bldg. (MP 808),
Southampton General Hospital, Tremona Rd., Southampton SO16 6YD, UK. Fax
 02380-794264; e-mail mjrz@soton.ac.uk.
Received February 10, 2009; accepted June 23, 2009.
Previously published online at DOI: 10.1373/clinchem.2008.120105
6 Nonstandard abbreviations: GST, glutathione S-transferase; CNV, copy-number
variation; ECACC, European Collection of Cell Cultures; FBAT, family-based
association test; Cq, quantification cycle; qPCR, quantitative PCR.
7 Human genes: GSTM1, glutathione S-transferase mu 1; GSTT1, glutathione
S-transferase theta 1; ALB, albumin.
Clinical Chemistry 55:9
1680–1685 (2009)
Molecular Diagnostics and Genetics
1680increase the susceptibility to lung cancer in smokers
(12) and in nonsmokers exposed to household envi-
ronmental tobacco smoke (13). There is also an in-
creased risk of cardiovascular disease in smokers who
have a GST deficiency (14). Polymorphisms for GST-
encoding gene deletions and environmental tobacco
smoke contribute to the development of childhood
asthma (15) and may make asthmatic children more
susceptible to the deleterious effects of ozone (16).
GrossdeletionsinGSTT1andGSTM1genesarecre-
ated by separate equal or unequal recombination events
involvingcrossing-overbetween2highlyhomologousre-
peat regions that flank each gene (9, 10).T h e s es e p a r a t e
recombination events produce deletion-junction regions
of up to several kilobases that have very high homology
( 98%) to the flanking repeat regions. This phenome-
non severely restricts the design of unique primer se-
quences for use in standard PCR methods to identify the
presence of a deletion. Sprenger et al. described a multi-
plex PCR method that uses unique priming sites in the
GSTT1 deletion junction (9).T h i sm e t h o da p p e a r st o
have limited suitability for use in large genetics studies
because 2 steps, PCR amplification followed by agarose
gel electrophoresis, are required to visualize the 1.46-kb
deletion junction and the 466-bp gene-specific PCR
products. Furthermore, unbiased coamplification of
products of different sizes can be problematic, especially
when the quality of the DNA is variable, because the
product with the higher PCR efficiency may be preferen-
tially amplified (17).
Brasch-Andersenetal.showedthatitispossibleto
use the increased sensitivity of real-time PCR assays to
provide dosage data for the GSTT1 and GSTM1 genes
(18).Thismethodcandistinguishbetweenindividuals
with 2, 1, or 0 copies of a gene. Because GSTT1 or
GSTM1 CNV correlates with altered enzyme activity
(9, 19), analysis in a dose-dependent manner would
best describe any association with disease outcome.
We developed new real-time PCR assays that use
minor groove–binding hydrolysis probe technology on
the 384-well ABI Prism 7900HT Sequence Detection
System(AppliedBiosystems)forhighersamplethrough-
put, and we used a novel interactive macro-driven Mi-
crosoft Excel spreadsheet for analyzing the CNV data.
MaterialsandMethods
QUANTITATIVE PCR DESIGN AND VALIDATION
WeusedPrimerExpressv2.0software(AppliedBiosys-
tems) to design novel minor groove–binding hydroly-
sis probe assays for target genes GSTT1 and GSTM1
and for reference gene ALB (albumin). We subse-
quently conducted a BLAST search (http://www.blast.
ncbi.nlm.nih.gov) to evaluate the specificity of these
assays. We performed PCR reactions with asymmetric
concentrationsofprimers(0.3–0.9 mol/L)andprobe
titrations(200–50nmol/L)tolowerthedetectionlimit
and to increase the cost-effectiveness of the assays, re-
spectively.Triplicatewellsofsimplex(GSTT1,GSTM1,
or ALB) and multiplex (i.e., GSTT1 plus ALB or
GSTM1 plus ALB) reactions containing a series of
2-folddilutionsofpooledDNAsamples(20–0.156ng/
reaction) from the European Collection of Cell Cul-
tures (ECACC) were used to determine the PCR effi-
ciencies of each assay. We performed a melting-curve
analysisofthePCRtoassessthespecificityoftheprim-
ers. Each 10- L reaction with SYBR Green I contained
5mmol/LMgCl2,0.2mmol/Lofeachdeoxynucleoside
triphosphate, 30 g/L SYBR Green I (dissolved in
DMSO),0.25UofGoldStarTaqDNApolymerase(Eu-
rogentec), 10 ng of pooled control DNA template, and
primers to the final concentrations detailed in Table 1
of the Data Supplement that accompanies the online
version of this article at http://www.clinchem.org/
content/vol55/issue9. To evaluate genotyping accu-
racy, we used replicate sample wells and conducted
transmission disequilibrium tests with family-based
association test (FBAT) v1.4 (20) as an inheritance
check for the family-based cohort.
DNA TEMPLATES
ECACC Human Random Control DNA samples
(HRC-1) (http://www.hpacultures.org.uk/collections/
ecacc.jsp) were used to optimize reaction conditions,
to determine the stability of reaction plate storage, and
to validate subsequent experiments as positive con-
trols.DetailsoftheECACCHRC-1DNAsamplesused
as controls are described in the user manual for CNV
analysisintheonlineDataSupplement.Weconducted
GSTT1andGSTM1CNVexperimentswith1478DNA
samples previously collected for an asthma study of
sibling pairs from 341 affected Caucasian families in
the UK (21). Samples were obtained with informed
consent after ethics approval from the Southampton
and South West Hampshire Local Research Ethics
Committee and the Portsmouth and South East
Hampshire Local Research Ethics Committee.
PROTOCOL
We transferred 2  L of 1-ng/ L genomic DNA in du-
plicate to a 384-well plate. Each plate also contained 3
positivecontrolsandaminimumof4negativecontrols
(water). Before adding the reaction mixture, we dried
the DNA for 10 min at 80 °C on a PCR thermal cycler.
We used 5  L for each multiplex assay, and each
wellcontainedthefollowing:2.5 Lof2 Precision-R
MasterMix (PrimerDesign), which contained 5 mmol/L
MgCl2, 200  mol/L of each deoxynucleoside triphos-
phate, 0.025 U/ L Taq polymerase, and 6-carboxy-X-
rhodamine reference dye; the necessary volume of
Real-Time PCR Analysis for Gene-Dosage Genotyping
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Table1intheonlineDataSupplementlistsprimerand
probe sequences and reagent concentrations in the re-
actions. All PCR reaction mixes were prepared in bulk
with 10% extra volume for pipetting and were trans-
ferred to the 384-well plate with an electronic multi-
channel pipettor. Primer/probe mixes were also pre-
pared in advance to reduce the interassay imprecision
attributable to setting up each PCR reaction mix.
The plates were heat-sealed (Thermo-Sealer;
ABgene) to stop any evaporation from occurring dur-
ing the DNA-rehydration step (30 min at 4 °C pro-
tected from light, with periodic mixing) and during
thermal cycling. PCR amplification and collection of
real-timefluorescencedatawereperformedontheABI
Prism 7900HT Sequence Detection System. The ther-
mal profile consisted of incubation at 95 °C for 10 min
followedby40cyclesof95 °Cfor15sand60 °Cfor60s
without 9600-emulated temperature ramping. Fluo-
rescence data were collected during the 60 °C anneal-
ing/extensioncycles,andquantificationcycle(Cq)val-
ues were calculated with the automatic Cq-analysis
settings on an absolute quantification run (SDS Plate
Utility v2.1; Applied Biosystems).
CNV ANALYSIS SPREADSHEET
We designed a macro-based Microsoft Excel spread-
sheet to analyze real-time PCR data for gene dosage
(Fig.1).Theresults(Cqvalues)andfilesofclippeddata
(normalizedfluorescencevaluesfromthereporterdyes
at the end of each extension phase) generated by the
SDS v2.1 software for each plate run can be imported
into the spreadsheet. Each duplicate data point is visu-
alized in a ranked xy scatter graph ( Cq value vs sam-
ples ranked by increasing  Cq). The  Cq value
( Cq Cqtarget Cqreference)foreachduplicatecanbe
Fig. 1. CNV analysis spreadsheet.
Real-time PCR data are imported into the analysis spreadsheet, and the macro calculates the difference between the target and
reference Cq values with the indicated formula.  Cq values are displayed in a ranked scatter graph (bottom chart), allowing
assignment of CNV-genotype groupings by moving the vertical dotted lines. The solid vertical line highlights any desired sample
and displays the PCR curves; this feature allows determination of the validity of any genotype assignment within the grouping.
The top 3 graphs display plots of PCR curves for each of the 3 possible CNV genotypes.  Rn, reporter signal normalized to ROX;
Ref, reference; NTCs, no-template controls.
1682 Clinical Chemistry 55:9 (2009)compared directly with the plots of real-time amplifi-
cation curves generated by each grouping of sample
wells. The interactive sliding windows allow semiauto-
mated assignment of genotype groups and outliers on
the basis of the grouping of  Cq values on the ranked
xyscattergraph.Importantly,interrogationoftheplots
of real-time amplification curves permits rapid deter-
minationofthevalidityofanygenotypecallandallows
manual correction. The spreadsheet automatically cal-
culates CNV and frequencies of a gene present or ab-
sent, deviation from the Hardy–Weinberg equilib-
rium,andseveralQCparameters(i.e.,mean Cqvalue
andSDofeachCNVgroup).Theinteractiveandcolor-
coded 384- and 96-well arrays of the plate layout gen-
erated by the macro also allows postanalysis visualiza-
tion of the well position for any genotype call, water
control,orreactionfailure.Thisutilityallowsmonitor-
ing for any problematic samples or experimental con-
trols. It also identifies any possible effects of the plate
edges on data quality. Finally, the macro exports all
analyzed data to a new sheet in the spreadsheet in a
database-compatible format (Microsoft Access ). The
CNV-analysis spreadsheet is available in the online
Data Supplement.
CALCULATIONS OF THE HARDY–WEINBERG EQUILIBRIUM
These calculations were performed on the parental
genotypes with the online version of the Definetti pro-
gram (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). A Pear-
son 
2Pvalue 0.05wasconsideredtoindicatesignif-
icant deviation of the genotype frequency from the
Hardy–Weinberg equilibrium.
Results
ASSAY OPTIMIZATION
The detection limits of the quantitative PCR (qPCR)
assays were substantially improved with the use of
asymmetric concentrations of primers (see Table 1 in
the online Data Supplement). These conditions re-
duced Cq values by up to 1.38 Cq. Titrations of the
probe concentration revealed that a final probe con-
centration of 150 nmol/L for each assay could be used
without decreasing the signal strength (lower signal-
to-noise ratio) or the detection limit (increase in Cq
value). An analysis of the SYBR Green I melting curve
revealedsinglemeltingpeaksforallassays(seeFig.1in
the online Data Supplement).
Under multiplex conditions and the optimized
asymmetric primer concentrations and probe concen-
trations described above, the calibration curves (see
Fig. 2 in the online Data Supplement) demonstrated
that the multiplex amplification reactions were linear
over the entire range of DNA template concentrations
(20–0.156 ng); all values for PCR reaction efficiency
(E 10
1/s,wheresistheslopeofthecalibrationcurve)
werebetween1.95and1.99,valuesclosetothetheoret-
ical maximum value (i.e., E   2.0, in which 1 Cq is
equivalent to a doubling of the PCR product with each
PCR cycle). The interassay variation in PCR efficiency
was  1% in both multiplex reactions (EGSTM1 and
EALB,0.65%;EGSTT1andEALB,0.01%),confirmingthat
both PCR products in the multiplex were amplifying
at nearly the same rate.
The SD for the mean  Cq ( Cq   Cqtarget  
Cqreference)determinedateachDNAdilutionalongthe
calibrationcurvewasusedtoestimatetheexperimental
variation in the  Cq value used to determine the copy
numberforthegeneofinterest.OvertherangeofDNA
dilutions (20–0.156 ng), the mean (SD)  Cq was
 0.72 (0.1) for the GSTM1 assay and  0.54 (0.08) for
the GSTT1 assay.
The initial genotyping results for the 2 genes
obtained for 176 DNA samples (Table 1) demonstrated
thatthesensitivityoftheqPCRassaywassufficientsothat
 Cq values could be used to distinguish a change in gene
copynumber.Themeandifferencein Cqbetweensam-
ples assigned a 2-copies or 1-copy genotype was 1.03 for
GSTM1and1.06forGSTT1.Thesevalueswereveryclose
to the theoretical 1 Cq value for a doubling in concentra-
tion (i.e., 1 extra copy of the gene). In practice, this value
varied slightly between plate runs (0.85–1.20), although
this variation did not affect genotyping accuracy be-
cause the data from each plate were analyzed indepen-
dently in the analysis spreadsheet.
GENOTYPING RESULTS
Genotyping accuracies for the GSTM1 (99.9%) and
GSTT1(99.5%)assaysweredeterminedbydividingthe
numberfornon-Mendelianinheritancesdetectedwith
the FBAT program by the number of child genotypes
(n   770 for GSTM1;n  735 for GSTT1). All of the
results indicating non-Mendelian inheritance (n   1
Table 1.  Cq values for GST CNV genotypes.
a
Gene
CNV
genotype
Samples,
n
Mean
 Cq
 Cq
SD
Mean
difference:
 Cq
2c o p i e s 
 Cq
1c o p y
GSTM1 25  1.25 0.09 1.03
1 64  0.22 0.16
0 112 12.90 1.14
GSTT1 2 54  1.67 0.15 1.06
1 90 0.61 0.18
0 30 15.66 0.49
a Mean  Cq values for each genotype group for 176 DNA samples.
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copies” genotype calls when the parental genotype
combinationpermittedonly0-or1-copyoffspring.To
test the interassay reproducibility of genotype assign-
ments, we re-genotyped 92 DNA samples for both
CNVs in a separate qPCR run; comparison of the 2
independent genotype calls demonstrated 100% con-
cordance. Table 2 shows the full cohort and parent ge-
notype frequencies for both gene CNVs and a lack of
statistical significance in Pearson tests for deviation
from the Hardy–Weinberg equilibrium. The rates for
undetermined CNV calls (i.e., 2, 1, and 0 copies) were
4% for GSTM1 and 9% for GSTT1, and 2% and 3%,
respectively, for the gene absent/present call.
ASSAY PLATE STABILITY
Testing performed at the 24-h, 48-h, and 72-h time
points with the ECACC HRC-1 DNA panel showed
that sealed reaction plates could be stored protected
from light at room temperature for 24 h before the
real-time PCR run without any degradation in data
quality (data not shown).
Discussion
This new methodology enhances the study of gene
CNV in the large sample sizes required in genetic-
association studies. This study is not the first applica-
tion of real-time PCR to assay GSTM1 and GSTT1
CNV; several other protocols have been described in
theliterature(18, 22).Thesemethodsarenoteffective,
however,forprocessingthelargesamplesizesrequired
in genetic-association studies, because the low sample
densityonreactionplatescausedbytheuseoftriplicate
wells and larger reaction volumes (10  L) result in a
highgenotypingcostpersample.Withourmethod,96
samplescanbegenotypedfor2CNVsinduplicatewells
onasinglereactionplate(or192samplesfor1CNV)in
 2 hours with a proportional 66% savings in the costs
for 2  Precision-R MasterMix (5  L vs 15  L), prim-
ers, and probe. The small amount of DNA template
used in the assay conserves DNA template (4 ng DNA
per CNV). Diluting the template also dilutes any po-
tential PCR inhibitors present in the sample, and dry-
ing the template reduces sample cross-contamination.
Wedetermined2ngDNAtobeoptimuminourgeno-
typing experiments because this quantity falls in the
central part of the range of calibrator dilutions where
Cq values have a direct relationship to the log of the
DNA template concentration, thus providing accurate
quantification. Minor groove–binding hydrolysis
probes were used because they permitted smaller reac-
tion volumes than required with standard hydrolysis
probes without compromising the assay’s detection
limit or reproducibility (23). The calibration curves
demonstrate that the multiplex PCR reactions are
highly efficient (E   1.95) and amplify at nearly the
same rate with a large dynamic range. The calibration
curves cover a DNA template concentration range of 7
“ordersofmagnitude”(i.e.,2
0–2
 7:20–0.156ngDNA
per PCR reaction).
The combination of assay optimization and use
of a novel analysis spreadsheet enabled these assays to
report 97%–98% of the individuals in our family co-
horts with gene present/absent genotype calls and
91%–96% of the individuals with full CNV genotypes
(i.e., 0, 1, or 2 copies) with high accuracy ( 99.5%, as
determined by evaluating inheritance in the family co-
hort). Success rates for calling full CNV genotypes ap-
proached those routinely achieved by standard tech-
nologies for calling genotypes for single-nucleotide
polymorphisms ( 95%) (24).As u b s e q u e n tr o u n do f
genotyping for the unassigned samples (between 6% and
9% for GSTM1 and GSTT1)i n c r e a s e st h eg e n o t y p i n g
success rate to the rates achieved with the genotyping
technologies used for single-nucleotide polymorphisms
whilestillobtainingagreaterproportionalsavingsincosts
comparedwithpreviouslydescribedGSTCNVprotocols
(18, 22).T h ed e t e c t i o no fas m a l ln u m b e ro fn o n -
Mendelian inheritances in our cohort of families may re-
flect a possible limitation of the manual sliding-window
methodtodeterminetheendofthe2-copies Cqgroup-
ing and the start of the single-copy grouping (i.e., 1-copy
individualscouldbeerroneouslyassignedtothe2-copies
group).Thestartandendofthe2groupingsofgenotypes
on the ranked xy scatter graph are usually distinct, how-
ever, and barring any outlying data points (outliers can
easily be distinguished by examining the quality of the
data for real-time PCR plots for the well grouping), the
FBAT-determinedinheritanceresultscouldsimplyreflect
the true genotyping error of the technique (i.e., sporadic
contamination not detected by the negative controls and
chance results). In support of this hypothesis, the geno-
types of re-genotyped samples were 100% concordant,
Table 2. Genotype frequencies.
a
Group Gene
CNV frequency, n (%)
HWE
P
2
Copies
1
Copy
0
Copies
Entire cohort GSTT1 415 (31) 690 (51) 247 (18) NA
GSTM1 98 (7) 534 (38) 786 (55) NA
Parents only GSTT1 193 (31) 321 (52) 103 (17) 0.117
GSTM1 42 (6) 250 (39) 356 (55) 0.831
a Calculations of the Hardy–Weinberg equilibrium (HWE) were not per-
formed on the full family cohort because the individuals are related; the
parents’ frequencies were analyzed separately as a surrogate of that of the
general population and found to be in HWE. NA, not applicable.
1684 Clinical Chemistry 55:9 (2009)and the lack of any discordant genotypes indicated that
the manual sliding-window method for assigning geno-
type groups was sound.
Theprotocoldescribedinthisreporthasadvantages
over previously published methodologies (18, 22),i n -
cluding a higher sample density per reaction plate, a
smaller reaction volume, and compatibility with liquid-
handling robotic platforms for DNA aliquoting, reaction
plate setup, and loading of plates onto the real-time PCR
machine. The analysis spreadsheet provides a complete
analysis, QC, troubleshooting capabilities, and a data-
handling solution to CNV genotyping on the ABI
7900HT Sequence Detection System. The macro-based
Excel spreadsheet eliminates the considerable bottleneck
involved in processing real-time PCR data and may be
applicable to CNV genotyping of other genes from any
genome.
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Background Oxidative stress is thought to be involved in the pathogenesis of
asthma. Glutathione-S-transferase (GST) enzymes, which play an
important role in antioxidant defences, may therefore influence
asthma risk. Two common deletion polymorphisms of GSTM1 and
GSTT1 genes and the GSTP1 Ile105Val polymorphism have been
associated with asthma in children and adults, but results are
inconsistent across studies.
Methods Systematic review and meta-analysis of the effects of GST
genes on asthma, wheezing and bronchial hyper-responsiveness
(BHR), with inclusion of unpublished data from three studies,
including the large Avon Longitudinal Study of Parents and
Children (ALSPAC). Random effect or fixed effect models were
used as appropriate, and sensitivity analyses were performed
to assess the impact of study characteristics and quality on
pooled results.
Results The meta-analyses of GSTM1 (n 22 studies) and GSTT1 (n 19)
showed increased asthma risk associated with the null genotype,
but there was extreme between-study heterogeneity and publication
bias and the association disappeared when meta-analysis was
restricted to the largest studies. Meta-analysis of GSTP1 Ile105Val
(n 17) and asthma suggested a possible protective effect of the Val
allele, but heterogeneity was extreme. Few studies evaluated
wheezing and BHR and most reported no associations, although
weak evidence was found for positive associations of GSTM1 null
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  Int. J. Epidemiol. Advance Access published January 4, 2010and GSTP1 Val allele with wheezing and a negative association of
GSTP1 Val allele with BHR.
Conclusions Our findings do not support a substantial role of GST genes alone
in the development of asthma. Future studies of large size should
focus on interactions of GST genes with environmental oxidative
exposures and with other genes involved in antioxidant pathways.
Quality of study conduct and reporting needs to be improved to
increase credibility of the evidence accumulating over time.
Keywords Meta-analysis, systematic review, glutathione-S-transferase genes,
GSTM1 gene, GSTT1 gene, GSTP1 gene, asthma, wheezing, bronchial
responsiveness, The Avon Longitudinal Study of Parents and
Children (ALSPAC)
Introduction
Asthma is characterized by chronic airway inflamma-
tion and oxidative stress in the lungs has been impli-
cated in its pathogenesis.
1 Sources of oxidant injury
are reactive oxygen and nitrogen species generated by
activated inflammatory cells and bronchial epithelial
cells and inhalation of atmospheric pollutants, nota-
bly tobacco smoke and oxidant gases, including
ozone, sulphur dioxide and nitrogen oxides.
2 These
are countered by enzymatic and non-enzymatic
antioxidants, including dietary antioxidants, such as
vitamins C and E, and glutathione, a major protective
antioxidant in the lungs that also has a role in
regulation of inflammatory responses.
3 A family of
enzymes, the glutathione-S-transferases (GSTs), has
the general function of conjugating glutathione with
electrophilic substances that are capable of generating
free radicals, thus leading to detoxification of their
effects. Genetic polymorphisms associated with
reduced activity of GSTs are therefore of interest in
the study of disease susceptibility. Two common
deletion polymorphisms of GSTM1 and GSTT1 genes
have been associated with asthma in children and
adults.
4–7 The Val allele of the GSTP1 Ile105Val poly-
morphism, although associated with reduced glu-
tathione activity,
8 has surprisingly been reported to
be highly protective for asthma and airway respon-
siveness in adults.
5,9,10 However, the Val105 allele
has also been reported to increase the risk of
asthma
11 and to increase susceptibility to the effects
of ozone on breathing difficulties in children with
asthma.
12 Others have reported no associations
between this GSTP1 polymorphism and asthma in
children and adults.
4,8,13 Many of the studies were
relatively small or confined to selected populations.
A systematic review of the literature can help under-
stand the reasons for the heterogeneity in study
results, and the pooling of results across similar stud-
ies in a meta-analysis can overcome the problem of
limited statistical power. With this aim, we have con-
ducted a systematic review and meta-analysis on the
associations between GSTM1, GSTT1 and GSTP1 poly-
morphisms and asthma phenotypes in children and
adults, with inclusion of unpublished data from a
large UK cohort study in children, a UK family-
based study in children and young adults and a
Spanish cohort study in children.
Methods
Primary studies
Methods of the three primary studies included in the
meta-analyses are briefly summarized below. Further
details are reported in the Supplementary Appendix 1
available as supplementary data at IJE online.
ALSPAC
The Avon Longitudinal Study of Parents and Children
(ALSPAC) is a longitudinal, population-based birth
cohort study that recruited 14541 pregnant women
in 1991–92, with 14062 liveborn children.
14,15
Ethical approval for the study was obtained from
the ALSPAC Law and Ethics Committee and the
Local Research Ethics Committees.
The study collected data on asthma and wheezing in
children at age 7.5 years, based on a questionnaire
sent to mothers. Children from multiple births were
excluded from the analyses. Asthma was defined as a
report of doctor diagnosis of asthma ever together
with reported asthma, wheeze or asthma treatment
in the previous 12 months. Wheezing was defined
as a positive response to the question ‘Has your
child had any wheezing with whistling on his/her
chest when he/she breathed in the past 12
months?’. Spirometry was performed at 8.5 years,
and bronchial hyper-responsiveness (BHR) to metha-
choline was defined as a 20% reduction from baseline
(post-saline) Forced Expired Volume in 1s (FEV1)a t
a cumulative dose of methacholine 41.2mg. In the
mothers’ population, asthma was defined as a positive
response to the question ‘Have you ever had asthma?’,
2 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYfrom a self-completion questionnaire administered
during pregnancy.
The majority of the children’s DNA samples were
extracted from cord blood or venous blood collected
at age 7 years with a small number extracted from
venous blood collected at 43–61 months. The majority
of maternal DNA samples were extracted from blood
taken during pregnancy and a small number were
buccal DNA extracted from mouthwash samples.
16
GSTP1 polymorphism Ile105Val was determined
using competitive allele specific polymerase chain
reaction (PCR) system (KASPar). Copy number vari-
ation (CNV) of GSTT1 and GSTM1 deletion polymorph-
isms was analysed using a real-time PCR method.
17
Genotyping was performed blind to the outcome
status of individuals.
The genetic effects of the three genes were evaluated
using between-genotype comparisons (variant homo-
zygotes vs wild homozygotes and heterozygotes vs
wild homozygotes). Since the samples of mothers and
children were not independent, the odds ratios (ORs)
used in the meta-analysis for the two groups were esti-
mated by analysing them within the same logistic
regression model, and calculating confidence intervals
(CIs) using Huber variances clustered by pregnancy.
AMICS-INMA study
The Menorca Asthma Multicentre Infant Cohort
Study (AMICS) is a population-based birth cohort
included in the Spanish environment and childhood
research network (INMA study). In 1997–98, the
study recruited 482 children at birth from 492 preg-
nant women resident in the island of Menorca, Spain.
The study has been described previously.
18,19 Ethical
approval was obtained from the Balearic Islands
Research Ethics Committee.
Information on asthma and wheezing in children
was collected through telephone questionnaires
administered yearly to mothers, for children up to
the age of 6 years. Presented here are data based on
the questionnaire at age 6 years. Asthma was defined
as doctor-diagnosis of asthma in the previous 12
months, and wheezing as a positive response to the
question ‘Has your child had any wheezing with
whistling on his/her chest when he/she breathed in
the past 12 months?’.
Most of the DNA samples (87%) were extracted
from blood obtained at age 4 years, and the rest
from saliva collected at age 6 years. GSTM1 and
GSTT1 gene deletions were detected by multiplex
PCR, with a method modified from Arand and coll
20
(Supplementary Appendix 1 available as supplemen-
tary data at IJE online). GSTP1 polymorphism
Ile105Val was determined using pyrosequencing
(Biotage, Uppsala, Sweden). All assays were per-
formed blind to the outcome status of the children.
GSTM1 and GSTT1 genetic effects were evaluated
assuming a recessive model (OR for the null
genotype), whereas the genetic effect of GSTP1 was
assessed using between-genotype comparisons.
Southampton study
The Southampton Asthma Cohort is a family study
that started in 1997 and recruited 341 families
(1508 individuals) from Southampton, Portsmouth,
Bournemouth and the Isle of Wight, UK.
21 Inclusion
criteria required two siblings (5–21 years) diagnosed
with asthma and currently using asthma medication.
Reported here are the associations of GSTM1 and
GSTT1 deletion polymorphisms with asthma, defined
as physician’s diagnosis and current use of medica-
tion, and bronchial responsiveness to methacholine,
only measured in participants with a baseline FEV1
570% predicted.
DNA from blood samples was analysed for CNV of
GSTM1 and GSTT1 genes, using quantitative real-time
PCR (Supplementary Appendix 1 available as supple-
mentary data at IJE online). Genotyping was per-
formed blind to the outcome status.
Data were analysed using Family Based Association
Tests (FBAT version 1.4 software; http://www.biostat
.harvard.edu/_fbat.htm), assuming an additive genetic
model with a null hypothesis of ‘no association and
no linkage’ between presence/absence of the gene and
asthma phenotypes.
22
Systematic review
This systematic review was conducted following a
protocol in accordance with the Human Genome
Epidemiology Network (HuGENet) guidelines.
23
Studies were identified through electronic search of
MEDLINE, EMBASE, ISI Web of Science and
HuGENet up to February 2008, using a comprehensive
search strategy (Supplementary Figure S1 available as
supplementary data at IJE online). Included were
population-based and family-based studies examining
the effect of GST polymorphisms on asthma pheno-
types. Although the original search strategy included
atopy, this article focuses on the association of GST
genes with asthma, wheezing and BHR. No restric-
tions were placed on language and type of report,
with inclusion of conference abstracts. When multiple
reports were available for a single study, only the
most recent article or that with the largest sample
size was included. Additional studies were identified
through cross-checking of reference lists of all rele-
vant studies, including previous reviews and editor-
ials. Two reviewers (C.M. and R.G.) independently
extracted data using a pre-piloted form, with a third
reviewer available for arbitration (J.W.H.). Authors of
eligible primary studies were contacted for further
information whenever the data required by the
meta-analysis were not fully reported in the article.
Study quality of primary studies was evaluated
based on the HuGENet guidelines
23 and
STrengthening the REporting of Genetic Association
studies (STREGA) recommendations for the reporting
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24 We also assessed the
epidemiological credibility of the results of our meta-
analyses by use of an index recently proposed for
assessing cumulative evidence in genetic associations
(Venice criteria), which classifies epidemiological
credibility of the results of a meta-analysis as
‘strong’, ‘moderate’ or ‘weak’, based on three ele-
ments: (i) amount of evidence, (ii) extent of replica-
tion and (iii) protection from bias.
25
Meta-analysis
The meta-analyses were performed on the population-
based studies, and included unpublished results from
the ALSPAC and AMICS-INMA studies, together with
those of studies identified through the systematic
review.
Most studies evaluated GSTM1 and GSTT1 as pres-
ence/absence of gene deletion, so that meta-analyses
of these polymorphisms were performed using a
single OR (null vs present). Results for GSTP1
Ile105Val are reported as two ORs, Ile/Val vs Ile/Ile
and Val/Val vs Ile/Ile. Given the absence of a priori
evidence on the genetic model for this polymorphism,
a ‘genetic model-free’ approach was also used to pool
results across genotype groups.
26 This approach does
not assume a specific genetic model but estimates it
from the data, with the only assumption that the
unknown genetic model is constant across studies.
The genetic model-free approach was implemented
within a Bayesian framework and assuming non-
informative prior distributions for all parameters.
27
Details of the model are reported in the Appendix 1.
In the presence of at least five studies, meta-
analyses were performed using random effects
models, which account for between-study heterogene-
ity. If less than five studies were included, meta-
analysis was performed only in the presence of
small between-study heterogeneity (I
2<25%), using
fixed-effect models. The presence of between-study
heterogeneity was investigated using the Q test and
its magnitude estimated using the I
2 statistic, which
measures the proportion of variation across studies
due to genuine differences rather than random
error.
28 Possible causes of heterogeneity were investi-
gated by subgroup analyses based on geographic loca-
tion, population age (adults vs children), size of the
study and definition of asthma. Additional sensitivity
analyses were performed by excluding studies with
poor methodological quality. Studies were considered
of poor quality if no definition of the disease out-
comes was provided and either the description of
the study sample (e.g. selection of cases/controls for
case–control studies) was incomplete or there was no
mention of Hardy–Weinberg equilibrium (HWE).
Although many more items were considered in the
quality assessment, we chose to limit exclusion to
those studies where poor quality seemed beyond any
reasonable doubt.
For each study, deviation from HWE was tested
using the exact test, and the magnitude of the depar-
ture measured using the disequilibrium coefficient.
Studies with large deviations from HWE were further
investigated for possible methodological problems,
including population stratification and genotyping
errors.
29 The presence of small-study bias, which is
a proxy for publication bias, was investigated both
graphically using funnel plots and formally using
Begg’s and Egger’s tests.
All analyses were performed using Stata for Windows
v10 (Stata Corp, College Station, TX, USA), with the
exception of the model-free approach, which was
implemented in WinBUGS 1.4.
30 For the Bayesian anal-
yses, 95% credible intervals (i.e. range in which the
probability that the parameter lies within this interval
is 95%) were calculated in place of 95% CIs.
Results
Primary studies
ALSPAC
For analyses on asthma in children, data were avail-
able from 5327, 5300 and 5330 children for GSTM1,
GSTT1 and GSTP1, respectively; corresponding figures
for wheezing were 5991, 5957 and 5992, and for bron-
chial responsiveness were 3430, 3402 and 3417. For
analyses on asthma in mothers, data were available
from 7049, 7017 and 7262, respectively. The allele
frequencies of GSTM1, GSTT1 and GSTP1 were similar
to those reported in other UK populations
31,32 and in
a White, non-Hispanic US population.
33 All gene poly-
morphisms were in HWE. Overall, there was no evi-
dence of substantial association of the three genes
with asthma phenotypes. The results for GSTM1 and
GSTT1, analysed as CNV with three-level genotype
data, showed no association for GSTM1, whereas a
possible small protective effect on asthma of the
GSTT1 null allele could not be excluded in mothers
(OR: 0.71; 95% CI: 0.57–0.90 and 0.84; 0.63–1.12,
for heterozygotes and null homozygotes, respectively,
compared with wild-type homozygotes). However,
evidence of a possible protective effect was weak in
children (0.91; 0.76–1.11 and 0.89; 0.70–1.13). In chil-
dren, the OR of GSTP1 Ile/Val vs Ile/Ile for asthma was
1.16 (95% CI 0.98–1.37) and for wheezing 1.25 (1.05–
1.49), but such association was not shown for GSTP1
Val/Val vs Ile/Ile, and the finding was not replicated
in mothers. Most subjects in both children’s and
mothers’ groups were White (96 and 98%, respec-
tively), and results did not change when excluding
non-White subjects from the analyses.
AMICS-INMA study
Data were available from 411 and 404 children for
analyses on asthma and wheezing, respectively.
GSTP1 genotype was in HWE. No association was
found between GSTM1 or GSTT1 and asthma or
4 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYwheezing (Figures 2, 3 and 5). GSTP1 showed no
association with asthma, but was associated with
wheezing (Figures 4 and 5). The ORs for GSTP1 and
wheezing were 2.32 (1.03–5.23) and 5.01 (1.72–14.58)
for Ile/Val and Val/Val vs Ile/Ile, respectively, which
suggests that the increased risk of wheezing asso-
ciated with the Val allele might follow an additive
genetic model.
Southampton study
Among the 341 families, the analyses on asthma
included 199 and 224 informative families for
GSTM1 and GSTT1, respectively; these figures were
206 and 227 for bronchial responsiveness. No associ-
ation was found for asthma or bronchial responsive-
ness with either GSTM1 or GSTT1, although the
presence of GSTT1 null allele was associated with an
increased severity score in patients with asthma
(P 0.015).
Systematic review and meta-analysis
The process of inclusion and exclusion of studies is
presented in Figure 1. Our initial search strategy
identified 804 articles, among which the full text of
87 articles was retrieved for more detailed evaluation.
Of the 30 eligible articles, 2 reported on family-based
studies and 28 articles reported on 26 population-
based studies. We contacted authors of 12 articles
for further information on genotype counts and out-
come definition, and received replies from 5.
Of the 26 eligible population-based studies, we could
include in the meta-analyses data from 25 studies
SEARCH up to Feb. 2008: 804 
AFTER SCREENING OF 
TITLES/ABSTRACTS: 83 
ADDITIONAL PAPERS IDENTIFIED: 4 
• C r o s s - c h e c k i n g   o f   r e f e r e n c e s :   3  
•  Contact with authors: 1 
PAPERS RETRIEVED FOR DETAILED 
EVALUATION: 87  PAPERS EXCLUDED: 57 
• O t h e r   o u t c o m e s   ( e . g .   C O P D ) :   1 6  
• M u l t i p l e   r e p o r t s   o f   t h e   s a m e   s t u d y :   1 5  
• A s t h m a   s e v e r i t y :   1 0  
• E d i t o r i a l s / r e v i e w s :   7  
•  Occupational asthma: 6 
• P r e l i m i n a r y   r e s u l t s   n o t   o n   GST genes: 2 
• M e t h o d o l o g i c a l   p a p e r :   1    
PAPERS REVIEWED: 30 
• P o p u l a t i o n   b a s e d :   2 8   ( 2 6   s t u d i e s )  
• F a m i l y   b a s e d :   2    
INCLUDED in GSTM1
meta-analyses: 20 
(19 studies) 
• Asthma: 18 (19 studies) 
• Wheezing: 2 
• BHR: 2 
INCLUDED in GSTT1
meta-analyses: 16 
• Asthma: 16 
• Wheezing: 0 
• BHR: 2 
INCLUDED in GSTP1
meta-analyses: 16 
• Asthma: 14 
• Wheezing: 1 
• BHR: 2 
Figure 1 Flow chart of the inclusion and exclusion of published articles in the review
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2 cross-sectional and 21 case–control studies. After
inclusion of the three primary studies (ALSPAC
mothers, ALSPAC children, AMICS-INMA) associa-
tion with asthma was evaluated in 22 studies on
GSTM1, 19 on GSTT1 and 17 on GSTP1. Asthma was
defined as doctor-diagnosed asthma in 19, 16 and 12
studies on GSTM1, GSTT1 and GSTP1, respectively.
Wheezing was evaluated in four studies on GSTM1,
two on GSTT1 and three on GSTP1. BHR, defined in
all studies as a FEV1 reduction of 520% after metha-
choline challenge, was considered in three studies on
GSTM1, three on GSTT1 and three on GSTP1. Overall,
10 studies were performed in children, 7 in adults,
6 in both, whereas for 2 studies the information
was not available. In terms of geographical location,
13 studies were performed in Asia, 8 in Europe, 2 in
North Africa and 2 in North America. Case–control
studies varied in sample size, from less than 100 to
approximately 1000. On the other hand, both cross-
sectional studies had around 3000 subjects and three
out of five cohort studies had large sample size of
4400–7200. Other characteristics of the population-
based studies included in the meta-analyses are sum-
marized in Table 1, and genotype counts by disease
outcome are reported in Table 2.
Two family studies were included in the systematic
review (Table 1), but only one provided complete
Table 1 Characteristics of the studies evaluating the effects of GST genes on asthma risk, wheezing and BHR
Study, year Study population
Location,
ethnicity
Adults/
children
Sample
size
a Definition of disease outcome
Case–control studies (n 21)
Fryer,
2000
9
Cases: from patient database
Controls: healthy volunteers
UK,
European
Adults 171 Atopic asthma diagnosed by a
physician [Criteria: a history of
wheezing, cough, dyspnoea and/or
chest tightness; spirometric demon-
stration of airflow obstruction
reversible with ab-agonist broncho-
dilator (415% change in FEV1); and
positive atopic status) BHR FEV1
reduction420% after methacholine]
Chung,
2002
59
Cases and controls: from
cohort of civil servants
and their families
Korea, Asian N/A 99 Asthma diagnosed by a physician
(Criteria: symptoms of wheezing/
chest tightness and FEV1 reduction
420% after methacholine challenge)
Freidin,
2002
60
Cases: hospitalized patients
Controls: healthy volunteers
Russia, Asian N/A 126 Atopic asthma diagnosed by a
physician (Criteria: N/A)
Sideleva,
2002
61
Cases: hospitalized patients
Controls: healthy volunteers
Russia,
European
Both 199 Atopic asthma diagnosed by a
physician (Criteria: the commonly
accepted clinical laboratory exami-
nation and analysis of the external
respiration function
62)
Vavilin,
2002;
39
Safronova,
2003
38
Cases: hospitalized patients
Controls: healthy volunteers
Russia,
European
Children 237 Asthma diagnosed by a physician
(Criteria: N/A)
Aynacioglu,
2004
41
Cases: consecutive asthma
outpatients
Controls: healthy volunteers
Turkey,
Asian
Adults 475 Asthma diagnosed by a physician
(Criteria: ECRHS protocol; medical
history, physical examination, lung
function tests, chest X-rays, SPT,
TOT IgE)
Saadat,
2004
6
Cases: N/A
Controls: healthy volunteers
Iran, Asian Both 170 Asthma diagnosed by a physician
[Yes to two or more criteria: (i)
history of wheezing/breathlessness;
(ii) airflow obstruction of 415%
FEV1; and (iii) PEF 420%]
Tamer,
2004
11
Cases: hospitalized patients
Controls: healthy volunteers
Turkey,
Asian
Adults 204 Asthma diagnosed by a physician
(Criteria: American Thoracic Society
statement
63)
Zhang,
2004
36
Cases: hospitalized patients
Controls: N/A
China, Asian Adults 120 Asthma diagnosed by a physician
(Criteria: N/A)
(Continued)
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Study, year Study population
Location,
ethnicity
Adults/
children
Sample
size
a Definition of disease outcome
Lee, 2005,
2008
10,64
Cases: school children
from three communities
Controls: healthy random
sample from same three
communities
Taiwan,
Asian
Children 397 Asthma parent-reported (positive
response to the question, ‘Has a
physician ever diagnosed your child
as having asthma?’) Wheezing
parent-reported (lifetime history)
Nickel,
2005
13
Cases: from Multicenter
Allergy Study
Controls: healthy volunteers
Germany,
European
Children 205 Asthma diagnosed by a physician
(Criteria: one or more episodes of
wheezingduringprevious12months)
Oh,
2005
37
Cases: recruited at an
allergy clinic
Controls: healthy subjects
Korea, Asian Both 273 Asthma diagnosed by a physician
(Criteria: N/A)
Arbag,
2006
65
Cases: cases of nasal polyposis
Controls: healthy individuals
from same geographic location
and same ethnicity as cases
Turkey,
Asian
Both 133 Asthma diagnosed by a physician
(Criteria: N/A; cases were receiving
regular inhaled corticosteroids and
beta2-adrenoreceptor stimulants for
use as required)
Ercan,
2006
1
Cases: random sample from
cohort of asthmatic children
Controls: healthy school
children
Turkey,
Asian
Children 563 Asthma diagnosed by a physician
[Criteria: history of intermittent
wheezing and the presence of
reversible airway obstruction as
defined by at least a 12% improve-
ment in FEV1 following bronchodi-
lator administration, therapeutic
response to anti-asthma treatment,
or an abnormal result in metha-
choline bronchoprovocation test
(PC20<8mg/dl)]
Holla,
2006
66
Cases and controls are unre-
lated subjects selected from
questionnaires
Czech
Republic,
European
Both 637 Asthma diagnosed by a physician
(Criteria: asthma symptoms and use
of antiasthma medication according
to the GINA guidelines
67)
Plutecka,
2006
35
Cases: N/A
Controls: healthy volunteers
Poland,
European
Adults 496 Asthma not defined
Abdel-Alim,
2007
40
Cases: children attending out-
patient clinic of allergy and
immunology
Controls: matched healthy
children enrolled in this work
Egypt, North
African
Children 90 Asthma diagnosed by a physician
(Criteria: GINA guidelines
68)
Hanene,
2007
5
Cases and controls from
a representative region
Tunisia,
North African
Children 347 Asthma not defined
Kamada,
2007a
69
Cases: recruited from a
medical centre
Controls: healthy volunteers
Japan, Asian Both 980 Asthma diagnosed by a physician
(Criteria: American Thoracic
Society
70)
Kamada,
2007b
69
Cases: recruited from a
medical centre
Controls: healthy volunteers
Japan, Asian Children 289 Asthma diagnosed by a physician
(Criteria: American Thoracic
Society
70)
Mak,
2007
8
Cases: recruited from
asthma clinic Controls:
random healthy subjects from
Hong-Kong population
China, Asian Adults 626 Asthma diagnosed by a physician
(Criteria: cough/wheeze/chest tight-
ness and airflow obstruction of
515% FEV1)
Cohort studies (n 5)
Imboden,
2007
71
SAPALDIA—a prospective
multicentre study on adult
Swiss general population,
investigating environmental
and genetic effects on lung
Switzerland,
European
Adults 4422 Asthma self-reported (positive
response to ‘Have you ever had
asthma?’ and ‘Was this confirmed
by a doctor?’) BHR FEV1 reduction
420% after methacholine
(Continued)
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Study, year Study population
Location,
ethnicity
Adults/
children
Sample
size
a Definition of disease outcome
Schroer
2009
42
CCAAPS study on allergy and
air pollution in infants with
at least one atopic parent
US, mixed
ethnicity
Children 498 Wheezing parent-reported (paren-
tal report of the child wheezing at
least once at 2 years in last 12
months)
ALSPAC
mothers
ALSPAC—a UK population-
based birth cohort, with
pregnant women recruited in
1990
UK,
European
Adults 7262 Asthma self-reported (history of
asthma reported in a questionnaire
administered during pregnancy)
ALSPAC
children
ALSPAC—children recruited
at birth and followed up to
investigate their health,
behaviour and development
UK,
European
Children 5330 Asthma parent-reported (positive
response to ‘Has a doctor ever said
that your child has asthma?’ at
7 years) Wheezing parent-reported
(current history) BHR FEV1 reduc-
tion 420% after methacholine
AMICS-
INMA
AMICS—a population-based
birth cohort included in the
Spanish environment and
childhood research network
(INMA study)
Spain,
European
Children 428 Asthma parent-reported (positive
response to ‘Has your child had any
wheezing with whistling on his/her
chest when he/she breathed in the
past 12 months?’ at age 6 years)
Wheezing parent-reported (current
wheeze at 6 years)
Cross-sectional studies (n 2)
Salam
2007;
7
Gilliland,
2002
33
Cross-sectional study as part
of the Children Health Study,
a Californian ongoing cohort
study of school children
in 12 communities
US, Mixed
ethnicity
Children 3081 Asthma parent-reported DDA
(Criteria: N/A) Wheezing parent-
reported (lifetime history)
Kabesch
2004
53
Cross-sectional study part of
ISAAC project, assessing
prevalence of asthma and
allergy in school children
Germany,
European
Children 3005 Asthma parent-reported DDA
(Criteria: N/A)
Family studies (n 3)
David
2003
34
Family study based on
case–parent triad design and
focused on gene–environment
interactions
Mexico,
Latin
American
Children 218
families
Asthma diagnosed by a physician
(Criteria: included skin-prick and
pulmonary function testing)
Brasch-
Andersen
2004
4
Family study that recruited
atopic families with asthmatic
children in two separate
samples. Sample A: asthma;
Sample B: atopic asthma
Denmark,
European
Children 246
families
(Sample A) Asthma diagnosed by
a physician (Criteria: clinical symp-
toms plus positive methacholine
challenge)
(Sample B) Atopic asthma diag-
nosed by a physician (Criteria:
clinical symptoms plus positive
specific IgE measurement)
Southa-
mpton
UK multicentre family
study that recruited families
with two siblings diagnosed
with asthma
UK,
European
Children
and young
adults
341
families
Asthma self and parent reported
(Criteria: three positive responses
to: ‘Have you ever had asthma?’
and, ‘Was this confirmed by a
doctor?’ and, ‘Have you used any
medicines to treat asthma, or any
breathing problems, at any time in
the last 12 months’) Bronchial
responsiveness methacholine dose
response measure
N/A: not available; DDA: doctor-diagnosed asthma; GINA: global initiative on asthma.
aWhen results are reported for more genotypes or outcomes, the largest sample size is reported.
ECRHS: european community respiratory health survey; SPT: skin prick tests; TOT: total; SAPALDIA: swiss cohort study on air
pollution and lung and heart diseases in adults; CCAAPS: cincinnati childhood allergy and air pollution study; ISAAC: international
study of asthma and allergies in childhood
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4 and no meta-analysis could be performed.
The study by Brasch-Andersen and colleagues,
4 con-
sisting of 246 Danish atopic families (452 asthmatic
children plus their parents) recruited in two separate
samples, evaluated the risk of asthma and atopic
asthma associated with the three genes. GSTM1 and
GSTT1 were analysed as CNV with full gene-dosage
information available. The study found strong evi-
dence of an association of the GSTM1 homozygous
deletion with asthma (P<0.0005), which became
even stronger when limiting the analyses to atopic
asthma (P<0.00005). An association of GSTT1 with
asthma was also found, but under an additive model
(P 0.019), with similar results obtained for atopic
asthma (P 0.021), whereas no association was
found with GSTP1. The study by David and collea-
gues,
34 consisting of 218 Mexican case–parent triads,
focused on the interaction between NQO1 (Pro187Ser
polymorphism) and GSTM1 genes in increasing the
risk of asthma in children exposed to high level of
ozone (Mexico City). The study, which evaluated
GSTM1 in terms of null genotype (homozygous dele-
tion), did not assess the effect of GSTM1 alone, but
showed a protective effect of the NQO1 Ser allele in
children with null GSTM1 genotype.
Quality of the studies included
We assessed the quality of the 27 articles, reporting
on the 25 studies included in the meta-analyses, and
the 2 family-based articles. Three articles
6,35,36 did not
describe the study population (selection of cases and/
or controls for case–control studies), and six arti-
cles
5,35–39 did not provide a definition of the outcome
considered (asthma in all cases). HWE was reported
to be assessed in less than half of the articles (46%).
All studies described the genotyping methods used.
Genotyping error was evaluated in a quarter of
them, mainly by repeating the genotyping in 5–15%
of the samples, and no errors were found in most
cases. However, only 14% of the studies reported
blinding of genotyping to the clinical status of the
subjects. Among the population-based studies, 35%
of the articles discussed the issue of population strat-
ification, although only a few discussed the potential
problem in some detail.
Four studies were identified as being of poor quality
(no outcome definition plus incomplete description of
study population/no assessment of HWE). All of them
were case–control studies with total sample size less
than 500, and they were published in Russian,
39
Chinese,
36 Korean
37 and international
35 journals.
Table 2 shows deviation from HWE for GSTP1 gene
in four studies of relatively small size (less than 500),
including three case–control studies of rather poor
quality,
38,40,41 and a cohort study
42. Only two of
them
41,42 performed quality control of genotyping
and found no genotyping error, and none of them
reported blinded genotyping. Only one of them
42
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10 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYmentioned the possibility that population stratifica-
tion might have occurred.
Meta-analyses on GSTM1 deletion polymorphism
A total of 19 published and 3 primary studies evalu-
ated the association of GSTM1 and asthma, including
a total of 4416 affected and 23902 non-affected indi-
viduals. The meta-analysis in Figure 2a shows an
increased risk of asthma associated with the GSTM1
null genotype (pooled OR 1.28; 95% CI 1.09–1.52).
However, large between-study heterogeneity was
observed (I
2 76%), which could not be explained
by age (adults/children) or ethnicity, as approximated
by study geographical location (continent). These sub-
group analyses, however, showed that most heteroge-
neity was present in studies on adults and in those
performed in Asia (Supplementary Figure S2 available
as supplementary data at IJE online). Similarly, exclu-
sion of two studies with poor quality
36,39 reduced the
pooled OR to 1.19 (1.03–1.38) with little reduction of
the I
2 (69%). The subgroup analysis by asthma defi-
nition (Figure 2b) could not explain heterogeneity
either, although it showed that heterogeneity was
limited to studies where asthma was diagnosed by a
physician and where asthma was not defined in the
article, whereas it was absent among studies with
self-reported asthma. However, studies using self-
reported asthma included those with the largest
sample size, therefore it is difficult to disentangle
the impact of asthma definition from that of study
size on the observed heterogeneity. In fact, the
funnel plot in Figure 2c strongly supports the pres-
ence of small-study bias. When the meta-analysis was
repeated by limiting inclusion to the nine studies at
the top of the funnel, the heterogeneity dropped from
76 to 38% and the OR became very close to 1 (1.02;
0.92–1.13).
As for the association of GSTM1 null genotype with
wheezing and BHR, only four and three studies were
available, respectively. As shown in Figure 5a, for
both outcomes results were very homogeneous
across studies. The meta-analysis showed no effect
on BHR (1.01; 0.90–1.15), and only a possible small
effect on wheezing (1.08; 0.99–1.19).
Meta-analyses on GSTT1 deletion polymorphism
A total of 16 published and 3 primary studies evalu-
ated the association of GSTT1 and asthma, including
3852 affected and 22880 non-affected individuals.
Similarly to GSTM1, the meta-analysis in Figure 3a
shows an OR of 1.39 (1.09–1.77), but with extreme
between-study heterogeneity (I
2 81%). As for
GSTM1, heterogeneity was absent within the subgroup
of studies with self-reported asthma (Figure 3b), and
small-study bias was the only factor substantially
explaining heterogeneity. When restricting the meta-
analysis to the nine largest studies at the top of the
funnel plot in Figure 3c, the OR became 0.93 (0.84–
1.03) and the heterogeneity disappeared (I
2 0%).
On the contrary, exclusion of the two studies with
poor quality
36,39 reduced the pooled OR to 1.19
(0.97–1.44), but did not reduce substantially the
degree of heterogeneity (I
2 70%). Subgroup
analyses by age and ethnicity did not provide addi-
tional insight on the causes of heterogeneity
(Supplementary Figure S3 available as supplementary
data at IJE online).
Similarly to GSTM1, the association of GSTT1 with
wheezing and BHR (Figure 5b) showed homogeneous
results across studies (two and three studies included,
respectively). The meta-analyses showed no genetic
effect for either outcome (wheezing 1.05; 0.86–1.30;
BHR 0.96; 0.81–1.13).
Meta-analyses on GSTP1 Ile105Val polymorphism
A total of 14 published and 3 primary studies with
3363 affected and 14442 non-affected individuals
were available for the meta-analysis of GSTP1 Ile/Val
vs Ile/Ile and asthma, whereas 13 published and 3
primary studies with 2160 affected and 9034 non-
affected individuals were available for the contrast
Val/Val vs Ile/Ile (Figure 4; Supplementary Figure S4
and S5 available as supplementary data at IJE online).
The meta-analyses in Figure 4 show no clear associa-
tion of GSTP1 with asthma, although the two pooled
estimates point to a possible protective effect of the
Val allele, with an OR of 0.93 (0.82–1.06) for Ile/Val
vs Ile/Ile and 0.79 (0.57–1.08) for Val/Val vs Ile/Ile.
Although between-study heterogeneity was moderate
for Ile/Val vs Ile/Ile (I
2 39%), it was large for Val/Val
vs Ile/Ile (72%), so that the result for the latter is
difficult to interpret. Heterogeneity could not be
explained by small-study bias (Supplementary
Figure S5c available as supplementary data at IJE
online), and was not reduced by removing the two
studies with poor quality
35,37 either. Ethnicity did
explain some heterogeneity (Supplementary Figure
S5b available as supplementary data at IJE online),
and exclusion of the two North African studies
(Egypt and Tunisia) brought the ORs close to
1 (Ile/Val vs Ile/Ile 0.98; 0.87–1.10, and Val/Val vs
Ile/Ile 0.94; 0.71–1.24) and reduced I
2 to 59%.
Pooling of the two African studies showed a marked
protective effect (Ile/Val vs Ile/Ile 0.52; 0.33–0.83, and
Val/Val vs Ile/Ile 0.24; 0.09–0.69). The subgroup
analysis by asthma definition showed similar results
as for GSTM1 and GSTT1, with no heterogeneity within
studies with self-reported asthma (Figure 4c and d).
Only three studies were available for the association
of GSTP1 with wheezing and BHR, and meta-analysis
could only be performed for the comparison of
Ile/Val vs Ile/Ile where the heterogeneity was small
(Figure 5c and d). For the Ile/Val vs Ile/Ile comparison
there is a suggestion of an increased risk associated
with the Val allele for both outcomes. Effects in oppo-
site directions are shown for the Val/Val vs Ile/Ile
comparison, with the Val allele having a protective
effect on BHR as with asthma, but being associated
GLUTATHIONE-S-TRANSFERASE GENES AND ASTHMA PHENOTYPES 11with increased risk of wheezing. These findings need
to be interpreted with caution since they are driven
by two relatively small studies, the study by Fryer
9
and the AMICS-INMA study, respectively.
The results of the analyses based on the model-free
approach were similar to those based on between-
genotype comparisons, giving an OR of 0.93 (0.77–
1.03) for Ile/Val vs Ile/Ile and 0.77 (0.49–1.14) for Val/
Val vs Ile/Ile. The model-free approach provided an
estimate of  , the parameter indicating the underlying
genetic model, of 0.27 (0.01–0.61), where 0 corre-
sponds to the recessive, 0.5 to the co-dominant and 1
to the dominant model.
26 Despite the wide CI, the esti-
mate of   seems to exclude a dominant genetic model
and suggests either a co-dominant or a recessive model.
Strength of the evidence from the meta-analyses
When applying the Venice criteria to assess credibil-
ity,
25 the cumulative evidence reviewed does not
clearly support a genetic effect for any of the three
GST genes on asthma. In fact, although the amount of
evidence is good for all three meta-analyses,
particularly those on GSTM1 and GSTT1, the degree
of heterogeneity across studies and the likely presence
of publication bias make the credibility of the evi-
dence weak. Moreover, when limiting the meta-
analyses to the largest studies, positive findings
shown by other studies could not be replicated, sug-
gesting that a genetic effect is likely to be either
absent or very small.
Discussion
Overall, the evidence synthesized in this review does
not support a substantial role of GST genes on asthma
phenotypes in either children or adults, although
small effects cannot be excluded and it is possible
that these genes act on airway disease through inter-
action with environmental exposures or other genes.
The weakness of the available evidence in supporting
an effect of GST genes on asthma is mainly due to
publication bias and large heterogeneity of study
results. Interestingly, the results from the three
(a)
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Figure 2 Random effects meta-analysis of GSTM1 (null vs present) effect on asthma: (a) forest plot for the main analysis;
(b) forest plot for the subgroup analysis by asthma diagnosis; (c) funnel plot, where studies classified as ‘small’ or ‘large’ in
the sensitivity analyses are represented by dots and triangles, respectively (Egger’s test: P 0.035; Begg’s test: P 0.135)
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Figure 2 Continued
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types were negative. The only exception was the asso-
ciation between GSTP1 and wheezing (but not
asthma) in the AMICS-INMA study, which suggested
an increased risk for the Val allele. It is important to
note that the ALSPAC, which provided negative
results consistently for all GST genes and asthma phe-
notypes, was the largest study included in all the
meta-analyses. In fact, the plan for the systematic
review and meta-analysis presented here originated
with the aim of putting the results of the ALSPAC
cohort into context, and understand the reasons for
the apparent disagreement with previous published
studies. The lack of evidence of an important role of
GST genes in the development of asthma, wheezing
and BHR is in agreement with negative findings on
lung function in children for all three GST genes from
the ALSPAC (data not shown), although an association
between GSTM1 and GSTP1 genes and lung function in
childhood has been previously suggested.
43
Although the meta-analyses on GSTM1 and GSTT1
with inclusion of all studies showed an increased
risk of asthma associated with the two null geno-
types, the presence of small-study bias and extreme
heterogeneity in study results make the credibility of
these findings very low. Despite our efforts to be as
inclusive as possible (comprehensive search strategy,
avoidance of language restrictions, inclusion of con-
ference abstracts), the meta-analyses showed clear
absence of small studies with negative results, sug-
gesting the presence of publication bias. This is an
important issue in meta-analysis of genetic associa-
tion studies, which needs to be highlighted and
addressed. We did so by repeating the analyses with
inclusion of only the largest studies, and we found
loss of the observed associations, with ORs very
close to 1. Positive results were not only confined to
small studies, but also to studies with poor quality,
the exclusion of which caused similar loss of the
observed associations. In support of an absence of
an association of GSTM1 and GSTT1 with airway dis-
ease are the negative findings of the meta-analyses on
wheezing and BHR. An exception might be the asso-
ciation between GSTM1 and wheezing, where the
NOTE: Weights are from random effects analysis
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(a)
Figure 3 Random effects meta-analysis of GSTT1 (null vs present) effect on asthma: (a) forest plot for the main analysis;
(b) forest plot for the subgroup analysis by asthma diagnosis; (c) funnel plot, where studies classified as ‘small’ or ‘large’ in
the sensitivity analyses are represented by dots and triangles, respectively (Egger’s test: P 0.003; Begg’s test: P 0.001)
14 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYmeta-analysis suggests a possible small effect of the
null genotype in increasing the risk of  10%.
Although the studies included in the meta-analyses
on wheezing and BHR were only few and the results
supported only weak evidence of associations, the
consistency in results and narrow CIs of the ORs
give some credibility to these findings. An important
methodological point regarding studies on GSTT1 or
NOTE: Weights are from random effects analysis
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Figure 4 Random effects meta-analysis of GSTP1 effect on asthma: (a) Ile/Val vs Ile/Ile; (b) Val/Val vs Ile/Ile; (c) subgroup
analysis by asthma diagnosis for Ile/Val vs Ile/Ile; (d) subgroup analysis by asthma diagnosis for Val/Val vs Ile/Ile
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GLUTATHIONE-S-TRANSFERASE GENES AND ASTHMA PHENOTYPES 17GSTM1 is that methods currently used to evaluate
these genes cannot distinguish between genotypes
with one or two copies of the gene. By classifying
the genotype as ‘present’ or ‘null’ they imply a reces-
sive model (one or two copies vs absence of the risk
allele), which may not reflect the true underlying
genetic model and thus may not provide a valid and
accurate estimate of the genetic risk. GSTT1 or GSTM1
CNVs (also known as ‘gene dosage’) are correlated
with altered enzyme activity, and analysis in a dose-
dependent manner would best describe any disease
outcome association.
44,45 Brasch–Andersen and collea-
gues have shown that it is possible to utilize the
increased sensitivity of real-time PCR assays to pro-
vide dosage of GSTT1 and GSTM1.
4 A similar approach
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Figure 5 Results on wheezing and BHR for: (a) GSTM1; (b) GSTT1; (c) GSTP1 Ile/Val vs Ile/Ile; (d) GSTP1 Val/Val vs Ile/Ile.
Fixed effects meta-analysis was performed for GSTM1, GSTT1 and GSTP1 Ile/Val vs Ile/Ile
18 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYwas utilized to obtain gene-dosage information in the
ALSPAC cohort.
17
The meta-analysis on GSTP1 Ile105Val polymorph-
ism and asthma suggested a possible, weak protective
effect of the Val allele. The Val substitution in the
GSTP1 gene is associated with altered substrate affi-
nities compared with the Ile105 wild-type allele
46 and
heterozygosity has also been associated with reduced
risk of chronic obstructive pulmonary disease.
47
Although in the meta-analysis on GSTP1 and asthma
there was no clear evidence of small-study bias, het-
erogeneity in study results was large and limited the
interpretability of the pooled estimates. Subgroup
analyses showed a potential role of ethnicity in
explaining such heterogeneity, with a protective
effect of the Val allele limited to the two North
African studies, where the association was very
strong. This finding might be explained by the pres-
ence of gene–environment or gene–gene interactions
in these study populations. GST genes effects on
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GLUTATHIONE-S-TRANSFERASE GENES AND ASTHMA PHENOTYPES 19asthma risk may be modified by exposures that pro-
duce lung oxidative injury, such as smoking, air pol-
lution and infections. For example, one might
speculate that smoking in North African countries is
a major problem, and the common waterpipe smoking
seems to produce even more free radicals than ciga-
rette smoking.
48 The value of such speculations is lim-
ited in the absence of supporting evidence, and bias
associated with selective reporting or poor quality
might be an alternative explanation for the positive
findings of the two North African studies. Future
research in these populations should collect informa-
tion on factors potentially interacting with GST genes
in modifying asthma risk, including oxidative expo-
sures. Only few studies evaluated the effects of GSTP1
on wheezing and BHR, and the findings were in
opposite directions for the two outcomes. The Val
allele was protective for BHR, in agreement with the
results for asthma, but associated with increased risk
of wheezing. These effects were suggested by two rel-
atively small studies, whereas the large ALSPAC
cohort did not provide convincing evidence of any
association with either outcome.
Failure to account for environmental exposures
in our meta-analyses might partly explain not
only the heterogeneity of results across studies,
but also the overall negative findings. Strong environ-
mental effects on asthma phenotypes could mask
modest genetic effects and, more importantly, gene–
environment interactions could make the effects of
GST genes become substantial only in the presence
of oxidative exposures and not detectable at a popu-
lation level.
49 Passive smoking, ambient air pollution
and endotoxin or other pathogen-associated mole-
cules are good candidates for gene–environment inter-
actions in asthma, particularly with genes involved in
antioxidant defence, such as the GST genes.
49–51 In
our review, variation in exposure to these environ-
mental factors across studies is likely to have hap-
pened given the diverse geographical setting of the
studies included, and gene–environment interactions
might partly explain the large heterogeneity observed.
Moreover, there is evidence that antioxidant supple-
mentation can modify these gene–environment inter-
active effects,
52 so that the nutritional status of the
study population could represent an additional source
of heterogeneity. The evaluation of gene–environment
interactions is problematic due to the lack of power of
statistical tests for interactions and the high measure-
ment error present in the assessment of most envi-
ronmental exposures. In fact, despite the strong
biological rationale, results from the literature on
gene–environment interactions in asthma remain
inconclusive.
51 Only a small proportion of the studies
reviewed in this article reported on gene–environment
interactions, including environmental tobacco
smoke (ETS),
33,39,53 in utero ETS
33,53 and air pollu-
tion,
7,54 and the same environmental exposure was
assessed in different ways across studies.
Researchers interested in the effects of GST genes
should be encouraged to collect information on rele-
vant environmental exposures and carefully choose
the methods to measure them. Standardization of
methods for environmental exposure assessment and
full reporting of the interactions tested will allow the
pooling of data across studies and to reach adequate
power to detect interactions. The study of possible
interactions between GST genes and environmental
exposures on asthma is important not only for our
understanding of the etiopathogenesis of this complex
disease, but also for its possible implications for
public health. Asthma prevalence is high and increas-
ing over time worldwide, and GST genes polymorph-
isms are frequent in the population, particularly the
GSTM1 null genotype, with reported frequencies in
different ethnic groups varying from 18 to 66%.
55
The possibility of implementing simple measures
such as antioxidant diet supplementation in subjects
at risk makes this topic worthwhile for further
research.
GSTs Mu-1, Theta-1 and Pi-1 have overlapping sub-
strate specificities, so that a deficiency in one isoform
may be compensated by another. A meta-analysis of
14 studies showed that adults with a combined
GSTM1 and GSTT1 null genotype were at a higher
risk of asthma (OR 2.15, 95% CI 1.21–3.71) and sug-
gested that smoking overloads the capacity of either
GSTM1 or GSTT1 detoxification systems.
56 We investi-
gated the effect of the combined null genotype using
published data from 16 studies and unpublished data
from the ALSPAC and AMICS-INMA study (data not
shown). Although we found an association with
increased asthma risk (OR 1.39, 95% CI 1.16–1.67),
the extreme between-study heterogeneity (I
2 88%)
and presence of publication bias greatly limit the
credibility of these findings. Moreover, the results
from the ALSPAC, which represented the largest
sample in the meta-analysis, were negative. On the
other hand, GST genes could interact with genes
coding for other detoxifying enzymes induced in
response to oxidative stress. Supporting this hypothe-
sis is some evidence of interaction between GSTM1
null genotype and NQO1 Pro187Ser polymorphism
on asthma.
34 Future large studies evaluating GST
genes in addition to other antioxidant genes are
needed to provide evidence on gene–gene interactive
effects on asthma.
This systematic review only focussed on asthma risk,
and did not consider the possible association of GST
genes with asthma severity in patients affected by the
disease. A finding from the Southampton study was
the association of the GSTT1 null allele with an
increased severity score in patients with asthma (data
not shown). There is evidence suggesting that GST
genes, in particular GSTM1 and GSTP1, might also inter-
act with air pollution and tobacco smoke exposures in
exacerbating respiratory symptoms and decreasing
lung function in asthmatic individuals.
12,32,57
20 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYDespite our attempt to investigate causes of hetero-
geneity in study results in the meta-analyses pre-
sented, we were limited by the availability of
relevant information in the published reports. For
example, although we did not find evidence of
effect modification by ethnicity and age at onset, we
cannot exclude the contribution of these factors to the
observed heterogeneity, given that we used crude
proxies for them (study geographical location for eth-
nicity, and age of study population instead of age at
onset for childhood vs adult asthma). Differences in
asthma definition may also have played a role in gen-
erating the observed heterogeneity. Asthma diagnosed
by a physician, self-reported doctor-diagnosed asthma
and self-reported history of asthma differ in sensitiv-
ity and specificity.
58 Moreover, asthmatic individuals
identified through questionnaire in a population-
based study may have lower severity than patients
recruited at a clinic. Although asthma definition
could not explain heterogeneity in our meta-analyses,
heterogeneity was not present within the subgroup of
studies that used self-reported asthma, where effects
were closer to the null hypothesis compared with
studies that used physician-diagnosed asthma and
those that did not report how asthma was defined.
However, interpretation of this finding is difficult,
since we could not disentangle the possible effect of
asthma definition from that of study design and study
size. Physician-diagnosed asthma was used by rela-
tively small case–control studies, whereas self-
reported asthma was used by large cohort and
cross-sectional studies. The presence of publication
bias, for example, could in theory explain the fact
that heterogeneity was limited to the smallest studies,
which happened to be case–control studies with phy-
sician-diagnosed asthma.
In conclusion, the evidence reviewed in this article
does not support a substantial role of GST genes alone
in the development of asthma. However, given the
potential for interactions between GST genes and
environmental toxins known to cause oxidative
damage to the lungs, future research should be
planned to explore gene–environment interactions.
Large studies with accurate measurement of the envi-
ronmental exposure are needed in order to reach ade-
quate power to detect such interactions. Similarly,
further research should evaluate possible interactions
between GST genes and other genes involved in the
antioxidant pathway. Future studies will also need to
improve their methodological quality and the report-
ing of their findings, in order to increase the credibil-
ity of the evidence accumulating over time.
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KEY MESSAGES
  Oxidative stress is involved in the pathogenesis of asthma, and glutathione-S-transferase (GST)
enzymes may therefore influence asthma risk.
  Common polymorphisms of the GSTM1, GSTT1 and GSTP1 genes have been associated with asthma in
children and adults, but published results are inconsistent across studies.
  Our meta-analyses do not support a substantial role of the GST genes alone in the development of
asthma, and they suggest presence of publication bias.
  Future studies should focus on possible interactions of the GST genes with environmental oxidative
exposures and with other genes involved in the antioxidant pathway.
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Appendix 1
WinBUGS code for the genetic model-free approach
Model
{
for(i in 1:17) {
case[i,1:3]   dmulti(p.case[i,], N.case[i])
control[i,1:3]   dmulti(p.ctrl[i,], N.ctrl[i])
p.ctrl[i,1] <- 1/(1 beta[i,1] beta[i,2])
p.ctrl[i,2] <- beta[i,1]/(1 beta[i,1] beta[i,2])
p.ctrl[i,3] <- beta[i,2]/(1 beta[i,1] beta[i,2])
beta[i,1]   dgamma(0.001,0.001)
beta[i,2]   dgamma(0.001,0.001)
p.case[i,1] <- 1/(1 theta[i,1]  theta [i,2])
p.case[i,2] <- theta [i,1]/(1  theta[i,1]  theta [i,2])
p.case[i,3] <- theta [i,2]/(1  theta[i,1]  theta [i,2])
theta[i,1] <- beta[i,1]
 exp(lambda
 delta[i])
theta[i,2] <- beta[i,2]
 exp(delta[i])
delta[i]   dnorm(d, prec)
}
d   dnorm(0.0,1.0E-6)
lambda   dbeta(0.5,0.5)
prec <- 1/var
var <- pow(sd,2)
sd   dnorm(0,1)I(0,)
OR_Gg <- exp(lambda
 d)
OR_GG <- exp(d)
}
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